"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03840850","Type 2 Diabetes: Risk Perceptions and Self-management Behaviour",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Other: Personalized Risk Communication for People with Type 2 Diabetes","Feasibility of implementing the intervention in primary care: Binary outcome (feasible / not feasible), as judged by the investigators|Recall of personalised risk information|Intentions to make lifestyle changes|Change in self-management behaviour","University of Oxford|NIHR Collaboration for Leadership in Applied Health Research and Care (Oxford)","All","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","17/NW/0267","September 15, 2017","February 9, 2018","February 9, 2018","February 15, 2019",,"February 15, 2019","27 Beaumont Street Surgery Practice, Oxford, Oxfordshire, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03840850/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03840850/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03840850"
2,"NCT04072523","An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes Patients","HF-Registry","Recruiting","No Results Available","Type 2 Diabetes",,"Prevalence of Left Ventricular dysfunction|Correlation of Left ventricular dysfunction and heart failure","AstraZeneca","All","Child, Adult, Older Adult",,"1000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","D1843R00300","December 3, 2019","May 31, 2020","May 31, 2020","August 28, 2019",,"May 5, 2020","Research Site, Ahemdabad, Gujrath, India|Research Site, Rajkot, Gujrat, India|Research Site, Rohtak, Haryana, India|Research Site, Bangalore, Karnataka, India|Research Site, Bangalore, Karnataka, India|Research Site, Delhi, New Delhi, India|Research Site, Delhi, New Delhi, India|Research Site, Amritsar, Punjab-, India|Research Site, Chandigarh, Punjab, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Hyderabad, Telangana, India|Research Site, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT04072523"
3,"NCT04100278","Effectiveness of Shared Care Diabetes Management in Patients With Type 2 Diabetes",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Behavioral: Shared Care diabetes management","HbA1c change|Blood Pressure change|LDL-c change|BMI change|SDSCA(Summary of Diabetes Self Care Activities) score change|C-DMSES(Chinese Diabetes Management Self-Efficacy Scale) score change|A-DQOL(Amendment Diabetes Quality of Life scale) score change|Morisky scale score change|DASS-C21scale score change","Beijing Chao Yang Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SCDM-T2DM","January 1, 2020","December 31, 2023","December 31, 2023","September 24, 2019",,"September 24, 2019","Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04100278"
4,"NCT03992248","Effect of Eating Within a Limited Time on Sugar Sensitivity and Liver Sugar Stores of People With Type 2 Diabetes.","TRF","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Behavioral: Time restricted feeding","Hepatic glycogen|Insulin sensitivity","Maastricht University|ZonMw: The Netherlands Organisation for Health Research and Development","All","50 Years to 75 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NL67610068","January 31, 2019","October 2019","December 2019","June 20, 2019",,"June 20, 2019","Maastricht University, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT03992248"
5,"NCT04114682","Longitudinal Assessment of Multiple Organs in Patients With Type 2 Diabetes","MODIFY","Recruiting","No Results Available","Type 2 Diabetes","Other: Multi parametric MRI scan","Magnetic Resonance Imaging metrics for liver fibro-inflammation in patients with type 2 diabetes|Correlation between Magnetic Resonance Imaging metrics for liver Fat infiltration and volume in patients with type 2 diabetes vs healthy people.|Correlation between Magnetic Resonance Imaging metrics for Pancreas, spleen, kidney and aorta indicating co-morbidities in patients with type 2 diabetes vs healthy people.|Detecting change in liver, spleen, pancreas and kidney using Magnetic Resonance Imaging metrics from baseline to 9 months|Detecting change in liver, spleen, pancreas and kidney using conventional biochemical biomarkers from baseline to 9 months|Impact of Multi parametric abdominal MRI on management of patients with type 2 diabetes|longer term evaluation of clinical outcomes","Perspectum Diagnostics Ltd|University of Liverpool|Liverpool University Hospitals NHS Foundation Trust|Oxford University Hospitals NHS Trust|Royal Free Hospital NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"150","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CA064","January 27, 2020","November 4, 2024","November 4, 2024","October 3, 2019",,"March 5, 2020","Aintree University Hospital NHS Foundation Trust, Liverpool, Merseyside, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom|Royal Free Hospital NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04114682"
6,"NCT04124484","DBPR108 Tablets in Type 2 Diabetes Mellitus Patients",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|Drug: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|Drug: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Drug: Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)","HBA1c|Fasting plasma glucose|2-hour postprandial plasma glucose|fasting glucagon|fasting Insulin|active Glucagon-like peptide-1（GLP-1）|The percentage of HbA1c≤6.5% or HbA1c≤7%|body weight","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSPC/HA1117/PRO-II","October 17, 2017","February 27, 2019","June 28, 2019","October 11, 2019",,"October 15, 2019","First Hospital of Peking Unversity, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04124484"
7,"NCT03909555","Effects of Short-term Intensive Insulin Therapy on Long-term Complications in Type 2 Diabetes",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Other: Complications assessment","Difference in the proportions of chronic complications|Difference of glycosylated hemoglobin A1C|Difference of fast blood glucose|Difference of C-peptides|Difference of insulin resistance|Difference of insulin usage|Difference of oral anti-diabetic drugs usage|Difference of attitudes toward diabetes|Difference of quality of life","Sun Yat-sen University|Guangdong Provincial People's Hospital|Zhujiang Hospital|The Third Affiliated Hospital of Guangzhou Medical University|The Third Affiliated Hospital of Southern Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|The First Affiliated Hospital of Guangzhou Medical University|Nanfang Hospital of Southern Medical University|First Affiliated Hospital of Jinan University|Guangzhou Red Cross Hospital|Dongguan Kanghua Hospital","All","25 Years and older   (Adult, Older Adult)",,"777","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","20181015","June 1, 2019","June 30, 2021","December 31, 2021","April 10, 2019",,"April 10, 2019","endocrinology department of the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03909555"
8,"NCT04161430","A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: DBPR108; Placebo matching sitagliptin|Drug: Placebo matching DBPR108; Sitagliptin; DBPR108|Drug: Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108","Change from baseline in HbA1c (%) compared to placebo comparator at week 24|Change from baseline in HbA1c (%) compared to active comparator at week 24|The percentage of subjects with HbA1c≤6.5% and HbA1c≤7% at week 24|Change from baseline in HbA1c (%) at week 12, week 40, week 52|The percentage of subjects with HbA1c≤6.5% and HbA1c≤7% at week 12, week 40, week 52|Change from baseline in fasting plasma glucose/2-hour postprandial plasma glucose/body weight at week 12,week 24","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSPC/DBPR108201903/PRO-III-1","January 20, 2020","April 27, 2024","June 28, 2024","November 13, 2019",,"November 13, 2019",,,"https://ClinicalTrials.gov/show/NCT04161430"
9,"NCT03829891","Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Beinaglutide|Drug: glargine","The proportion and rate of the fasting blood glucose control.|Proportion of patients with glycosylated hemoglobin < 7%.|Changes of blood sugar variation .|Change percentage of glycosylated hemoglobin|Change of blood glucose|Change of blood pressure|Change of blood lipids|Change of body weight report in kilograms|Change of body mass index report in kg/m^2|Waist-hip ration change|Oxidative Stress Indice (8-Iso-PGF2α) change|Inflammatory factors (MCP-1) change|Inflammatory factors (hs-CRP) change","Xijing Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY20182008-1","August 3, 2018","May 30, 2019","August 30, 2019","February 4, 2019",,"February 4, 2019","Chang'an Hospital, Xi'an, China,Shanxi, China|Shaanxi Aerospace Hospital, Xi'an, China,Shanxi, China",,"https://ClinicalTrials.gov/show/NCT03829891"
10,"NCT03940482","Time Restricted Eating As Treatment (TREAT) for Diabetes Mellitus: A Pre-Post 12 Week Study on the Effectiveness of Intermittent Fasting in Asians With Type 2 Diabetes Mellitus","TREAT","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Behavioral: Time Restricted Eating As Treatment (TREAT) for Diabetes.","Change in glycaemic control of patients as measured by >= 5% reduction in glycosylated haemoglobin (HbA1C) over a 12 week period.|Change in glycaemic control of patients as measured by fasting glucose and 2 hour post prandial glucose over a 12 week period.|Change in Blood Pressure (BP) over a 12 week period.|Change in Weight over a 12 week period.|Change in Body Mass Index (BMI) over a 12 week period.|Change in Waist Circumference (WC) over a 12 week period.|Change in the lipid profiles of patients, namely Total Cholesterol (TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides (TG), over a 12 week period.|Change in a levels of ketonemia (Serum Beta-Hydroxybutyrate 0.5-3.0 mmol/L) over a 12 week period.","Singapore General Hospital|Duke-NUS Graduate Medical School","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TREAT-DM-01","January 14, 2019","June 30, 2020","June 30, 2020","May 7, 2019",,"March 19, 2020","Singapore General Hospital (Clinical Trials and Research Centre), Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03940482"
11,"NCT04208620","Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus",,"Active, not recruiting","No Results Available","Type 2 Diabetes","Drug: Placebo|Drug: Cotadutide","Incidence of treatment-emergent adverse events (TEAEs)|Incidence of treatment-emergent serious adverse events (TESAEs)|Clinically important changes in 12-lead electrocardiogram (ECG)|Vital signs as measured by pulse rate (bpm)|Vital signs as measured by blood pressure (mmHg)|ABPM (Ambulatory blood pressure monitoring) to measure pulse rate (bpm) and blood pressure (mmHg)|Physical examination (abnormality to be reported as part of adverse events)|Clinical laboratory evaluations|Area under the concentration-time curve (AUC) during the dosing interval (AUCtau)|Maximum observed concentration (Cmax)|Time to Cmax (tmax)|Trough plasma concentration (Ctrough)|Anti-drug antibodies (ADAs) to Cotadutide|Change in average glucose levels (mg/dL)|Change in coefficient of variation|Change in percentage time spent in hyperglycemia (> 140 mg/dL)|Change in percentage time spent in normoglycemia (70 -140 mg/dL)|Change in percentage time spent in clinically significant hypoglycemia (< 54 mg/dL)|Change in estimated hemoglobin A1c (HbA1c)|Change in fasting plasma glucose (mg/dL)|Change in HbA1c|Percentage change in body weight|Absolute change in body weight (kg)|Proportion of subjects achieving > 5% body weight loss","AstraZeneca|MedImmune LLC","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5671C00003","January 21, 2020","July 27, 2020","July 27, 2020","December 23, 2019",,"April 24, 2020","Research Site, Shinjuku-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suita-shi, Japan",,"https://ClinicalTrials.gov/show/NCT04208620"
12,"NCT04196231","Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","BEYOND","Recruiting","No Results Available","Type 2 Diabetes","Drug: IDegLira|Drug: IGlarLixi|Drug: Insulin/Canaglifozin|Drug: Insulin/Dapaglifozin|Drug: Insulin/Empaglifozin|Drug: Basal Bolus","Hba1c variability change|Proportions of patients with significant HbA1c change|Weight Change|BMI Change|Waist circumference change|Blood pressure change|Fasting glycemia change|Post-prandial glycemia change|C-peptide change|Change in total daily insulin dose|Change in lipide profile|Change in eGFR|Diabetes treatment satisfaction","University of Campania ""Luigi Vanvitelli""","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 4","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BEYOND Protocol","January 1, 2020","December 31, 2021","January 31, 2023","December 12, 2019",,"March 18, 2020","Unit of Endocrinology and Metabolic Diseases, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT04196231"
13,"NCT04023539","Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes","Dietary Supplement: Cinnamomum zeylanicum|Other: Placebo","Glycated hemoglobin|Fasting plasma glucose|Total cholesterol|HDL|LDL|Triglycerides|Weight|Waist circumference|Body Mass Index|Blood pressure","Universidad de Sonora","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Cinnamon-T2D-MEX-2019","September 4, 2019","March 20, 2020","April 23, 2020","July 17, 2019",,"May 28, 2020","C.A.A.P.S., Hermosillo, Sonora, Mexico|ISSSTE Family Medicine Clinic, Hermosillo, Sonora, Mexico",,"https://ClinicalTrials.gov/show/NCT04023539"
14,"NCT03932084","Effects of Glucose Fluctuation Intervention on the Prognosis of Patients With Type 2 Diabetes and Cerebral Infarction",,"Recruiting","No Results Available","Type 2 Diabetes and Cerebral Infarction","Behavioral: Control group|Behavioral: Glucose fluctuation targeted intervention","Stroke severity|Glycemic variability|Glucose fluctuation|Disability and health-related quality of life after stroke|Independent living skills|Glycemic control|Blood lipids","Nanjing University of Traditional Chinese Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N2017003","February 1, 2017","May 25, 2019","June 18, 2019","April 30, 2019",,"April 30, 2019","Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03932084"
15,"NCT04213547","Sleep and Glycemic Control in Type 2 Diabetes Adolescents",,"Not yet recruiting","No Results Available","Type 2 Diabetes","Behavioral: Loss frame sleep extension intervention","Sleep duration|Glycemic control|BMI","Children's Hospital of Philadelphia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","12 Years to 20 Years   (Child, Adult)","Not Applicable","15","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","19-016599|2T32DK063688-16","June 2020","January 1, 2021","January 1, 2021","December 30, 2019",,"March 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04213547"
16,"NCT03997331","Chronicare for Type 2 Diabetes (Chronicare-T2D)","CRX-T2D","Not yet recruiting","No Results Available","Type 2 Diabetes","Other: CRx Health|Other: Chronicare","Change in HbA1c|Fasting Blood Glucose|Mean Duration of Time to Reach Optimal Insulin Glargine Dose|Proportion of Patients Reaching Optimal Insulin Glargine Dose|Median Adherence to Insulin Glargine|Median Adherence to Metformin","QuiO|SHL Medical|MidMichigan Health","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","1433742-2","May 2020","December 2020","February 2021","June 25, 2019",,"March 31, 2020","Clinical Research Department, Midland, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03997331"
17,"NCT03979768","Risk Assessment of Type 2 Diabetes in Pharmacies",,"Completed","No Results Available","Type2 Diabetes","Other: Diabetes risk assessment service in Norwegian community pharmacies","Number of Participants with undiagnosed type 2 diabetes|Explore if there was any difference in the number of participants with a high risk of developing type 2 diabetes in the risk test only (RTO)- group and the group that also offered a HbA1c-measurement (HbA1c-group)","University of Bergen","All","45 Years and older   (Adult, Older Adult)","Not Applicable","368","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2016/808","September 15, 2016","June 30, 2017","May 30, 2019","June 7, 2019",,"October 16, 2019",,,"https://ClinicalTrials.gov/show/NCT03979768"
18,"NCT04107259","IRAPe, Irisin and IL-34 in Patients With Type 2 Diabetes",,"Completed","No Results Available","Type2 Diabetes Mellitus","Diagnostic Test: Blood sample","Fasting blood glucose (FBG) levels|Fasting plasma insulin (FPI)|HOMA-IR index|plasma IL-34|serum visfatin|IRAPe","Damanhour University|Tanta University","All","35 Years to 65 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","IRAPe, Irisin and IL-34","January 19, 2019","June 30, 2019","July 20, 2019","September 27, 2019",,"September 27, 2019","Tanta University, Tanta, El-Gharbia, Egypt",,"https://ClinicalTrials.gov/show/NCT04107259"
19,"NCT04004793","Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)",,"Not yet recruiting","No Results Available","Type 2 Diabetes","Behavioral: Intensive lifestyle intervention|Drug: Dapagliflozin 10 MG|Drug: Placebo oral tablet","Incidence of patients with diabetes remission|Proportion of patients with diabetes remission|Net change in body weight|Net change in waist circumference|Net change in HOMA-IR|Net change in serum lipids|Net change in HbA1c|Net change in body fat|Net change in SBP|Net change in Serum Creatine|Net change in Albuminuria","Shanghai Zhongshan Hospital","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 4","328","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B2019-043R","August 1, 2019","October 30, 2021","October 30, 2021","July 2, 2019",,"July 9, 2019",,,"https://ClinicalTrials.gov/show/NCT04004793"
20,"NCT04014582","Taking Action: a Care for Type 2 Diabetes Intervention for Couples","TACTIC","Completed","No Results Available","Type 2 Diabetes","Behavioral: Communal Coping Intervention|Behavioral: Diabetes Education","Change in depressive symptoms|Change in life satisfaction|Change in perceived stress|Change in relationship satisfaction--QMI|Change in relationship satisfaction--PAIR|Change in diabetes self-care|Change in perceived emotional responsiveness|Change in generalized self-efficacy|Change in diabetes specific self-efficacy","Carnegie Mellon University","All","Child, Adult, Older Adult","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","STUDY2019_00000227","July 20, 2019","April 14, 2020","April 14, 2020","July 10, 2019",,"May 1, 2020","Carnegie Mellon Universityl, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04014582"
21,"NCT03887416","Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes",,"Recruiting","No Results Available","Type2 Diabetes","Drug: Dapagliflozin 10 MG Oral Tablet [Farxiga]|Drug: Placebo Oral Tablet","Changes in nighttime blood pressure|Changes in office blood pressure. Both systolic and diastolic blood pressure will be assessed|Changes in albuminuria|Changes in HBA1C","LM Diagnósticos S.L.|AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","225","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","DAPA-ESR-16-12460|2017-002125-38","April 12, 2019","February 2020","February 2020","March 25, 2019",,"September 3, 2019","Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03887416/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03887416"
22,"NCT04108299","Family Intervention for Chinese Americans With Type 2 Diabetes",,"Not yet recruiting","No Results Available","Type 2 Diabetes","Behavioral: Wait-list control group|Behavioral: SMS intervention","Feasibility of study intervention|Acceptability|HbA1c|Self-efficacy measured using Diabetes Management Self-Efficacy Scale (DMSES)|Diabetes Self-Management Questionnaire (DSMQ)|23-item Michigan Diabetes Knowledge Test","NYU Langone Health","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","19-01275","October 19, 2019","November 2019","November 2020","September 30, 2019",,"September 30, 2019","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04108299"
23,"NCT03870724","Women and Risk of Type 2 Diabetes",,"Enrolling by invitation","No Results Available","Type 2 Diabetes Mellitus",,"Type 2 diabetes","University of Oslo|Norwegian Diabetes Association","Female","27 Years to 60 Years   (Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018/2517","August 27, 2019","December 2020","December 2021","March 12, 2019",,"January 21, 2020","University of Oslo, Faculty of Medicine, Institute of Health and Society, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT03870724"
24,"NCT03944616","Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes","SODAS","Recruiting","No Results Available","Type 2 Diabetes","Behavioral: Diet Beverage|Behavioral: Water","HbA1c|Time In Range|Glycemic Variability|Other CGM metrics|Lipid panel (Total cholesterol, LDL cholesterol, HDL cholesterol, Fasting Triglycerides), all mg/dL|Kidney function|Fasting glucose and Insulin|Fructosamine/Glycated Albumin|Blood pressure|Weight (kg)|Dietary Quality (Healthy Eating Index)|DHP-18|Food Craving Inventory|Sleep Quality and Patterns|Physical activity|Serotonin|Leptin|Thyroid Stimulating Hormone (TSH)|Neuropeptide Y|cholecystokinin (CCK)|Gut Microbiome|Comprehensive metabolomics|Dietary Practices","University of California, Irvine|University of Minnesota|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","35 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","R01DK117028|1R01DK117028-01A1","June 6, 2019","July 31, 2022","July 31, 2022","May 9, 2019",,"October 3, 2019","University of California, Irvine, Irvine, California, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03944616"
25,"NCT04003194","Pinto Beans and Glycemic Control in Adults With Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes","Other: Pinto Beans|Other: Green Beans - control","Change in Glucose|Postprandial glucose|Change in Hemoglobin A1c","University of Colorado, Colorado Springs|Iowa State University","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UCCS09-028","March 1, 2009","December 31, 2010","December 31, 2010","July 1, 2019",,"July 1, 2019",,,"https://ClinicalTrials.gov/show/NCT04003194"
26,"NCT04005261","C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes Treated With Insulin","Diagnostic Test: C-peptide concentrations","The incidence of adequate, borderline and insufficient beta cell reserves assessed by the fasting C-peptide concentrations|Correlations of fasting C-peptide concentrations with patients characteristics and biochemical findings","Goztepe Training and Research Hospital","All","18 Years and older   (Adult, Older Adult)",,"249","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","C-peptide2019","November 1, 2018","February 1, 2019","March 1, 2019","July 2, 2019",,"July 2, 2019","IMU Goztepe Education and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04005261"
27,"NCT03893526","Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes","NEPT2D","Recruiting","No Results Available","Type2 Diabetes","Drug: Entresto|Drug: Sitagliptin|Drug: Valsartan|Drug: Placebo","Blood Glucose|Plasma Concentrations of GLP-1|Plasma Concentrations of GIP|Plasma Concentrations of Glucagon|Plasma Concentrations of Insulin|Plasma Concentrations of C-Peptide|Plasma Concentrations of Amino Acids","University of Copenhagen|Hvidovre University Hospital","Male","30 Years to 70 Years   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NEPT2D","January 25, 2019","January 1, 2021","September 1, 2021","March 28, 2019",,"March 24, 2020","Hvidovre Hospital, Hvidovre, RegionH, Denmark",,"https://ClinicalTrials.gov/show/NCT03893526"
28,"NCT04164784","Effect of ""Therapeutic Monitoring"" on Blood Glucose Control in Type 2 Diabetes",,"Not yet recruiting","No Results Available","Type2 Diabetes","Behavioral: therapeutic monitoring","HbA1c|TIR|Fasting glucose levels|Fasting c-peptide levels|Serum Triglycerides|Serum total Cholesterol|Serum HDL-c|Serum LDL-c|Body weight|Height|Blood pressure|Creatinine|Uric acid|UCAR","Shanghai Jiao Tong University School of Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ruijin-20191101","December 10, 2019","August 15, 2020","November 15, 2020","November 15, 2019",,"December 13, 2019","Ruijin hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04164784"
29,"NCT04155996","Data Acquisition Study in Inadequately Balanced Patients With Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Type2 Diabetes","Device: data collection","Data collection - Blood glucose levels|Data collection - Number of steps|Data collection - Sleep hours|Data collection - Daily meals information|Data collection - Physical activity information|Data collection - Medical treatment information","ValoTec|APHP","All","35 Years and older   (Adult, Older Adult)",,"20","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","VTC-MLS-EC01","January 20, 2019","December 31, 2019","December 31, 2019","November 7, 2019",,"November 13, 2019","GH Pitié Salpêtrière Charles Foix, Paris, Ile De France, France",,"https://ClinicalTrials.gov/show/NCT04155996"
30,"NCT04181424","Lowering the Impact of Food Insecurity in African American Adults With Type 2 Diabetes Mellitus (LIFT-DM)","LIFT-DM","Active, not recruiting","No Results Available","Type 2 Diabetes","Behavioral: Diabetes Education Plus Monthly Food Vouchers|Behavioral: Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes|Behavioral: Diabetes Education Only|Behavioral: Diabetes Education Plus Monthly Stock Boxes","Glycemic control (HbA1c)|Quality of Life as measured by the SF-12|LDL-Cholesterol|Blood Pressure","Medical College of Wisconsin","All","21 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","5R01MD013826","December 15, 2019","December 31, 2023","December 31, 2023","November 29, 2019",,"May 6, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04181424"
31,"NCT03982238","Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients",,"Completed","No Results Available","Type 2 Diabetes","Drug: Insulin|Drug: Metformin|Drug: Dapagliflozin","total testosterone levels|bioavailable testosterone|free testosterone","Majianhua|Nanjing First Hospital, Nanjing Medical University","Male","18 Years to 60 Years   (Adult)","Phase 4","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY20190530-12","June 15, 2019","November 15, 2019","December 31, 2019","June 11, 2019",,"April 3, 2020","Nanjing First Hospital, Nanjing, China",,"https://ClinicalTrials.gov/show/NCT03982238"
32,"NCT04031417","Effect of a Simulated Flight in Patients With Type 2 Diabetes and Healthy Volunteers","FlyBar","Completed","No Results Available","Type 2 Diabetes","Other: Hypoxia|Other: Low Humidity","Hypoxia and low humidity on the endothelial function in healthy volunteers and patients with type 2 diabetes using Wilcoxon signed rank test","Hull University Teaching Hospitals NHS Trust","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R1276","March 2013","January 2014","January 2015","July 24, 2019",,"July 24, 2019",,,"https://ClinicalTrials.gov/show/NCT04031417"
33,"NCT03861052","A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes","SURPASS J-mono","Active, not recruiting","No Results Available","Type 2 Diabetes","Drug: Tirzepatide|Drug: Dulaglutide","Change from Baseline in Hemoglobin A1c (HbA1c)|Percentage of Participants with HbA1c of <7.0%|Change from Baseline in Fasting Serum Glucose|Change from Baseline in Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Change from Baseline in Body Weight|Percentage of Participants who Achieve Weight Loss ≥5% from Baseline|Change from Baseline in Fasting Insulin|Change from Baseline in Fasting C-Peptide|Change from Baseline in Homeostasis Model Assessment B (HOMA-2B)|Change from Baseline in HOMA-2S|Rate of Total Hypoglycemia|Number of Participants with Anti-Tirzepatide Antibodies","Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 3","636","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17077|I8F-JE-GPGO","May 7, 2019","March 17, 2021","April 14, 2021","March 4, 2019",,"April 22, 2020","Medical corporation THY Tokuyama Clinic, Chiba Mihama-ku, Chiba, Japan|Akaicho Clinic, Chiba-shi, Chiba, Japan|National Hospital Organization Kure Medical Center, Kure, Hiroshima, Japan|Hasegawa Medicine Clinic, Chitose, Hokkaido, Japan|Yuri Ono Clinic, Sapporo, Hokkaido, Japan|Watanabe Naika Clinic, Nishinomiya, Hyogo, Japan|Hayashi Clinic, Nishinomiya, Hyogo, Japan|Naka Memorial Clinic, Naka, Ibaraki, Japan|Hayashi Diabetes Internal Medicine, Chigasaki-sh, Kanagawa, Japan|Matoba Diabetes Clinic, Ebina, Kanagawa, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Kanto Rosai Hospital, Kawasaki, Kanagawa, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan|H.E.C. Science Clinic, Yokohama, Kanagawa, Japan|OCROM Clinic, Suita, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Senrichuo Ekimae Clinic, Toyonaka, Osaka, Japan|Asano Clinic, Kawagoe, Saitama, Japan|Kawaguchi General Hospital, Kawaguchi, Saitama, Japan|Wakakusa Clinic, Shimotsuke, Tochigi, Japan|Seiwa Clinic, Adachi-ku, Tokyo, Japan|Meiwa Hospital, Chiyodaku, Tokyo, Japan|HDC Atlas Clinic, Chiyoda, Tokyo, Japan|Asahi Life Foundation Adult Disease Research Center, Chuo-ku, Tokyo, Japan|Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan|Sato Naika Clinic, Ota-ku, Tokyo, Japan|Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan|Tomonaga Clinic, Shinjuku-ku, Tokyo, Japan|Shinjuku Research Park Clinic, Shinjuku-Ku, Tokyo, Japan|Shinei Clinic, Suginami, Tokyo, Japan|Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan|Futata Tetsuhiro Clinic, Fukuoka, Japan|JR Hiroshima Hospital, Hiroshima, Japan|Yoshimura Clinic, Kumamoto, Japan|Keiseikai Kajiyama Clinic, Kyoto, Japan|Abe Diabetes Clinic, Oita, Japan|OKAYAMA Medical Center, Okayama, Japan|AMC nishi-umeda clinic, Osaka, Japan|Kitada Clinic, Osaka, Japan|Nanko Clinic, Osaka, Japan|Suruga Clinic, Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT03861052"
34,"NCT04105608","GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients.","VAS","Completed","No Results Available","Type-2 Diabetes","Dietary Supplement: High-fiber vegetarian meal|Dietary Supplement: Mediterranean-like meal","Changes in serum GLP-1 concentration|Changes in plasma oxyntomodulin concentration|Serum glucose and insulin levels|Hunger-satiety scores (millimeters)","Antonio Di Mauro|Campus Bio-Medico University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08/2017","November 1, 2017","December 1, 2017","February 28, 2018","September 26, 2019",,"September 26, 2019","Campus Bio-Medico University of Rome, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04105608"
35,"NCT04092569","Effectiveness of Pre-medical Consultation Diabetes Self-care Education Programme on Glycemic Control in Type 2 Diabetes","PMC-SEP","Recruiting","No Results Available","Type 2 Diabetes","Behavioral: Pre-medical consultation structured diabetes self-care education programme","Change from Baseline Blood Glycosylated haemoglobin, HbA1c at 6 months|Change from Baseline Blood Glycosylated haemoglobin, HbA1c at 9 months|The Chinese version of the Diabetes Management Self-Efficacy Scale Questionnaire|The Chinese version of the Diabetes Empowerment Scale Questionnaire - Short Form","Chinese University of Hong Kong","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2019.255","September 10, 2019","December 31, 2020","December 31, 2020","September 17, 2019",,"September 25, 2019","Diabetes Centre, Alice Ho Miu Ling Nethersole Hospital, Tai Po, New Territories, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04092569"
36,"NCT03883412","Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)","ZQL007","Recruiting","No Results Available","Type2 Diabetes","Other: Exercise|Drug: Liraglutide","Microvascular Blood Volume - change from baseline|Augmentation Index - change from baseline|Flow Mediated Dilation - change from baseline|Pulse Wave Velocity - change from baseline|Post Ischemic Flow Velocity-Change from baseline|Insulin Sensitivity-Change from baseline","University of Virginia|American Diabetes Association|National Institutes of Health (NIH)","All","21 Years to 60 Years   (Adult)","Phase 4","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20320","February 28, 2019","March 2022","March 2022","March 20, 2019",,"March 20, 2019","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03883412"
37,"NCT04025281","Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes","Other: Extra Virgin Olive Oil|Other: Refined Olive Oil","Endothelial Function (EF) Assessment|Office Blood Pressure","Griffin Hospital","All","25 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2018-12","July 9, 2019","August 22, 2019","August 22, 2019","July 18, 2019",,"March 30, 2020","Yale-Griffin Prevention Research Center, Derby, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04025281"
38,"NCT04057677","Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes","RECOVER","Recruiting","No Results Available","Type 2 Diabetes","Other: Bed Rest Intervention|Other: Resistance Exercise Program","Change in leg lean mass measured at 5 time points|Change in protein synthesis rate assessed in muscle biopsy specimens using deuterium oxide, and also a mathematical model|Change in mitochondrial respiration measured in permeabilized muscle fibers using the Oxygraph 2K system","Translational Research Institute for Metabolism and Diabetes, Florida","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1461891","December 20, 2019","May 2023","May 2023","August 15, 2019",,"March 10, 2020","AdventHealth Translational Research Institute, Orlando, Florida, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT04057677/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04057677"
39,"NCT03982381","SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes","SMARTEST","Recruiting","No Results Available","Type 2 Diabetes","Drug: Metformin|Drug: Dapagliflozin 10 MG","Time to first occurence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer.|Ordinal analysis of components of primary endpoint (see above)|Time to first occurence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer (ICD10 diagnosis codes) or initiation of insulin treatment.|Time to first occurence of a confirmed composite endpoint of non-fatal myocardial infarction, stroke, heart failure, unstable angina or cardiovascular death.|Time to first occurence of a confirmed composite endpoint of heart failure or cardiovascular death.|Death|Microvascular events, first of; occurrence or progression of retinopathy, nephropathy, diabetic foot lesions|Need for insulin treatment|Treatment failure, defined as add-on or switch to another glucose-lowering drug|Change in glycemic control|Change in LDL-cholesterol|Change in HDL-cholesterol|Change in total cholesterol|Change in triglycerides|Change in albuminuria|Change in blood pressure|Change in body weight|Change in BMI|Health care costs|Health-related quality of life|Health-related quality of life with respect to diabetes treatment satisfaction.","Uppsala University|Uppsala University Hospital|Swedish Healthcare Regions|Swedish National Board of Health and Welfare|The Swedish National Diabetes Register","All","18 Years and older   (Adult, Older Adult)","Phase 4","4300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SMART-2019|2019-001046-17","September 5, 2019","December 31, 2023","September 20, 2024","June 11, 2019",,"March 24, 2020","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT03982381"
40,"NCT04001231","Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus",,"Withdrawn","No Results Available","Type 2 Diabetes","Drug: Exenatide Once-Weekly Suspension","Plasma concentrations versus time profile of exenatide|Cmax|tmax|AUC(0-8h)|AUC(0-168h)|AUCτ,ss|Cav,ss|λ z|t½|CL/F|Vss/F|Rac|Ctrough|Electrocardiograms (ECGs)|Blood pressure (BP)|Pulse rate|Body temperature|Safety and tolerability as determined by abnormality in clinical chemistry compared to baseline.|Safety and tolerability as determined by abnormality in hematology compared to baseline.|Safety and tolerability as determined by abnormality in urinalysis compared to baseline.|Fasting blood glucose|Calcitonin|Number of subjects with adverse events|The presence and titer of anti-exenatide antibodies","AstraZeneca","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","D5553C00008","June 30, 2020","July 2, 2021","July 2, 2021","June 28, 2019",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04001231"
41,"NCT03990857","Comprehensive Care Protocol in New Diagnosis of Type 2 Diabetes Mellitus and Associated Comorbidities in Primary Care","PICDM2","Active, not recruiting","No Results Available","Type 2 Diabetes","Other: Comprehensive care protocol in new diagnosis of Type 2 Diabetes Mellitus and associated comorbidities in Primary Care","Change is being assessed in Health Related Quality of Life will be measured through the EuroQoL (EQ-5D)|HbA1c|Change is being assessed in Weigh|Dietary habits: PREDIMED|Physical activity: IPAQ|Use of services in the last year","Jordi Gol i Gurina Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","123","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","4R16/045","September 1, 2019","September 30, 2021","September 30, 2021","June 19, 2019",,"January 10, 2020","Institut català de la salut, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03990857"
42,"NCT03987919","A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes","SURPASS-2","Active, not recruiting","No Results Available","Type 2 Diabetes","Drug: Tirzepatide|Drug: Semaglutide","Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)|Change from Baseline in HbA1c (5 mg)|Change from Baseline in Body Weight|Percentage of Participants Achieving an HbA1c Target Value of <7%|Change from Baseline in Fasting Serum Glucose|Mean Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Change from Baseline in Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Rate of Documented Symptomatic Hypoglycemic Episodes","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1872","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17001|I8F-MC-GPGL|2018-004422-29","July 30, 2019","January 26, 2021","February 23, 2021","June 17, 2019",,"June 4, 2020","Cahaba Research, Birmingham, Alabama, United States|Syed Research Consultants, LLC, Sheffield, Alabama, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|National Research Institute, Panorama City, California, United States|Artemis Institute for Clinical Research, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, LLC, Hamden, Connecticut, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|East Coast Institute For Research, Lake City, Florida, United States|South Florida Wellness & Clinical Research Institute, Margate, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|South Broward Research LLC, Pembroke Pines, Florida, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Sky Clinical Research Network, Union City, Georgia, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|University of Iowa Hospital & Clinic, Iowa City, Iowa, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Clinvest Research LLC, Springfield, Missouri, United States|Premier Research, Trenton, New Jersey, United States|Endocrine Group, LLP, Albany, New York, United States|PharmQuest, Greensboro, North Carolina, United States|Diabetes & Endocrinology Consultants PC, Morehead City, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Aventiv Research, Columbus, Ohio, United States|Intend Research, Norman, Oklahoma, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Capital Area Research, Camp Hill, Pennsylvania, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Green & Seidner Family Practice Associates PC, Lansdale, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians- Bower Hill, Pittsburgh, Pennsylvania, United States|Holston Medical Group, Bristol, Tennessee, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Biopharma Informatic, Inc., Houston, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Carl R. Meisner Medical Clinic, PLLC, Sugar Land, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Capital Clinical Research Center, Olympia, Washington, United States|Vancouver Clinic, Vancouver, Washington, United States|Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L., Caba, Buenos Aires, Argentina|Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada, Caba, Buenos Aires, Argentina|CEDIC-Centro de Investigaciones Clinicas, Caba, Buenos Aires, Argentina|Mautalen Salud e Investigacion-Centro de Osteopatías Médicas, Ciudad Autonoma De Buenos Air, Buenos Aires, Argentina|Centro de Investigacion y Prevencion Cardiovascular (CIPREC), Ciudad Autonoma de, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|CIPADI, Godoy Cruz, Mendoza, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Buenos Aire, Argentina|Instituto Centenario, Ciudad Autonoma de Buenos Aire, Argentina|Cemediab - Centro Médico Diabetológico Dr. Alejandro Chertkoff, Ciudad Autonoma de Buenos Aire, Argentina|Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina|Sanatorio Norte, Santiago del Estero, Argentina|Paratus Clinical Blacktown Clinic, Blacktown, New South Wales, Australia|Campbelltown Medical & Dental Centre, Campbelltown, New South Wales, Australia|Paratus Clinical Kanwal Clinic, Kanwal, New South Wales, Australia|Holdsworth House Medical Practice, Sydney, New South Wales, Australia|GenesisCare - Bundaberg, Bundaberg, Queensland, Australia|Royal Brisbane and Womens Hospital, Herston, Queensland, Australia|CORE Research Group Pty Ltd, Milton, Queensland, Australia|AusTrials Pty Ltd, Taringa, Queensland, Australia|Eastern Clinical Research Unit, Box Hill, Victoria, Australia|Barwon Health - The Geelong Hospital, Geelong, Victoria, Australia|GenesisCare Joondalup WA, Joondalup, Western Australia, Australia|GenesisCare - Wexford Medical Centre WA, Murdoch, Western Australia, Australia|Adelaide Medical Solutions, Woodville South, Australia|Cedoes Centro Diagnostico Pequisa Osteoporose E Santo Ltd, Vitoria, ES, Brazil|Centro de Pesquisas em Diabetes, Porto Alegre, Rio Grande Do Sul, Brazil|CPQuali Pesquisa Clínica Ltda., São Paulo, SP, Brazil|Cpclin Centro de Pesquisas Clinicas, São Paulo, SP, Brazil|CEPIC-Centro Paulista de Investigacao Clinica, São Paulo, SP, Brazil|ISPEM - Instituto São José dos Campos em Pesquisas Médicas, São José dos Campos, Brazil|Dr. Consulta Clínica Médica LTDA, São Paulo, Brazil|Manna Research, Inc., Burlington, Ontario, Canada|Milestone Research Inc., London, Ontario, Canada|Manna Research, Inc., Nepean, Ontario, Canada|Bluewater Clinical Research Group Inc, Sarnia, Ontario, Canada|Manna Research, Inc., Stoney Creek, Ontario, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Toronto, Ontario, Canada|Manna Research, Inc., Toronto, Ontario, Canada|Manna Research (Quebec), Levis, Quebec, Canada|Meir Medical Center, Kfar Saba, HaMerkaz, Israel|Clalit Health Services - Shuali Clinic, Raanana, HaMerkaz, Israel|Sheba Medical Center, Ramat Gan, HaMerkaz, Israel|Hadassah Medical Center, Jerusalem, Yerushalayim, Israel|Sakhnin Community Clinic, Clalit Health Services, Sakhnin, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv Jaffa, Israel|Diabetes Medical Center (DMC), Tel Aviv, Israel|Rambam Health Care Campus, Haifa, Ḥeifā, Israel|Linn Medical Center, Haifa, Ḥeifā, Israel|Centro Especializado en Diabetes Obesidad y Enfermedades, Mexico, D.f., Mexico|Diseno y Planeacion en Investigacion Medica S.C., Guadalajara, Jalisco, Mexico|Unidad de Investigacion Clinica, Guadalajara, Jalisco, Mexico|Instituto Jalisciense de Investigacion en Diabetes y Obesida, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Unidad Medica para la Salud Integral (UMSI), San Nicolás de los Garza, Nuevo León, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasc, Ciudad Madero, Tamaulipas, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Paola Mansilla-Letelier, MD, Guaynabo, Puerto Rico|Ararat Research Center, Ponce, Puerto Rico|Research and Cardiovascular Corp., Ponce, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|Martha Gomez Cuellar M.D., San Juan, Puerto Rico|Oldfield Surgery, Bath, Avon, United Kingdom|The Staploe Medical Centre, Ely, Cambridgeshire, United Kingdom|Fowey River Practice, Fowey, Cornwall, United Kingdom|Oak Tree Surgery, Liskeard, Cornwall, United Kingdom|Rame Medical Ltd, Torpoint, Cornwall, United Kingdom|Ashgate Medical Practice, Chesterfield, Derbyshire, United Kingdom|Knowle House Surgery, Plymouth, Devon, United Kingdom|Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom|Lister Hospital, Stevenage, Herts, United Kingdom|Oakenhurst Medical Practice, Blackburn, Lancashire, United Kingdom|Leicester General Hospital, Leicester, Leicestershire, United Kingdom|University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Warwickshire, United Kingdom|Rowden Surgery, Chippenham, United Kingdom|Wickersley Health Centre - Clifton Medical Centre, Rotherham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03987919"
43,"NCT04093752","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)",,"Recruiting","No Results Available","Type 2 Diabetes","Drug: Tirzepatide|Drug: Insulin Glargine","Mean Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)|Mean Change from Baseline in HbA1c (5 mg)|Mean Change from Baseline in Body Weight|Mean Change from Baseline in HbA1c|Percentage of Participants Achieving an HbA1c Target Value of <7.0%|Mean Change from Baseline in Fasting Serum Glucose|Mean Change from Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Change from Baseline in Patient-Reported Outcomes as Measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Rate of Documented Symptomatic Hypoglycemic Episodes","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","956","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17210|I8F-MC-GPHO","December 9, 2019","February 10, 2022","March 10, 2022","September 18, 2019",,"June 4, 2020","Paratus Clinical Blacktown Clinic, Blacktown, New South Wales, Australia|Campbelltown Medical & Dental Centre, Campbelltown, New South Wales, Australia|Paratus Clinical Kanwal Clinic, Kanwal, New South Wales, Australia|Holdsworth House Medical Practice, Sydney, New South Wales, Australia|Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia|Barwon Health - The Geelong Hospital, Geelong, Victoria, Australia|Adelaide Medical Solutions, Woodville South, Australia|The Second People's Hospital of Hefei, Hefei, Anhui, China|Peking University Peoples Hospital, Beijing, Beijing, China|Huizhou Municipal Central Hospital, Huizhou, Guangdong, China|CANGZHOU People's Hospital, Cangzhou, Hebei, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The 1st Affiliated Hospital of Henan Science and technology, Luoyang, Henan, China|Wuhan Union (Xiehe) Hospital, Wuhan, Hubei, China|The First People Hospital of Yueyang, Yueyang, Hunan, China|Baotou Central Hospital, Bao Tou, Inner Mongolia, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|The Affliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China|The First Hospital of Nanjing, Nanjing, Jiangsu, China|Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Suzhou Municipal Hospital, Suzhou, Jiangsu, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|Dalian University - The Affiliated Zhongshan Hospital, Dalian, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|1st affiliated Hospital of Shanxi Medical University, Tai Yuan, Shan XI, China|Jinan Central Hospital, Jinan, Shandong, China|Qingdao Central Hospital, Qingdao, Shandong, China|Shanghai 6th People's Hospital Affiliated to Jiao Tong, Shanghai, Shanghai, China|Shanghai Tongren Hospital, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi'an Medical University, XI 'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Chengdu Fifth People's Hospital, Chengdu, Sichuan, China|Chongqing Three Gorges Central Hospital, Chongqing, Wanzhou, China|Chongqing General Hospital, Chongqing, Yuzhong District, China|Huzhou Central Hospital, Huzhou, Zhejiang, China|Shaoxing People's Hospital, Shaoxing, Zhejiang, China|Peking Union Medical College Hospital, Beijing, China|Beijing Pinggu Hospital, Beijing, China|Beijing Tsinghua Changgung Hospital, Beijing, China|The Third Hospital of Nanchang, Nanchang, China|Pingxiang People's Hospital, Pingxiang, China|Shanghai Putuo District Center Hospital, Shanghai, China|Shanghai Yangpu District Central Hospital, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|Tianjin People's Hospital, Tianjin, China|The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China|The Fourth People's Hospital of Zigong City, Zigong, China|King Edward Memorial Hospital and Research Center, Mumbai, Maharashtra, India|BSES Municipal General Hsptl, Mumbai, Maharashtra, India|Apollo Gleneagles Hospitals, Kolkata, West Bengal, India|Fortis Hospital, New Delhi, India|Kyung Hee University Hospital, Seoul, Gangdong-gu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Geonggi-do, Korea, Republic of|Bucheon St. Mary's Hospital, Bucheon,, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Yonse University Wonju Severance Christian Hospital, Gangwon-do, Kang Won-do, Korea, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Korea University Anam Hospital, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Taegu-Kwangyǒkshi, Korea, Republic of|Korea University Ansan Hospital, Kyunggi-Do, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04093752"
44,"NCT04053959","Effect of Artificial Intelligence Assisted Insulin Titration System on Glucose Control in Type 2 Diabetes Mellitus Patients",,"Not yet recruiting","No Results Available","Type 2 Diabetes","Drug: AI assisted insulin system|Drug: Physician based insulin regime","Proportion of time in which the blood glucose level is well controlled|Proportion of time in which the blood glucose level is over 10 mmol/L|Proportion of time in which the blood glucose level is below 3.9 mmol/L|Total insulin dose","Shanghai Zhongshan Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCDSS","August 15, 2019","September 7, 2019","November 15, 2019","August 13, 2019",,"August 13, 2019",,,"https://ClinicalTrials.gov/show/NCT04053959"
45,"NCT04039503","A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin","SURPASS-5","Active, not recruiting","No Results Available","Type 2 Diabetes","Drug: Tirzepatide|Drug: Placebo","Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)|Change from Baseline in HbA1c|Change from Baseline in Body Weight|Percentage of Participants Achieving an HbA1c Target Value of <7%|Change from Baseline in Fasting Serum Glucose|Mean Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Change from Baseline in Daily Mean Insulin Glargine Dose|Rate of Documented Symptomatic Hypoglycemic Episodes|Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","472","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16998|I8F-MC-GPGI|2019-000860-99","August 30, 2019","January 25, 2021","January 25, 2021","July 31, 2019",,"June 4, 2020","Valley Endocrine, Fresno, Fresno, California, United States|Sun Coast Clinical Research, Inc, New Port Richey, Florida, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Manhattan Medical Research, New York, New York, United States|Intend Research, Norman, Oklahoma, United States|Milan Kvapil s.r.o., Pribram, Středočeský Kraj, Czechia|Diacentrum Brandys n.L. s.r.o., Brandys Nad Labem-Stara Bolesl, Czechia|Diabetologicka ordinace pro dospele, Krnov, Czechia|Diahelp s.r.o., Interni a diabetologicka ambulance, Pardubice, Czechia|Lekarna Dr. Max, Praha 1, Czechia|Milan Kvapil s.r.o., Praha 4, Czechia|RESTRIAL s.r.o., Praha 8, Czechia|Praxis Dr. Jörg Lüdemann, Falkensee, Brandenburg, Germany|Arztpraxis Dr. Cornelia Marck, Pohlheim, Hessen, Germany|InnoDiab Forschung GmbH, Essen, Nordrhein-Westfalen, Germany|Institut für Diabetesforschung Münster GmbH, Münster, Nordrhein-Westfalen, Germany|Praxis Dr. Kempe - Dr. Stemler, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany|Schwerpunktpraxis Diabetes, Saint Ingbert-Oberwürzbach, Saarland, Germany|SMO.MD GmbH, Magdeburg, Sachsen-Anhalt, Germany|RED-Institut GmbH, Oldenburg in Holstein, Schleswig Holstein, Germany|Diabetologische Schwerpunktpraxis B. Scholz/Dr. B. Paschen, Hamburg, Germany|Gemeinschaftspraxis für innere Medizin und Diabetologie, Hamburg, Germany|Kashiwa hospital, Kashiwa, Chiba, Japan|Manda Hospital, Sapporo, Hokkaido, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|The Institute for Adult Diseases, Asahi Life Foundation, Chuou-ku, Tokyo, Japan|Sato Naika Clinic, Ota-ku, Tokyo, Japan|Jinnouchi Hospital, Kumamoto, Japan|Centrum Medyczne AMED, Warszawa, Mazowieckie, Poland|NZOZ ZDROWIE Osteo-Medic, Bialystok, Podlaskie, Poland|Centrum Badan Klinicznych, PI House, Gdansk, Pomorskie, Poland|NZOZ Przychodnia Specjalistyczna MEDICA, Lublin, Poland|Centro de Endocrinologia y Nutricion del Turabo, Caguas, Puerto Rico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Ambulancia vnútorného lekárstva Hnúša (Diabetes care), Hnusta, Slovakia|Sin Azucar, Malacky, Slovakia|Dia-Clarus.s.r.o., Prievidza, Slovakia|JAL, Trnava, Slovakia|Medivasa, s.r.o., Zilina, Slovakia|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Andalucia, Spain|Hospital de la Ribera, Alcira, Valencia, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Infanta Luisa, Sevilla, Spain|Hospital Universitari i Politecnic La Fe-ENDO, València, Spain",,"https://ClinicalTrials.gov/show/NCT04039503"
46,"NCT04170998","Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control",,"Not yet recruiting","No Results Available","Type2 Diabetes","Drug: Evogliptin 5mg|Drug: Evogliptin Placebo|Drug: Dapagliflozin 10mg|Drug: Metformin ≥ 1000mg","Change from baseline in HbA1c (%) After 24 weeks|Change from baseline in FPG(mg/dL) After 24 weeks|Change from baseline in HbA1c response rate(<7.0% ,<6.5%) After 24 weeks|Change from baseline in 7-point SMBG After 24 weeks","Dong-A ST Co., Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 3","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DA1229_DMTD_III","November 14, 2019","July 30, 2022","July 30, 2022","November 20, 2019",,"November 20, 2019","Seoul St, Mary's Hospital,The Catholic University of Korea, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04170998"
47,"NCT04090580","Impact on Glycemic Variability After Treatment With Dapagliflozin on Type 2 Diabetes Patients",,"Recruiting","No Results Available","Type 2 Diabetes","Diagnostic Test: Continuous glucose monitoring","Impact of dapagliflozin in glycemic variability|Impact of dapagliflozin in insulin level concentration|Impact of dapagliflozin in Hba1c|Impact of dapagliflozin on patients weight|Impact of dapagliflozin in blood pressure|Impact of dapagliflozin in waist circumference","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|AztraZeneca","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 4","36","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3089","August 27, 2019","May 27, 2020","August 27, 2020","September 16, 2019",,"February 28, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ''INCMNSZ'', Ciudad de mexico, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04090580/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04090580/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04090580"
48,"NCT04163757","The Effects of Crocin Supplementation on Metabolic Parameters, Oxidative Stress, AMP- Activated Protein Kinase and Inflammation-promoting Genes Expression in Peripheral Blood Mononuclear Cells in Patients With Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes","Dietary Supplement: crocin|Dietary Supplement: placebo","type 2 diabetes","National Nutrition and Food Technology Institute|Vahideh Behrouz|Ali Dastkhosh","All","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","899","January 20, 2019","March 6, 2019","June 3, 2019","November 15, 2019",,"November 15, 2019","National Nutrition and Food Technology Research Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04163757"
49,"NCT04006028","Kidney Biopsy Indications in Type 2 Diabetes Patients","RIB-R2D2","Recruiting","No Results Available","Type 2 Diabetes, Chronic Kidney Disease",,"Non-diabetic renal disease|Renal survival|Patient survival","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","35RC19_30031_RIB-R2D2","June 6, 2019","September 6, 2019","September 6, 2019","July 2, 2019",,"July 2, 2019","AP-HM, Hôpital de la Conception, Marseille, France|AP-HP, Hôpital Bichat-Claude Bernard, Paris, France|AP-HP, Hôpital Necker-Enfants Malades, Paris, France|Rennes University Hospital, Rennes, France|Hôpital Bretonneau, Tours, France",,"https://ClinicalTrials.gov/show/NCT04006028"
50,"NCT04091854","The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type2 Diabetes Mellitus","Drug: HMS5552","HbA1c|Fasting glucose|Postprandial glucose|C peptide|TNF-α|IL-6|8-iso PGF2α","Majianhua|Nanjing First Hospital, Nanjing Medical University","All","18 Years to 80 Years   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KY20190530-01-KS-01","September 16, 2019","March 31, 2021","June 30, 2021","September 17, 2019",,"September 17, 2019",,,"https://ClinicalTrials.gov/show/NCT04091854"
51,"NCT04195243","Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Dapagliflozin Pill|Drug: Empagliflozin Pill|Drug: Placebo pill","Flow Mediated Dilation|Fasting plasma glucose|Total cholesterol|Triglycerides|High-density lipoprotein cholesterol|Low-density lipoprotein cholesterol|Creatinine|Blood pressure","Centro Universitario de Ciencias de la Salud, Mexico","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 3","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","CUCS-INTEC-MV-HADES-001","December 2, 2019","June 29, 2020","December 30, 2020","December 11, 2019",,"December 11, 2019","Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico",,"https://ClinicalTrials.gov/show/NCT04195243"
52,"NCT03918148","Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","GIOIA","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: SGLT-2i|Drug: DPP-4i","Carotid intima-media thickness (CIMT)|Myocardial stiffness indexes|Urinary albumin to creatinine ratio excretion|Weight|Body mass index (BMI)|Waist circumference (WC)|Blood pressure|estimated Glomerular filtration rate (eGFR)","University of Campania ""Luigi Vanvitelli""","All","35 Years to 75 Years   (Adult, Older Adult)",,"555","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2193/2018","January 15, 2018","December 31, 2023","December 31, 2025","April 17, 2019",,"April 17, 2019","Unit of Diabetes, Naples, Campania, Italy",,"https://ClinicalTrials.gov/show/NCT03918148"
53,"NCT03901248","Study of Association of Salivary Adipokines With Prediabetes and Type 2 Diabetes Mellitus",,"Completed","No Results Available","Type2 Diabetes Mellitus","Other: No Intervention","Interrelationship of adipokines such as adiponectin, apelin, visfatin and vaspin in different glycaemic stages|Change in BMI|Change in Blood Pressure|Change in fasting blood glucose|Change in postprandial blood glucose|Comparative assessment of the sensitivity of the assays of the biomarkers in saliva and serum|Levels of these biomarkers in the presence of periodontitis|Change in HbA1c","India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","All","35 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IDRFARH005","July 2015","September 2019","December 2019","April 3, 2019",,"January 10, 2020",,,"https://ClinicalTrials.gov/show/NCT03901248"
54,"NCT04029480","Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Ertugliflozin 5 mg|Drug: Ertugliflozin 15 mg|Drug: Placebo|Biological: Insulin|Drug: Metformin","Change from Baseline in Hemoglobin A1C (HbA1C) at 24 weeks|Number of Participants Who Experience an Adverse Event (AE)|Number of Participants Who Experience an AE|Number of Participants Who Discontinue Study Treatment Due to an AE|Change from Baseline in Fasting Plasma Glucose (FPG) at 24 Weeks|Change from Baseline in Hemoglobin A1C at 54 Weeks|Change from Baseline in FPG at 54 Weeks","Merck Sharp & Dohme Corp.|Pfizer","All","10 Years to 17 Years   (Child)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","8835-059|MK-8859-059|PHRR190913-002184","October 8, 2019","July 10, 2025","July 10, 2025","July 23, 2019",,"June 5, 2020","The University of Alabama at Birmingham ( Site 2207), Birmingham, Alabama, United States|Children's Hospital - Los Angeles ( Site 2201), Los Angeles, California, United States|Center of Excellence in Diabetes and Endocrinology ( Site 2203), Sacramento, California, United States|Joe Dimaggio Children's Hospital ( Site 2217), Hollywood, Florida, United States|ICCT Research International, Inc. ( Site 2211), Chicago, Illinois, United States|Barry J. Reiner MD LLC ( Site 2204), Baltimore, Maryland, United States|William Beaumont Hospital ( Site 2219), Royal Oak, Michigan, United States|CHEAR Center LLC ( Site 2200), Bronx, New York, United States|The Children's Hospital of Philadelphia ( Site 2205), Philadelphia, Pennsylvania, United States|Southern Endocrinology and Associates PA ( Site 2218), Mesquite, Texas, United States|Cliniques Universitaires Saint-Luc ( Site 2300), Brussels, Bruxelles-Capitale, Region De, Belgium|London Health Sciences Centre ( Site 0002), London, Ontario, Canada|Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0001), Montreal, Quebec, Canada|Centro De Diabetes Cardiovascular IPS Ltda ( Site 0101), Barranquilla, Atlantico, Colombia|MedPlus Medicina Prepagada S.A. ( Site 0102), Bogota, Distrito Capital De Bogota, Colombia|Clinica Los Yoses ( Site 0200), San Jose, Costa Rica|Hospital Infantil Dr. Robert Reid Cabral ( Site 0300), Santo Domingo, Distrito Nacional (Santo Domingo), Dominican Republic|CHU du BOCAGE ( Site 0407), Dijon, Cote-d'Or, France|Consultorio Privado Dr. Geraldine Utrilla ( Site 0501), Chiquimula, Guatemala|Endopedia ( Site 0503), Guatemala, Guatemala|Clinicas Las Americas ( Site 0502), Guatemala, Guatemala|Pecsi Tudomanyegyetem Klinikai Kozpont Gyermekgyogyaszati Klinika ( Site 0708), Pecs, Baranya, Hungary|Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0705), Gyula, Bekes, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0701), Miskolc, Borsod-Abauj-Zemplen, Hungary|Szabolcs Szatmar Bereg Megyei Korhazak es Egyetemi Oktato korhaz ( Site 0704), Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary|Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0702), Budapest, Hungary|Semmelweis Egyetem II. sz. Gyermekgyogyaszati Klinika ( Site 0703), Budapest, Hungary|Soroka University Medical Center ( Site 0802), Beer Sheva, HaDarom, Israel|Armon M.C ( Site 0803), Haifa, Heifa, Israel|Rambam Medical Center ( Site 0801), Haifa, Heifa, Israel|The Edmond and Lily Safra Children s Hospital ( Site 0804), Ramat Gan, Tell Abib, Israel|Hadassah Mount Scopus ( Site 0800), Jerusalem, Yerushalayim, Israel|AOU Meyer ( Site 0901), Firenze, Italy|IRCCS G. Gaslini ( Site 0900), Genova, Italy|IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0903), Roma, Italy|Hospital Universiti Sains Malaysia ( Site 1102), Kubang Kerian, Kelantan, Malaysia|Hospital Taiping ( Site 1104), Taiping, Perak, Malaysia|Hospital Pulau Pinang. ( Site 1101), Georgetown, Pulau Pinang, Malaysia|University Malaya Medical Centre ( Site 1100), Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia|Hospital Putrajaya ( Site 1103), Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia|Unidad de Investigacion Clinica Cardiometabolica de Occidente ( Site 1007), Guadalajara, Jalisco, Mexico|Centro de Investigacion Medica de Occidente S.C. ( Site 1001), Zapopan, Jalisco, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 1003), Madero, Tamaulipas, Mexico|Centro de Atencion e Investigacion Clinica SC ( Site 1009), Aguascalientes, Mexico|Centro de Diagnostico Medicont S.A. de C.V ( Site 1006), Mexico City, Mexico|CAIMED Investigación en Salud S.A de C.V ( Site 1008), Mexico, Mexico|Radiologia Total SAPI de CV ( Site 1004), Queretaro, Mexico|Davao Doctors Hospital ( Site 1400), Davao, Davao Del Sur, Philippines|Institute for Studies on Diabetes Foundation Inc. ( Site 1402), Marikina, Rizal, Philippines|West Visayas State University Medical Center ( Site 1401), Iloilo, Philippines|Bashkir State Medical University Hospital ( Site 1603), Ufa, Baskortostan, Respublika, Russian Federation|Federal State Budget Institution Endocrinological Research Center ( Site 1611), Moscow, Moskva, Russian Federation|Children's City Clinical Hospital #1 ( Site 1604), Novosibirsk, Novosibirskaya Oblast', Russian Federation|Rostov Scientific Research Institution of Obstetrics and Pediatry ( Site 1606), Rostov-on-Don, Rostovskaya Oblast', Russian Federation|Samara City Pediatric Clinical Hospital n.a. N.N. Ivanova ( Site 1610), Samara, Samarskaya Oblast', Russian Federation|St.Petersburg State Pediatric Medical University ( Site 1600), Saint Petersburg, Sankt-Peterburg, Russian Federation|Kazan State Medical University ( Site 1601), Kazan, Tatarstan, Respublika, Russian Federation|Siberian State Medical University ( Site 1602), Tomsk, Tomskaya Oblast', Russian Federation|Voronezh State Medical University named after N.N.Burdenko ( Site 1608), Voronezh, Voronezskaja Oblast', Russian Federation|King Abdulaziz Medical City - Al Ahsa ( Site 1730), Al Ahsa, Ar Riyad, Saudi Arabia|King Abdul Aziz Medical City - AlRiyadh ( Site 1700), Riyadh, Ar Riyad, Saudi Arabia|King Abdul Aziz Medical City - AlRiyadh ( Site 1705), Riyadh, Ar Riyad, Saudi Arabia|King Salman bin Abdulaziz hospital - Al Riyadh ( Site 1720), Riyadh, Ar Riyad, Saudi Arabia|King Salman bin Abdulaziz hospital Al Riyadh ( Site 1710), Riyadh, Ar Riyad, Saudi Arabia|King Abdul Aziz Medical City. National Guard Health Affairs ( Site 1715), Jeddah, Makkah Al Mukarramah, Saudi Arabia|Hera General Hospital ( Site 1725), Mecca, Makkah Al Mukarramah, Saudi Arabia|Cukurova Uni. Tip Fakultesi ( Site 2403), Adana, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 2400), Istanbul, Turkey|Municipal Medical Institution Regional Children Clinical Hospital ( Site 1910), Chernivtsi, Chernivetska Oblast, Ukraine|MHI Regional Childrens Clinical Hospital ( Site 1908), Kharkiv, Kharkivska Oblast, Ukraine|Ukr Center of Endocrine Surgery and Transplatation MOH Ukraine ( Site 1903), Kyiv, Kyivska Oblast, Ukraine|Institute of Endocrinology and Metabolism n.a. Komissarenko ( Site 1905), Kyiv, Kyivska Oblast, Ukraine|Odessa Regional Children Clinical Hospital ( Site 1912), Odesa, Odeska Oblast, Ukraine|Vinnitsa Regional Endocrinology Dispensary, VNMU n.a. M.I.Pyrogov ( Site 1901), Vinnytsia, Vinnytska Oblast, Ukraine|Thumbay Hospital ( Site 2001), Ajman, 'Ajmān, United Arab Emirates|Dubai Diabetes Center ( Site 2002), Dubai, Dubayy, United Arab Emirates|Mediclinic City Hospital ( Site 2005), Dubai, Dubayy, United Arab Emirates|Al Jalila Children s Specialty Hospital ( Site 2004), Dubai, Dubayy, United Arab Emirates|Rashid Center For Diabetes and Research ( Site 2006), Ajman, United Arab Emirates|Royal London Hospital (Whitechapel) ( Site 2100), London, London, City Of, United Kingdom|West Middlesex University Hospital ( Site 2104), London, London, City Of, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04029480"
55,"NCT04153981","A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India",,"Suspended","No Results Available","Type 2 Diabetes Mellitus","Drug: Insulin Glargine","Number or Participants with Hypoglycemic Events|Basal Insulin Dose|Change from Baseline in Body Weight|Change from Baseline in Hemoglobin A1c (HbA1c)|Change from Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values|Change from Week 4 in Insulin Treatment Satisfaction Questionnaire (ITSQ)","Eli Lilly and Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","250","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17225|I4L-IN-ABEX","December 16, 2019","December 30, 2020","December 30, 2020","November 6, 2019",,"May 19, 2020","Sir Ganga Ram Hospital, New Delhi, Delhi, India|DIACARE, Ahemdabad, Gujarat, India|Gujarat Endocrine Center, Ahmedabad, Gujarat, India|Nirmal Hospital Private Limited, Surat, Gujarat, India|Government Medical College & Sir Sayajirao General Hospital, Vadodara, Gujarat, India|Sumandeep Vidhyapeeth & Dhiraj General Hospital, Vadodara, Gujarat, India|Bangalore Diabetes Center, Bangalore, Karnataka, India|Supe Heart & Diabetes Hospital & Research Centre, Nasik, Maharashtra, India|GSVM Medical College, Kanpur, Uttar Pradesh, India|Popular Hospital, Varanasi, Uttar Pradesh, India|Maharaja Agrasen Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT04153981"
56,"NCT04100473","Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus","T2DM","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Inhaled Human Insulin|Drug: Insulin Lispro (Humalog U-100)","Primary Pharmacokinetic Endpoint - PK 1|Primary Pharmacokinetic Endpoint - PK 2|Primary Pharmacodynamic Endpoint - PD 1|Primary Pharmacodynamic Endpoint - PD 2|Secondary Pharmacokinetic Endpoint - PK 1|Secondary Pharmacokinetic Endpoint - PK 2|Secondary Pharmacokinetic Endpoint - PK 3|Secondary Pharmacokinetic Endpoint - PK 4|Secondary Pharmacokinetic Endpoint - PK 5|Secondary Pharmacodynamic Endpoint - PD 1|Secondary Pharmacodynamic Endpoint - PD2|Secondary Pharmacodynamic Endpoint - PD3","Dance Biopharm Inc.|Profil Institut für Stoffwechselforschung GmbH","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Samba-04","April 23, 2018","August 11, 2018","August 1, 2019","September 24, 2019",,"September 24, 2019","Profil Mainz, Mainz, Malakoff-Passage, Germany",,"https://ClinicalTrials.gov/show/NCT04100473"
57,"NCT03862716","Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","REMITiDegLira","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: IDegLira|Drug: insulin degludec|Drug: Metformin|Behavioral: Lifestyle Therapy","Proportion of participants achieving drug-free diabetes remission|Proportion of participants achieving drug-free normoglycemia|Proportion of participants achieving drug-free diabetes regression","Population Health Research Institute|Novo Nordisk A/S","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 3","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REMITiDegLira","April 23, 2019","September 30, 2020","December 31, 2021","March 5, 2019",,"June 5, 2019","University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|McMaster University, Hamilton, Ontario, Canada|St. Joseph's Hospital, London, Ontario, Canada|Western University, London, Ontario, Canada|LMC Manna Research, Oakville, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03862716"
58,"NCT04120623","Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Dapagliflozin 10 MG|Drug: Insulin Aspart","the effect of dapagliflozin combined with CSII on glucose profile|the effects of dapagliflozin combined with CSII on weight|the effects of dapagliflozin combined with CSII on blood pressure|the effects of dapagliflozin combined with CSII on lipid metabolism(total cholesterol in mmol/l, total glyceride in mmol/l)","Nanjing First Hospital, Nanjing Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","KY20190926-03","October 1, 2019","December 31, 2019","February 28, 2020","October 9, 2019",,"October 9, 2019",,,"https://ClinicalTrials.gov/show/NCT04120623"
59,"NCT03986073","Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: TQ-F3083 capsule 10 mg|Drug: TQ-F3083 capsule 20 mg|Drug: TQ-F3083 blank analog capsule|Drug: Linagliptin blank analog tablet|Drug: Linagliptin tablet","Glycosylated hemoglobin (HbA1c)|Fasting plasma glucose (FPG)|2 hours-postprandial blood sugar (2h-PPG）|Weight|HbA1c|DPP-4 activity ( dipeptidyl peptidase-4)|GLP-1 (glucagon-like peptide-1)","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TQ-F3083-II-01","January 1, 2020","June 30, 2020","September 30, 2020","June 14, 2019",,"March 13, 2020","The Second Affiliated Hospital of Chongqing Medical Uversity, Chongqing, Chongqing, China|Chongqing General Hospital, UCAS, Chongqing, Chongqing, China|The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Yuncheng Central Hospital, Jinan, Shandong, China|Jincheng Geberal Hospital, Jincheng, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|The First People's Hospital of Yunnan Province, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT03986073"
60,"NCT03943940","BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients","T2DM","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Biological: BM-MNC and UC-MSC|Other: Control","The level of C-peptid and HOMA-β|The level of HOMA-IR and cytokines TNF-α, IL-1β|Blood glucose level|Hemoglobin A1c (HbA1c) level|Adverse events|Insulin dose and drug dosage","Van Hanh General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TNLS012019-TBG","April 24, 2019","December 30, 2019","August 30, 2020","May 9, 2019",,"May 10, 2019","Van Hanh General Hospital, Ho Chi Minh City, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03943940"
61,"NCT03952143","A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes",,"Suspended","No Results Available","Type 2 Diabetes Mellitus","Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Glargine|Drug: Insulin Degludec","Change from Baseline in Hemoglobin A1c (HbA1c)|1-hour Postprandial Glucose (PPG) Excursion during Mixed-Meal Tolerance Test (MMTT)|2-hour PPG Excursion during MMTT|Rate of Severe Hypoglycemia|Rate of Documented Symptomatic Postmeal Hypoglycemia|Change From Baseline in 1,5-Anhydroglucitol (1,5-AG)|Change from Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values|Change from Baseline in Insulin Dose|Proportion of Participants with HbA1c <7% and ≤6.5%","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","564","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16830|I8B-FH-ITSE","May 27, 2019","February 1, 2021","February 1, 2021","May 16, 2019",,"June 5, 2020","Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Buenos Aire, Argentina|Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|CANGZHOU People's Hospital, Cangzhou, Hebei, China|First hospital of Qinhuangdao, Qinhuangdao, Hebei, China|Xingtai People's Hospital, Xingtai, Hebei, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Hospital of Qiqihar, Qiqihar, Heilongjiang, China|The 1st Affiliated Hospital of Henan Science and technology, Luoyang, Henan, China|Wuhan Pu'ai Hospital, Wuhan, Hubei, China|Wuhan Central Hospital, Wuhan, Hubei, China|Yichang central people's hospital, Yichang, Hubei, China|Chenzhou NO.1 People's Hospital, Chenzhou, Hunan, China|The First People Hospital of Yueyang, Yueyang, Hunan, China|Inner Monglia People's Hospital, Hohhot, Inner Mongolia, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|The Affliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|The First Hospital of Nanjing, Nanjing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China|China-Japan Union Hospital, CJUH., Changchun, Jilin, China|Siping central people's hospital, Siping, Jilin, China|Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|Qinghai University Affiliated Hospital, Xining, Qinghai, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai 6th People's Hospital Affiliated to Jiao Tong, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi'an Medical University, XI 'an, Shanxi, China|Chongqing General Hospital, Chongqing, Yuzhong District, China|Peking Union Medical College Hospital, Beijing, China|Beijing Pinggu Hospital, Beijing, China|The Third Hospital of Nanchang, Nanchang, China|Pingxiang People's Hospital, Pingxiang, China|Shanghai Putuo District Center Hospital, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|Unidad de patologia Clinica, Guadalajara, Jalisco, Mexico|Centro de Inv. Medica de Occidente, SC, Zapopan, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Unidad Medica para la Salud Integral (UMSI), Monterrey, Nuevo León, Mexico",,"https://ClinicalTrials.gov/show/NCT03952143"
62,"NCT03952728","The Long-term Effects of an Intensive Lifestyle Intervention for Type 2 Diabetes on Medicare Outcomes",,"Active, not recruiting","No Results Available","Type 2 Diabetes Mellitus","Behavioral: Intensive lifestyle intervention|Behavioral: Diabetes support and education","Total inpatient (general hospital/acute care) discharges|Total inpatient (general hospital/acute care) days|Total number of emergency department visits|Medicare Part D Prescription Drug Fill Count|Total Medicare spending|Medicare inpatient payments|Medicare Part D drug payments|Medicare Part D drug costs|Medicare outpatient visits|Medicare hospital outpatient payments|Medicare Part B physician payments|Medicare SNF payments","University of Minnesota|University of Southern California|Wake Forest University","All","45 Years to 75 Years   (Adult, Older Adult)",,"3574","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","UP-16-00706","December 19, 2016","June 2021","June 2021","May 16, 2019",,"November 1, 2019",,,"https://ClinicalTrials.gov/show/NCT03952728"
63,"NCT03882970","A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes","SURPASS-3","Active, not recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Tirzepatide|Drug: Insulin Degludec","Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)|Change from Baseline in HbA1c|Change from Baseline in Body Weight|Change from Baseline in Fasting Serum Glucose|Percentage of Participants Achieving an HbA1c Target Value of <7%|Change from Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Change from Baseline in Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Rate of Documented Symptomatic Hypoglycemic Episodes","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16997|I8F-MC-GPGH|2018-003422-84","April 1, 2019","December 11, 2020","January 8, 2021","March 20, 2019",,"February 5, 2020","Arkansas Clinical Research, Little Rock, Arkansas, United States|Valley Research, Fresno, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|National Research Institute, Panorama City, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|East Coast Clinical Research, Jacksonville, Florida, United States|East Coast Institute For Research, Jacksonville, Florida, United States|Bayside Clinical Research, LLC, New Port Richey, Florida, United States|East Coast Institute For Research, Macon, Georgia, United States|Sky Clinical Research Network, Union City, Georgia, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|Humphreys Diabetes Center, Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Springfield Diabetes & Endocrine Center, Springfield, Illinois, United States|Crescent City Clinical Research, Metairie, Louisiana, United States|Endocrine and Metabolic Consultants, Rockville, Maryland, United States|Troy Internal Medicine, PC, Troy, Michigan, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Aventiv Research, Columbus, Ohio, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Office of Dr. Osvaldo Brusco, Corpus Christi, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Mautalen Salud e Investigación - Servicio de Endocrinología, Caba, Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L., Caba, Buenos Aires, Argentina|CEDIC-Centro de Investigaciones Clinicas, Caba, Buenos Aires, Argentina|Centro de Investigacion y Prevencion Cardiovascular (CIPREC), Ciudad Autonoma de, Buenos Aires, Argentina|CIPADI, Godoy Cruz, Mendoza, Argentina|AXISMED SRL - Bioclinica Research Network, Buenos Aires, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Buenos Aire, Argentina|Instituto Centenario, Ciudad Autonoma de Buenos Aire, Argentina|CENUDIAB, Ciudad Autonoma de Buenos Aire, Argentina|Landesklinikum Korneuburg-Stockerau, Standort Stockerau, Stockerau, Niederösterreich, Austria|Universitätsklinikum Graz, Graz, Steiermark, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|KA Rudolfstiftung, Wien, Austria|Iatriko Palaiou Falirou, Medical Center, Palaio Faliro, Athens, Greece|Laiko General Hospital of Athens, Ampelokipoi, Attica, Greece|Gen Hospital of Athens G Gennimatas, Athens, Attiki, Greece|General Hospital of Thessaloniki Papageorgiou, N. Efkarpia, Thessaloniki, Greece|Thermi Clinic, Thermi, Thessaloniki, Greece|Athens Euroclinic, Athens, Greece|University General Hospital of Larissa, Larissa, Greece|AHEPA Hospital, Thessaloniki, Greece|Ippokrateio General Hospital of Thessaloniki, Thessaloniki, Greece|Euromedica - General Clinic of Thessaloniki, Thessaloniki, Greece|Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hajdu-Bihar, Hungary|Szent Margit Rendelointezet, Budapest, Hungary|ClinDiab Kft., Budapest, Hungary|XIII.ker Onkormanyzat Egeszsegugyi Szolgalat, Budapest, Hungary|Strazsahegy Medicina Bt., Budapest, Hungary|TRANTOR 99 Bt., Budapest, Hungary|Kanizsai Dorottya Korhaz, Nagykanizsa, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Azienda ospedaliero-universitaria Mater Domini, Germaneto, Catanzaro, Italy|Policlinico Univ. Agostino Gemelli, Roma, Lazio, Italy|Centro Cardiologico Monzino, IRCCS, Milano, MI, Italy|Azienda Ospedaliera Policlinico Consorziale, Bari, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Ospedale Santa Maria Goretti, Latina, Italy|Bucheon St. Mary's Hospital, Bucheon,, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Korea, Republic of|Korea University Ansan Hospital, Ansan-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Kyunghee University Hospital at Gangdong, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ambulatorium Barbara Bazela, Elblag, Warminsko-Mazurki, Poland|NZOZ ZDROWIE Osteo-Medic, Bialystok, Poland|Poradnia Diabetologiczna SN ZOZ Lege Artis, Bialystok, Poland|NZOZ Diab-Endo-Met, Krakow, Poland|Gabinet Lekarski Malgorzata Saryusz-Wolska, Lodz, Poland|Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A., Lodz, Poland|NZOZ Przychodnia Specjalistyczna MEDICA, Lublin, Poland|NZOZ Przychodnia Specjalistyczna Henryk RudzkiAndrzej Wittek, Ruda Slaska, Poland|Latin Clinical Trial Center, San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|San Miguel Medical, Trujillo Alto, Puerto Rico|S. C. Grandmed S.R.L., Str., Oradea, Bihor, Romania|Spitalul Judetean de Urgenta Satu Mare, Satu-Mare, Jud Satu-Mare, Romania|SC Diamed Obesity SRL, Galati, Judetul Galati, Romania|CMI DNBM Dr. Pop Lavinia, Baia Mare, Maramures, Romania|Cosamext SRL, Targu Mures, Mures, Romania|Societatea Civila Medicala ""Dr. Paveliu"", Bucuresti, Sect.5, Romania|Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL, Brasov, Romania|Cabinetul Medical Nicodiab SRL, Bucharest, Romania|SC Nutrilife SRL, Bucuresti, Romania|Consultmed SRL, Iasi, Romania|Hospital Infanta Luisa, Sevilla, Andalucía, Spain|Hospital Universitario Marques De Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Instituto de Ciencias medicas, Alicante, Spain|Hospital Clinico Universitario San Cecilio, Granada, Spain|Clinica Juaneda, Palma de Mallorca, Spain|Clinica Nuevas Tecnologias en Diabetes y Endocrinologia, Seville, Spain|Policlinica Galileo, Teruel, Spain|Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung City, Taiwan|Taipei Medical University- Shuang Ho Hospital, New Taipei, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taiwan|Kuang Tien General Hospital, Taichung County, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi-Mei Medical Center, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Dnipro City Clinical Hospital #9, Dnipro, Ukraine|V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine, Kyiv, Ukraine|Communal Institution ""Poltava Reg.Cl.H. n.a.M.V.Sklifosovskogo"", Poltava, Ukraine|Vinnytsia Regional Clinical Highly Specialized Endocrinology Center, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03882970"
64,"NCT03861039","A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes",,"Active, not recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Tirzepatide","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Change from Baseline in Hemoglobin A1c (HbA1c)|Percentage of Participants who Achieve HbA1c <7%|Change from Baseline in Fasting Serum Glucose|Change from Baseline in Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Change from Baseline in Body Weight|Percentage of Participants who Achieve Weight Loss of ≥5% from Baseline|Change from Baseline in Fasting Insulin|Change from Baseline in Fasting C-Peptide|Change from Baseline in Homeostasis Model Assessment B (HOMA-2B)|Change from Baseline in HOMA-2S|Rate of Total Hypoglycemia|Number of Participants with Anti-Tirzepatide Antibodies","Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 3","441","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17078|I8F-JE-GPGP","March 30, 2019","February 2, 2021","March 2, 2021","March 4, 2019",,"March 17, 2020","Akaicho Clinic, Chiba-shi, Chiba, Japan|Kashiwa hospital, Kashiwa, Chiba, Japan|Yuri Ono Clinic, Sapporo, Hokkaido, Japan|Manda Hospital, Sapporo, Hokkaido, Japan|Miyanomori Hospital, Sapporo, Hokkaido, Japan|Ikeda Hospital, Amagasaki, Hyogo, Japan|Nakamoto Naika Clinic, Mito, Ibaraki, Japan|Naka Memorial Clinic, Naka, Ibaraki, Japan|Ohishi Naika Clinic, Tsuchiura, Ibaraki, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Tsuruma Kaneshiro Diabetes Clinic, Yamato, Kanagawa, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan|H.E.C. Science Clinic, Yokohama, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Otsu City Hospital, Otsu, Shiga, Japan|Wakakusa Clinic, Shimotsuke, Tochigi, Japan|Seiwa Clinic, Adachi-ku, Tokyo, Japan|HDC Atlas Clinic, Chiyoda, Tokyo, Japan|Asahi Life Foundation Adult Disease Research Center, Chuo-ku, Tokyo, Japan|Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|Kanno Naika, Mitaka, Tokyo, Japan|Shinjuku Research Park Clinic, Shinjuku-Ku, Tokyo, Japan|Futata Tetsuhiro Clinic, Fukuoka, Japan|Morinaga Ueno Clinic, Kumamoto, Japan|Jinnouchi Hospital, Kumamoto, Japan|Abe Diabetes Clinic, Oita, Japan|Saiseikai Noe Hospital, Osaka, Japan|Kitada Clinic, Osaka, Japan|Kansai Denryoku Hospital, Osaka, Japan|Shizuoka City Shizuoka Hospital, Shizuoka, Japan|Suruga Clinic, Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT03861039"
65,"NCT04014192","Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Dapagliflozin|Drug: Empagliflozin|Drug: Canagliflozin","Change from baseline to post-treatment in insulin sensitivity.|Change from baseline to post-treatment in islet beta cell secretory function.|Change from baseline to post-treatment in islet alpha cell secretory function.|Change from baseline to post-treatment in weight.|Change from baseline to post-treatment in fasting blood glucose and non-fasting blood glucose.|Change from baseline to post-treatment in fasting insulin level.|Change from baseline to post-treatment in blood lipid including cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol.|Change from baseline to post-treatment in urine volume and urine glucose level.|Change from baseline to post-treatment in urinary output of uric acid, sodium, calcium, and phosphorus.","Peking Union Medical College Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Yuan-SGLT2","September 1, 2019","July 31, 2020","July 31, 2020","July 10, 2019",,"September 24, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04014192"
66,"NCT03973515","Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus",,"Completed","No Results Available","Type2 Diabetes Mellitus","Drug: glucokinase activator|Drug: Placebo","Time to peak(Tmax)|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|The change for fasting plasma glucose (FPG)|The change for postprandial plasma glucose (PPG)|The change for plasma C-peptide|The change for plasma insulin","PegBio Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PB-201","August 27, 2019","December 19, 2019","December 19, 2019","June 4, 2019",,"January 22, 2020","Peking University Third Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03973515"
67,"NCT03954834","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone","SURPASS-1","Active, not recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Tirzepatide|Drug: Placebo","Change from Baseline in Hemoglobin A1c (HbA1c)|Change from Baseline in Body Weight|Percentage of Participants with HbA1c Target Value of <7%|Change from Baseline in Fasting Serum Glucose|Percentage of Participants with HbA1c Target Value of <5.7%|Mean Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values|Percentage of Participants who Achieved Weight Loss ≥5%|Rate of Documented Symptomatic Hypoglycemic Episodes|Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","472","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17000|I8F-MC-GPGK","June 3, 2019","October 5, 2020","November 2, 2020","May 17, 2019",,"March 17, 2020","National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|National Research Institute, Panorama City, California, United States|Southern California Dermatology, Santa Ana, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Encore Medical Research, LLC, Hollywood, Florida, United States|Axcess Medical Research, Loxahatchee Groves, Florida, United States|South Florida Wellness & Clinical Research Institute, Margate, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Sky Clinical Research Network, Atlanta, Georgia, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|StudyMetrix Research, LLC, Saint Peters, Missouri, United States|Aventiv Research, Columbus, Ohio, United States|Intend Research, Norman, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Capital Clinical Research Center, Olympia, Washington, United States|Rockwood Clinic Research Center, Spokane, Washington, United States|Dr. Jivraj Mehta Smarak Health Foundation, Ahmedabad, Gujarat, India|Bangalore Medical College and Research Institute, Bangalore, Karnataka, India|M S Ramaiah Medical College Hospital, Bangalore, Karnataka, India|BSES Municipal General Hsptl, Mumbai, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Vijay Vallabh Hospital, Virar, Maharashtra, India|Lifepoint Multispecialty Hsptl, Wakad, Pune, India|Ramdevrao Hospital, Hyderabad, Telangana, India|Gandhi Hospital, Telangana, India|Minamiakatsuka Clinic, Mito, Ibaraki, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Tsuruma Kaneshiro Diabetes Clinic, Yamato, Kanagawa, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Meiwa Hospital, Chiyodaku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan|Sato Naika Clinic, Ota-ku, Tokyo, Japan|Hospital Universitario UANL, Monterrey, Nuevo León, Mexico|Unidad Medica para la Salud Integral (UMSI), Monterrey, Nuevo León, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasc, Madero, Tamaulipas, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03954834"
68,"NCT04047537","Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes",,"Enrolling by invitation","No Results Available","Type 2 Diabetes Mellitus","Other: Medical Food Formulation 1|Other: Medical Food Formulation 2|Other: Placebo","Hemoglobin A1c|3-hour blood glucose Area Under the Curve (AUC)|3-hour plasma glucose AUC|3-hour blood glucose AUC|24-hour CGM|Fasting Lipid Panel|Body weight|Adverse Events|Change from baseline in Laboratory Chemistry Values|Change from baseline in Laboratory Complete Blood count Values","Pendulum Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","AFCRO-104","August 6, 2019","June 30, 2020","June 30, 2020","August 6, 2019",,"May 28, 2020","Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork, Ireland",,"https://ClinicalTrials.gov/show/NCT04047537"
69,"NCT03962010","A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: GX-G6|Drug: Control","Change in HbA1c","Genexine, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GX-G6-002","June 1, 2019","June 1, 2022","July 1, 2022","May 23, 2019",,"May 23, 2019",,,"https://ClinicalTrials.gov/show/NCT03962010"
70,"NCT03893422","Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Other: WB-010|Other: WB-011|Other: Placebo","3-hour plasma glucose AUC|CRP|Incremental glucose AUC|Hemoglobin A1c|Fasting plasma glucose concentration|Fasting plasma insulin concentration|Plasma insulin AUC|Homeostatic Model Assessment (HOMA) of Insulin Resistance (IR)|Matsuda index|Fasting Lipid Panel|Inflammatory markers|Body weight in kilograms|Body Mass Index (BMI)|Waist Circumference|Fecal Microbiome Profile|Adverse Events|Laboratory (Chemistry panel + CBC) Values|Hospital Anxiety and Depression Scale","Pendulum Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","WB201-202","October 22, 2017","August 16, 2018","September 14, 2018","March 28, 2019",,"February 27, 2020","Science 37, Torrance, California, United States|Orange County Research Center, Tustin, California, United States|Northside Medical Center, Youngstown, Ohio, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Juno Research, LLC, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03893422"
71,"NCT03798054","Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","Lixilan-O-AP","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)|Drug: Insulin glargine (HOE901)|Drug: Lixisenatide (AVE0010)|Drug: Metformin","Change in HbA1c|Change in postprandial plasma glucose (PPG)|Change in fasting plasma glucose (FPG)|Change in self-monitored plasma glucose (SMPG) profile|Patients with HbA1c <7.0%|Patients with HbA1c ≤ 6.5%|Change in body weight|Patients with HbA1c <7.0% with no body weight gain|Patients with HbA1c <7.0% with no body weight gain and no documented symptomatic hypoglycemia|Confirmed hypoglycemia|Adverse events (AEs)|Immunogenicity (antibody variables)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","940","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC14943|U1111-1190-7669","February 15, 2019","January 2021","January 2021","January 9, 2019",,"November 19, 2019","Investigational Site Number 1560001, Beijing, China|Investigational Site Number 1560006, Beijing, China|Investigational Site Number 1560049, Beijing, China|Investigational Site Number 1560039, Cangzhou, China|Investigational Site Number 1560009, Changchun, China|Investigational Site Number 1560027, Changchun, China|Investigational Site Number 1560016, Changsha, China|Investigational Site Number 1560053, Chengdu, China|Investigational Site Number 1560056, Chengdu, China|Investigational Site Number 1560010, Chenzhou, China|Investigational Site Number 1560037, Chongqing, China|Investigational Site Number 1560050, Chongqing, China|Investigational Site Number 1560044, Dongguan, China|Investigational Site Number 1560033, Guangzhou, China|Investigational Site Number 1560028, Guangzhou, China|Investigational Site Number 1560012, Handan, China|Investigational Site Number 1560023, Hangzhou, China|Investigational Site Number 1560035, Harbin, China|Investigational Site Number 1560036, Harbin, China|Investigational Site Number 1560011, Hengshui, China|Investigational Site Number 1560024, Hohhot, China|Investigational Site Number 1560047, Hohhot, China|Investigational Site Number 1560025, Huang Shi, China|Investigational Site Number 1560026, Huanggang, China|Investigational Site Number 1560048, Huizhou, China|Investigational Site Number 1560034, Huzhou, China|Investigational Site Number 1560005, Jinan, China|Investigational Site Number 1560052, Jinhua, China|Investigational Site Number 1560031, Jinzhou, China|Investigational Site Number 1560022, Nanjing, China|Investigational Site Number 1560014, Nanjing, China|Investigational Site Number 1560043, Nanjing, China|Investigational Site Number 1560041, Nanning, China|Investigational Site Number 1560032, Qingdao, China|Investigational Site Number 1560038, Qinhuangdao, China|Investigational Site Number 1560013, Shanghai, China|Investigational Site Number 1560007, Shanghai, China|Investigational Site Number 1560004, Shanghai, China|Investigational Site Number 1560029, Shanghai, China|Investigational Site Number 1560003, Shenyang, China|Investigational Site Number 1560054, Shenzhen, China|Investigational Site Number 1560019, Suzhou, China|Investigational Site Number 1560059, Suzhou, China|Investigational Site Number 1560021, Tianjin, China|Investigational Site Number 1560017, Tianjin, China|Investigational Site Number 1560058, Urumqi, China|Investigational Site Number 1560018, Wuhan, China|Investigational Site Number 1560008, Xi'An, China|Investigational Site Number 1560055, Xi'An, China|Investigational Site Number 1560051, Xingtai, China|Investigational Site Number 1560030, Xining, China|Investigational Site Number 1560040, Yanji, China|Investigational Site Number 1560060, Yueyang, China|Investigational Site Number 1560046, Yueyang, China|Investigational Site Number 1560045, Zhengzhou, China|Investigational Site Number 1560002, Zhenjiang, China|Investigational Site Number 1560015, Zhuzhou, China|Investigational Site Number 1560057, Zigong, China|Investigational Site Number 3440001, Shatin, Nt, Hong Kong|Investigational Site Number 4100009, Ansan-Si, Korea, Republic of|Investigational Site Number 4100012, Busan, Korea, Republic of|Investigational Site Number 4100008, Daegu, Korea, Republic of|Investigational Site Number 4100010, Guri-Si, Gyeonggi-Do, Korea, Republic of|Investigational Site Number 4100004, Gwangju, Korea, Republic of|Investigational Site Number 4100006, Jeju-Si, Korea, Republic of|Investigational Site Number 4100003, Seongnam-Si, Korea, Republic of|Investigational Site Number 4100016, Seoul, Korea, Republic of|Investigational Site Number 4100011, Seoul, Korea, Republic of|Investigational Site Number 4100013, Seoul, Korea, Republic of|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4100014, Uijeongbu-Si, Korea, Republic of|Investigational Site Number 4100005, Wonju, Korea, Republic of|Investigational Site Number 4580001, Kelantan, Malaysia|Investigational Site Number 4580005, Kuala Lumpur, Malaysia|Investigational Site Number 4580003, Kuala Lumpur, Malaysia|Investigational Site Number 4580006, Kuching, Malaysia|Investigational Site Number 4580002, Putrajaya, Malaysia|Investigational Site Number 4580004, Seremban, Malaysia|Investigational Site Number 1580001, Kaohsiung, Taiwan|Investigational Site Number 1580003, Taichung, Taiwan|Investigational Site Number 1580005, Tainan Hsien, Taiwan|Investigational Site Number 1580002, Tainan, Taiwan|Investigational Site Number 1580004, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03798054"
72,"NCT04013581","Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: TZD group|Drug: SGLT-2 group","Change of HbA1c|glucose|Adverse events|Change of kidney function|Change of liver enzymes","Yonsei University","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4-2019-0393","August 2019","June 2022","June 2022","July 9, 2019",,"July 9, 2019","Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04013581"
73,"NCT03798080","Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin","Lixilan-L-CN","Active, not recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)|Drug: Insulin glargine (HOE901)|Drug: Metformin","Change in HbA1c|Patients with HbA1c <7.0%|Patients with HbA1c ≤ 6.5%|Change in postprandial plasma glucose (PPG)|Change in self-monitored plasma glucose (SMPG) profile|Patients with HbA1c <7.0% with no body weight gain|Change in body weight|Patients with HbA1c <7.0% with no body weight gain and no documented symptomatic hypoglycemia|Patients requiring rescue therapy|Change in fasting plasma glucose (FPG)|Confirmed hypoglycemia|Adverse events (AEs)|Immunogenicity (antibody variables)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","426","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC14944|U1111-1190-7781","February 19, 2019","November 2020","November 2020","January 9, 2019",,"May 12, 2020","Investigational Site Number 1560044, Baotou, China|Investigational Site Number 1560001, Beijing, China|Investigational Site Number 1560039, Beijing, China|Investigational Site Number 1560005, Changchun, China|Investigational Site Number 1560054, Changchun, China|Investigational Site Number 1560015, Changsha, China|Investigational Site Number 1560010, Chenzhou, China|Investigational Site Number 1560030, Chongqing, China|Investigational Site Number 1560025, Fuzhou, China|Investigational Site Number 1560016, Guangzhou, China|Investigational Site Number 1560053, Guangzhou, China|Investigational Site Number 1560045, Guangzhou, China|Investigational Site Number 1560021, Hefei, China|Investigational Site Number 1560018, Hohhot, China|Investigational Site Number 1560019, Huanggang, China|Investigational Site Number 1560041, Jiaxing, China|Investigational Site Number 1560040, Jinan, China|Investigational Site Number 1560007, Jinan, China|Investigational Site Number 1560026, Jinzhou, China|Investigational Site Number 1560042, Kaifeng, China|Investigational Site Number 1560003, Kunming, China|Investigational Site Number 1560032, Lanzhou, China|Investigational Site Number 1560033, Luoyang, China|Investigational Site Number 1560028, Nanjing, China|Investigational Site Number 1560013, Nanjing, China|Investigational Site Number 1560017, Nanjing, China|Investigational Site Number 1560035, Nanjing, China|Investigational Site Number 1560038, Nanjing, China|Investigational Site Number 1560046, Nantong, China|Investigational Site Number 1560008, Pingxiang, China|Investigational Site Number 1560037, Qingdao, China|Investigational Site Number 1560031, Qinhuangdao, China|Investigational Site Number 1560011, Shanghai, China|Investigational Site Number 1560002, Shanghai, China|Investigational Site Number 1560027, Shanghai, China|Investigational Site Number 1560047, Shanghai, China|Investigational Site Number 1560012, Shenyang, China|Investigational Site Number 1560006, Tianjin, China|Investigational Site Number 1560049, Urumqi, China|Investigational Site Number 1560020, Xining, China|Investigational Site Number 1560050, Xining, China|Investigational Site Number 1560036, Xuzhou, China|Investigational Site Number 1560023, Yangzhou, China|Investigational Site Number 1560022, Zhuzhou, China|Investigational Site Number 1560052, Zigong, China",,"https://ClinicalTrials.gov/show/NCT03798080"
74,"NCT04088851","""The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes""",,"Recruiting","No Results Available","Type2 Diabetes","Drug: Metformin","The gluconeogenic flux rates from pyruvate (lactate, alanine) and glycerol are higher in patients with T2D compared to the healthy control group.","German Diabetes Center|Prof. Dr. Gerald Shulman, Yale University, New Haven, Conneticut, USA","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","IMPACT","September 11, 2019","January 31, 2020","February 20, 2021","September 13, 2019",,"September 13, 2019","German Diabetes Center, Duesseldorf, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT04088851"
75,"NCT03980236","Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]","LISA Pilot","Recruiting","No Results Available","Type 2 Diabetes Treated With Insulin","Device: Livongo-Insulia Study App","Change in A1c","Livongo Health|Voluntis|Evidation Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CP04573.A","May 6, 2019","November 2019","November 2019","June 10, 2019",,"June 10, 2019","Livongo, Mountain View, California, United States",,"https://ClinicalTrials.gov/show/NCT03980236"
76,"NCT03813316","Approaches To Therapy Escalation In T2D","ATTACC","Withdrawn","No Results Available","Type2 Diabetes","Drug: DPP-4 inhibitor|Drug: SGLT2 inhibitor|Drug: SGLT2 inhibitor and DPP-4 inhibitor","The percentage of participants achieving an A1C value of ≤ 7% at 24 weeks|The percentage of participants achieving an A1C value ≤ 7% at 12 weeks|The absolute reduction in A1C from Baseline at 24 weeks|The percentage of participants requiring a change of therapy or rescue therapy at 12 weeks|Drug tolerability including percentage of participants with hypoglycemic events, and percentage with adverse events.events.|The absolute reduction in FPG from Baseline at 24 weeks|The absolute change in body weight from Baseline at 24 weeks|The absolute change in systolic blood pressure from Baseline at 24 weeks|The percentage of participants achieving the composite outcome of A1C ≤ 7.0%, no weight gain and no hypoglycemia at Week 24.|The percentage of participants on statin therapy at 24 weeks|The percentage of participants on antihypertensive therapy at Week 24.","LMC Diabetes & Endocrinology Ltd.|Merck Sharp & Dohme Corp.|Syreon Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","58214","May 1, 2019","September 18, 2019","September 18, 2019","January 23, 2019",,"September 27, 2019",,,"https://ClinicalTrials.gov/show/NCT03813316"
77,"NCT03832725","Pathobiology of Remission of Type 2 Diabetes",,"Recruiting","No Results Available","Newly Diagnosed Type 2 Diabetes|Obese","Other: High Protein (HP) weight loss diet|Other: High carbohydrate (HC) weight loss diet","Remission of Type 2 Diabetes|Weight loss|Cardiovascular Risk Factors (CVR)|Inflammation markers such as cytokines,|Metabolom Markers","University of Tennessee Health Science Center","All","20 Years to 50 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","UTennHSCFS","March 1, 2018","July 31, 2024","July 31, 2024","February 6, 2019",,"February 7, 2019","University of Tennessee Health Science Center, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03832725"
78,"NCT04061200","Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria","EmpaSema","Not yet recruiting","No Results Available","Type 2 Diabetes With Renal Manifestations","Drug: Semaglutide, 1.34 mg/mL|Other: Placebo, 1,34 mg/mL|Drug: Empagliflozin 25 MG","Albuminuria|Hba1c|GFR|24 hour blood pressure|Vasoactive hormones|Inflammatory and endothelial biomarkers","Steno Diabetes Center Copenhagen|Novo Nordisk A/S","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019-003175-19","November 1, 2019","July 1, 2021","August 1, 2021","August 19, 2019",,"August 19, 2019","Steno Diabetes Center Copenhagen, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT04061200"
79,"NCT04127084","Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes",,"Recruiting","No Results Available","Type 2 Diabetes|Diabetic Nephropathy","Drug: SGLT2 Inhibition","Change in urinary albuminuria|Change in eGFR|change in nephrin|change in TGF-β1|change in IL-6|change in TNFα|changes of AGEs|changes of 8-OH-dG|Change in uric acid|Change in aldosterone|Change in rennin|Change in angiotensin","Zhongshan Hospital Xiamen University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20191005","October 15, 2019","October 2020","August 2021","October 15, 2019",,"October 21, 2019","Zhongshan Hospital Xiamen University, Xiamen, Fujian, China",,"https://ClinicalTrials.gov/show/NCT04127084"
80,"NCT04063930","The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia","ZIRCUS","Recruiting","No Results Available","Type 2 Diabetes Mellitus With Kidney Complications","Drug: LOKELMA 5 GM Powder for Oral Suspension|Drug: Placebos","Urinary albumin creatinine ratio (UACR)|Estimated glomerular filtration rate (eGFR)|Urinary sodium|Urinary potassium","Steno Diabetes Center Copenhagen|AstraZeneca|Zealand University Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019-000595-42","October 2019","December 2020","December 2021","August 21, 2019",,"October 16, 2019","Steno Diabetes Center Copenhagen, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT04063930"
81,"NCT04057261","Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease","Lirabolic","Not yet recruiting","No Results Available","Type 2 Diabetes|Cardiovascular Diseases","Drug: Liraglutide Pen Injector [Victoza]|Drug: Placebo","Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months|change in left ventricular diastolic function|change in left ventricular systolic function|Changes in systolic and diastolic blood pressure (mmHg)|body weight|Changes in NT-proBNP serum levels (pg/ml)|Differences of the serum lipid profile between Liraglutide treatment group and placebo group|changes of serum levels of glucose, HbA1c, glucagon, insulin, C-Peptide, β-Hydroxybutyrate between Liraglutide treatment group and placebo group|Heart rate variability|Resting energy expenditure|Respiratory Exchange Ratio|Differences in gut microbiome composition measured by 16S rRNA targeted gene sequencing of feces between Liraglutide treatment group and placebo group|Albumin excretion|changes in inflammasome analyses|Differences in circulation inflammatory cell composition by flow cytometry analyses (FACS) between Liraglutide treatment group and placebo group","RWTH Aachen University|Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","17-162","November 2020","August 2022","November 2022","August 15, 2019",,"March 10, 2020","Department of Internal Medicine I, University Hospital, Aachen, Germany",,"https://ClinicalTrials.gov/show/NCT04057261"
82,"NCT04014023","Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","T2DM (Type 2 Diabetes Mellitus)","Drug: DWP16001|Drug: Placebo","Change from baseline in HbA1c|Change from baseline in FPG|The proportion of patients who achieve HbA1c < 7.0%, HbA1c < 6.5% and HbA1c reduction >0.5% from baseline","Daewoong Pharmaceutical Co. LTD.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","196","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DWP16001201","July 10, 2019","March 2020","June 2020","July 10, 2019",,"July 18, 2019","Daewoong pharmatceutical, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04014023"
83,"NCT03885869","Relationships Between Joint Position Sense, Plantar Sensation, Balance and Dual Task Performance in Individuals With Type 2 Diabetes",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus|Balance","Other: Ankle Joint Position Sensation Evaluation|Other: Knee Joint Position Sensation Evaluation|Other: The Evaluation of Plantar Sensation|Other: The Evaluation of Balance|Other: Evaluation of Dual Task Performance|Other: General Evaluation Form","The Evaluation of Ankle Joint Position Sensation|The Evaluation of Knee Joint Position Sensation|The Evaluation of Plantar Sensation|Evaluation of Balance Performance|The Evaluation of Dual Task Performance","Ankara Yildirim Beyazıt University","All","30 Years to 65 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","2019-83","March 25, 2019","August 25, 2019","March 25, 2020","March 22, 2019",,"March 25, 2019","Ankara Yıldırım Beyazıt University, Institute of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT03885869"
84,"NCT04194450","Exogenous Ketones in Type 2 Diabetes",,"Recruiting","No Results Available","Ketosis|Type 2 Diabetes","Dietary Supplement: Ketone monoester|Dietary Supplement: Placebo","Plasma glucose|Plasma insulin|Plasma C-peptide|Plasma free fatty acids|Plasma tumour necrosis factor alpha|Plasma tumour interleukin-1beta|Plasma tumour interleukin-6|Cerebral blood flow|Blood pressure|Cognitive function|Brain-derived neurotrophic factor|Blood monocytes|Self reported hunger and fullness|Gastrointestinal symptoms|Total energy consumed|Monocyte histone acetylation","University of British Columbia","All","20 Years to 69 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","H19-02947","January 15, 2020","March 31, 2020","July 30, 2020","December 11, 2019",,"March 13, 2020","University of British Columbia, Okanagan, Kelowna, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04194450"
85,"NCT04159766","A Study With NLY01 in Subjects With Type 2 Diabetes",,"Active, not recruiting","No Results Available","Type2 Diabetes|Diabetes Mellitus, Type 2","Drug: NLY01|Drug: Placebo","Number of participants with Treatment Emergent Adverse Events|Number of Incidences of Adverse Events|Plasma glucose|Change in serum insulin|Change in plasma glucagon","Neuraly, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NLY01-D1","October 16, 2019","September 2020","September 2020","November 12, 2019",,"April 14, 2020","Profil Institute fur Stoffwechselforschung GmbH, Neuss, Germany|Profil Institute, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT04159766"
86,"NCT04190199","Exploring Nutritype Signature of Type 2 Diabetes Risks in Women Post-Gestational Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type 2 Diabetes|Gestational Diabetes","Other: Observational","Nutritype signature of T2DM risks in women post-GDM|Prevalence of glucose intolerance|Socio-demographic background|Obstetric history|Nutritional status|Metabolite profile|Dietary pattern|Sleeping pattern|Perceived Stress Scale score|Physical activity level|Smoking habit and exposure","Universiti Putra Malaysia|Ministry of Health, Malaysia|Universiti Teknologi Mara","Female","18 Years to 50 Years   (Adult)",,"270","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","5540099","May 2020","May 2021","May 2021","December 9, 2019",,"December 9, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,"https://ClinicalTrials.gov/show/NCT04190199"
87,"NCT04026139","Elastic Band Resistance Exercise on Glycated Haemoglobin and Muscle Strength, Balance, and Physical Function in Patients With Comorbid Type 2 Diabetes Mellitus and Knee Osteoarthritis",,"Completed","No Results Available","Elastic Band Resistance Exercise With Comorbid Type 2 Diabetes Mellitus and Knee Osteoarthritis","Other: Elastic Band Resistance Exercise|Other: active joint range-of-motion exercises and isometric contraction exercises","HbA1c level|WOMAC physical function subscale scores|30-s chair stand test [CST]|3-m timed up and go test [TUG]","Shu-Mei Chen|Chang Gung Memorial Hospital","All","60 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","201700009B0D001","August 1, 2017","January 31, 2018","January 31, 2018","July 19, 2019",,"July 19, 2019","Shu-Mei Chen, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT04026139"
88,"NCT04149951","Effect of VeSTAL Device in Type 2 Diabetes Mellitus",,"Enrolling by invitation","No Results Available","Type 2 Diabetes|Metabolic Syndrome","Device: Vestal Device|Device: Placebo device","Glycated Hemoglobin (HbA1c)|Difference in mean weight loss between the active-product and sham-treated groups.|Daily caloric intake|Blood pressure|Waist circumference|Hip circumference|Body mass index|Appetite|Cravings|Fullness","Neurovalens Ltd.|Compliance Solutions Ltd|University College Dublin|Exploristics Ltd","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCD2","June 3, 2020","December 2020","December 2020","November 4, 2019",,"June 1, 2020","St Vincents Hospital, Dublin, Ireland",,"https://ClinicalTrials.gov/show/NCT04149951"
89,"NCT03909269","Glycaemic Markers in Persons With Type 2 Diabetes on Haemodialysis","GLYCOHEMO","Recruiting","No Results Available","Diabetic Nephropathy Type 2|Type2 Diabetes","Device: Continuous glucose monitoring|Diagnostic Test: Glycaemic markers|Radiation: Erythrocyte life span|Device: Carbon monoxide (CO)-rebreathing method","HbA1c evaluated by the total mean glucose from continuous glucose monitoring|Erythrocyte life span|Glycated albumin|Fructosamine|HbA1c evaluated by the mean glucose from continuous glucose monitoring for each week|Blood volume|Standard deviation|Coefficient variation|Low Blood Glucose Index|High Blood Glucose Index|Time in hypoglycaemic range below 3.0 mmol/l|Time in hypoglycaemic range below 3.9 mmol/l to 3.0 mmol/l|Time in target range from 3.9 mmol/l to 10.0 mmol/l|Time in hyperglycaemic range above 10.0 mmol/l|Time in hyperglycaemic range above 13.9 mmol/l|Hypoglycaemic events","Rigshospitalet, Denmark|Steno Diabetes Center Copenhagen","All","18 Years to 90 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GLYCOHEMO","April 1, 2018","March 1, 2020","March 1, 2020","April 9, 2019",,"April 9, 2019","Rigshospitalet, København Ø, Denmark",,"https://ClinicalTrials.gov/show/NCT03909269"
90,"NCT04203927","Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes","EJB051","Recruiting","No Results Available","Type2 Diabetes|Insulin Sensitivity","Drug: Empagliflozin 25 MG|Drug: Placebo oral tablet","Myocardial microvascular perfusion|Flow Mediated Dilation (FMD) Vascular measure of conduit artery stiffness Change in Flow Mediated Dilation (FMD) between baseline and after 2 hour insulin clamp Vascular measure of conduit artery stiffness Flow Mediated Dilation ( FMD)|Augmentation Index ( AI)|Pulse Wave Velocity ( PWV)","University of Virginia|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 60 Years   (Adult)","Early Phase 1","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","21403|1R01HL142250-01A1","February 1, 2020","October 22, 2022","November 30, 2022","December 18, 2019",,"February 24, 2020","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04203927"
91,"NCT03940937","Cadence and Intensity in Adults With Type 2 Diabetes","CADENCE-T2DM","Recruiting","No Results Available","Type 2 Diabetes Mellitus|Walking",,"Cadence (steps/min)|Oxygen consumption (VO2; mL/kg/min)","University of Massachusetts, Amherst","All","40 Years to 65 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CADENCE-T2DM","May 2019","October 2019","October 2019","May 7, 2019",,"May 7, 2019","Totman Building, Amherst, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03940937"
92,"NCT04146155","Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease",,"Recruiting","No Results Available","Type 2 Diabetes|Peripheral Vascular Disorder Due to Diabetes Mellitus","Drug: Liraglutide+standard-of-care treatment|Other: standard-of-care treatment","Initial and absolute claudication distance|Assess the effects on ABI of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Assess the effects on endothelial function of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Muscle microvascular perfusion by CEU|Assess the effects on the endothelial circulating progenitor cells concentration of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Changes from baseline in HbA1c","Second Affiliated Hospital, School of Medicine, Zhejiang University","All","40 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","zhengchao","May 1, 2020","December 31, 2021","December 31, 2021","October 31, 2019",,"May 12, 2020","The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04146155"
93,"NCT04176276","Determining Serum and Urinary Levels of miRNA 192 and miRNA 25 in Patients With and Without Type 2 Diabetes.",,"Completed","No Results Available","Diabetic Kidney Disease|Type2 Diabetes","Other: no interventions required.","Serum expression of miR-192|Serum expression of miR-25|Urine expression of miR-192|Urine expression of miR-25","University of Pisa","All","18 Years to 75 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","AS0004","March 1, 2018","December 31, 2019","March 1, 2020","November 25, 2019",,"June 5, 2020","University of Pisa, Pisa, Italy",,"https://ClinicalTrials.gov/show/NCT04176276"
94,"NCT03910361","Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases",,"Enrolling by invitation","No Results Available","Type2 Diabetes|Non-Alcoholic Fatty Liver Disease","Drug: Evogliptin|Drug: Pioglitazone","Changes from baseline intrahepatic fat (%)","Dong-A ST Co., Ltd.","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DA1229_NAFLD_IV","May 7, 2019","September 30, 2020","September 30, 2020","April 10, 2019",,"July 9, 2019","Samsung Medical Center, Changwon, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Korea, Republic of|Keimyung Dongsan University Medical Center, Daegu, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Catholic University of Seoul ST.Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03910361"
95,"NCT03926598","Guide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D)","GTG","Recruiting","No Results Available","Type2 Diabetes Mellitus","Behavioral: Patient and/or Family Member Intervention|Behavioral: Certified Diabetes Educator Intervention|Behavioral: Physician Intervention|Behavioral: Front Desk Staff Intervention|Behavioral: Nurse Intervention","Participant Task Completion Rate for Usability Testing Session","Georgia Institute of Technology|Emory University","All","12 Years and older   (Child, Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H18426","June 5, 2019","September 30, 2020","December 20, 2020","April 24, 2019",,"October 31, 2019","Children's Helathcare of Atlanta, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03926598"
96,"NCT03950505","To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes",,"Not yet recruiting","No Results Available","Non-alcoholic Steatohepatitis|Type2 Diabetes","Drug: Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks","A degree of liver steatosis|A degree of liver fibrosis|Clinical glucometabolic parameters : HbA1c|Clinical glucometabolic parameters : Lipid parameters|Clinical glucometabolic parameters : Liver enzymes|Clinical glucometabolic parameters :Anthropometric parameters","Yonsei University","All","20 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4-2018-0203","June 2019","June 2020","December 2020","May 15, 2019",,"May 15, 2019","Division of Geriatrics, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03950505"
97,"NCT03867500","Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus|Obesity","Drug: Niacin|Other: Saline","Difference in insulin-stimulated glucose disposal between overnight saline control study and overnight/insulin clamp niacin infusion study.|Difference in insulin-stimulated phosphorylation of insulin-responsive signaling molecules between overnight saline control study and overnight/insulin clamp niacin infusion study.|Difference in incorporation of 13-palmitate and D9-palmitate into intramyocellular lipid intermediates between overnight saline control study and overnight/insulin clamp niacin infusion study.|Effects of niacin on adipocyte lipolysis proteins","Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 55 Years   (Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17-009977|5R01DK045343-27","November 1, 2018","December 31, 2021","December 31, 2021","March 8, 2019",,"April 8, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03867500"
98,"NCT03877783","DEMAND - Multifactorial Study to Reduce Dementia in People With Type 2 Diabetes","DEMAND","Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus|Mild Cognitive Impairment","Dietary Supplement: mediterranean diet|Behavioral: individualized fitness program|Other: recommended modified pharmacological treatment","inclusion rate|adherence rate|retention rate|Metabolic change|Memory function","Umeå University|Uppsala University","All","65 Years and older   (Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","DEMAND pilot","February 1, 2020","December 31, 2021","June 30, 2022","March 18, 2019",,"February 7, 2020","Uppsala University, Uppsala, Uppsala Län, Sweden|Umeå University, Umeå, Västerbotten, Sweden",,"https://ClinicalTrials.gov/show/NCT03877783"
99,"NCT04016584","Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy","DiabPueblo","Recruiting","No Results Available","Type2 Diabetes","Behavioral: Diabetes Pueblo","Success (evaluated by a Yes/No format) recruiting and completing a new targeted diabetes and insulin education program, Diabetes Pueblo, for Latino adults with type 2 diabetes.|Diabetes self management evaluated by questionnaire|Insulin treatment evaluated by questionnaire|Participant evaluation of Diabetes Pueblo evaluated by questionnaire","Sansum Diabetes Research Institute|Eli Lilly and Company","All","19 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY2017-6000","May 10, 2019","March 30, 2020","March 30, 2020","July 11, 2019",,"March 20, 2020","Sansum Diabetes Research Institute, Santa Barbara, California, United States",,"https://ClinicalTrials.gov/show/NCT04016584"
100,"NCT04120844","Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China",,"Completed","No Results Available","Diabete Type 2","Behavioral: Motivational interviewing (MI)-based patient empowerment program (PEP)|Behavioral: Traditional lecture style health education","Problem Areas in Diabetic (PAID) Questionnaire|""Patient Enablement Index"" (PEI) score|Stages of Change score","The University of Hong Kong-Shenzhen Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","JCYJ20150331142757385","May 1, 2016","April 1, 2017","September 26, 2019","October 9, 2019",,"October 9, 2019",,,"https://ClinicalTrials.gov/show/NCT04120844"
101,"NCT03796975","Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease",,"Active, not recruiting","No Results Available","Type2 Diabetes Mellitus|Non-alcoholic Fatty Liver Disease","Drug: Combination of Pioglitazone and Metformin Tablets|Drug: Metformin Hydrochloride Tablets","Decreased of liver fat content of fatty liver after 24 weeks treatment as assessed by B-ultrasound|Change of B-cell function after 24 weeks treatment as assessed by homeostasis model assessment of insulin resistance index|Change of liver enzyme after 24 weeks treatment as assessed by blood test|Decreased of HbA1c after 24 weeks treatment as assessed by blood test|Decreased of fasting blood glucose after 24 weeks treatment as assessed by blood test|Change of weight and waistline after 24 weeks treatment as assessed by standard measurement","Xijing Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KY20172053-1","April 20, 2018","February 2019","February 2019","January 8, 2019",,"January 8, 2019","Xijing Hospital, Fourth Military Medical university, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT03796975"
102,"NCT03821636","Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.","PRECI-Surg","Not yet recruiting","No Results Available","Diabetes Mellitus Type 2 in Obese","Procedure: Standard Roux-en-Y gastric bypass|Procedure: Long alimentary limb Roux-en-Y gastric bypass","Rate of type 2 diabetes remission|Absolute weight loss (aWL in kg)|Excess Weight Loss percentage (EWL%)|Excess BMI Loss percentage (EBL%)|Medical and surgical complication rates|Type and severity of early and late complications for each procedure|Patient's quality of life score according to the Impact of Weight on Quality of Life (IWQOL) questionnaire|Patient's quality of life score according to the Gastrointestinal Quality of Life Index (GIQLI) questionnaire adapted to bariatric surgery.|Change in glucose homeostasis|Change in HbA1c|Change in fasting glycemia|changes in fasting insulinemia|change in fasting c-peptide|Number of antidiabetic treatments|Changes in blood lipids profile|change in vitamins status assessment|change in prealbumin levels","University Hospital, Lille|Ministry of Health, France","All","18 Years to 60 Years   (Adult)","Not Applicable","396","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2017_02|2017-A01761-52|PHRCI-16-090","December 2019","January 2022","January 2022","January 30, 2019",,"July 11, 2019",,,"https://ClinicalTrials.gov/show/NCT03821636"
103,"NCT03923205","Assessing the Effects of a Buckwheat Beverage on Postprandial Glucose Metabolism on Healthy and T2D Individuals","BUCKFOOD","Recruiting","No Results Available","Healthy|Type2 Diabetes","Other: Dietary Intervention","post prandial blood glucose (recording cmax)|AUC for postprandial glucose|post prandial blood insulin in blood ( including AUC)|Buckwheat beverage key bioactives bioavailability and metabolism.|Urine ratio of myo and D-chiro inositol|Urine glucose concentration","University of Aberdeen|NHS Grampian","All","18 Years and older   (Adult, Older Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2-088-18","March 7, 2019","September 7, 2020","March 31, 2021","April 22, 2019",,"April 22, 2019","Rowett Institute, University of Aberdeen, Aberdeen, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03923205"
104,"NCT04164030","Education and Exercise Program for Adults With Type 2 Diabetes",,"Recruiting","No Results Available","Type 2 Diabetes","Behavioral: Education and Exercise Program for Adults with Type 2 Diabetes|Behavioral: Nutrition Education plus Occupational Therapy plus Yoga","Change in habits measured using the Self-Report Habit Index|Change in diabetes distress measured using the Diabetes Distress Scale","Colorado State University|American Occupational Therapy Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140898","August 26, 2019","June 15, 2020","September 30, 2020","November 15, 2019",,"November 15, 2019","Colorado State University, Fort Collins, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04164030"
105,"NCT04161170","Digital Integrated Healthcare Platform in Patients With Type 2 Diabetes",,"Recruiting","No Results Available","Type 2 Diabetes","Device: Digital integrated healthcare platform","Change of HbA1c (glycated hemoglobin) at 6months from baseline|HbA1c|number of intervention for education in interventinal group C|hypoglycemic events|adverse events|patient satisfaction questionnaire score|body weight|BMI (body mass index)|body fat (%)|step count|burned calories|walking distances|intake calories|fasting glucose level|total cholesterol level|HDL cholesterol level|Triglycerides level|LDL cholesterol level|mean glucose level by CGMS (continuous glucose monitoring system) in interventional group C|glycemic variability by CGMS in interventional group C|standard deviation by CGMS in interventional group C|average applying time of CGMS in interventional group C|time in range of <54mg/dL by CGMS in interventional group C|time in range of <70mg/dL by CGMS in interventional group C|time in range of 70-180 mg/dL by CGMS in interventional group C|time in range of >180 mg/dL by CGMS in interventional group C|time in range of >250 mg/dL by CGMS in interventional group C","Samsung Medical Center","All","19 Years to 70 Years   (Adult, Older Adult)","Not Applicable","294","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-05-028-007","November 20, 2019","August 31, 2021","December 31, 2021","November 13, 2019",,"January 18, 2020","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04161170"
106,"NCT04081766","Pharmacist-Led Study in Controlling Hypoglycemia in Older Adults With Type 2 Diabetes Mellitus","ROSE-ADAM","Recruiting","No Results Available","Diabetes Mellitus Type 2 With Hypoglycemia","Behavioral: SUGAR Handshake","Frequency of total episodes of hypoglycaemia|Frequency of severe hypoglycaemia|Frequency of asymptomatic hypoglycemia|Frequency of symptomatic hypoglycemia|Change in HbA1c level.","University of Lincoln","All","65 Years and older   (Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2019-May-0170","February 9, 2020","September 2020","October 2020","September 9, 2019",,"March 2, 2020","King Abdullah University Hospital, Irbid, Jordan",,"https://ClinicalTrials.gov/show/NCT04081766"
107,"NCT04025775","Closed-loop in Adults With T2D Requiring Dialysis","AP-Renal","Recruiting","No Results Available","Type 2 Diabetes|End Stage Renal Disease","Device: CamAPS HX Closed-loop|Other: Multiple Daily Insulin Injections (Control)","Time in the target glucose range (5.6 to 10.0 mmol/l)|Time spent above target glucose (10.0 mmol/l)|Mean glucose|Time spent in hypoglycaemia (<3.9 mmol/l)|Time spent below target glucose (5.6 mmol/l)|Standard deviation of glucose levels|Coefficient of variation of glucose levels|Time spent below <3.0 mmol/l|Time in significant hyperglycaemia (> 20 mmol/l)|Total, basal and bolus insulin dose|AUC of glucose below 3.5 mmol/l","University of Cambridge|University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP-Renal","August 1, 2019","December 2020","December 2020","July 19, 2019",,"February 18, 2020","Inselspital, Bern University Hospital, Bern, Switzerland|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04025775"
108,"NCT03826472","Almond Butter and Fasting Glucose",,"Completed","No Results Available","Type2 Diabetes","Other: Almond Butter","Fasting glucose|Glucose trends|Inhibitory control","Penn State University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PKE AlmondButter","March 8, 2019","March 1, 2020","March 1, 2020","February 1, 2019",,"March 27, 2020","Penn State, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03826472"
109,"NCT04175665","Real-world Health Outcomes in Canadian Patients Using Semaglutide",,"Completed","No Results Available","Type 2 Diabetes","Drug: Semaglutide","Change in HbA1c|Change in body weight|Change in body mass index (BMI)|Change in systolic blood pressure (SBP)|Change in diastolic blood pressure (DBP)|Change in triglycerides|Change in LDL cholesterol|Change in non-HDL cholesterol|Change in estimated glomerular filtration rate (eGFR)|Change in alanine amino transaminase (ALT)|Proportion of patients who report ≥ 1 weekly incidence of any hypoglycemia|Proportion of patients who report ≥ 1 yearly incidence of severe hypoglycemia|Proportion of patients who achieve HbA1c ≤7.0%|Proportion of patients who achieve HbA1c ≤8.0%|Proportion of patients who achieve HbA1c reduction ≥0.5%|Proportion of patients who achieve HbA1c reduction ≥1.0%|Proportion of patients who achieve weight loss ≥5%|Proportion of patients who achieve weight loss ≥10%","LMC Diabetes & Endocrinology Ltd.","All","18 Years and older   (Adult, Older Adult)",,"1133","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SPARE","January 6, 2020","February 9, 2020","February 9, 2020","November 25, 2019",,"February 21, 2020","LMC Diabetes & Endocrinology, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04175665"
110,"NCT04081064","Impact of Body Composition and Exercise on Clinical, Metabolic and Molecular Parameters in Type 2 Diabetics in Qatar",,"Recruiting","No Results Available","Type 2 Diabetes","Behavioral: 10-week exercise programme based on aerobic interval and resistance training","Insulin sensitivity|Glucose regulation/ insulin sensitivity|Pancreatic beta-cell function|Hepatic insulin resistance index|Vascular reactivity|Body Mass Index (BMI)|Body fat profiling|Total body fat|Non-fat mass|Visceral adipose volume|Cardiorespiratory fitness (estimated maximal oxygen uptake)|Upper body strength|Physical function|Lower body strength|Fasting Plasma glucose","Hamad Medical Corporation|Hamad Bin Khalifa University","All","18 Years to 60 Years   (Adult)","Not Applicable","60","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRC-03-17-0025","January 15, 2019","December 31, 2020","July 31, 2022","September 6, 2019",,"October 7, 2019","Hamad Medical Corporation, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT04081064"
111,"NCT04190160","Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)","XETD2","Active, not recruiting","No Results Available","Type2 Diabetes","Drug: IDegLira","Self reported quality of Life (CASP-19)|The Diabetes Treatment Satisfaction (DTSQ)|Glycemic control|Hypoglycaemia|Self reported depression (GDS)|Hypoglycaemic related hospitalizations|Cognitive function (MMSE)","Stefano Rizza|University of Rome Tor Vergata","All","75 Years to 99 Years   (Older Adult)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","141/18 XETD2","November 19, 2018","November 22, 2019","March 16, 2020","December 9, 2019",,"December 9, 2019","Stefano Rizza, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04190160"
112,"NCT04075110","Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Obesity; Endocrine; Diabetes Type 2","Drug: Montelukast 10mg","Change in HbA1c|Percent change in body weight|BMI|Visceral Adiposity Index|Adiponectin|TNF-α|IL-6|leukotriene B4","Sadat City University","All","18 Years to 60 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0066/2019","July 1, 2019","September 1, 2020","December 31, 2020","August 30, 2019",,"September 3, 2019","Faculty of Medicine, Shebin Elkom, Egypt",,"https://ClinicalTrials.gov/show/NCT04075110"
113,"NCT04132934","Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN","DIA-RAMADAN","Completed","No Results Available","Type 2 Diabetes",,"Proportion of patients with at least one Hypoglycemia event","Servier Affaires Médicales|Servier","All","18 Years and older   (Adult, Older Adult)",,"1200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","DIM-05762-004","March 11, 2019","October 4, 2019","October 4, 2019","October 21, 2019",,"June 5, 2020","Servier Affaires Medicales, Suresnes, France",,"https://ClinicalTrials.gov/show/NCT04132934"
114,"NCT03948347","Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus","LAMP","Not yet recruiting","No Results Available","Ischemic Stroke|Transient Ischemic Attack|Type 2 Diabetes Mellitus","Drug: Liraglutide","Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic)|Percentage of patients with the 90-day new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death)|Percentage of patients with the 90-day Modified Rankin Scale (mRS) ≤ 2","First Affiliated Hospital of Jinan University","All","50 Years and older   (Adult, Older Adult)","Phase 3","1708","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","LAMP20190508","May 2019","May 2022","May 2023","May 13, 2019",,"May 20, 2019",,,"https://ClinicalTrials.gov/show/NCT03948347"
115,"NCT04109235","Family Health Team High-Intensity Interval Training","FHT HIIT","Recruiting","No Results Available","Type 2 Diabetes","Other: High-Intensity Interval Training Physical Activity (PA) Advice|Other: Population-Based Physical Activity (PA) Advice","Change in HbA1C|Blood Pressure|Weight|Physical Activity (minutes per week)","Western University, Canada|East Elgin Family Health Team","All","18 Years and older   (Adult, Older Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","111930","February 13, 2020","February 13, 2021","February 13, 2021","September 30, 2019",,"February 26, 2020","East Elgin Family Health Team, Aylmer, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04109235"
116,"NCT03949582","Acute Mycoprotein Effect on Glycaemic Control in South Asians","ACMYCO","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Other: Test food containing different types of dietary protein","Blood glucose|Blood insulin|Subjective appetite feelings|Ad libitum energy intake|Energy intake 72 hours post study visit","Imperial College London","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","18HH4870","May 1, 2019","June 30, 2021","June 30, 2021","May 14, 2019",,"September 17, 2019","NIHR Imperial Clinical Research Facility, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03949582"
117,"NCT03794336","Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive","ACADEMIC","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Alogliptin|Drug: Acarbose|Drug: Metformin|Drug: Aspirin","Change in Hemoglobin A1c|Overall Gastrointestinal tolerability|Percentage of patients achieving HbA1c <7%|Percentage of patients achieving HbA1c <7% without gastrointestinal effects|Change in Fasting Plasma Glucose (FPG)|Occurrence of hypoglycemia events|Other Adverse Events (AEs)|Overall tolerability|Change in Postprandial Plasma Glucose 2-h (PPG)|Change in Homeostasis model assessment-β (HOMA- β)|Change in Total Cholesterol (TC)|Change in Tri Glycerides (TG)|Change in High Density Lipoprotein-Cholesterol (HDL-C)|Change in Low Density Lipoprotein-Cholesterol (LDL-C)|Change in body weight|Overall adherence to Investigational Medicinal Product (IMP)|Medication possession ratio (MPR)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 4","1218","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALOGLC08867|U1111-1210-0679","June 29, 2019","June 2021","June 2021","January 7, 2019",,"March 12, 2020","CHINA, China, China",,"https://ClinicalTrials.gov/show/NCT03794336"
118,"NCT03938441","Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study",,"Recruiting","No Results Available","Diabetes Type 2|Pre-diabetes","Other: Intermittent Fasting","Number of hypoglycemic events","gino gaddini|Mike O'Callaghan Military Hospital","All","18 Years to 69 Years   (Adult, Older Adult)","Not Applicable","40","U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FWH20190059H","July 31, 2019","December 2020","December 2020","May 6, 2019",,"May 21, 2020","Mike O'Callaghan Military Medical Center, Nellis Air Force Base, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT03938441"
119,"NCT04007133","Statin Compliance of Patients With Non-insulin-dependent Diabetes","DIOS","Terminated","No Results Available","Non-insulin-dependent Diabetes","Other: Girerd test","Compliance rate with statin measured by the Girerd test|Compliance rate with statin according to the type of prevention|Compliance rate with statin according to risk factors","Lille Catholic University|University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"119","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RC-P0064","January 31, 2018","July 12, 2018","July 12, 2018","July 5, 2019",,"July 17, 2019","Lille Catholic Hospitals, Lomme, Nord, France",,"https://ClinicalTrials.gov/show/NCT04007133"
120,"NCT03902288","Short-term Effect of Pomegranate Juice on Blood Sugar and Its Controlling Hormones in Pre-diabetic and Type II Diabetic Patients.",,"Completed","No Results Available","Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)","Other: Fresh pomegranate juice","Fasting serum glucose measurement|Insulin hormone measurement|Erythropoietin hormone measurement|Thyroxine hormone measurement|Cortisol hormone measurement|Melatonin hormone measurement|Testosterone hormone measurement|Aldosterone hormone measurement|Serum total antioxidant activity measurement","Jordan University of Science and Technology","All","35 Years to 60 Years   (Adult)","Not Applicable","85","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-20120189","October 2012","April 2013","April 2013","April 4, 2019",,"April 4, 2019","Jordan University of Science and Technology, Irbid, Jordan",,"https://ClinicalTrials.gov/show/NCT03902288"
121,"NCT03862963","Lifestyle Intervention to Treat Diabetes in the Marshall Islands",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Behavioral: Standard of diabetes care|Behavioral: Lifestyle Intervention","Fasting glucose|HbA1c|Fasting insulin|HOMA-IR|Usage of diabetes medications|Cholesterol (total, HDL, LDL) and triglycerides|Blood pressure|Heart rate|High-sensitivity C-reactive protein|Body weight|Body mass index (BMI)|Waist circumference","University of Alabama at Birmingham|United States Department of Defense|Loma Linda University|Brenda Davis Nutrition Consultation Services|Canvasback Missions, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","138","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-170414009","June 1, 2006","July 31, 2008",,"March 5, 2019",,"March 5, 2019",,,"https://ClinicalTrials.gov/show/NCT03862963"
122,"NCT03837405","(R33 Phase) Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger","Delish R33","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Behavioral: Carbohydrate-restricted diet|Behavioral: Mindfuless","diet adherence between intervention arms as measured by ketones|diet adherence between intervention arms as measured by 24- hour diet recall--dichotomous|executive functioning /decreased impulsivity-Delayed Discounting|emotion-related eating|Glycemic control--a1c|frequency of eating in response to cravings|diet adherence between intervention arms as measured by 24- hour diet recall--total carbs, continuous|executive functioning /decreased impulsivity--Relative Reinforcing Value of Food (RRVF)|Salzburg Stress Eating Scale|dietary resilience (resumption of dietary adherence) after dietary non-adherence occurs|Weight change","University of California, San Francisco|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","4R33AT009333|AT009333","December 12, 2018","September 30, 2021","September 30, 2021","February 12, 2019",,"February 12, 2019","Osher Center for Integrative Medicine, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03837405"
123,"NCT04086043","The MILESTONE Study",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus","Device: Endovascular Denervation","Changes in Oral Glucose Tolerance Test from baseline to 6 months|Changes in glycosylated hemoglobin from baseline to 6 months|Changes in Oral Glucose Tolerance Test up to 2 years|Changes in glycosylated hemoglobin up to 2 years|Changes in insulin up to 2 years|Changes in catecholamine up to 2 years|Changes in glucagon up to 2 years|Changes in blood pressure up to 2 years|Changes in creatinine up to 2 years|Changes in blood urea nitrogen (BUN) up to 2 years","Zhongda Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDNT2DM-2019","September 10, 2019","September 9, 2022","December 31, 2022","September 11, 2019",,"September 11, 2019","Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04086043"
124,"NCT03817099","Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study","MyDia-RNP","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Other: Nutrition Intervention based on My Dia-RNP|Other: Usual Care","Rate of participants completed the study|Rate of participants adhered to the intervention|Efficacy potential on the rate of hypoglycemia|Efficacy potential on the fructosamine level|Efficacy potential on fasting glucose|Efficacy potential on glycemic control|Efficacy potential on functional status|Efficacy potential on body mass index","Universiti Putra Malaysia|Nestle Health Science|Joslin Diabetes Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MyDia-RNP study","April 1, 2019","December 1, 2019","December 30, 2019","January 25, 2019",,"August 12, 2019","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",,"https://ClinicalTrials.gov/show/NCT03817099"
125,"NCT03955952","Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes",,"Completed","No Results Available","Obesity|Type2 Diabetes|Bariatric Surgery Candidate","Procedure: Bariatric Surgery","Composite of All-Cause Mortality and Cardiovascular Outcomes|Incidence of Major Adverse Cardiovascular Event (MACE-3)|All-Cause Mortality|Incidence of Coronary Disease Events|Incidence of Cerebrovascular Events|Incidence of Heart Failure|Development of Nephropathy|Incidence of Atrial Fibrillation","The Cleveland Clinic","All","18 Years to 80 Years   (Adult, Older Adult)",,"13722","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19-066","June 5, 2019","July 12, 2019","August 26, 2019","May 20, 2019",,"January 2, 2020","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03955952"
126,"NCT03968354","NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)","NADRANK-1","Not yet recruiting","No Results Available","Diabetes type2|NASH - Nonalcoholic Steatohepatitis|NAFLD","Biological: ""Collection of additional blood tubes; Biobanking (plasma, liver tissue).","Measure of RANKL mRNA expression in the liver|Serum concentrations of RANKL|Serum osteoprotegerin concentrations|HOMA-IR|Measure of RANKL mRNA|Measure of RANKL protein levels|Measure of RANK mRNA|Measure of RANK protein levels|RANK/RANKL genes polymorphisms|NF-kB pathway in hepatocytes and Kupffer cells","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","K171105J|2018-A02468-47","February 2020","June 2021","October 2021","May 30, 2019",,"January 28, 2020",,,"https://ClinicalTrials.gov/show/NCT03968354"
127,"NCT03826381","NAFLD Among Patients With Type 2 Diabetes and CKD",,"Recruiting","No Results Available","Non-Alcoholic Fatty Liver Disease|Chronic Kidney Diseases|Type2 Diabetes","Diagnostic Test: Magnetic resonance (MR) spectroscopy of the liver|Diagnostic Test: Fibroscan|Device: Continuous glucose monitoring (CGM) for four days.|Radiation: Dual Energy X-ray Absorptiometry (DEXA) scan|Biological: Blood samples|Other: Clinical and demographic data","Prevalence of NAFLD and actual estimate of liver signal measured by MR spectroscopy|Prevalence and actual estimate of liver lipid signal measured by MR spectroscopy in relation to bile acids measured in the blood|NAFLD, as measured by MR spectroscopy, and its association with metabolomics and lipidomic profiles measured in the blood in relation to impaired renal function|The prevalence of fibrosis|NAFLD, as measured by MR spectroscopy, and its association with glucose profiles in relation to impaired renal function","Rigshospitalet, Denmark","All","18 Years to 90 Years   (Adult, Older Adult)",,"108","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","NAFLD and CKD - Study 1","May 6, 2019","August 2021","December 2021","February 1, 2019",,"May 30, 2019","Department of Nephrology, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03826381"
128,"NCT03847116","Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease",,"Completed","No Results Available","Nonalcoholic Fatty Liver Disease|Light-to-moderate Alcohol Consumption|Type2 Diabetes Mellitus",,"Light-to-moderate alcohol consumption (LMAC) and risk of prevalent type 2 diabetes mellitus (T2DM)|LMAC and incident risk of T2DM","Ningbo No. 1 Hospital","All","18 Years and older   (Adult, Older Adult)",,"14014","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LHNAFLD 2018-V1.0","January 1, 2009","January 1, 2019","February 10, 2019","February 20, 2019",,"July 5, 2019","Ningbo first hospital, Ningbo, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03847116"
129,"NCT04049149","Precision Medicine in Chinese Patients With Young Onset Diabetes",,"Recruiting","No Results Available","Type 2 Diabetes","Other: Biogenetic explanation and endocrinologist intensive managment|Other: Usual care management","Prevalence of C-Peptide (CP) and Glutamic Acid Decarboxylase Antibody (GADA) in Chinese adult patients with T2D (Part 1 of study)|The correlation of C-Peptide (CP) and Glutamic Acid Decarboxylase Antibody (GADA) on clinical outcomes (Part 1 of study)|Incidence of young-onset type 2 diabetes and its genetic susceptibility (Part 2 of study)|Incidence of any diabetes-related micro/macrovascular endpoints (Part 3 of study)|The levels of CP and GADA and the number of genetic variants for disease prognositication and classification to guide precision medicine in YOD (Part 1 and 2 of study)|The number of genetic variants for disease prognositication and classification to guide precision medicine in YOD (Part 1 and 2 of study)|The number of novel targets and pathways for discovery of drug targets with companian diagnostics (Part 1 and 2 of study)|The number of patients attaining ≥3 cardiometabolic risk factors (Part 3 of study)|Incidence of severe hypoglycaemia (Part 3 of study)|Rate of changes in glycaemic control (Part 3 of study)|On-treatment changes in blood pressure (Part 3 of study)|On-treatment changes in lipid profiles (Part 3 of study)|On-treatment changes in Body Mass Index (Part 3 of study)|On-treatment changes in CP (Part 3 of study)|Rate of changes in use of medications (Part 3 of study)|Changes in patient's Quality of life (Part 3 of study)|Changes in patient's reported outcomes : Depression (Part 3 of study)|Changes in patient's compliance (Part 3 of study)|Changes in patient's diabetes empowerment (Part 3 of study)|Changes in patient's diabetes self care activities (Part 3 of study)|Changes in patient's perceived personal control (Part 3 of study)|Changes in patient's genetic counseling satisfaction (Part 3 of study)|Changes in patient's diabetes related distress (Part 3 of study)|Changes in patient's Depression Anxiety Stress (Part 3 of study)","Chinese University of Hong Kong","All","18 Years to 50 Years   (Adult)","Not Applicable","860","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CRE-2019.080","January 14, 2020","September 1, 2023","September 1, 2023","August 7, 2019",,"January 21, 2020","The Chinese University of Hong Kong, Sha Tin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04049149"
130,"NCT03931434","Effect of Aged Garlic Extract (AGE) on Improving Coronary Atherosclerosis in People With Type 2 Diabetes Mellitus",,"Completed","No Results Available","Coronary Arteriosclerosis|Endothelial Dysfunction|Type 2 Diabetes Mellitus","Dietary Supplement: Aged Garlic Extract (AGE)|Dietary Supplement: Placebo","Progression rates of low attenuation plaque under influence of Aged Garlic Extract (AGE) as compared to placebo.|Rate of change in inflammatory biomarkers (CRP,IL-6)|Rate of change in endothelial function","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","All","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Garlic-5","February 23, 2016","May 7, 2018","May 7, 2018","April 30, 2019",,"April 30, 2019","Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT03931434"
131,"NCT03959501","Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy",,"Recruiting","No Results Available","Type 2 Diabetes|Ketonemia","Drug: Dapagliflozin 10 mg|Drug: Sitagliptin 100mg","Change in serum ketone levels after treatment|Change in fasting glucose|Change in glycated haemoglobin|Change in body weight|Change in blood pressure|Change in fasting lipid|Change in free fatty acid levels|Change in fasting glucagon levels|Change in homeostasis model assessment 2 steady-state beta-cell function","The University of Hong Kong","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW-17-166","August 16, 2017","June 30, 2020","June 30, 2020","May 22, 2019",,"May 24, 2019","L2 Diabetes Centre, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03959501"
132,"NCT04125082","A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections",,"Active, not recruiting","No Results Available","Type 2 Diabetes Treated With Insulin","Drug: Afrezza Inhalant Product","Time In Range|Hypoglycemia|Hemoglobin A1c|Quality of Life Questionnaires","Diabetes and Glandular Disease Clinic|Mannkind Corporation|DexCom, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","29","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MK-001","February 27, 2019","March 15, 2020","March 15, 2020","October 14, 2019",,"January 30, 2020","Diabetes and Glandular Disease Clinic, P.A., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04125082"
133,"NCT04129268","Determining the Minimal Amount of Exercise to Improve Glycaemic Control","MiniEx","Recruiting","No Results Available","Type 2 Diabetes","Other: Cycle ergometry exercise at 60% VO2max","Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities|Lowering of serum insulin values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities","Lancaster University","Male","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","248319|19/NW/0066","October 2019","December 2020","December 2020","October 16, 2019",,"October 22, 2019","Royal Lancaster Infirmary, Lancaster, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04129268"
134,"NCT04183868","Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)","FIORE","Recruiting","No Results Available","Type 2 Diabetes|Cardiovascular Risk Factor","Drug: Empagliflozin 10 MG|Drug: Glimepiride 2 mg","Change of myocardial metabolic rate of glucose|Change of glycemic parameters|Change of insulin sensitivity|Change of blood pressure|Change of left ventricular systolic and diastolic function|Change of pro-BNP|Change of inflammatory state|Change of cardiovascular biomarkers|Change of heart rate variability|Change of lipid profile","University of Catanzaro","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 4","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2016.43","April 2016","December 2020","April 2021","December 3, 2019",,"December 3, 2019","Universital Hospital Mater Domini, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04183868"
135,"NCT04197635","Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF","DAPA-VO2","Recruiting","No Results Available","Heart Failure With Reduced Ejection Fraction|Type 2 Diabetes","Diagnostic Test: Maximal functional capacity by cardiopulmonary exercise testing|Diagnostic Test: Echocardiography|Behavioral: Evaluation of quality of life health related|Diagnostic Test: Submáximal functional capacity assesment by 6 minutes walk test|Other: Clinical evaluation","Functional capacity|Echocardiografy parameters|Evaluation of quality of life helath related: Minnesota Living with Heart Failure Questionnaire (MLHFQ)|Submáximal functional capacity assesment by 6 minutes walk test","Fundación para la Investigación del Hospital Clínico de Valencia","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ESR-17-13447(DAPA-HF)|2018-002614-12","June 1, 2019","October 31, 2019","February 28, 2021","December 13, 2019",,"December 20, 2019","Hospital Clínico Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04197635"
136,"NCT03983551","Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas",,"Completed","No Results Available","Type 2 Diabetes Mellitus|Proteinuria","Drug: Dipeptidyl Peptidase 4 Inhibitor|Drug: Sulfonylurea","Change in urinary albumin-to-creatinine ratio|Change in serum glycated hemoglobin A1c|Change in body weight|Change in serum creatinine|Change in systolic blood pressure","Changhua Christian Hospital","All","20 Years to 95 Years   (Adult, Older Adult)","Phase 4","101","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","190512","March 1, 2016","February 10, 2018","February 28, 2018","June 12, 2019",,"June 14, 2019",,,"https://ClinicalTrials.gov/show/NCT03983551"
137,"NCT03832933","Comparing High and Normal Protein Diets for the Dietary Remission of Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Type 2|Obesity|Diet Modification","Behavioral: High Protein Diet|Behavioral: Standard Protein Diet","Change in body weight by weight scale|Change in T2D diagnosis criteria|Change in % body fat|Change in % fat free mass (FFM)|Change in % FFM","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300002928","July 1, 2019","September 30, 2020","September 30, 2021","February 6, 2019",,"April 17, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03832933"
138,"NCT03978286","Vortioxetine vs Sertraline in Mexicans",,"Completed","No Results Available","Depression|Type 2 Diabetes Mellitus","Drug: Vortioxetine|Drug: Sertraline","Effect of antidepressant treatment (sertraline versus vortioxetine) in remission of depression in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in severity of depression in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in treatment of diabetes related stress in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in fasting plasma glucose level in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in glycemic control in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in cholesterol control in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in triglycerides control in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in weigh in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in waist circumference in depressed type 2 diabetic patients.|Effect of antidepressant treatment (sertraline versus vortioxetine) in anthropometric variables in depressed type 2 diabetic patients.","Universidad Juárez Autónoma de Tabasco","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00228/16.","June 30, 2016","June 30, 2017","June 30, 2018","June 7, 2019",,"June 13, 2019",,,"https://ClinicalTrials.gov/show/NCT03978286"
139,"NCT04082351","Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients.",,"Completed","No Results Available","Type2 Diabetes","Dietary Supplement: Nanotechnology structured water ( Magnalife)|Dietary Supplement: ordinary water","HbA1c","ALI KAMAL M. SAMI|University of Sulaimani","All","Child, Adult, Older Adult","Not Applicable","387","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","USulaimani","July 3, 2016","February 16, 2018","February 16, 2018","September 9, 2019",,"September 10, 2019",,,"https://ClinicalTrials.gov/show/NCT04082351"
140,"NCT04156685","Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1",,"Completed","No Results Available","Type2 Diabetes Mellitus","Drug: Part A, Reference (D635 10/500mg, Astrazeneca)|Drug: Part B, Reference (D635 10/500mg, Astrazeneca)","Part A : Cmax under fasting condition|Part A : AUClast under fasting condition|Part B : Cmax under fed condition|Part B : AUClast under fed condition|Part A : AUCinf under fasting condition|Part A : Tmax under fasting condition|Part A : t1/2 under fasting condition|Part B : AUCinf under fed condition|Part B : Tmax under fed condition|Part B : t1/2 under fed condition","Chong Kun Dang Pharmaceutical","All","19 Years to 45 Years   (Adult)","Phase 1","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","A84_07BE1908","August 6, 2019","August 30, 2019","October 2, 2019","November 7, 2019",,"November 7, 2019","Korea University Anam Hospital, Seoul, Seongbuk-Gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04156685"
141,"NCT04127994","Glycemic Variability Comparing Two vs Six Meals in Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus Type 2|Overweight and Obesity|Meal Time","Other: Comparing 3 versus 6 meals in type 2 diabetes patients","Impact of 3 stroke diet in glycemic variability compared to a 6 stroke diet|Impact of 3 stroke diet in Hba1c levels compared to a 6 stroke diet|Impact of 3 stroke diet in fasting glucose levels compared to a 6 stroke diet|Impact of 3 stroke diet in triglycerides levels compared to a 6 stroke diet|Impact of 3 stroke diet in cholesterol levels compared to a 6 stroke diet|Impact of 3 stroke diet in FGF-21 levels compared to a 6 stroke diet|Impact of 3 stroke diet in systolic and diastolic blood pressure compared to a 6 stroke diet|Impact of 3 stroke diet in satiety compared to a 6 stroke diet|Impact of 3 stroke diet in weight loss compared to a 6 stroke diet","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|L.N. Adrián Romero Villaseñor|L.N. Aurora Ramos Flores|L.N. Mariana Galindo Guzmán|Dr. Daniel Cuevas Ramos|Dr. Adrian Soto Mota|Dr. Francisco J. Gómez Pérez|Dr. Alfonso Gulias Herrero|Lucía Palacios Baez|Gerardo Saavedra Jiménez|Hector Donaldo Espinosa Salazar|Issa Lill Santiago Falfán|Cristina Aurora Tlapanco Beltrán|Horacio Correa Carranza|Alejandra Dominguez Sanchez","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2100","August 17, 2018","December 12, 2019","February 2020","October 16, 2019",,"October 16, 2019","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ''INCMNSZ'', Ciudad de mexico, Mexico","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04127994/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04127994/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT04127994"
142,"NCT03917576","Heart Rate During Exercise in Type 2 Diabetes","HRinT2DM","Completed","No Results Available","Type2 Diabetes Mellitus|Hyperglycemia|Heart Rate|Exercise Training","Other: Behavioral|Other: Exercise training intervention","Maximum heart rate|Resting heart rate|Heart rate pre each HIIT-interval|Heart rate post each HIIT-interval","Universidad de Los Lagos|Universidad de la Frontera","Female","18 Years to 60 Years   (Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","RP010317","January 4, 2018","April 4, 2018","April 7, 2018","April 17, 2019",,"April 17, 2019","Cristian ALvarez, Osorno, Chile","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03917576/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03917576"
143,"NCT03792607","Network-based Approach in Type 2 Diabetes and Its Cardiovascular Risk","PIRAMIDE","Recruiting","No Results Available","Type 2 Diabetes Mellitus|Cardiovascular Diseases",,"DNA methylation status both of CD4+ and CD8+ cells|Bioinformatics analysis to predict putative novel T2D candidate genes|RNA sequencing analysis both in CD4+ and CD8+ cells|ROC curves to evaluate putative DNA methylation/microRNA interactions as prognostic biomarkers of cardiovascular dysfunction in T2D patients","Giuditta Benincasa|University of Campania ""Luigi Vanvitelli""","All","50 Years and older   (Adult, Older Adult)",,"35","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RRC-2015-2360454","February 14, 2019","January 14, 2020","June 14, 2020","January 3, 2019",,"September 18, 2019","Università della Campania Luigi Vanvitelli, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT03792607"
144,"NCT04207541","Promoting Insulin Initiation Among Suboptimal Diabetic Control Patients",,"Recruiting","No Results Available","Type 2 Diabetes","Behavioral: Brief motivational interview","Proportion of insulin acceptance|Proportion of insulin initiation","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UW 19-614","October 1, 2019","September 30, 2020","June 30, 2021","December 23, 2019",,"December 23, 2019","Hospital Authority, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04207541"
145,"NCT03818581","Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus|Insomnia|Sleep Disorder|Inflammation","Drug: Suvorexant|Other: Placebo","Subjective Total Sleep Time|Subjective Wake After Sleep Onset|Insomnia Severity Index","Massachusetts General Hospital","All","25 Years to 75 Years   (Adult, Older Adult)","Phase 4","86","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2019P000076","March 15, 2019","March 15, 2021","September 15, 2021","January 28, 2019",,"August 14, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03818581"
146,"NCT03839667","Intensive Diet and Physical Activity on Diabetes","IDEATE","Recruiting","No Results Available","Type2 Diabetes|Life Style","Behavioral: intensive diet intervention|Behavioral: Enhanced physical activity intervention|Behavioral: Standard education","change in HbA1C level (%)|proportion of reversal of diabetes|reduction in the dosage of hypoglycemic drugs|change in insulin sensitivity|change in islet β-cell function|change in liver steatosis quantified by MRI-PDFF (percentage)|change in pancreatic adipose content quantified by MRI-PDFF (percentage)|change in body mass index (BMI)|change in visceral fat (cm^2)|change in serum fetuin-A concentration (μg/mL)|change in serum GREM2 concentration (pg/ml)|change in serum Caspase-cleaved Keratin 1 concentration (U/L)|changes in serum FGF21 concentration (pg/ml)|changes in overall gut microbiota profile|depression|health related quality of life|cardiovascular risk","Shanghai Jiao Tong University School of Medicine","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","324","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ruijin-2018-174-2","February 28, 2019","July 15, 2020","July 15, 2020","February 15, 2019",,"February 15, 2019","Ruijin hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03839667"
147,"NCT04101669","EndoBarrier System Pivotal Trial(Rev B)","STEP-1","Recruiting","No Results Available","Diabetes type2|Obesity","Device: EndoBarrier Liner|Other: Sham","Change in HbA1c|HbA1c value|Weight Loss|Insulin use|LDL cholesterol|Triglycerides|Blood pressure|Change in daily fasting glucose level|Change in Nonalcoholic Fatty Liver Disease (NAFLD)|Change in Nonalcoholic Steatohepatitis (NASH)|HOMA-IR|Questionnaire|Change in Risk Level of CKD eGFR|Change in Risk Level of CKD albumin","GI Dynamics|Biostatistical Consulting, Inc.","All","30 Years to 55 Years   (Adult)","Not Applicable","240","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","18-1","September 9, 2019","April 1, 2023","April 1, 2024","September 24, 2019",,"September 24, 2019","Surgical Specialists of Louisianna, Metairie, Louisiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Michigan Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, Michigan, United States|Jefferson University Hospital/Diabetes Research Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04101669"
148,"NCT04127448","Exergaming Versus Aerobic Exercises on Mild Cognitive Impairment",,"Completed","No Results Available","Type 2 Diabetes|Cognitive Impairment","Other: Exergaming Training Group|Other: Aerobic Exercise Group","Change in Standardized Mini-mental State Examination (SMMSE) from baseline to 6th week.|Change in Montreal cognitive assessment scale (MOCA, Urdu version) from baseline to 6th week.|Change in Trail Making Test-A (TMT-A) from baseline to 6th week|Change in Trail Making Test-B (TMT-B) from baseline to 6th week|Change in Verbal fluency test (VFT) from baseline to 6th week|Change in Random Blood sugar (RBS) from baseline to 6th week","Riphah International University","All","50 Years and older   (Adult, Older Adult)","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Riphah IU Raana Ali","March 1, 2017","August 1, 2017","August 1, 2017","October 15, 2019",,"October 15, 2019","Riphah International University, Islamabad, Federal, Pakistan",,"https://ClinicalTrials.gov/show/NCT04127448"
149,"NCT04024631","Phenotyping Genetic Risk for Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Genetics","Other: 75g glucose beverage (Glucola, Trutol, or similar brand)|Other: DXA, whole body","Glucose response to an oral glucose load|Visceral adiposity index|HOMA-IR|Disposition index","University of Pennsylvania","All","10 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","831865","June 17, 2019","June 30, 2023","June 30, 2023","July 18, 2019",,"July 19, 2019","Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04024631"
150,"NCT03805191","A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients","FLAT","Recruiting","No Results Available","Type 2 Diabetes Mellitus|Poor Glycemic Control",,"The extent of change in MAGE|The extent of change in PPGE,LAGE|The control rate of HbA1c","Qilu Hospital of Shandong University|Bayer","All","18 Years and older   (Adult, Older Adult)",,"900","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","RD-OI-1257","January 1, 2019","November 30, 2020","December 30, 2022","January 15, 2019",,"April 12, 2019","Qilu Hospital of Shandong University, Jinan, China",,"https://ClinicalTrials.gov/show/NCT03805191"
151,"NCT03847701","Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients",,"Recruiting","No Results Available","Type2 Diabetes","Other: Balanced diet high in Slowly Digestible Starch|Other: Balanced diet low in Slowly Digestible Starch","MAGE comparison following 3 months of intake of a diet either high or low in SDS|Glycemia iAUC characterisation of a standard challenge test (FlexMeal) during the first metabolic day|Insulin iAUC characterisation of a standard challenge test (FlexMeal) during the first metabolic day|GLP1 iAUC characterisation of a standard challenge test (FlexMeal) during the first metabolic day|Inflammatory status comparison during the first metabolic day : CRPus concentration|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : TNFa iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : IL6 iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : IL1Ra iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the first metabolic day : IL18 iAUC|Glycemic impacts comparison following the intake of a diet either high or low in SDS during the time course of the study|Insulinemic impacts comparison following the intake of a diet either high or low in SDS during the time course of the study|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : CRPus concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : TNFa concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : IL6 concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : IL1Ra concentration|Inflammatory impacts comparison following the intake of a diet either high or low in SDS during the time course of the study : IL18 concentration|Oxidative Stress comparison following the intake of a diet either high or low in SDS during the time course of the study : MDA concentration|Oxidative Stress comparison following the intake of a diet either high or low in SDS during the time course of the study : Urinary isoprostanes concentration|Cardiovascular risk markers comparison following the intake of a diet either high or low in SDS during the time course of the study : MCP1 concentration|Cardiovascular risk markers comparison following the intake of a diet either high or low in SDS during the time course of the study : sICAM concentration|Cardiovascular risk markers comparison following the intake of a diet either high or low in SDS during the time course of the study : sVCAM concentration|Glycemic impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day|Insulinemic impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day|GLP1 iAUC characterisation of a standard challenge test (FlexMeal) during the second metabolic day|Inflammatory impacts comparison following 3 months of intake of a diet either high or low in SDS : CRPus concentration|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : TNFa iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : IL6 iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : IL1Ra iAUC|Inflammatory impacts characterisation of a standard challenge test (FlexMeal) during the second metabolic day : IL18 iAUC|Cardiovascular risk markers characterisation following the intake of a diet either high or low in SDS : MCP1 concentration|Cardiovascular risk markers characterisation following the intake of a diet either high or low in SDS : sICAM concentration|Cardiovascular risk markers characterisation following the intake of a diet either high or low in SDS : sVCAM concentration|Oxydative stress characterisation following the intake of a diet either high or low in SDS : MDA concentration|Oxydative stress characterisation following the intake of a diet either high or low in SDS : Urinary isoprostanes concentration|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : MAGE|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : MAGE|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : TIR|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : TIR|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : CV|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : CV|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : SD|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : SD|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : MIME|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : MIME|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : MODD|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : MODD|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : CONGA|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : CONGA|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : ADRR|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : ADRR|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : LGBI|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : LGBI|Glycemic profile parameters following the intake of a diet either high or low in SDS during the time course of the study : HGBI|Glycemic profile parameters following the 3 months consumption of a diet either high or low in SDS : HGBI|Mean daylong incremental Area Under the Curve (iAUC), measured by CGMS, following the intake of a diet either high or low in SDS during the time course of the study|Mean daylong total Area Under the Curve (tAUC), measured by CGMS, following the intake of a diet either high or low in SDS during the time course of the study|Compare diabetes follow-up markers during the first metabolic day : HbA1c|Compare diabetes follow-up markers following the intake of a diet either high or low in SDS during the time course of the study : HbA1c concentration|Compare diabetes follow-up markers following the 3 months consumption of a diet either high or low in SDS : HbA1c concentration|Compare Diabetes follow-up markers during the first metabolic day : Fructosamine concentration|Compare Diabetes follow-up markers following the intake of a diet either high or low in SDS during the time course of the study : fructosamine concentration|Compare Diabetes follow-up markers following the 3 months consumption of a diet either high or low in SDS : Fructosamine concentration|Compare Diabetes follow-up markers during the first metabolic day : Glycated Albumin concentration|Compare Diabetes follow-up markers following the intake of a diet either high or low in SDS during the time course of the study : glycated albumin concentration|Compare Diabetes follow-up markers following the 3 months consumption of a diet either high or low in SDS : Glycated Albumin concentration|Arterial Endothelial Function characterisation following the intake of a diet either high or low in SDS during the time course of the study : RHI|Arterial Endothelial Function characterisation following the intake of a diet either high or low in SDS during the time course of the study : AI|Arterial Endothelial Function characterisation following the intake of a diet either high or low in SDS during the time course of the study : HRV|Anthropometry parameters characterisation during the first metabolic day : height|Anthropometry parameters characterisation during the first metabolic day : body weight|Anthropometry parameters characterisation during the first metabolic day : waist circumference|Anthropometry parameters characterisation during the first metabolic day : hip circumference|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : height|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : body weight|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : waist circumference|Anthropometry parameters characterisation following the intake of a diet either high or low in SDS during the time course of the study : hip circumference|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : height|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : body weight|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : waist circumference|Anthropometry parameters characterisation following the 3 months consumption of a diet either high or low in SDS : hip circumference|Body composition parameters characterisation during the first metabolic day: total body water|Body composition parameters characterisation during the first metabolic day: body fat|Body composition parameters characterisation during the first metabolic day: lean mass.|Body composition parameters characterisation following the 3 months consumption of a diet either high or low in SDS : total body water|Body composition parameters characterisation following the 3 months consumption of a diet either high or low in SDS : body fat|Body composition parameters characterisation following the 3 months consumption of a diet either high or low in SDS : lean mass|Resting energy metabolism profile during the first metabolic day: Resting Metabolism Rate|Resting energy metabolism profile following the 3 months consumption of a diet either high or low in SDS : Resting Metabolism Rate|Diabetic glycemic variability characterisation following the 3 months consumption of a diet either high or low in SDS|Level of physical activity characterisation following the intake of a diet either high or low in SDS during the time course of the study : IPAQ|Characterisation of acceptability to H-SDS diet in free living conditions|Characterisation of the percent of compliance to H-SDS diet in free living conditions","Mondelēz International, Inc.|Centre de Recherche en Nutrition Humaine Rhone-Alpe|Biofortis Mérieux NutriSciences","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","80","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","KBE045","June 25, 2019","July 2020","December 2020","February 20, 2019",,"May 27, 2020","Centre de Recherche en Nutrition Humaine Rhone-Alpes, Pierre-Bénite, France",,"https://ClinicalTrials.gov/show/NCT03847701"
152,"NCT03964428","Serum Ferritin and Hepicidin Concentration in Chronic Periodontitis Patients With T2DM",,"Completed","No Results Available","Periodontitis|Type2 Diabetes",,"ferritin concentration|hepicidin concentration","Fayoum University","All","30 Years to 50 Years   (Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","fayoum dentistry","September 1, 2018","January 30, 2019","January 30, 2019","May 28, 2019",,"June 11, 2019","Nayroz Abelfattah Tarrad, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03964428"
153,"NCT03814915","Diabetes Research on Patient Stratification","DIRECT","Completed","No Results Available","Type2 Diabetes",,"Glycemic deterioration","Lund University","All","35 Years to 74 Years   (Adult, Older Adult)",,"3049","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMIDIRECT_2012","October 15, 2012","July 31, 2019","July 31, 2019","January 24, 2019",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT03814915"
154,"NCT03867656","Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus","Other: GLP-2|Other: GIP|Other: Placebo","CTX|P1NP|PTH|Sclerostin|Glucose|Insulin|C-peptide|GIP|GLP-2|Glucagon|Blood pressure|Heart rate","University of Copenhagen|Hvidovre University Hospital","Male","25 Years to 70 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","KS-4-Diabetes-19","February 26, 2019","June 26, 2020","June 26, 2020","March 8, 2019",,"January 18, 2020","Hvidovre University Hospital, Hvidovre, Denmark",,"https://ClinicalTrials.gov/show/NCT03867656"
155,"NCT03969719","A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Non-alcoholic Steatohepatitis","Drug: Placebo|Drug: PF-06835919","Percent change from baseline in whole liver fat at Week 16|Change from baseline in glycosylated hemoglobin (HbA1c) at Week 16|Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)|Number of Participants With Treatment Emergent Treatment-Related Hypoglycemia Adverse Events (HAEs)|Number of Participants With Clinical Laboratory Abnormalities|Change from Baseline in Blood Pressure|Number of Participants With Abnormal Electrocardiogram (ECG)|Percent change from baseline in high-sensitivity C-Reactive Protein (hs-CRP)|Change from baseline in fasting insulin|Change from baseline in fasting glucose|Change from baseline in HOMA-IR|Percent change from baseline in alanine aminotransferse (ALT)|Change from baseline in glycosylated hemoglobin (HbA1c)","Pfizer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","C1061011|DOSE RESPONSE IN PATIENTS","July 18, 2019","February 10, 2021","February 10, 2021","May 31, 2019",,"April 22, 2020","Horizon Clinical Research Associates, PLLC, Gilbert, Arizona, United States|Scottsdale Medical Imaging Research, LLC, Gilbert, Arizona, United States|Dignity Health, Phoenix, Arizona, United States|St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Clinical Research Consortium, Tempe, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|San Diego Imaging SDI, Chula Vista, California, United States|Holy Trinity Medical Clinic, Harbor City, California, United States|Innovative Clinical Research, Inc., Harbor City, California, United States|eStudySite, La Mesa, California, United States|Clinical Trials Research, Lincoln, California, United States|National Research Institute, Los Angeles, California, United States|Renaissance Imaging Medical Associates, Northridge, California, United States|Huntington Medical Research Institute, Pasadena, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Diagnostic Radiological Imaging Sacramento, Sacramento, California, United States|Precision Research Institute, San Diego, California, United States|Sharp and Children's MRI Center, LLC, San Diego, California, United States|Sharp & Children's MRI Center, LLC, San Diego, California, United States|West Coast Radiology, Santa Ana, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Liberty Pacific Advanced Imaging, Tarzana, California, United States|Harbor - UCLA Diagnostic Imaging Center, Torrance, California, United States|Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center, Torrance, California, United States|University Clinical Investigators, Incorporated, Tustin, California, United States|Independant Imaging, Atlantis, Florida, United States|Twin Lakes Imaging, Daytona Beach, Florida, United States|Life Radiology, Doral, Florida, United States|MD Clinical LLC, Hallandale Beach, Florida, United States|Borland Groover, Jacksonville, Florida, United States|Multi-Specialty Research Associates, Inc., Lake City, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Health Care Family Rehab and Research Center, Miami, Florida, United States|Clinical Research of Miami, Miami, Florida, United States|Finlay Medical Research, Miami, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Y & L Advance Health Care, Inc D/B/A Elite Clinical Research, Miami, Florida, United States|Stand Up MRI of Miami, Miami, Florida, United States|Vital Imaging Center, Miami, Florida, United States|Vital Imaging, Miami, Florida, United States|Unique Imaging, Miami, Florida, United States|International Research Associates, Miami, Florida, United States|Advanced Gastroenterology Associates, LLC, Palm Harbor, Florida, United States|Rose Radiology, Palm Harbor, Florida, United States|Castillo & Torres MD PA, Palm Springs, Florida, United States|Altus Research, Inc., Palm Springs, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Qps-Mra, Llc, South Miami, Florida, United States|Physicians Research Associates , LLC, Lawrenceville, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Alliance Multispecialty Research, LLC, Wichita, Kansas, United States|AA MRC, Flint, Michigan, United States|Nebraska Medicine, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|SIMONMED, Las Vegas, Nevada, United States|Alliance Multispecialty Research, LLC, Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|SimonMed Imaging, Las Vegas, Nevada, United States|Northwell Imaging of Garden City, Garden City, New York, United States|Northwell Health - Center for Liver Diseases and Transplantation, Manhasset, New York, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Gastroenterology Associates of the Piedmont, PA, Winston-Salem, North Carolina, United States|PMG Research of Winston Salem, Winston-Salem, North Carolina, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|ProScan, Cincinnati, Ohio, United States|RAS Health, Marion, Ohio, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center Department of Radiology, Philadelphia, Pennsylvania, United States|Dallas Diabetes and Endocrine Research Center, Dallas, Texas, United States|Prime Diagnostic Imaging, Dallas, Texas, United States|Southwest Diagnostics Imaging Center, Dallas, Texas, United States|HRMD Research, Dallas, Texas, United States|PrimeCare Medical Group, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Woodlake MRI, Houston, Texas, United States|Endocrine IPS, PLLC, Houston, Texas, United States|The Endocrine Center, Houston, Texas, United States|Texas Center for Drug Development, Houston, Texas, United States|Houston Medical Imaging, Houston, Texas, United States|South Texas Radiology Imaging Centers, Live Oak, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Diabetes and Glandular Disease Clinic, P.A., San Antonio, Texas, United States|South Texas Radiology Imaging Center, San Antonio, Texas, United States|STRIC Northeast Imaging Center, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, LLC (NECRSA, LLC), Schertz, Texas, United States|Collaborative Advanced Research Imaging, Richmond, Virginia, United States|Clinical Research Partners, Richmond, Virginia, United States|Virginia Endoscopy Group, Richmond, Virginia, United States|VCU Gateway Building Basement, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Salem VA Medical Center, Salem, Virginia, United States|Harborview Medical Center Investigational Drug Services, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|West Coast Medical Imaging, Victoria, British Columbia, Canada|Nova Scotia Health Authority QE II Health Sciences Centre, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority QE II Health Sciences Centre, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority - Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Aggarwal and Associates Limited, Brampton, Ontario, Canada|The Western Centre for Functional and Metabolic Mapping, London, Ontario, Canada|Oxford Medical Imaging, Mississauga, Ontario, Canada|Bluewater Clinical Research Group, Inc., Sarnia, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Resonance Magnetique du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Clinique de Medecine Urbaine du Quartier Latin, Montreal, Quebec, Canada|McGill University Health Centre (MUHC) Royal Victoria Hospital Research Pharmacy, Montreal, Quebec, Canada|McGill University Health Centre (MUHC), Montreal, Quebec, Canada|MRI TTT Philips Radiation Oncology, Montreal, Quebec, Canada|Research Institute of the MUHC, Montreal, Quebec, Canada|Radiologie Varad, Montreal, Quebec, Canada|IRM Quebec, Quebec, Canada|Centre de Recherche Saint-Louis, Quebec, Canada|ALPHA Recherche Clinique Lebourgneuf, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03969719"
156,"NCT04203173","Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1","FINANCE-DM","Active, not recruiting","No Results Available","Type 2 Diabetes","Behavioral: FINANCE-DM|Behavioral: Active Comparator","Glycemic control (HbA1c)|Resource Utilization and Cost|LDL-Cholesterol|Quality of Life as measured by SF-12|Systolic and Diastolic Blood Pressure|Self-Care Behavior|Self-Care Behavior Brooks Medication Adherence Scale (BMAS)","Medical College of Wisconsin","All","21 Years and older   (Adult, Older Adult)","Not Applicable","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","1R01DK120861","December 1, 2019","March 31, 2024","March 31, 2024","December 18, 2019",,"May 6, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04203173"
157,"NCT04203147","Home-based Diabetes-Modified Behavioral Activation Treatment for Low Income Seniors With T2DM","HOME DM-BAT","Suspended","No Results Available","Type 2 Diabetes","Behavioral: Supportive Therapy (Control)|Behavioral: Home DM-BAT","LDL-Cholesterol|Systolic and Diastolic Blood Pressure|Glycemic control (HbA1c)|Quality of Life as measured by SF-12|Self-Care Behaviors","Medical College of Wisconsin","All","65 Years and older   (Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","1R01DK118038-01A1","January 3, 2020","January 31, 2024","January 31, 2024","December 18, 2019",,"May 6, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04203147"
158,"NCT04151849","Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota",,"Recruiting","No Results Available","Type 2 Diabetes","Drug: GLP-1 receptor agonist|Drug: SGLT2 inhibitor","Urinary aldosterone at 3 months|Change in gastrointestinal microbiota.|Urinary aldosterone at 12 months","University of Tartu","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","290/T-20","January 10, 2020","December 31, 2023","December 31, 2023","November 5, 2019",,"January 13, 2020","Tartu University Hospital, Tartu, Estonia",,"https://ClinicalTrials.gov/show/NCT04151849"
159,"NCT04120571","Non-REm Sleep inTervention to improvE Diabetes RESTED","RESTED","Recruiting","No Results Available","Type 2 Diabetes","Other: Sleep Audiological Intervention Device (SleepAID)|Other: sham control","Blood glucose (CGM)|Blood glucose (OGTT)","University of Lincoln|University of Leeds","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","18092","April 1, 2019","November 1, 2020","August 1, 2021","October 9, 2019",,"October 9, 2019","University of Lincoln, Lincoln, Lincolnshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04120571"
160,"NCT03959306","Efficacy of Black Seed Oil in Patients With Type 2 Diabetes Mellitus",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: Black Seed Oil|Drug: Anti-Diabetics","Effect on Markers of Endothelial Dysfunction(The change in the level of soluble intercellular adhesion molecule ( ICAM) in serum using ELISA kit)|Effect on Glycemic Control (Measurement of fasting blood glucose )|Effect on Glycemic Control (Measurement of glycated hemoglobin)|Effect on Lipid Profile ( Measurement of TC,TG, HDL-C,LDL-C)|Effect on Inflammatory Status ( Measurement of High sensitive C-Reactive Protein using ELISA kit)|Effect on Quality of Life ( Using Diabetes-39 questionnaire )","Ain Shams University","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PHCL14","April 24, 2019","August 2019","August 2019","May 22, 2019",,"May 22, 2019","Ain Shams University Hospitals, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03959306"
161,"NCT03940183","Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Trelagliptin Succinate|Drug: Placebo Oral Tablet","HbA1c|Fasting blood glucose|2-hour postprandial blood glucose|fasting insulin|fasting glucagon|active Glucagon-like peptide-1（GLP-1） level|The percentage of HbA1c＜6.5% and HbA1c＜7%|body weight|Body Mass Index","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSPC/HC1425/201801","July 8, 2019","June 30, 2021","July 31, 2021","May 7, 2019",,"April 28, 2020","Beijing Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03940183"
162,"NCT04092023","Self-care Management Programme for Type 2 Adult DM Patients With Poor Glycemic Control","T2DM","Completed","No Results Available","Type 2 Diabetes","Other: nursing education","Glycemic control|Diabetes Knowledge|Self-Efficacy: Diabetes Empowerment Scale - Short Form (C-DES-SF)|QOL: Audit of Diabetes Dependent Quality of Life (ADDQoL-19)","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","ChanCY_RP1","October 2, 2018","September 1, 2019","September 1, 2019","September 17, 2019",,"September 18, 2019","KWC FM & PHC, Hospital Authority, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04092023"
163,"NCT03983187","Effect of Rotating Magnetic Therapy on Blood Glucose Spectrum of Type 2 Diabetic Patients With Glargine Therapy",,"Not yet recruiting","No Results Available","Type 2 Diabetes","Device: Rotating Magnetic Therapy","the standard deviation of blood glucose|mean blood glucose|time in range","Majianhua|Nanjing First Hospital, Nanjing Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY20190530-03","June 15, 2019","November 15, 2019","December 31, 2019","June 12, 2019",,"June 17, 2019",,,"https://ClinicalTrials.gov/show/NCT03983187"
164,"NCT04184947","Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists",,"Completed","No Results Available","Type 2 Diabetes","Drug: SGLT2 inhibitor|Drug: GLP-1 receptor agonist","3 point major adverse cardiovascular events (4P-MACE)|Hospitalization for cardiovascular causes|Death|Myocardial infarction|Heart failure|Stroke|Revascularization","University of Padova","All","18 Years to 90 Years   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DIMEDDEI3","March 1, 2014","December 31, 2018","February 29, 2020","December 4, 2019",,"March 11, 2020","Division of Metabolic Diseases, University Hospital of Padova, Padova, Italy",,"https://ClinicalTrials.gov/show/NCT04184947"
165,"NCT04210024","Rural Dwelling Older Adults With T2DM",,"Enrolling by invitation","No Results Available","Type2 Diabetes","Other: Diabetes Empowerment Education Program","Change in Diabetes Knowledge|Change in Health Literacy","Brittany L Smalls|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","45657|1K01DK116923","May 30, 2019","December 31, 2024","December 31, 2024","December 24, 2019",,"December 24, 2019","UK Center for Excellence in Rural Health, Kentucky Homeplace, Hyden, Kentucky, United States|Stinnett Area Community Center, Stinnett, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04210024"
166,"NCT04070794","Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions",,"Not yet recruiting","No Results Available","Type2 Diabetes","Drug: Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)|Drug: Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)","Peak Plasma Concentration (Cmax) of gemigliptin, LC 15-0636 and metformin|AUC0-tlast of gemigliptin, LC 15-0636 and metformin|AUC0-∞ of gemigliptin, LC 15-0636 and metformin","LG Chem","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LG-DMCL008","November 1, 2019","November 30, 2019","December 30, 2019","August 28, 2019",,"August 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04070794"
167,"NCT04050098","Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.",,"Not yet recruiting","No Results Available","Type2 Diabetes","Drug: gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|Drug: Gemigliptin tartrate sesquihydrate and metformin","bioequivalence study","LG Chem","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LG-DMCL007","November 1, 2019","November 30, 2019","November 30, 2019","August 8, 2019",,"August 8, 2019",,,"https://ClinicalTrials.gov/show/NCT04050098"
168,"NCT03944200","A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fed State",,"Completed","No Results Available","Type2 Diabetes","Drug: DA-1229_01(A), Sugamet SR Tab 5/1000mg®|Drug: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)","Area under the concentration-time curve(AUCt)|Maximum plasmaconcentration of drug in plasma(Cmax)|Area under the plasma drug concentration-time curve from time 0 to infinity(AUCinf)|AUCt/AUCinf|Time to reach the maximum plasma concentration(Tmax)|Terminal elimination rate constant(ramda z)|Terminal elimination half-life(t1/2)","Dong-A ST Co., Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","DDS18-034BE","February 7, 2019","March 25, 2019","March 25, 2019","May 9, 2019",,"May 20, 2020","Metro Hospital, Anyang si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03944200"
169,"NCT03939143","A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State",,"Completed","No Results Available","Type2 Diabetes","Drug: DA-1229_01(A), Sugamet SR Tab 5/1000mg®|Drug: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)","Area under the concentration-time curve(AUCt)|Maximum plasmaconcentration of drug in plasma(Cmax)|Area under the plasma drug concentration-time curve from time 0 to infinity(AUCinf)|AUCt/AUCinf|Time to reach the maximum plasma concentration(Tmax)|Terminal elimination rate constant(ramda z)|Terminal elimination half-life(t1/2)","Dong-A ST Co., Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","DDS18-033BE","February 7, 2019","April 4, 2019","April 4, 2019","May 6, 2019",,"May 20, 2020","Metro Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03939143"
170,"NCT04208230","Progression and Etiology of Cortical Porosity in Diabetic Bone Disease","PREPT2D","Recruiting","No Results Available","Type 2 Diabetes","Device: XtremeCT","Amount of fat within cortical pores at the distal tibia at baseline|Amount of vessels within cortical pores at the distal tibia at baseline.|Association between Type 2 diabetes status, marrow, and longitudinal changes in cortical porosity at the distal tibia","University of California, San Francisco","All","50 Years to 70 Years   (Adult, Older Adult)",,"96","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","iRIS 16-20196","January 3, 2017","December 31, 2021","December 31, 2021","December 23, 2019",,"December 24, 2019","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04208230"
171,"NCT04192292","Study of Sulphonylurea Synergy With DPP4 Inhibitors","SSS","Recruiting","No Results Available","Type 2 Diabetes","Drug: Sulfonylurea|Drug: DPP4 Inhibitor","Difference in incretin effect between mixed meal tests|Insulin secretory response analysed by KCNJ11 genotype|Variation in blood glucose during intervention blocks analysed by continuous glucose monitoring","University of Dundee","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2018DM13","October 8, 2019","September 30, 2020","December 31, 2020","December 10, 2019",,"December 10, 2019","Ninewells Hospital and Medical School, Dundee, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04192292"
172,"NCT03845179","GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide",,"Recruiting","No Results Available","Type2 Diabetes","Other: Placebo|Other: GIP receptor antagonist|Drug: DPP-4 inhibitor|Other: Placebo tablet","C-peptide|Plasma glucose|Insulin|Total and intact GIP|Total and intact GLP-1|Glucagon|CTX|Lipids","University Hospital, Gentofte, Copenhagen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","H-18040916","May 29, 2019","March 1, 2020","February 2022","February 19, 2019",,"February 24, 2020","Center for Clinical Metabolic Research, Copenhagen, Hellerup, Denmark",,"https://ClinicalTrials.gov/show/NCT03845179"
173,"NCT04137705","MultiOrgan Multi-Parametric MRI Study","MORIS","Not yet recruiting","No Results Available","Type 2 Diabetes","Other: Multiparametric MRI","Assessment of repeatability (precision under the same conditions in the same subjects: 2 separate MRI acquisitions on the same scanner) of body composition and multiple organ metrics.|Assessment of the reproducibility (precision under different measurement conditions: same participants scanned on separate MRI scanners at both 1.5T and 3T) of multiparametric MRI for the assessment of body composition and multiple organ metrics.","Perspectum Diagnostics Ltd","All","18 Years and older   (Adult, Older Adult)",,"188","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","CA0080","November 25, 2019","November 25, 2021","November 25, 2021","October 24, 2019",,"October 24, 2019",,,"https://ClinicalTrials.gov/show/NCT04137705"
174,"NCT03792399","Continuous Glucose Monitoring With Immediate or Delayed Counseling Feedback",,"Completed","No Results Available","Type2 Diabetes","Behavioral: feedback counseling","Change of HbA1c|Change of score for self efficacy|Change of score for diabetes associated stress|Change of score for depression|Change in diet composition|Change in exercise amount, time spent in light activity|Change in exercise amount, time spent in moderate activity|Change in exercise amount, time spent in intense activity|Change in exercise amount (time spent in sedentary behavior)","National Cheng-Kung University Hospital","All","45 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","NCKUH-10508011","March 7, 2016","October 12, 2017","October 12, 2017","January 3, 2019",,"January 3, 2019",,,"https://ClinicalTrials.gov/show/NCT03792399"
175,"NCT04099745","Comparing the Accuracy of Different Blood Glucose Monitoring Systems (CGM and FGM)",,"Not yet recruiting","No Results Available","Type 2 Diabetes","Device: CGM|Device: FGM","Accuracy of different blood glucose monitoring systems (CGM and FGM) with intravenous blood glucose level as the gold standard|three-day blood glucose fluctuation of CGM|forty-day blood glucose fluctuation of FGM","Nanjing First Hospital, Nanjing Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","KY20190823-02","October 1, 2019","December 30, 2019","February 1, 2020","September 23, 2019",,"September 23, 2019",,,"https://ClinicalTrials.gov/show/NCT04099745"
176,"NCT04074603","Comparing the Effects of Insulin Glargine on Blood Glucose Between Needle-free Jet Injection and Insulin Pen",,"Not yet recruiting","No Results Available","Type 2 Diabetes","Device: The needle-free jet injector|Device: Conventional insulin pen","Blood glucose profile|Sensitivity Questionnaire of Patients","Majianhua|Nanjing First Hospital, Nanjing Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY20190530-02-KS-01","September 1, 2019","July 31, 2020","December 31, 2020","August 30, 2019",,"August 30, 2019",,,"https://ClinicalTrials.gov/show/NCT04074603"
177,"NCT04043065","Liver-enriched Antimicrobial Peptide 2",,"Completed","No Results Available","Type 2 Diabetes","Biological: Liver-enriched antimicrobial peptide 2|Other: Placebo","Plasma insulin|Beta-cell secretion|LEAP-2|Resting energy expenditure|Appetite, satiety, and general well-being","University Hospital, Gentofte, Copenhagen|Gubra ApS","Male","18 Years to 25 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LEAP-2","January 28, 2019","May 20, 2019","May 20, 2019","August 2, 2019",,"August 5, 2019","Center for Clinical Metabolic Research, Hellerup, Denmark",,"https://ClinicalTrials.gov/show/NCT04043065"
178,"NCT03959865","GLP-1 REceptor Agonists and Real World EvIdeNce","GLP-1REWIN","Active, not recruiting","No Results Available","Type 2 Diabetes","Drug: Long-acting GLP-1RA|Drug: Short-acting GLP-1RA|Drug: Human-based GLP-1RA|Drug: Exendin-based GLP-1RA|Drug: Fixed ratio BI/GLP-1RA combination|Drug: Flexible BI/GLP-1RA combination","HbA1c|Weight|Blood pressure|Persistence","University of Padova|Azienda Ospedaliera di Padova","All","18 Years to 80 Years   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","4462/AO/18","December 19, 2018","February 11, 2019","May 31, 2019","May 22, 2019",,"May 22, 2019","Servizio di Diabetologia UOC Medicina Generale, Cittadella, Padova, Italy|U.O.S Diabetologia, Ospedale di Schiavonia, Monselice, Padova, Italy|U.O. Diabetologia ULSS2, Pieve di Soligo, Treviso, Italy|U.O. Diabetologia e Dietetica ULSS6, Padova, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Diabetologia ULSS2, Treviso, Italy",,"https://ClinicalTrials.gov/show/NCT03959865"
179,"NCT03960424","Patient and Caregiver-Centered Diabetes Telemanagement Program for Hispanic/Latino Patients",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus|Type2 Diabetes","Other: Comprehensive Outpatient Management|Behavioral: Diabetes Telemonitoring","HbA1c|Hypoglycemia episodes|Adherence|Diabetes self-efficacy|PAID|Weight|Cholesterol|Blood Pressure|Diabetes Quality of life","Northwell Health|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AD-2017C3-9185","September 1, 2019","May 1, 2022","June 30, 2022","May 23, 2019",,"July 22, 2019","Feinstein Institute of Medical Research, Manhasset, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/ICF_003.pdf","https://ClinicalTrials.gov/show/NCT03960424"
180,"NCT04126291","Type 2 Diabetes Prevention Toolkit for Health-Care Professionals",,"Recruiting","No Results Available","Childhood Obesity","Behavioral: Evaluation of whiteboard videos","Change in self-efficacy/confidence related to pediatric obesity management|Change in knowledge|Change in self-efficacy/confidence related to pediatric weight management|Change in practice related to pediatric weight management","The Hospital for Sick Children|University of Ottawa","All","18 Years and older   (Adult, Older Adult)","Not Applicable","65","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1000060439","October 1, 2019","October 2020","December 2020","October 15, 2019",,"March 24, 2020","The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04126291"
181,"NCT03998267","Qatar Diabetes Mobile Application Trial","QDMAT","Recruiting","No Results Available","Type2 Diabetes Mellitus","Device: Droobi|Other: Standard of care","Difference in mean HbA1c|Subject perceptions of diabetes self management|Change in subjects attitudes towards disease|Changes in insulin doses|Changes in reported hypoglycemia|Time to achieve normoglycemia|Number of clinical interactions|Missed clinical appointments|Weight|Blood Pressure|Lipids","Hamad Medical Corporation|Qatar Computing Research Institute (QCRI)|Droobi Health","All","18 Years to 60 Years   (Adult)","Not Applicable","180","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","17292","August 22, 2019","August 17, 2020","December 31, 2020","June 26, 2019",,"February 17, 2020","Hamad General Hospital, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT03998267"
182,"NCT03871621","Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","ELUCIDATE","Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Diabetes Medicines|Drug: Dapagliflozin","Cardiac global longitudinal strain (GLS)|Anthropometric measures by body mass index (BMI)|Left ventricle (LV) mass|Left atrial (LA) volume|Epicardial fat thickness (EAT)|Homeostatic Model Assessment of Insulin Resistance, HOMA-IR|Plasma biomarker: N-terminal pro-brain natriuretic peptide (Nt-proBNP)|Plasma biomarker: Fatty acid binding protein (FABP)|Plasma biomarker: Growth differentiation factor-15 (GDF-15)|Plasma biomarker: Procollagen type III N-terminal peptide (PIIINP)|Plasma biomarker: Lipoprotein-associated phospholipase A2 (Lp-PLA2)","Mackay Memorial Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 4","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18MMHIS149e","April 1, 2019","June 30, 2020","July 31, 2020","March 12, 2019",,"March 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03871621"
183,"NCT04058730","Comparative Interventional Study to Evaluate the Role of LRYGBP, LSG & SMM",,"Active, not recruiting","No Results Available","Type 2 Diabetes Mellitus","Procedure: Laparoscopic Roux en Y Gastric by pass surgery|Procedure: Laparoscopic Sleeve Surgery|Other: Standard Medical Management","Glycosylated Haemoglobin less than 6.5 mg/dl","Max Institute of Minimally Access, Metabolic & Bariatric Surgery","All","30 Years to 60 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAMBS04","April 1, 2015","April 2020","April 2020","August 15, 2019",,"November 21, 2019","Max Institute of Minimal Access Metabolic and Bariatric Surgery, New Delhi, India|Max Institute of Minimal Access, Metabolic & Bariatric Surgery, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT04058730"
184,"NCT03793023","Observational Study to Evaluate the Efficacy and Safety of Teneligliptin",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Teneligliptin 20mg","Change in HbA1c|Change in FBG|Change in body weight, BMI|Change in lipid profile(Total cholesterol, LDL cholesterol, HDL cholesterol)|The percentage of patients with HbA1c <7.0% and <6.5%|The percentage of patients with a decrease from baseline in HbA1c|Safety Outcome","Handok Inc.","All","19 Years and older   (Adult, Older Adult)",,"4875","Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","HD_TEN_OS2015","January 2016","December 2020","December 2020","January 4, 2019",,"January 7, 2019","Ajou University Hospital, Suwon, Gyeonggi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03793023"
185,"NCT03934593","Building a Healthy Temple: a Diabetes Self-management Support Program in Hispanic Faith Community Settings",,"Recruiting","No Results Available","Type2 Diabetes Mellitus","Behavioral: Faith-Based (FB, BHT DSMS)|Other: Faith-Placed (FP, Stanford DSMP)","The change in HbA1c|Waist circumference|Body Mass Index|Quality of Life (QoL)|Diabetes Self-care practices|The barriers to diabetes care.|Physical Activity (PA) level assessment|Occupational physical activity","The University of Texas at San Antonio|American Diabetes Association","All","21 Years to 85 Years   (Adult, Older Adult)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","ADA#1-17-ICTS-029","January 1, 2017","June 30, 2020","June 30, 2020","May 2, 2019",,"May 2, 2019","Human Nutrition Lab, UTSA, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03934593"
186,"NCT04091373","A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Combination Product: cotadutide multidose pen injection","Area under the plasma concentration time curve|Maximum observed plasma drug concentration|Area under the plasma concentration time curve from zero to infinity|Time to maximum observed plasma drug concentration|Terminal phase elimination half life|Apparent clearance|Anti drug antibody incidence and titer|Incidence of treatment-emergent adverse events, including those related to changes in vital signs (including body temperature, heart rate, blood pressure) and safety laboratory evaluations (including hematology, chemistry, plasma glucose, urinalysis).","MedImmune LLC","All","18 Years to 60 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","D5670C00025","September 27, 2019","March 6, 2020","March 6, 2020","September 16, 2019",,"April 7, 2020","Research Site, Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04091373"
187,"NCT03849261","Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy Adults",,"Active, not recruiting","No Results Available","Type2 Diabetes Mellitus","Drug: CKD-387|Drug: D635","Cmax of Dapagliflozin|Cmax of Metformin|AUClast of Dapagliflozin|AUClast of Metformin|AUCinf of Dapagliflozin|AUCinf of Metformin|Tmax of Dapagliflozin|Tmax of Metformin|T1/2 of Dapagliflozin|T1/2 of Metformin|Vd/F of Dapagliflozin|Vd/F of Metformin|CL/F of Dapagliflozin|CL/F of Metformin","Chong Kun Dang Pharmaceutical","All","19 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","184BE18026","January 14, 2019","February 1, 2019","February 22, 2019","February 21, 2019",,"February 21, 2019","Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03849261"
188,"NCT04077216","Effect of Extra Virgin Olive Oil on Postprandial Blood Glucose in Type 2 Diabetes Mellitus Patients",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: Extra Virgin Olive Oil (EVOO)","trans-meal blood glucose","Makati Medical Center","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","MakatiMedCtr","September 1, 2018","November 30, 2018","November 30, 2018","September 4, 2019",,"September 4, 2019","Makati Medical Center, Makati City, NCR, Philippines","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT04077216/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04077216"
189,"NCT03919656","SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Dapagliflozin 10 mg|Drug: Placebo Oral Tablet","Metabolomics changes in blood|Metabolomics changes in urine|BMI (body mass index) changes|Changes in insulin resistance|Changes in metabolic control|Changes in Quality of Life: 36-Item Short Form Health Survey (SF-36) questionnaire|Changes in albuminuria","Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","FIM-DAPA-2018-01","May 2019","December 2019","April 2020","April 18, 2019",,"April 23, 2019","Virgen de la Victoria University Hospital. Endocrinology Department, Malaga, Spain",,"https://ClinicalTrials.gov/show/NCT03919656"
190,"NCT03864705","Compliance of Diabetic Patients Treated With Metformin","CODAMET","Recruiting","No Results Available","Type 2 Diabetes Mellitus","Diagnostic Test: Measurement of plasma metformin levels","Plasma metformin levels","Institute for Clinical and Experimental Medicine","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","001","March 1, 2019","December 31, 2020","December 31, 2020","March 6, 2019",,"March 6, 2019","Institute for Clinical and Experimental Medicine, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT03864705"
191,"NCT03864432","An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: Gemigliptin 25mg|Drug: Gemigliptin 50mg|Drug: Gemigliptin 100mg|Drug: Gemiglptin 50mg multiple dose","AUClast of Gemigliptin|Cmax of Gemigliptin","LG Chem","All","19 Years to 45 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LG-DPCL020","July 2, 2019","October 3, 2019","February 28, 2020","March 6, 2019",,"March 3, 2020","Shanghai Xuhui Central hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03864432"
192,"NCT03849495","Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: CKD-370|Drug: D745","AUClast of Empagliflozin|Cmax of Empagliflozin|AUCinf of Empagliflozin|Tmax of Empagliflozin|T1/2 of Empagliflozin|CL/F of Empagliflozin|Vd/F of Empagliflozin","Chong Kun Dang Pharmaceutical","All","19 Years to 50 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191BE18033","February 19, 2019","March 17, 2019","March 21, 2019","February 21, 2019",,"March 12, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03849495"
193,"NCT03849339","Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition",,"Active, not recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: CKD-387|Drug: D635","Cmax of Metformin|AUClast of Metformin|AUCinf of Metformin|Tmax of Metformin|t1/2 of Metformin|CL/F of Metformin|Vd/F of Metformin","Chong Kun Dang Pharmaceutical","All","19 Years to 55 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","184BE18028","January 28, 2019","February 21, 2019","February 28, 2019","February 21, 2019",,"February 21, 2019","Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03849339"
194,"NCT03848637","The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: CKD-375|Drug: D387","Maximum plasma concentration of Empagliflozin|Maximum plasma concentration of Metformin|Area under the plasma concentration of Empagliflozin-time curve from time zero to time of last measurable concentration|Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration|Area under the plasma concentration of Empagliflozin-time curve from time zero to infinity|Area under the plasma concentration of Metformin-time curve from time zero to infinity|Time to reach maximum (peak) plasma concentration of Empagliflozin following drug administration|Time to reach maximum (peak) plasma concentration of Metformin following drug administration|Half-life of Empagliflozin|Half-life of Metformin|Apparent clearance of Empagliflozin|Apparent clearance of Metformin|Apparent volume of distribution of Empagliflozin|Apparent volume of distribution of Metformin","Chong Kun Dang Pharmaceutical","All","19 Years to 50 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","192BE18036","April 14, 2019","April 24, 2019","May 1, 2019","February 21, 2019",,"March 6, 2019",,,"https://ClinicalTrials.gov/show/NCT03848637"
195,"NCT03926806","Yoghurt Consumption, Body Weight Management and Glycemic Control of T2DM Patients",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Other: Plain yoghurt|Other: Vitamin B yoghurt","Body weight management|Glycemic control|Change of ghrelin response|Change of GLP-1 response","Harokopio University|National and Kapodistrian University of Athens","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","1354.18-11-16","November 25, 2016","August 8, 2018","December 29, 2018","April 25, 2019",,"April 26, 2019",,,"https://ClinicalTrials.gov/show/NCT03926806"
196,"NCT04089280","Probiotics in Metformin Intolerant Patients With Type 2 Diabetes","ProGasMet","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Metformin Adverse Reaction","Dietary Supplement: Sanprobi Barrier-multispecies probiotic|Other: Placebo Comparator","Adverse gastrointestinal symptoms related to metformin treatment|Intestinal barrier permeability and inflammation - zonulin blood concentration|Intestinal barrier permeability and inflammation - immunoglobulins (IG) against zonulin|Intestinal barrier permeability and inflammation - CRP|Intestinal barrier permeability and inflammation - stool concentration of zonulin|Intestinal barrier permeability and inflammation - blood concentration of calprotectin|Intestinal barrier permeability and inflammation - stool concentration of calprotectin|Faecal microbiota composition|Short chain fatty acids (SCFAs)|Cardiometabolic state - lipid parameters|Cardiometabolic state - Body Mass Index|Cardiometabolic state - blood pressure|Cardiometabolic state - heart rate|Cardiometabolic state - HbA1c|Oxidative stress markers - SOD|Oxidative stress markers - GPx|Oxidative stress markers - CAT|Oxidative stress markers - GR|Oxidative stress markers - TOC|Oxidative stress markers - LHP|Oxidative stress markers - LPS|Oxidative stress markers - PSH|Oxidative stress markers - MDA|Oxidative stress markers - GSH|Oxidative stress markers - TAS","Medical University of Silesia|Sanprobi Sp. z o.o., Sp. k., Szczecin, Poland","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SilesianMU2","October 16, 2018","October 16, 2020","May 16, 2021","September 13, 2019",,"September 26, 2019","Department of Internal Diseases, Diabetology and Nephrology, Zabrze, Poland",,"https://ClinicalTrials.gov/show/NCT04089280"
197,"NCT03907202","A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM",,"Recruiting","No Results Available","Type II Diabetes Mellitus","Drug: Daily injection of KBP/placebo for up to 28 days","Treatment Emergent Adverse Events (TEAEs).|Vital sign - Blood Pressure.|Vital sign - Pulse (beats per min).|Vital sign - Body Temperature.|Vital sign - Respiratory frequency.|Electrocardiogram (ECG) - PQ interval.|Electrocardiogram (ECG) - QRS complex.|Electrocardiogram (ECG) - QT interval.|Safety laboratory parameter - lipids.|Safety laboratory parameter - haematology.|Safety laboratory parameter - coagulation.|Safety laboratory parameter - urinalysis.|Pharmacokinetic Evaluation - KBP-089 Area Under Curve.|Pharmacokinetic Evaluation - KBP-089 Cmax.|Gastric emptying - Paracetamol Cmax.|Gastric emptying - Paracetamol Tmax.|Gastric emptying - Paracetamol Area Under Curve (AUC).|Fasting and postprandial glucose concentration.|Fasting and postprandial insulin concentration.|Fasting and postprandial C-peptide concentration.|Fasting and postprandial glucagon concentration.|Body weight.|N-(1-deoxy)-fructosyl-haemoglobin (HbA1c).|Fridericia's corrected QT interval (QTcF).","KeyBioscience AG|Eli Lilly and Company|Nordic Bioscience A/S|Profil Institut für Stoffwechselforschung GmbH","All","18 Years to 64 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","KBP089/CD/002","April 17, 2018","December 2019","December 2019","April 8, 2019",,"April 8, 2019","Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT03907202"
198,"NCT03967561","Progressive vs. Non-progressive Water-based Aerobic Training on Type 2 Diabetes Control: a Randomized Clinical Trial","PAT-DM2","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: Progressive water-based aerobic training|Other: Non-progressive aerobic training","Glycated Hemoglobin levels (HbA1c)|Fasting plasma glucose|Fasting insulin|Insulin-resistance index (HOMA-IR)|Total cholesterol|High density lipoprotein|Low density lipoprotein|Triglycerides|Plasma renin|C-reactive protein|Peak oxygen uptake|Oxygen uptake at the second ventilatory threshold.|Percentage of oxygen consumption in the second ventilatory threshold from the peak oxygen uptake|Systolic blood pressure.|Diastolic blood pressure.|Resting heart rate|Maximum dynamic muscle strength (1RM) in the knees extension exercise|Muscular resistance (maximal repetitions) in the knees extension exercise.|Timed up-and-go test performed at the usual speed.|Timed up-and-go test performed at the maximal speed.|Overall quality of life and in physical, psychological, social relationships and environment domains, evaluated by instrument of World Health Organization (WHOQOL).|Depressive symptoms, evaluated by Depression Inventory Patient Health Questionnaire (PHQ-9)|Sleep quality, evaluated by Pittsburgh Sleep Scale|Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Long Form.","Federal University of Rio Grande do Sul|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2.855.513","June 10, 2019","October 30, 2019","November 15, 2019","May 30, 2019",,"June 4, 2019",,,"https://ClinicalTrials.gov/show/NCT03967561"
199,"NCT04209075","Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)",,"Recruiting","No Results Available","Diabetes","Dietary Supplement: Biomebliss|Drug: Metformin|Dietary Supplement: Placebo","GI Tolerability score|Stool Short Chain Fatty Acids (SCFA)","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","10 Years to 25 Years   (Child, Adult)","Phase 2","50","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","200018|20-DK-0018","March 10, 2020","December 14, 2023","December 14, 2023","December 23, 2019",,"March 27, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04209075"
200,"NCT03829514","Fenofibrate in Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type II","Drug: Fenofibrate","change in levels of individual plasma proteins, measured as ion current, in proteomic analysis via liquid chromatography-mass spectrometry","Medical University of South Carolina","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00079289","February 4, 2019","June 28, 2020","September 30, 2020","February 4, 2019",,"March 6, 2020","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03829514"
201,"NCT03810846","Feasibility and Safety of Walking Football in Patients With Type 2 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Walking football exercise program","Exercise intensity - subjective internal load|Exercise intensity - objective internal load|Exercise intensity - external load|Acute glycemic effect|Acute systolic blood pressure effect|Acute diastolic blood pressure effect|Incidence of falls|Incidence of foot injuries|Incidence of musculoskeletal injuries|Rate of Enjoyment|Glycemic control|Blood lipid profile|Clinical systolic blood pressure|Clinical diastolic blood pressure|Body mass index|Waist circumference|Body fat|Body lean mass|Agility/balance|Habitual physical activity|Food pattern|Cognitive state|Health-related quality of life|Medication","Universidade do Porto|Federação Portuguesa de Futebol, Portugal|Administração Regional de Saúde do Norte, Portugal|Fédération Internationale de Football Association","Male","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISPUP-RMFIFA2018","September 17, 2018","January 31, 2019","June 30, 2019","January 22, 2019",,"August 22, 2019","Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal",,"https://ClinicalTrials.gov/show/NCT03810846"
202,"NCT04016415","Decreasing Stress in Type 2 Diabetes","DESTRESS-T2D","Recruiting","No Results Available","Stress|Diabetes Mellitus, Type 2","Behavioral: Mindfulness Based Stress Reduction|Behavioral: Stress Management Education","Change in Hemoglobin A1c from Baseline to 6 months|Change in Hemoglobin A1c from Baseline to 1 year|Change in Hemoglobin A1c from Baseline to 2 months|Change in Diabetes Distress Scale from Baseline to 2 months|Change in Diabetes Distress Scale from Baseline to 6 months|Change in Diabetes Distress Scale from Baseline to 1 year|Change in Perceived Stress Scale-10 from Baseline to 2 months|Change in Perceived Stress Scale-10 from Baseline to 6 months|Change in Perceived Stress Scale-10 from Baseline to 1 year","Milton S. Hershey Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health (NIH)|Penn State University|Rowan University|West Chester University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","290","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10532|1R01DK119379-01","July 1, 2020","March 31, 2025","March 31, 2025","July 11, 2019",,"March 30, 2020","Penn State College of Medicine, Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04016415"
203,"NCT03804905","STUDIIO-Diabetes Pilot: STUdy of Drug Insurance to Improve Outcomes of Diabetes",,"Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus|Medication Adherence|Medication Compliance|Medication Nonadherence","Other: Drug cards","Lacking medication insurance|Visit during the run-in period|Use of the Ocean app|Response to the insurance status question|Use of the drug card|Time from allocation to receipt of drug card|Time from allocation to use of drug card","Sunnybrook Health Sciences Centre|Canadian Institutes of Health Research (CIHR)","All","25 Years to 64 Years   (Adult)","Not Applicable","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","103-2018","April 1, 2020","March 31, 2022","March 31, 2022","January 15, 2019",,"September 25, 2019",,,"https://ClinicalTrials.gov/show/NCT03804905"
204,"NCT04020445","Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes",,"Recruiting","No Results Available","HBA1c|Body Weight|Hypoglycemia","Other: de-escalation of complex insulin regimens","change in HbA1c|change in body weight|change in risk of hypoglycemia","Bekes County Central Hospital|University of Debrecen|Szeged University","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","BekesCCH","January 1, 2016","January 1, 2021","January 1, 2021","July 16, 2019",,"July 16, 2019","Zoltán Taybani, Békéscsaba, Békés, Hungary",,"https://ClinicalTrials.gov/show/NCT04020445"
205,"NCT03953963","Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Insulin Resistance","Device: HydraSolve T2D™","Change in blood glucose control|Lack of serious adverse events (SAEs)|Change in Insulin Sensitivity|Change in fasting plasma glucose (FPG)|Reduction in body weight","Medality Medical","All","22 Years to 75 Years   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIP-00001","October 18, 2019","July 30, 2021","March 15, 2022","May 17, 2019",,"March 5, 2020","University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03953963"
206,"NCT04040595","The Genetics of Adipose Tissue Function and Its Link to Type 2 Diabetes and Heart Disease","FATFUNgenes","Recruiting","No Results Available","Diabetes Mellitus","Procedure: Abdominal fat biopsy","Mean adipocyte size (µm2) assessed using Image J software.|Adipose tissue expression of genes that are markers of adipogenesis (PPARy, CREBP).|Adipose tissue expression of genes that are markers of fibrosis (SPARC, collagens, TGFbeta, LOX).|Adipose tissue expression of genes that are determinants of adipose inflammation (IL-1beta, IL-6, and 8, TNFalpha, MCP-1/CCL2).","Royal Devon and Exeter NHS Foundation Trust|University of Exeter|NIHR Exeter Clinical Research Facility","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRAS: 257693|105009|19/SW/0012|1909872","March 7, 2019","February 28, 2021","August 31, 2021","July 31, 2019",,"July 31, 2019","Royal Devon and Exeter NHS Foundation Trust / University of Exeter, Exeter, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04040595"
207,"NCT04097483","Treatment Adherence Intervention in Patients With Type 2 Diabetes and Comorbid Depression","TELE-DD","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2|Depression","Behavioral: Telephone Intervention Group","Diabetes control measured by Glycosylated Haemoglobin|Patient Health Questionnaire (PHQ-9)|Medication possession ratio (MPR)|MBG questionnaire|LDL-Cholesterol|Diabetes Distress Scale (DDS)|Sociodemographic data Gender, age, marital status, education, occupation, economical level|Blood pressure|Body mass index (BMI)|Research nurse qualitative and quantitative evaluation about Treatment Adherence and diseases management.","Instituto de Investigación Sanitaria Aragón|Universidad de Zaragoza","All","21 Years and older   (Adult, Older Adult)","Not Applicable","428","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","TELE-DD","January 2017","December 2018","March 2020","September 20, 2019",,"February 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04097483"
208,"NCT04068285","Neuromuscular Adaptations to Exercise In Patients With Type 2 Diabetes Mellitus",,"Completed","No Results Available","Gait, Unsteady|Aerobic Exercise","Other: Aerobic Exercise","walking speed","Pamukkale University","All","30 Years to 60 Years   (Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","60116787-0","November 4, 2019","June 1, 2020","June 1, 2020","August 28, 2019",,"June 4, 2020","Pamukkale University, Denizli, Turkey",,"https://ClinicalTrials.gov/show/NCT04068285"
209,"NCT03908281","Fasted Exercise Training in Type 2 Diabetes","FED","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Fasted Exercise|Behavioral: Postprandial Exercise","Concentration of HbA1c (mmol/mol)|Liver fat (%)|Pancreatic fat (%)|Muscle fat (%)|Concentrations of Fasting glucose|Concentrations of Fasting insulin|Concentrations of Fasting lipids|Concentrations of Liver enzymes|Aerobic fitness|Height (centimeters)|Waist circumference (centimeters)|Hip circumference (centimeters)|Body weight (kilograms)|Continuous glucose monitoring","University of Alberta","All","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00088195","September 1, 2019","December 2020","January 2021","April 9, 2019",,"September 26, 2019","University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03908281"
210,"NCT04104243","Power-Up: An Effectiveness Trial of the Diabetes Prevention Program","Power-Up","Not yet recruiting","No Results Available","Type 2 Diabetes|Pre-Diabetes","Other: Men-Tailored DPP (Power-Up)","Percent of Patients with Weight Loss|Comparison of Engagement and Retention of Men vs Standard Diabetes Prevention Program","Albert Einstein College of Medicine|New York City Department Of Health and Mental Hygiene (NYCDOHMH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Male","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2019-10343|R01DK121896","March 2021","January 2024","June 2024","September 26, 2019",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04104243"
211,"NCT03829800","Formulas for Diabetes With Sucromalt & Isomaltulose on Glycemic Index, Hormones & Subjective Appetite in Type 2 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: Ensure® Abbott Nutrition|Dietary Supplement: Glucerna® Abbott Nutrition|Dietary Supplement: Diasip® Nutricia Advanced|Dietary Supplement: Glicolab®","Change from baseline Glycemia at 180 minutes|Change from baseline Insulin at 180 minutes|Glycemic Index (GI)|Glycemic Load (GL)|Change from baseline GLP-1 at 180 minutes|Change from baseline GIP at 180 minutes|Change from baseline Hunger at 180 minutes|Change from baseline Fullness at 180 minutes|Change from baseline Desire to eat at 180 minutes|Change from baseline Prospective food consumption at 180 minutes|Change from baseline Subjective appetite at 180 minutes|Age|Weight|Height|Body Mass Index|Hip Circumference|Total Cholesterol|HDL-C|LDL-C|Triacylglycerides|HbA1c","Universidad del Zulia","All","51 Years to 63 Years   (Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science","1001092016","September 1, 2016","September 1, 2017","November 15, 2018","February 4, 2019",,"February 4, 2019",,,"https://ClinicalTrials.gov/show/NCT03829800"
212,"NCT04126551","Mitochondrial Methylation in Type 2 Diabetes",,"Recruiting","No Results Available","Obesity|Diabetes Mellitus, Type 2|Insulin Resistance","Other: Methylation status","Mitochondrial DNA methylation|Mitochondrial Function","University of Arizona","All","35 Years to 55 Years   (Adult)",,"36","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1901254125","July 23, 2019","December 31, 2021","December 31, 2022","October 15, 2019",,"October 15, 2019","Clinical and Translational Research Center (CaTS), Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04126551"
213,"NCT04141241","Phase 2a Study to Evaluate the Safety and Efficacy of PH100 Tablet in T2DM Patients With Recent Cardiovascular","PH100_IIa","Completed","No Results Available","Type 2 Diabetes Mellitus With Circulatory Complciation","Drug: Ecklonia cava Phlorotannin","hs-CRP (high-sensitivity C-reactive protein)|hs-CRP|hs-CRP: monthly rate of change|Interleukin-6 (IL-6)|Tumor Necrosis Factor-α (TNF- α)|Malondialdehyde (MDA)|Oxidized Low Density Lipoprotein (Oxidized LDL)|Glutathione Peroxidase (GPX)|Superoxide Dismutase (SOD)|Total AntiOxidants (TAS)|HbA1c|Adiponectin|Free Fatty Acid|High Density Lipoprotein-cholesterol (HDL-C)|Low Density Lipoprotein-cholesterol (LDL-C)|Triglyceride (TG)|Total Cholesterol (TC)|Homocysteine|Fibrinogen|MACE (Major Adverse Cardiovascular Events)|Left Ventricular Ejection Fraction|Blood Pressure (Systolic Blood Pressure, Diastolic Blood Pressure)|BMI|Waist-hip ratio|AE (Adverse Events)|Pulse|Body Temperature","Bota Bio Co., Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 2","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","BOTAB-DBCVC-PH100","March 4, 2016","May 4, 2018","May 4, 2018","October 28, 2019",,"November 6, 2019",,,"https://ClinicalTrials.gov/show/NCT04141241"
214,"NCT03805802","Influence of a Liquid Oat Bran Product on Blood Glucose in Patients With Poorly Controlled Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Obesity|Overweight|Metabolic Syndrome","Other: active product|Other: reference product","Fasting glucose|HBA1c|Self-documented glucose|Weight|BMI|Lipid metabolism: Serum triglycerides|Lipid metabolism: apolipoprotein A (mg/dl)|Lipid metabolism: Apolipoprotein B mg/dl|Lipid metabolism: Apolipoprotein B / Apolipoprotein A ratio|Lipid metabolism: HDL-cholesterol|Lipid metabolism: LDL- cholesterol mg/dl|Microbiome|Inflammation: Il-6|Inflammation: hsCRP","Stoffwechselzentrum Rhein - Pfalz|Glucanova AB","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","012019","February 4, 2019","December 2019","March 2020","January 16, 2019",,"April 4, 2019","Stoffwechselzentrum Rhein-Pfalz, Mannheim, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT03805802"
215,"NCT03914326","A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes","SOUL","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Placebo (semaglutide)","Time to first occurrence of a major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death/non-fatal myocardial infarction/non-fatal stroke|Time to first occurrence of a composite endpoint|Time to occurrence of CV death|Time to first occurrence of major adverse limb events (MALE), a composite endpoint consisting of: acute limb ischemia hospitalisation/chronic limb ischemia hospitalisation|Time to first occurrence of an expanded MACE composite endpoint consisting of: CV death/non-fatal myocardial infarction/ non-fatal stroke/coronary revascularisation/unstable angina requiring hospitalisation|Time to first occurrence of a composite heart failure endpoint consisting of: CV death/heart failure requiring hospitalisation/urgent heart failure visit|Time to first occurrence of a composite CKD endpoint|Time to occurrence of all-cause death|Time to first occurrence of non-fatal myocardial infarction (MI)|Time to first occurrence of non-fatal stroke|Time to first occurrence of heart failure requiring hospitalisation|Time to first occurrence of urgent heart failure visit|Time to first occurrence of coronary revascularisation|Time to first occurrence of unstable angina requiring hospitalisation|Time to occurrence of renal death|Time to first occurrence of onset of persistent 50% or more reduction in eGFR|Time to first occurrence of onset of persistent eGFR (CKD-EPI) below 15 mL/min/1.73 m^2|Time to first occurrence of initiation of chronic renal replacement therapy (dialysis or kidney transplantation)|Time to first occurrence of a composite endpoint consisting of: all-cause death/non-fatal myocardial infarction/non-fatal stroke|Time to first occurrence of acute limb ischemia|Time to first occurrence of chronic limb ischemia|Annual rate of change in eGFR (CKD-EPI) (total eGFR slope)|Change in glycosylated haemoglobin (HbA1c)|Change in body weight|Number of severe hypoglycaemic episodes|Time to first occurrence of a severe hypoglycaemic episode","Novo Nordisk A/S","All","50 Years and older   (Adult, Older Adult)","Phase 3","9642","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EX9924-4473|2018-003141-42|U1111-1218-5368","June 17, 2019","July 29, 2024","July 29, 2024","April 16, 2019",,"June 11, 2020","Novo Nordisk Investigational Site, Montgomery, Alabama, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Los Alamitos, California, United States|Novo Nordisk Investigational Site, Mission Hills, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Torrance, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, Franklin, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Michigan City, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Slidell, Louisiana, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Lebanon, New Hampshire, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, New Bern, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Marion, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Twinsburg, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Murrells Inlet, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Oran, Algeria|Novo Nordisk Investigational Site, Setif, Algeria|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Capital Federal, Argentina|Novo Nordisk Investigational Site, Cordoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Lanus Este, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Rosario, Santa Fe, Argentina|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Saint Stefan, Austria|Novo Nordisk Investigational Site, Vienna, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Kortrijk, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Roeselare, Belgium|Novo Nordisk Investigational Site, Brasilia, Distrito Federal, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Passo Fundo, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Barrie, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Mirabel, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Cangzhou, Hebei, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Barranquilla, Colombia|Novo Nordisk Investigational Site, Bucaramanga, Colombia|Novo Nordisk Investigational Site, Cali, Colombia|Novo Nordisk Investigational Site, San Juan De Pasto, Colombia|Novo Nordisk Investigational Site, Soledad, Colombia|Novo Nordisk Investigational Site, Krapinske Toplice, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Pula, Croatia|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Split, Croatia|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Zadar, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Chrudim, Czechia|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Moravska Ostrava, Czechia|Novo Nordisk Investigational Site, Ostrava, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Plzeň, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Hillerød, Denmark|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Slagelse, Denmark|Novo Nordisk Investigational Site, Svendborg, Denmark|Novo Nordisk Investigational Site, Besançon cedex, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, Le Coudray, France|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pessac, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Jerichow, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Witten, Germany|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Guwahati, Assam, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Rohtak, Haryana, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Coimbatore, Tamil Nadu, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Thriruvananthapuram, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Nahariya, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Bari, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Chieti, Italy|Novo Nordisk Investigational Site, Lucca, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Padova, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Perugia, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Bunkyo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chiba, Japan|Novo Nordisk Investigational Site, Ehime, Japan|Novo Nordisk Investigational Site, Fukui, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Kyoto-shi, Kyoto, Japan|Novo Nordisk Investigational Site, Kyoto, Japan|Novo Nordisk Investigational Site, Miyagi, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Nagano, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Saga-shi, Saga, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Takamatsu-shi, Kagawa, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokorozawa-shi, Saitama, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Gyeonggi-do, Korea, Republic of|Novo Nordisk Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Alor Setar, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Malaysia|Novo Nordisk Investigational Site, Kota Samarahan, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuching, Malaysia|Novo Nordisk Investigational Site, Putrajaya, Malaysia|Novo Nordisk Investigational Site, Sarawak, Malaysia|Novo Nordisk Investigational Site, Seremban, Malaysia|Novo Nordisk Investigational Site, Sungai Buloh, Malaysia|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Tlalpan, México, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, San Nicolas de los Garza, Nuevo León, Mexico|Novo Nordisk Investigational Site, Hermosillo, Sonora, Mexico|Novo Nordisk Investigational Site, Merida, Yucatan, Mexico|Novo Nordisk Investigational Site, Mérida, Yucatan, Mexico|Novo Nordisk Investigational Site, Aguascalientes, Mexico|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Delft, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Groningen, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Maastricht, Netherlands|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Targoviste, Dambovita, Romania|Novo Nordisk Investigational Site, Targu Mures, Mures, Romania|Novo Nordisk Investigational Site, Tirgu Mures, Mures, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Bacau, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Galati, Romania|Novo Nordisk Investigational Site, Sibiu, Romania|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kemerovo, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Krompachy, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Poprad, Slovakia|Novo Nordisk Investigational Site, Prievidza, Slovakia|Novo Nordisk Investigational Site, Rimavska Sobota, Slovakia|Novo Nordisk Investigational Site, Roznava, Slovakia|Novo Nordisk Investigational Site, Vrutky, Slovakia|Novo Nordisk Investigational Site, Benoni, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Berea, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Alcorcón, Spain|Novo Nordisk Investigational Site, Antequera, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Burela, Spain|Novo Nordisk Investigational Site, Córdoba, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, Las Palmas de Gran Canaria, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Pozuelo de Alarcon, Spain|Novo Nordisk Investigational Site, Sanlúcar De Barrameda - Cádiz-, Spain|Novo Nordisk Investigational Site, Santander, Spain|Novo Nordisk Investigational Site, Santiago de Compostela, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Changhua City, Taiwan|Novo Nordisk Investigational Site, Taichung City, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan|Novo Nordisk Investigational Site, Bangkoknoi, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Nakhon Ratchasima, Thailand|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Bursa, Turkey|Novo Nordisk Investigational Site, Erzurum, Turkey|Novo Nordisk Investigational Site, Eskisehir, Turkey|Novo Nordisk Investigational Site, Hatay, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Sivas, Turkey|Novo Nordisk Investigational Site, Trabzon, Turkey|Novo Nordisk Investigational Site, Cherkasy, Ukraine|Novo Nordisk Investigational Site, Chernivtsi, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Odesa, Ukraine|Novo Nordisk Investigational Site, Poltava, Ukraine|Novo Nordisk Investigational Site, Uzhhorod, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Addlestone, United Kingdom|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Bradford-on-Avon, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Chippenham, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Harrogate, United Kingdom|Novo Nordisk Investigational Site, Hinckley, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Norfolk, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Redhill, United Kingdom|Novo Nordisk Investigational Site, Soham, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03914326"
216,"NCT04168541","Glycemic Response in Persons With Type 2 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Other: Oral Nutrition Supplement","Area under the blood glucose curve (ACU 0-240 minutes)|Area under the insulin curves (AUC 0-240)|Insulinogenic index [Change in Ins30/Change in Glu30]","Nestlé","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","17.11.US.HCN","February 5, 2018","April 18, 2018","April 18, 2018","November 19, 2019",,"November 19, 2019","Orange County Research Center, Tustin, California, United States",,"https://ClinicalTrials.gov/show/NCT04168541"
217,"NCT04054284","Safety and Efficacy of Herbal Tea in Type 2 Diabetics","DIABHerbMix","Completed","No Results Available","Type 2 Diabetes|Herbal Medicine Adverse Reaction","Dietary Supplement: Antidiabetic Herbal Tea|Dietary Supplement: Herbal Tea","Number of patients with adverse event|Glycated Hemoglobin|Fasting Glucose","Josip Juraj Strossmayer University of Osijek|Dom zdravlja Osijek (Health Centre Osijek)|Osijek University Hospital","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening","JJStrossmayerU-1","July 1, 2019","February 10, 2020","February 12, 2020","August 13, 2019",,"February 13, 2020","Department of Food and Nutrition Research, Faculty of Food Technology, Osijek, Croatia|Health Centre Osijek, Osijek, Croatia|University Hospital Centre, Osijek, Croatia",,"https://ClinicalTrials.gov/show/NCT04054284"
218,"NCT03855449","A Task Analysis Study of DECIDE For African American Patients With Type 2 Diabetes","eDECIDE","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Task Analysis Intervention Group","Task Analysis study process chart|Task Analysis Wireframe Development part 1|Task Analysis Wireframe Development part 2","University of Kansas Medical Center|Wichita State University|National Heart, Lung, and Blood Institute (NHLBI)","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","4","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","STUDY00141460|1K01HL135472-01A1","June 5, 2019","July 31, 2020","January 31, 2023","February 26, 2019",,"March 26, 2020","University of Kansas Medical Center, Wichita, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03855449"
219,"NCT03851432","Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Janagliflozin plus metformin|Device: Placebo plus metformin","Change in Hemoglobin A1c (HbA1c) From Baseline to Week 24 (Core period)|Change in HbA1c From Baseline to Week 52|Percentage of Patients With HbA1c <7% at Week 24 (Core period) and Week 52 (Extension period)|Percentage of Patients With HbA1c <6.5% at Week 24 (Core period) and Week 52 (Extension period)|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in 2-hour Post-prandial Glucose From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Blood Lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Blood Pressure (systolic blood pressure and diastolic blood pressure) From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Body Weight From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Fasting C-peptide From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Insulin Sensitivity From Baseline to Week 24 (Core period) and Week 52 (Extension period) by calculation Homeostasis model assessment-insulin resistance|Change in β-cell Function From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period)","Sihuan Pharmaceutical Holdings Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","390","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","5695-DIA-3002","February 28, 2019","December 31, 2020","December 31, 2021","February 22, 2019",,"February 22, 2019",,,"https://ClinicalTrials.gov/show/NCT03851432"
220,"NCT03951753","A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)",,"Suspended","No Results Available","Diabetes Mellitus, Type 2","Drug: Tirzepatide|Drug: Semaglutide|Drug: Placebo","Change from Baseline in Total Clamp Disposition Index (cDI)|Change from Baseline in Fasting Glucose|Change from Baseline in Postmeal Glucose|Change from Baseline in Hemoglobin A1c (HbA1c)|Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min)|Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value|Glucagon Concentration at Fasting|Glucagon Concentration at Postmeal|Change from Baseline in Food Intake During Ad Libitum Meal","Eli Lilly and Company","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1","117","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17091|I8F-MC-GPGT|2018-003343-37","June 28, 2019","March 16, 2021","March 16, 2021","May 15, 2019",,"April 22, 2020","Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany|Profil Mainz GmbH & Co. KG, Mainz, Rheinland-Pfalz, Germany",,"https://ClinicalTrials.gov/show/NCT03951753"
221,"NCT03864562","Gastric Emptying - Implications for the Pathogenesis of Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2",,"Gastric emptying rate|Serum Insulin concentration|Whole blood glucose concentration|Plasma glucagon concentration|Plasma GLP-1 concentration|Plasma GIP concentration|Serum C-peptide concentration|Attrition rate|Recruitment rate","University of Nottingham|University of Adelaide","All","18 Years to 60 Years   (Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","226-1901","March 1, 2019","March 28, 2021","June 30, 2021","March 6, 2019",,"March 24, 2020","David Greenfield Human Physiology Unit, University of Nottingham, Nottingham, Notts, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03864562"
222,"NCT03928379","A Study of LY3305677 in Participants With Type 2 Diabetes",,"Suspended","No Results Available","Diabetes Mellitus, Type 2","Drug: LY3305677|Drug: Placebo","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug|Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3305677|PK: Area Under the Concentration-Time Curve (AUC) of LY3305677|Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose|PD: Change from Baseline in Fasting Plasma Insulin","Eli Lilly and Company","All","20 Years to 69 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17011|I8P-MC-OXAD|2018-004779-11","October 27, 2019","November 25, 2020","November 25, 2020","April 26, 2019",,"April 22, 2020","Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT03928379"
223,"NCT03972982","Effects of Structured Simplified Short-term Intensive Insulin Therapy on Long-term Glycemic Remission",,"Not yet recruiting","No Results Available","Newly Diagnosed Type 2 Diabetes|Simplified Short-term Intensive Insulin Therapy|Glycemic Remission","Drug: Simplified intensive insulin therapy regimen|Drug: Traditional Short-term Intensive insulin therapy","remission rate","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018YFC1314102","June 1, 2019","December 31, 2021","December 31, 2022","June 4, 2019",,"June 4, 2019","endocrinology department of the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03972982"
224,"NCT04064996","Effectiveness of Foot Exercise People With Type 2 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Peripheral Neuropathy","Other: Routine rehabilitation program patient education|Other: Routine rehabilitation program + foot exercise training","Pain assessment with Algometry|Pain assessment with The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale|Pain assessment With Visual Analog Scale|Muscle Strength with Hand held dynamometer|Range Of Motion with goniometer|Baseline Tactile Semmes-Weinstein Monofilament|Edema measurement of tape|Evaluation of functional capacity with 6 minutes walking test|Two Point Discrimation Test|The Foot and Ankle Ability Measure|HbA1c|Serum creatinine|Albumin levels","Istanbul University","All","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","199292","April 1, 2019","July 30, 2019","November 30, 2019","August 22, 2019",,"April 13, 2020","Istanbul University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04064996"
225,"NCT04185662","Effects of Artificial Sweeteners on Glucose Metabolism in Patients With Type 2 Diabetes","SWEETS","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: sucralose","Fasting glucose|postprandial blood sugar|HbA1c","RenJi Hospital|ShiBei Hospital , JingAn District, Shanghai|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|PuNan Hospital ,Shanghai","All","30 Years to 60 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","T2DM20190619","December 1, 2019","August 30, 2021","September 30, 2021","December 4, 2019",,"December 4, 2019","Renji Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04185662"
226,"NCT04136067","A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: NNC0268-0965|Drug: insulin glargine","Number of treatment-emergent adverse events (AEs)|Number of treatment-emergent hypoglycaemic episodes|Area under the serum NNC0268-0965 concentration-time curve during one dosing interval at steady state|Maximum observed serum NNC0268-0965 concentration after the last dose","Novo Nordisk A/S","All","18 Years to 64 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN1965-4457|U1111-1227-8683|2019-000754-58","October 29, 2019","July 28, 2020","July 28, 2020","October 23, 2019",,"April 27, 2020","Novo Nordisk Investigational Site, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT04136067"
227,"NCT04143802","A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: LY3437943|Drug: Dulaglutide|Drug: Placebo","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of LY3437943|PK: Maximum Concentration (Cmax) of LY3437943|Change from Baseline in Mean Daily Plasma Glucose (PG)","Eli Lilly and Company","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17137|J1I-MC-GZBB","December 18, 2019","December 10, 2020","December 10, 2020","October 29, 2019",,"June 5, 2020","Anaheim Clinical Trials, LLC, Anaheim, California, United States|Miami Research Associates, Miami, Florida, United States|PRA Health Sciences, Lenexa, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04143802"
228,"NCT03972904","A Clinical Trial of Overweight/Obesity With Type 2 Diabetes","ELFOOD","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Overweight and Obesity","Dietary Supplement: Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance|Dietary Supplement: A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance","Dynamic blood glucose changes (average blood glucose)|Insulin resistance index changes|Blood glucose control compliance rate|Glycated albumin changes","Peking Union Medical College Hospital|Hebei Dongfangyun Health Management Co.,Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","HS-1910","June 20, 2019","September 20, 2020","July 20, 2021","June 4, 2019",,"May 20, 2020","Dongcheng district，Peking union medical college hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03972904"
229,"NCT03811561","A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes","FOCUS","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Placebo (semaglutide)","Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.|Time from randomisation to first at least 3 steps ETDRS subject level progression or central involved diabetic macular oedema (ciDME) in either eye.|Change in visual acuity in the worse seeing eye.|Change in visual acuity in the better seeing eye.|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with focal/grid laser photocoagulation.|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with pan-retinal laser photocoagulation.|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with intravitreal injection with anti-vascular endothelial growth factor (VEGF).|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with intravitreal injection with steroid.|Occurrence of treatment for diabetic retinopathy or diabetic macular oedema in either eye with vitrectomy.|Presence of at least 3 steps ETDRS subject level improvement.|Presence of at least 2 steps ETDRS subject level progression.|Presence of at least 2 steps ETDRS subject level improvement.|Presence of persistent visual acuity up to 38 ETDRS letters in either eye.|Presence of persistent at least 2 lines (10 letters) ETDRS worsening in visual acuity in either eye from baseline.|Presence of persistent at least 3 lines (15 letters) ETDRS worsening in visual acuity in either eye from baseline.|Presence of persistent at least 2 lines (10 letters) ETDRS improvement in visual acuity in either eye from baseline.|Persistent at least 3 lines (15 letters) ETDRS improvement in visual acuity in either eye from baseline.|Presence of ciDME in either eye.|Change in glycosylated haemoglobin (HbA1c).|Change in body weight.|Change in systolic and diastolic blood pressure.|Change in Lipids: Total-cholesterol, High density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides.","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN9535-4352|U1111-1201-6256|2017-003619-20","May 8, 2019","January 13, 2026","February 18, 2026","January 22, 2019",,"June 4, 2020","Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Moreno Valley, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, Santa Monica, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Paducah, Kentucky, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Ann Arbor, Michigan, United States|Novo Nordisk Investigational Site, Richfield, Minnesota, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Shavano Park, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Murray, Utah, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Oakville, Ontario, Canada|Novo Nordisk Investigational Site, Ottawa, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Praha 10, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Delhi, New Delhi, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Madurai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Bangalore, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Jelgava, Latvia|Novo Nordisk Investigational Site, Ogre, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Distrito Federal, México, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Chorzow, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Plonsk, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Almada, Portugal|Novo Nordisk Investigational Site, Aveiro, Portugal|Novo Nordisk Investigational Site, Coimbra, Portugal|Novo Nordisk Investigational Site, Guimarães, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Matosinhos, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Setubal, Portugal|Novo Nordisk Investigational Site, Cluj Napoca, Cluj, Romania|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Hospitalet de Llobregat, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, Pamplona, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Norfolk, United Kingdom|Novo Nordisk Investigational Site, North Yorkshire, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Nuneaton, United Kingdom|Novo Nordisk Investigational Site, Somerset, United Kingdom|Novo Nordisk Investigational Site, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03811561"
230,"NCT04057248","Digital Self-Management and Health Coaching for Type 2 Diabetes - Impact on Diabetes Clinical and Wellness Indicators",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Device: Dario Blood Glucose Monitoring System|Behavioral: CDE","HbA1C taken in blood test","LabStyle Innovations Ltd.","All","35 Years and older   (Adult, Older Adult)","Not Applicable","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CP-0010","July 9, 2018","June 1, 2019","June 1, 2019","August 15, 2019",,"September 4, 2019","Diabetes and Endocrinology Consultants of Pennsylvania, LLC (Decpa LLC), Feasterville, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04057248"
231,"NCT03793855","Nutritional Strategy for Glycemic Control in Patients With Type 2 Diabetes Mellitus (NUGLIC)",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Nutritional Strategy|Behavioral: Dietary Prescription","HbA1C|B-PAID|DSCA","Hospital do Coracao","All","30 Years and older   (Adult, Older Adult)","Not Applicable","370","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NUGLIC","May 6, 2019","September 2020","December 2020","January 4, 2019",,"February 17, 2020","Universidade Federal de Juiz de Fora, Governador Valadares, Brazil|Hospital de Clínicas de Porto Alegre - Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil|Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil|Instituto Estadual de Cardiologia Aloysio de Castro, Rio De Janeiro, Brazil|Universidade Federal da Bahia, Salvador, Brazil|Hospital do Coracao, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03793855"
232,"NCT03848793","A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: HS-20004","HbA1c|Change in Fasting Plasma Glucose|Change in Body Weight","Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HS-20004-201","March 15, 2019","September 15, 2019","January 15, 2020","February 21, 2019",,"February 21, 2019",,,"https://ClinicalTrials.gov/show/NCT03848793"
233,"NCT03811587","Clinical Feasibility and Efficacy of Intermittent Use of a Fasting Mimicking Diet in the Treatment of Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: Fasting Mimicking diet","Concentration of HbA1c|Dosage of antidiabetic medication used","Leiden University Medical Center|Dutch Diabetes Research Foundation|Health Holland|IFOM, The FIRC Institute of Molecular Oncology|L-Nutra","All","18 Years to 74 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL63892.058.18 - P18.049","November 5, 2018","September 1, 2021","December 31, 2021","January 22, 2019",,"February 20, 2020","Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03811587"
234,"NCT04032197","A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Placebo (semaglutide)","Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries|Change in maximum target-to-background ratio (TBR) for 68Ga-DOTATATE in the carotid arteries|Change in myocardial perfusion reserve (MPR)|Change in total wall volume of the most diseased carotid artery","Novo Nordisk A/S","All","50 Years and older   (Adult, Older Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN9535-4430|U1111-1215-4058|2018-002289-38","August 12, 2019","May 6, 2020","September 30, 2021","July 25, 2019",,"February 19, 2020","Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Gentofte, Denmark|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT04032197"
235,"NCT04109547","A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes","PIONEER 11","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Oral semaglutide|Drug: Placebo","Change in (glycosylated haemoglobin) HbA1c|Change in body weight|Change in fasting plasma glucose (FPG)|Change in fasting 7 point self-measured plasma glucose (SMPG) profile: Mean 7-point profile|Change in fasting 7 point self-measured plasma glucose (SMPG) profile: Mean postprandial increment (over all meals)|Change in body mass index (BMI)|Change in waist circumference|Change in fasting lipid profile: total cholesterol|Change in fasting lipid profile: low-density lipoprotein (LDL) cholesterol|Change in fasting lipid profile: high-density lipoprotein (HDL) cholesterol|Change in fasting lipid profile: triglycerides|Change in Short Form-36 version 2 (SF-36v2™) (acute version) health survey|If a subject achieves HbA1c below 7.0 percent (53 mmol/mol) (American Diabetes Association (ADA) target) (yes/no)|If a subject achieves HbA1c equal to or below 6.5 percent (48 mmol/mol) (American Association of Clinical Endocrinologists (AACE) target) (yes/no)|If a subject achieves HbA1c reduction equal to or above 1 percent-point (10.9 mmol/mol) (yes/no)|If a subject achieves body weight loss equal to or above 3 percent (yes/no)|If a subject achieves body weight loss equal to or above 5 percent (yes/no)|If a subject achieves body weight loss equal to or above 10 percent (yes/no)|If a subject achieves HbA1c below 7.0 percent (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes) and no body weight gain (yes/no)|If a subject achieves HbA1c reduction equal to or above 1 percent-point (10.9 mmol/mol) and body weight loss equal to or above 3 percent (yes/no)|Time to rescue medication|Number of treatment-emergent adverse events (TEAEs) during exposure to trial product|Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during exposure to trial product|Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during exposure to trial product (yes/no)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","664","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN9924-4338|U1111-1188-1173|2018-002590-22","October 1, 2019","September 1, 2021","October 7, 2021","September 30, 2019",,"June 11, 2020","Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Chongqing, Chongqing, China|Novo Nordisk Investigational Site, ChongQing, Chongqing, China|Novo Nordisk Investigational Site, Fuzhou, Fujian, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Huizhou, Guangdong, China|Novo Nordisk Investigational Site, Shantou, Guangdong, China|Novo Nordisk Investigational Site, Cangzhou, Hebei, China|Novo Nordisk Investigational Site, Handan, Hebei, China|Novo Nordisk Investigational Site, Hengshui, Hebei, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Zhengzhou, Henan, China|Novo Nordisk Investigational Site, Shiyan, Hubei, China|Novo Nordisk Investigational Site, Changde, Hunan, China|Novo Nordisk Investigational Site, Chenzhou, Hunan, China|Novo Nordisk Investigational Site, Yueyang, Hunan, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Huai'an, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Wuxi, Jiangsu, China|Novo Nordisk Investigational Site, Xuzhou, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Jiaxing, Jiangxi, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Yinchuan, Ningxia, China|Novo Nordisk Investigational Site, Xining, Qinghai, China|Novo Nordisk Investigational Site, Xi'an, Shaanxi, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Jining, Shandong, China|Novo Nordisk Investigational Site, Qingdao, Shandong, China|Novo Nordisk Investigational Site, Pudong New District, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Chengdu, Sichuan, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Changsha, China|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, Hungary|Novo Nordisk Investigational Site, Tatabánya, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Khmelnytskyi, Ukraine|Novo Nordisk Investigational Site, Mykolaiv, Ukraine|Novo Nordisk Investigational Site, Poltava, Ukraine|Novo Nordisk Investigational Site, Ternopil, Ukraine|Novo Nordisk Investigational Site, Zaporizhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT04109547"
236,"NCT03799796","Combining Flash Glucose Monitoring and Online Peer Support to Improve Outcomes in Hispanics With Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Flash Glucose Monitoring with Online Peer Support","Time-in-Range|A1C|Online peer support engagement","University of Utah|La Trobe University","All","21 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ADC-SRR-IIS-18-23","December 16, 2019","August 2020","September 2020","January 10, 2019",,"February 7, 2020","University of Utah College of Nursing, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03799796"
237,"NCT04017832","A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes","PIONEER 12","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Oral semaglutide|Drug: Sitagliptin|Drug: Placebo (oral semaglutide)|Drug: Placebo (sitagliptin)","Change in (glycosylated haemoglobin) HbA1c|Change in body weight|Change in fasting plasma glucose (FPG)|Change in fasting 7 point self-measured plasma glucose (SMPG) profile: Mean 7-point profile|Change in fasting 7 point self-measured plasma glucose (SMPG) profile: Mean postprandial increment (over all meals)|Change in body mass index (BMI)|Change in waist circumference|Change in fasting lipid profile: total cholesterol|Change in fasting lipid profile: low-density lipoprotein (LDL) cholesterol|Change in fasting lipid profile: very-low-density lipoprotein (VLDL) cholesterol|Change in fasting lipid profile: high-density lipoprotein (HDL) cholesterol|Change in fasting lipid profile: triglycerides|Change in fasting lipid profile: free fatty acids|Change in Short Form-36 version 2 (SF-36v2™) (acute version) health survey|If a subject achieves HbA1c below 7.0 percent (53 mmol/mol) (American Diabetes Association (ADA) target) (yes/no)|If a subject achieves HbA1c equal to or below 6.5 percent (48 mmol/mol) (American Association of Clinical Endocrinologists (AACE) target) (yes/no)|If a subject achieves HbA1c reduction equal to or above 1 percent-point (10.9 mmol/mol) (yes/no)|If a subject achieves body weight loss equal to or above 3 percent (yes/no)|If a subject achieves body weight loss equal to or above 5 percent (yes/no)|If a subject achieves body weight loss equal to or above 10 percent (yes/no)|If a subject achieves HbA1c below 7.0 percent (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes) and no body weight gain (yes/no)|If a subject achieves HbA1c reduction equal to or above 1 percent-point (10.9 mmol/mol) and body weight loss equal to or above 3 percent (yes/no)|Time to rescue medication|Number of treatment-emergent adverse events (TEAEs) during exposure to trial product|Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during exposure to trial product|Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during exposure to trial product (yes/no)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","1444","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN9924-4309|U1111-1188-1256|2018-002589-38","July 29, 2019","August 11, 2021","September 13, 2021","July 12, 2019",,"June 2, 2020","Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Chongqing, Chongqing, China|Novo Nordisk Investigational Site, Quanzhou, Fujian, China|Novo Nordisk Investigational Site, Foshan, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Huizhou, Guangdong, China|Novo Nordisk Investigational Site, Shantou, Guangdong, China|Novo Nordisk Investigational Site, Cangzhou, Hebei, China|Novo Nordisk Investigational Site, Hengshui, Hebei, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Kaifeng, Henan, China|Novo Nordisk Investigational Site, Luoyang, Henan, China|Novo Nordisk Investigational Site, Zhengzhou, Henan, China|Novo Nordisk Investigational Site, Shiyan, Hubei, China|Novo Nordisk Investigational Site, Wuhan, Hubei, China|Novo Nordisk Investigational Site, Changsha, Hunan, China|Novo Nordisk Investigational Site, Chenzhou, Hunan, China|Novo Nordisk Investigational Site, Hengyang, Hunan, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Suzhou, Jiangsu, China|Novo Nordisk Investigational Site, Suzhou, Jiangsu, China|Novo Nordisk Investigational Site, Wuxi, Jiangsu, China|Novo Nordisk Investigational Site, Xuzhou, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Yinchuan, Ningxia, China|Novo Nordisk Investigational Site, Xining, Qinghai, China|Novo Nordisk Investigational Site, Xi'an, Shaanxi, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Qingdao, Shandong, China|Novo Nordisk Investigational Site, Weifang, Shandong, China|Novo Nordisk Investigational Site, Pudong New District, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Hangzhou, Zhejiang, China|Novo Nordisk Investigational Site, Beijing, China|Novo Nordisk Investigational Site, Changsha, China|Novo Nordisk Investigational Site, Pingxiang, China|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Chrudim, Czechia|Novo Nordisk Investigational Site, Liberec, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Constanta, Romania|Novo Nordisk Investigational Site, Oradea, Romania|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Arcadia, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Kempton Park, Gauteng, South Africa|Novo Nordisk Investigational Site, Soshanguve, Gauteng, South Africa|Novo Nordisk Investigational Site, Brits, North West, South Africa|Novo Nordisk Investigational Site, Kuilsriver, Western Cape, South Africa|Novo Nordisk Investigational Site, Paarl, Western Cape, South Africa|Novo Nordisk Investigational Site, Alberton, South Africa|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04017832"
238,"NCT03921242","Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Renal Insufficiency, Chronic","Drug: Metformin|Drug: Sulfonylurea|Drug: DPP-4 inhibitor|Drug: SGLT2 inhibitor|Drug: GLP1 receptor agonist","Incidence of Severe Hypoglycemia Assessed from EMR|Difference in Glycosylated Hemoglobin (HbA1c) level (mmol/mol)|Heterogeneity of Treatment Effect Via Pre-specified Sub-Group Analyses|Incidence of acidosis, hospitalization for hyperglycemia, acute myocardial infarction, stroke, heart failure hospitalization, and heart failure emergency room visits|Difference in Body-Mass Index Assessed From EMR (BMI) (kg/m2)|Difference in Laboratory-Measured eGFR (mL/min)","Weill Medical College of Cornell University|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)",,"16000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","1809019555","August 1, 2019","March 1, 2021","March 1, 2021","April 19, 2019",,"September 26, 2019","University of North Carolina, Chapel Hill, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03921242"
239,"NCT04149067","Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Dapagliflozin|Drug: Sitagliptin","0.5% in Hb1Ac and 1.5 kg in body weight|Evaluate the results due to the use of SGLT2i/DPP4i|Evaluate the security of the treatment","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)",,"1080","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","FIS-DAP-2016-01","June 5, 2017","March 15, 2019","March 15, 2019","November 4, 2019",,"November 4, 2019","Cristóbal Morales Portillo, Sevilla, Andalucía, Spain",,"https://ClinicalTrials.gov/show/NCT04149067"
240,"NCT04027023","Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Diabetes mellitus Type 2 De-escalation treatment (DET)","impact of a temporary personalized poly-pharmaceutical treatment on the disease stage in patients with type 2 diabetes|HbA1c measurement to evaluate the impact of the poly-pharmaceutical treatment on the glycemic control|RBP4 will be measured to evaluate the impact of the poly-pharmaceutical treatment on the RBP4 level|the biomarker adiponectin will be measured to evaluate the impact of the poly-pharmaceutical treatment on the adiponectin level|insulin, c-peptide, intact proinsulin, glucagon will be measured to evaluate the impact of a temporary personalized poly-pharmaceutical treatment on beta-cell function|hsCRP, IL-6, angiopoetin 2 will be measured to evaluate the impact of a temporary personalized poly-pharmaceutical treatment on biomarkers of inflammation|Questionnaire about the diabetes treatment satisfaction (DTSQ) will be filled by the patient to evaluate the impact of a temporary personalized poly-pharmaceutical treatment on the quality of Life|Renal function|Liver function|Heart function|Electrolytic balance","Sciema UG|Innovative Diabetes Treatment Studies LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 4","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCTI-DET-001","October 30, 2019","September 30, 2020","October 31, 2020","July 19, 2019",,"March 17, 2020","NYC Research, Inc., New York, New York, United States|Pfützner Science & Health Institute GmbH, Mainz, Rhineland-Palatinate, Germany",,"https://ClinicalTrials.gov/show/NCT04027023"
241,"NCT03960814","A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin detemir","Age at all cause death or censoring|Age at death of cardiovascular disease","Novo Nordisk A/S","All","40 Years and older   (Adult, Older Adult)",,"12847","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NN304-4528|U1111-1233-0930|EUPAS29708","May 21, 2019","June 7, 2019","June 7, 2019","May 23, 2019",,"July 18, 2019","Novo Nordisk Investigational Site, Bagsværd, Denmark",,"https://ClinicalTrials.gov/show/NCT03960814"
242,"NCT04030091","Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Drug: 3 hours humulin R 100 IU/mL PIT|Drug: 2 hours humulin R 100 IU/mL PIT","Endothelial function|Renal function|nerve function|Retinopathy|HbA1c|Insulin resistance|Diabetes treatment satisfaction questionnaire","Sciema UG|Innovative Diabetes Treatment Studies LLC.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCTI-PIT-001","September 6, 2019","June 2020","July 2020","July 23, 2019",,"January 18, 2020","NYC Research, Inc., New York, New York, United States|Pfützner Science & Health Institute GmbH, Mainz, Rhineland-Palatinate, Germany",,"https://ClinicalTrials.gov/show/NCT04030091"
243,"NCT04194515","Gut Microbiota and Bile Acids in Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Metformin|YH1","Drug: YH1|Drug: metformin","bile acid profile","Chang Gung Memorial Hospital","Male","20 Years to 65 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201901022A3C601","January 1, 2020","November 30, 2020","November 30, 2020","December 11, 2019",,"January 27, 2020","Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04194515"
244,"NCT04012775","Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Biological: Insulin Humulin® NPH|Biological: Insulin Rinsulin® NPH","Antibody Response|Hypoglycemic episodes (glucose level < 3.9 mmol/l) frequency|Change in BMI from baseline|Occurrence of adverse events|Occurrence of Injection Site Reaction|Change in HbA1c from baseline|Change in fasting plasma glucose level from baseline|Change in basal insulin dose per body weight (U/kg) from baseline|Change in total basal insulin dose (U) from baseline","Geropharm","All","18 Years and older   (Adult, Older Adult)","Phase 3","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RINPH-IM","April 20, 2017","September 24, 2018","September 24, 2018","July 9, 2019",,"July 9, 2019","Chelyabinsk Railway Clinical Hospital, Chelyabinsk, Russian Federation|Moscow Endocrinological Dispensary, Moscow, Russian Federation|Moscow Clinical Hospital № 71, Moscow, Russian Federation|Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russian Federation|V.A. Baranov Republic Hospital, Petrozavodsk, Russian Federation|City Polyclinic № 6, Saint Petersburg, Russian Federation|City Hospital № 2, Saint Petersburg, Russian Federation|City Polyclinic № 17, Saint Petersburg, Russian Federation|Medical Sanitary Unit № 157, Saint Petersburg, Russian Federation|Institute of Medical Research, Saint Petersburg, Russian Federation|Research Center Eco-Safety, Saint Petersburg, Russian Federation|Saint Petersburg State Diagnostic Center № 85, Saint Petersburg, Russian Federation|Diabetes Center, Samara, Russian Federation|Clinical Hospital № 3, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04012775"
245,"NCT03817463","A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor","Number of participants hospitalized for heart failure|Number of participants with all-cause mortality|Number of participants with both hospitalization for heart failure and all cause mortality|Number of participants with myocardial infraction (MI), stroke, all cause mortality|Number of participants with Cardiovascular mortality|Number of participants with a composite outcome including hospitalization for heart failure and cardiovascular (CV) mortality|Number of participants with 3-point major adverse cardiovascular (CV) events (MACE), defined as a composite outcome including myocardial infarction (MI),stroke, and cardiovascular (CV) mortality|Number of participants with coronary revascularization procedure|Number of participants with end-stage renal disease (ESRD)|Number of participants with estimated glomerular filtration rate (eGFR) decline|Number of participants with progression from normoalbuminuria to micro- or macroalbuminuria|Number of participants with a composite outcome including eGFR decline and progression to micro- or macroalbuminuria|Number of participants with bone fracture|Number of participants with diabetic ketoacidosis|Number of participants with severe hypoglycemia|Number of participants with lower-limb amputation|Number of participants with acute kidney injury requiring dialysis|Healthcare resource utilization|Cost of care","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)",,"150000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1245-0195","April 15, 2019","January 1, 2021","January 1, 2021","January 25, 2019",,"June 4, 2020","Steno Diabetes Center Copenhagen, Department of Clinical Epidemiology, Gentofte, Denmark|Helsinki University Hospital, Helsinki, Finland|University of Ulm, Institute for Epidemiology and medical biometry, Ulm, Germany|Maccabi Healthcare Services, Tel Aviv, Israel|Gifu University, Gifu, Japan|Ajou University Hospital, Suwon, Korea, Republic of|Oslo University Hospital, Department of Clinical Lipidology, Oslo, Norway|Oslo University Hospital, Department of Cardiology, Oslo, Norway|Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain|TFS Trial Form Support International AB, Lund, Sweden|Quantify Research AB, Stockholm, Sweden|Taiwan Society for Pharmacoeconomics and Outcome Research (TaSPOR), Taipei City, Taiwan|Leicester Real World Evidence Unit, Leicester general Hospital, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03817463"
246,"NCT04006938","Effect of Continuous vs Intermittent Aerobic Exercise on Glycemic Control in a Barbadian Population With Type 2 Diabetes",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Single Bout ('S')|Behavioral: Multiple Bout ('M')","2 hour post prandial blood glucose level after breakfast|2 hour post prandial blood glucose level after lunch|2 hour post prandial blood glucose level after dinner|Fasting blood sugar level","Springfield College","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KCK00000001","July 2019","February 2020","April 2020","July 5, 2019",,"July 5, 2019",,,"https://ClinicalTrials.gov/show/NCT04006938"
247,"NCT04153929","A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: BI 456906|Drug: Placebo|Drug: Semaglutide","Absolute change in HbA1c from baseline to 16 weeks|The relative body weight change from baseline to 16 weeks (key secondary endpoint)|The absolute body weight change from baseline to 16 weeks.|The absolute change in waist circumference from baseline to 16 weeks|The percentage of patients with 5% or greater body weight loss from baseline to 16 weeks|The percentage of patients with 10% or greater body weight loss from baseline to 16 weeks","Boehringer Ingelheim","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","410","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1404-0002|2019-002390-60","April 30, 2020","August 2, 2021","August 30, 2021","November 6, 2019",,"June 4, 2020","Boden Institute of Obesity, Nutrition, Exercies and Eating Disorders, Camperdown, New South Wales, Australia|Hunter Diabetes Centre, Merewether, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT04153929"
248,"NCT04009642","Cardiac Rest and Stress Metabolism in Patients With Type 2 Diabetes","CardioMET","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Metabolic Cardiomyopathy|Metabolic Disturbance|Fatty Acid Oxidation Disorder","Other: Surely observational based on disease state","The difference in myocardial FA extraction fraction (%) between T2D patients and non-diabetic controls at rest.","University of Leicester","All","18 Years and older   (Adult, Older Adult)",,"44","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0633","March 5, 2018","February 28, 2020","February 28, 2020","July 5, 2019",,"July 8, 2019","Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04009642"
249,"NCT03811288","An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes","CAPTURE-IO","Completed","No Results Available","Diabetes Mellitus, Type 2","Other: No treatment given","Participants with a history of established cardiovascular disease (CVD)|Participants with high risk of CVD according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"7548","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","NN2211-4446|U1111-1215-4005","December 10, 2018","September 30, 2019","September 30, 2019","January 22, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Batna, Algeria|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Tiaret, Algeria|Novo Nordisk Investigational Site, Tizi Ouzou, Algeria|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Chacabuco, Argentina|Novo Nordisk Investigational Site, Cordoba, Argentina|Novo Nordisk Investigational Site, Coronel Suarez, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Godoy Cruz, Argentina|Novo Nordisk Investigational Site, Lanus Este, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Morón, Argentina|Novo Nordisk Investigational Site, Blacktown, New South Wales, Australia|Novo Nordisk Investigational Site, Brookvale, New South Wales, Australia|Novo Nordisk Investigational Site, Campbelltown, New South Wales, Australia|Novo Nordisk Investigational Site, Coffs Harbour, New South Wales, Australia|Novo Nordisk Investigational Site, Maroubra, New South Wales, Australia|Novo Nordisk Investigational Site, Wollongong, New South Wales, Australia|Novo Nordisk Investigational Site, Herston, Queensland, Australia|Novo Nordisk Investigational Site, Morayfield, Queensland, Australia|Novo Nordisk Investigational Site, North Ipswich, Queensland, Australia|Novo Nordisk Investigational Site, Sherwood, Queensland, Australia|Novo Nordisk Investigational Site, Victoria Point, Queensland, Australia|Novo Nordisk Investigational Site, Forest Hill, Victoria, Australia|Novo Nordisk Investigational Site, Moonee Ponds, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Preston, Victoria, Australia|Novo Nordisk Investigational Site, Ringwood, Victoria, Australia|Novo Nordisk Investigational Site, Fremantle, Western Australia, Australia|Novo Nordisk Investigational Site, Geelong, Australia|Novo Nordisk Investigational Site, Fortaleza, Ceara, Brazil|Novo Nordisk Investigational Site, Aparecida de Goiania, Goias, Brazil|Novo Nordisk Investigational Site, Goiânia, Goias, Brazil|Novo Nordisk Investigational Site, Belo Horizonte, Minas Gerais, Brazil|Novo Nordisk Investigational Site, Belo Horizonte, Minas Gerais, Brazil|Novo Nordisk Investigational Site, Uberaba, Minas Gerais, Brazil|Novo Nordisk Investigational Site, Campina Grande do Sul, Parana, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Maringa, Parana, Brazil|Novo Nordisk Investigational Site, Maringa, Parana, Brazil|Novo Nordisk Investigational Site, Passo Fundo, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Santo André, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Tatui, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Votuporanga, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Fortaleza, Brazil|Novo Nordisk Investigational Site, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Lanzhou, Gansu, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guiyang, Guizhou, China|Novo Nordisk Investigational Site, Wuxi, Jiangsu, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Luzhou, Sichuan, China|Novo Nordisk Investigational Site, Nanchong, Sichuan, China|Novo Nordisk Investigational Site, Ningbo, Zhejiang, China|Novo Nordisk Investigational Site, Nanjing, China|Novo Nordisk Investigational Site, Bat Yam, Israel|Novo Nordisk Investigational Site, Beer sheva, Israel|Novo Nordisk Investigational Site, Beer-Sheva HaDarom, Israel|Novo Nordisk Investigational Site, Bnei Brak, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kiryat Bialik, Israel|Novo Nordisk Investigational Site, Nahariya, Israel|Novo Nordisk Investigational Site, Nazareth, Israel|Novo Nordisk Investigational Site, Petach Tikva, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Ra'anana, Israel|Novo Nordisk Investigational Site, Tel Aviv, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Zefat, Israel|Novo Nordisk Investigational Site, Chiba-shi, Chiba, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Ebina-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Fukushima, Japan|Novo Nordisk Investigational Site, Hamamatsu-Shi Shizuoka, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kawagoe-shi, Saitama, Japan|Novo Nordisk Investigational Site, Koshigaya-shi,Saitama, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Nishi-ku Sapporo, Japan|Novo Nordisk Investigational Site, Oita-shi, Japan|Novo Nordisk Investigational Site, Okawa-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Oyama-shi, Japan|Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Shinjyuku-ku Tokyo, Japan|Novo Nordisk Investigational Site, Tijuana, Baja California Norte, Mexico|Novo Nordisk Investigational Site, Monclova, Coahuila, Mexico|Novo Nordisk Investigational Site, Mexico, Estado De México, Mexico|Novo Nordisk Investigational Site, Celaya, Guanajuato, Mexico|Novo Nordisk Investigational Site, León, Guanajuato, Mexico|Novo Nordisk Investigational Site, Acapulco de Juarez, Guerrero, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Puerto Vallarta, Jalisco, Mexico|Novo Nordisk Investigational Site, Zapopan, Jalisco, Mexico|Novo Nordisk Investigational Site, Zapopan, Jalisco, Mexico|Novo Nordisk Investigational Site, Cuernavaca, Morelos, Mexico|Novo Nordisk Investigational Site, Benito Juárez, México, D.F., Mexico|Novo Nordisk Investigational Site, Cuauhtemoc, México, D.F., Mexico|Novo Nordisk Investigational Site, Gustavo A Madero, México, D.F., Mexico|Novo Nordisk Investigational Site, Mexico City, México, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, San Luis Potosí, San Luis Potosi, Mexico|Novo Nordisk Investigational Site, Culiacán, Sinaloa, Mexico|Novo Nordisk Investigational Site, Hermosillo, Sonora, Mexico|Novo Nordisk Investigational Site, Ciudad Madero, Tamaulipas, Mexico|Novo Nordisk Investigational Site, Aguascalientes, Mexico|Novo Nordisk Investigational Site, Guadalajara, Mexico|Novo Nordisk Investigational Site, Mexico City, Mexico|Novo Nordisk Investigational Site, Monterrey, Mexico|Novo Nordisk Investigational Site, Queretaro, Mexico|Novo Nordisk Investigational Site, San Luis Potosi, Mexico|Novo Nordisk Investigational Site, Veracruz, Mexico|Novo Nordisk Investigational Site, Al Ihsa, Saudi Arabia|Novo Nordisk Investigational Site, Buraydah, Saudi Arabia|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Taif, Saudi Arabia|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Edirne, Turkey|Novo Nordisk Investigational Site, Elazig, Turkey|Novo Nordisk Investigational Site, Eskisehir, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Malatya, Turkey|Novo Nordisk Investigational Site, Tekirdag, Turkey|Novo Nordisk Investigational Site, Zonguldak, Turkey",,"https://ClinicalTrials.gov/show/NCT03811288"
250,"NCT03888157","A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine","VIEW-Iran","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Liraglutide","Change in glycated haemoglobin A1c (HbA1c) (percentage)|Change in HbA1c (mmol/mol)|Change in body weight (kilogram)|Change in body weight (percentage)|Change in waist circumference|Change in fasting blood glucose (FBG) (self-measured)|Change in total cholesterol (TC)|Change in low density lipoprotein cholesterol (LDL-C)|Change in high density lipoprotein cholesterol (HDL-C)|Change in triglyceride (TG)|Change in free fatty acid (FFA)|Number of patients permanently discontinuing treatment with Victoza®|Reasons for permanent treatment discontinuations|Changes in quality of life (EQ-5D index score)|Changes in quality of life (EQ VAS)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"830","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN2211-4438|U1111-1213-4238","March 10, 2019","August 14, 2020","August 14, 2020","March 25, 2019",,"April 6, 2020","Novo Nordisk Investigational Site, Ahvaz, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Ardabil, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Babol, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Gorgan, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Hamedan, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Hormozgan, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Isfahan, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Islamshahr, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Karaj, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Kerman, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Mashad, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Mashahd, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Mashhad, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Sari, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Shiraz, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Tehran, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Yazd, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03888157"
251,"NCT03945656","A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin 287|Drug: Insulin glargine","Clinically significant hypoglycaemia (Double dose): Clinically significant hypoglycaemia (Plasma glucose [PG] less than 3.0 mmol/L [54 mg/dL]) after 2 times the individualised optimal basal dose of insulin|PG (nadir) - PG concentration at nadir after 2 and 3 times the individualised optimal basal dose of insulin|t (decline, PG 5.5 mmol/L - PG 3.0 mmol/L) - Time from start of hypoglycaemia induction until a PG concentration of 3.0 mmol/L (54 mg/dL) is reached after 2 and 3 times the individualised optimal basal dose of insulin|t (decline, PG 5.5 mmol/L - PG nadir) - Time from start of hypoglycaemia induction until PGnadir is reached after 2 and 3 times the individualised optimal basal dose of insulin|t (recovery, PG nadir - PG 5.5 mmol/L) - Time to increase from PGnadir to a PG concentration of 5.5 mmol/L (100 mg/dL) after 2 and 3 times the individualised optimal basal dose of insulin|C (glucagon, PG nadir) - Plasma glucagon concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|C (adrenaline, PG nadir) - Plasma adrenaline concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|C (noradrenaline, PG nadir) - Plasma noradrenaline concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|C (growth hormone [GH], PG nadir) - Serum growth hormone concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|C (cortisol, PG nadir) - Serum cortisol concentration at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Pulse (PG 5.5 mmol/L - PG nadir) - Change in pulse rate from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Diastolic blood pressure (DBP) (PG 5.5 mmol/L - PG nadir) - Change in diastolic blood pressure from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Systolic blood pressure (SBP) (PG 5.5 mmol/L - PG nadir) - Change in systolic blood pressure from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Digit Symbol Substitution Test (DSST) (PG 5.5 mmol/L - PG nadir) - Change in DSST score from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Four-Choice Reaction Time (4CRT) (reaction 4CRT) (PG 5.5 mmol/L - PG nadir) - Change in 4CRT performance from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|4CRT (% correct answers) (PG 5.5 mmol/L - PG nadir) - Change in 4CRT performance (% correct answers) from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Trail Making B test (TMB) (PG 5.5 mmol/L - PG nadir) - Change in TMB from a PG concentration of 5.5 mmol/L (100 mg/dL) until PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Hypoglycaemic symptoms score (HSS) (PG 5.5 mmol/L - PG nadir) - Change in HSS from a PG concentration of 5.5 mmol/L (100 mg/dL) to PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|Hypoglycaemia awareness (HA) (PG nadir) - HA at PGnadir after 2 and 3 times the individualised optimal basal dose of insulin|AUC (GIR, recovery, PG nadir -PG 5.5 mmol/L) - Area under the glucose infusion rate-time profile during recovery from PGnadir to a PG concentration of 5.5 mmol/L (100 mg/dL) after 2 and 3 times the individualised optimal basal dose of insulin|AUC (GIR, recovery, PG 5.5 mmol/L, 0-6h)-Area under the glucose infusion rate-time profile during 6 hours at a PG concentration of 5.5 mmol/L (100 mg/dL) after recovery from hypoglycaemia after 2 & 3 times the individualised optimal basal dose of insulin|Clinically significant hypoglycaemia (Triple dose) - Clinically significant hypoglycaemia [PG less than 3.0 mmol/L (54 mg/dL)], after 3 times the individualised optimal basal dose of insulin","Novo Nordisk A/S","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 1","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN1436-4462|U1111-1214-2688|2018-001993-74","May 7, 2019","November 20, 2020","November 20, 2020","May 10, 2019",,"April 6, 2020","Novo Nordisk Investigational Site, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT03945656"
252,"NCT04050553","A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Hypoglycemia","Drug: Tirzepatide|Drug: Placebo","Change in Mean Glucagon Concentration During Induced Hypoglycemia from Target Plasma Glucose (PG) Concentration of 100 Milligrams per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL|Change in Mean Insulin Concentrations from Induced Hypoglycemia Target PG Nadir Concentration of 45 mg/dL to Recovery (PG Concentration 72 mg/dL)|Time from Termination of Insulin Infusion at PG Concentration of 45 mg/dL to Reach Recovery PG Concentration (72 mg/dL)|Change in Hypoglycemia Symptoms Score from Induced Hypoglycemia Target PG Nadir Concentration of 45 mg/dL to Recovery (PG Concentration 72 mg/dL)|Mean Change in Blood Pressure from Induced Hypoglycemia Target PG Nadir Concentration of 45 mg/dL to Recovery (PG Concentration 72 mg/dL)|Mean Change in Heart Rate from Induced Hypoglycemia Target PG Nadir Concentration of 45 mg/dL to Recovery (PG Concentration 72 mg/dL)","Eli Lilly and Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17222|I8F-MC-GPHG|2019-001360-29","February 24, 2020","May 24, 2021","May 24, 2021","August 8, 2019",,"June 5, 2020","Universitätsklinikum Graz, Graz, Steiermark, Austria",,"https://ClinicalTrials.gov/show/NCT04050553"
253,"NCT03862690","A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria","B Simple","Withdrawn","No Results Available","Diabetes Mellitus, Type 2","Drug: BIAsp 30","Change in glycosylated haemoglobin A1c (HbA1c)|Participants achieving HbA1c below 7.0%|Particpants achieving HbA1c below 7.5%|Partcipants achieving HbA1c below 8.0%|Change in rate of severe hypoglycaemia|Change in total insulin dose|Change in Diabetes Treatment Satisfaction (DTSQ) score|Change in health-related quality of life (EQ-5D)","Novo Nordisk A/S","All","19 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BIASP-4439|U1111-1208-5168","May 28, 2020","June 28, 2021","June 28, 2021","March 5, 2019",,"June 4, 2020","Novo Nordisk Investigational Site, Algiers, Algeria",,"https://ClinicalTrials.gov/show/NCT03862690"
254,"NCT04023344","Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Diabetes Mellitus","Drug: Humalog Mix25|Drug: Insulin Lispro Biphasic 25","Antibody Response|Adverse Events frequency and degree|HbA1c|Fasting Plasma Glucose Level|Seven-Point Glucose Testing|Insulin Dose|Body Mass Index|Treatment Satisfaction","Geropharm","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LISPRO25-IM","March 14, 2018","January 15, 2019","April 18, 2019","July 17, 2019",,"July 17, 2019","Chelyabinsk Railway Clinical Hospital, Chelyabinsk, Russian Federation|Railway Clinical Hospital N.A. Semashko, Moscow, Russian Federation|Endocrinology Research Centre (Moscow), Moscow, Russian Federation|Moscow Endocrinological Dispensary, Moscow, Russian Federation|Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russian Federation|V.A. Baranov Republic Hospital, Petrozavodsk, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|City Polyclinic № 77, Saint Petersburg, Russian Federation|City Hospital № 2, Saint Petersburg, Russian Federation|City Polyclinic № 117, Saint Petersburg, Russian Federation|City Polyclinic № 17, Saint Petersburg, Russian Federation|Institute of Medical Research, Saint Petersburg, Russian Federation|Research Center Eco-Safety, Saint Petersburg, Russian Federation|City Hospital №40, Saint Petersburg, Russian Federation|Pokrovskaya Municipal Hospital, Saint Petersburg, Russian Federation|Diabetes Center, Samara, Russian Federation|Clinical City Hospital № 9, Saratov, Russian Federation|Siberian State Medical University, Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04023344"
255,"NCT04034524","Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: GLP-1 receptor agonist|Drug: Insulin","Time until first composite CV event (myocardial infarction, stroke)|Time until first myocardial infarction|Time until first stroke|Time until first serious hypoglycemic event|Time until first episode of acute pancreatitis|Time until first episode of acute cholecystitis","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)",,"20000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2011P002580-118","May 1, 2019","October 31, 2019","October 31, 2019","July 26, 2019",,"July 31, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04034524"
256,"NCT04038528","Telemedical Devices in the Management of Type 2 Diabetes Mellitus to Improve Diabetic Control and Quality of Life",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: telemonitoring of T2DM","glycated hemoglobin (GlyH) level|Quality of life perception|Body mass index (BMI)|Abdominal circumference|Triglyceride|LDL-cholesterol|Systolic Blood Pressure (BP)|Diastolic BP|Compliance|Hyperglycemic events","Centro Studi Internazionali, Italy|GPI SpA","All","18 Years and older   (Adult, Older Adult)",,"350","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2018-DC-2-0","March 1, 2018","March 1, 2020","July 31, 2020","July 31, 2019",,"July 31, 2019","ASP Catanzaro, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04038528"
257,"NCT04083820","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)","SURE FRANCE","Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 2","Drug: semaglutide","Change in Glycated Haemoglobin A1c (HbA1c)|Change in body weight|Change in waist circumference|HbA1c level below 8.0% (64 mmol/mol) (yes/no)|HbA1c level below 7.5% (59 mmol/mol) (yes/no)|HbA1c level below 7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c of 1.0% point or more (yes/no)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"217","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN9535-4495|U1111-1222-5620","September 16, 2019","September 15, 2021","September 15, 2021","September 10, 2019",,"June 4, 2020","Novo Nordisk Investigational Site, Angers, France|Novo Nordisk Investigational Site, Annecy, France|Novo Nordisk Investigational Site, Auffay, France|Novo Nordisk Investigational Site, Avignon, France|Novo Nordisk Investigational Site, Besançon, France|Novo Nordisk Investigational Site, Bethoncourt, France|Novo Nordisk Investigational Site, Beze, France|Novo Nordisk Investigational Site, Bourgoin-jallieu, France|Novo Nordisk Investigational Site, Bry sur Marne, France|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Challes les Eaux, France|Novo Nordisk Investigational Site, Chalon sur Saone, France|Novo Nordisk Investigational Site, Chalons Sur Saone, France|Novo Nordisk Investigational Site, Charleville-Mézières, France|Novo Nordisk Investigational Site, Chelles, France|Novo Nordisk Investigational Site, Clichy, France|Novo Nordisk Investigational Site, Colmar, France|Novo Nordisk Investigational Site, Colmar, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, Dijon, France|Novo Nordisk Investigational Site, Dole, France|Novo Nordisk Investigational Site, Doudeville, France|Novo Nordisk Investigational Site, Elancourt, France|Novo Nordisk Investigational Site, Guiscard, France|Novo Nordisk Investigational Site, La Bouëxière, France|Novo Nordisk Investigational Site, La Madeleine, France|Novo Nordisk Investigational Site, Lambersart, France|Novo Nordisk Investigational Site, Le Puy en Velay, France|Novo Nordisk Investigational Site, Lomme, France|Novo Nordisk Investigational Site, Lyon, France|Novo Nordisk Investigational Site, Maison-Alfort, France|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Montélimar, France|Novo Nordisk Investigational Site, Nevers, France|Novo Nordisk Investigational Site, NICE cedex 3, France|Novo Nordisk Investigational Site, Noisy le Grand, France|Novo Nordisk Investigational Site, Orry-la-ville, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pessac, France|Novo Nordisk Investigational Site, Pierre-Bénite, France|Novo Nordisk Investigational Site, Six Fours les plages, France|Novo Nordisk Investigational Site, Ste Foy Lès Lyon, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Toulouse, France|Novo Nordisk Investigational Site, Tours, France|Novo Nordisk Investigational Site, Valence, France|Novo Nordisk Investigational Site, Vichy, France|Novo Nordisk Investigational Site, Vienne, France|Novo Nordisk Investigational Site, Vitré, France|Novo Nordisk Investigational Site, Yerres, France",,"https://ClinicalTrials.gov/show/NCT04083820"
258,"NCT04191525","Phase II Clinical Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: BPL-1 Probiotic capsules|Dietary Supplement: Placebo","Fasting glucose|Glycated haemoglobin|Insulin|HOMA-IR|Total cholesterol|HDL-cholesterol|LDL-cholesterol|Triglycerides|Body Mass Index (BMI)|Body Fat Percentage (%BF)|Blood pressure|Waist perimeter","Mónica Marazuela Azpíroz|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PROBIDEM","September 10, 2018","June 26, 2019","June 26, 2019","December 9, 2019",,"December 19, 2019","Hospital Universitario de La princesa, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04191525"
259,"NCT03819153","A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease","FLOW","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Placebo (semaglutide)","Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease|Annual rate of change in eGFR (chronic kidney disease - epidemiology collaboration (CKD-EPI)) (total eGFR slope)|Time to first occurrence of a composite cardiovascular major adverse cardiovascular event (MACE) endpoint consisting of: Non-fatal myocardial infarction, non-fatal stroke, and cardiovascular (CV) death|Time to occurrence of all-cause death|Time to occurrence of each of the individual components of the primary composite endpoint and of the confirmatory secondary MACE endpoint|Time to first occurrence of major adverse limb events (MALE), a composite endpoint consisting of: Acute limb ischemia hospitalisation and chronic limb ischemia hospitalisation|Annual rate of change in eGFR (CKD-EPI) (chronic eGFR slope)|Change in eGFR (CKD-EPI)|Change in eGFR (cystatin C CKD-EPI)|Relative change in urinary albumin-to-creatinine ratio (UACR)|Change in body weight|Change in glycosylated haemoglobin (HbA1c)|Change in systolic blood pressure|Change in diastolic blood pressure|Number of severe hypoglycaemic episodes","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","3160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN9535-4321|U1111-1217-6259|2018-002878-50|JapicCTI-194843","June 17, 2019","August 19, 2024","August 19, 2024","January 28, 2019",,"June 11, 2020","Novo Nordisk Investigational Site, Anniston, Alabama, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Chula Vista, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Lakewood, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lincoln, California, United States|Novo Nordisk Investigational Site, Loma Linda, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, Port Hueneme, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, Rialto, California, United States|Novo Nordisk Investigational Site, Roseville, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Dimas, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Torrance, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Coral Gables, Florida, United States|Novo Nordisk Investigational Site, Fleming Island, Florida, United States|Novo Nordisk Investigational Site, Gainesville, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Homestead, Florida, United States|Novo Nordisk Investigational Site, Miami Lakes, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Port Charlotte, Florida, United States|Novo Nordisk Investigational Site, Saint Augustine, Florida, United States|Novo Nordisk Investigational Site, Sarasota, Florida, United States|Novo Nordisk Investigational Site, Winter Haven, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Nampa, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Valparaiso, Indiana, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, United States|Novo Nordisk Investigational Site, Manhattan, Kansas, United States|Novo Nordisk Investigational Site, Paducah, Kentucky, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Annapolis, Maryland, United States|Novo Nordisk Investigational Site, Beltsville, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Minnesota, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Mineola, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, United States|Novo Nordisk Investigational Site, New Bern, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Winston-Salem, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Bethlehem, Pennsylvania, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Little River, South Carolina, United States|Novo Nordisk Investigational Site, Murrells Inlet, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Orangeburg, South Carolina, United States|Novo Nordisk Investigational Site, Bartlett, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, El Paso, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Rockwall, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Schertz, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Salem, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Tacoma, Washington, United States|Novo Nordisk Investigational Site, Wauwatosa, Wisconsin, United States|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Villa Dominico, Argentina|Novo Nordisk Investigational Site, Gosford, New South Wales, Australia|Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Westmead, New South Wales, Australia|Novo Nordisk Investigational Site, Milton, Queensland, Australia|Novo Nordisk Investigational Site, Caulfield, Victoria, Australia|Novo Nordisk Investigational Site, Clayton, Victoria, Australia|Novo Nordisk Investigational Site, Fitzroy, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Jette, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Liège, Belgium|Novo Nordisk Investigational Site, Roeselare, Belgium|Novo Nordisk Investigational Site, Fortaleza, Ceara, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Santo André, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Kozloduy, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Sliven, Bulgaria|Novo Nordisk Investigational Site, Smolyan, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Red Deer, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, St. Johns, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Burlington, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Nepean, Ontario, Canada|Novo Nordisk Investigational Site, Oshawa, Ontario, Canada|Novo Nordisk Investigational Site, Oshawa, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Scarborough, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Laval, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Beijing, China|Novo Nordisk Investigational Site, Annonay, France|Novo Nordisk Investigational Site, BRON cedex, France|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Grenoble - Cédex 09, France|Novo Nordisk Investigational Site, La Roche-sur-yon, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Saint Herblain, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Bad Oeynhausen, Germany|Novo Nordisk Investigational Site, Düsseldorf, Germany|Novo Nordisk Investigational Site, Erlangen, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Haidari-Athens, Greece|Novo Nordisk Investigational Site, Lamia, Greece|Novo Nordisk Investigational Site, Patra, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Baja, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Gyula, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, Hungary|Novo Nordisk Investigational Site, Pécs, Hungary|Novo Nordisk Investigational Site, Siófok, Hungary|Novo Nordisk Investigational Site, Szombathely, Hungary|Novo Nordisk Investigational Site, Guntur, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderbad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Rehovot, Israel|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Pisa, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Chiba, Japan|Novo Nordisk Investigational Site, Fukui, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukushima, Japan|Novo Nordisk Investigational Site, Gunma, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Ishikawa, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Kyoto, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Okayama, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Saitama, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Alor Setar, Malaysia|Novo Nordisk Investigational Site, Ipoh, Perak, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuching, Malaysia|Novo Nordisk Investigational Site, Pulau Pinang, Malaysia|Novo Nordisk Investigational Site, Serdang, Malaysia|Novo Nordisk Investigational Site, Actopan, Hidalgo, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Distrito Federal, México, D.F., Mexico|Novo Nordisk Investigational Site, Mexico City, México, D.F., Mexico|Novo Nordisk Investigational Site, Culiacán, Sinaloa, Mexico|Novo Nordisk Investigational Site, Ciudad Madero, Tamaulipas, Mexico|Novo Nordisk Investigational Site, Alkmaar, Netherlands|Novo Nordisk Investigational Site, Almelo, Netherlands|Novo Nordisk Investigational Site, Almere, Netherlands|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Arnhem, Netherlands|Novo Nordisk Investigational Site, Hilversum, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Kielce, Poland|Novo Nordisk Investigational Site, Olsztyn, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Radom, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kemerovo, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Voronezh, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Lubochna, Slovakia|Novo Nordisk Investigational Site, Lucenec, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Trebisov, Slovakia|Novo Nordisk Investigational Site, Trstena, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Bloemfontein, Free State, South Africa|Novo Nordisk Investigational Site, Benoni, Gauteng, South Africa|Novo Nordisk Investigational Site, Cosmo City, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, South Africa|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Burela, Spain|Novo Nordisk Investigational Site, Getafe, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Bangkoknoi, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Kahramanmaras, Turkey|Novo Nordisk Investigational Site, Kocaeli, Turkey|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Ivano-Frankivsk, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Zaporizhia, Ukraine|Novo Nordisk Investigational Site, Zaporizhia, Ukraine|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Ipswich, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Tooting, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03819153"
260,"NCT04030364","Implementation of a Multi-component, Supervised Exercise Program for Patients With Type 2 Diabetes Mellitus.",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Exercise","Behavioral: CrossFit group exercise classes","Program adherence|Program uptake|Program retention|Health-related quality of life|Psychological experience with exercise|Willingness to recommend|Blood pressure|Hemoglobin A1c|Hypothetical program cost per patient","Ottawa Hospital Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20190116-01H","September 2019","December 2019","February 2020","July 24, 2019",,"September 6, 2019",,,"https://ClinicalTrials.gov/show/NCT04030364"
261,"NCT04113239","Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Metagenome|Genetic Predisposition","Diagnostic Test: 16S rRNA gene sequencing|Genetic: DNA-microarray genotyping","HbA1C|Glucose|Gut microbiome composition of participants|Genotypes of participants|Physical activity questionnaire|Food frequency questionnaire","Atlas Biomed","All","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","T2D+FFQ/GPAQ/Genome/Metagenome","November 27, 2019","October 20, 2021","March 25, 2022","October 2, 2019",,"December 2, 2019","City Clinical Hospital V.P. Demikhova, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04113239"
262,"NCT03823339","A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates","INTENSIFY","Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin degludec/liraglutide","Change in laboratory measured glycosylated haemoglobin A1c (HbA1c)|Patients reached HbA1c less than 7% at end of study (Yes/No )|Change in laboratory measured fasting plasma glucose (FPG)|Average dose step of Xultophy® at end of the study|Change of body weight|Change in number of patient self-reported overall non-severe hypoglycaemic episodes based on recollection|Change in number of patient self-reported nocturnal non-severe hypoglycaemic episodes based on recollection|Change in number of patient self-reported severe hypoglycaemic episodes based on recollection (overall)|Reason(s) for discontinuing treatment with Xultophy® during the treatment period, if applicable","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"343","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN9068-4458|U1111-1213-4338","January 15, 2019","September 25, 2020","September 25, 2020","January 30, 2019",,"March 6, 2020","Novo Nordisk Investigational Site, AbuDhabi, United Arab Emirates|Novo Nordisk Investigational Site, Ajman, United Arab Emirates|Novo Nordisk Investigational Site, Dubai, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT03823339"
263,"NCT03985293","A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Placebo|Drug: PF-06882961","Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16|Percentage of Participants Achieving Less Than (<) 7% Glycosylated Hemoglobin (HbA1c) Levels|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 2|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 4|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 6|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 8|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12|Change from baseline in fasting plasma glucose at week 2|Change from baseline in fasting plasma glucose at week 4|Change from baseline in fasting plasma glucose at week 6|Change from baseline in fasting plasma glucose at week 8|Change from baseline in fasting plasma glucose at week 12|Change from baseline in fasting plasma glucose at week 16|Change from baseline in body weight at week 2|Change from baseline in body weight at week 4|Change from baseline in body weight at week 6|Change from baseline in body weight at week 8|Change from baseline in body weight at week 12|Change from baseline in body weight at week 16|Incidence of treatment emergent adverse events (AEs and SAEs)|Incidence of treatment emergent clinical laboratory abnormalities|Incidence of treatment emergent vital signs abnormalities|Incidence of treatment emergent ECG abnormalities","Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C3421005|2019-000218-12","July 1, 2020","April 28, 2021","May 26, 2021","June 13, 2019",,"January 18, 2020","National Research Institute, Los Angeles, California, United States|Rancho Cucamonga Clinical Research, Rancho Cucamonga, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Incorporated, Tustin, California, United States|Diablo Clinical Research Incorporated, Walnut Creek, California, United States|Accel Research Sites - DeLand Clinical Research Unit, DeLand, Florida, United States|NewPhase Clinical Trials, Corp., Miami Beach, Florida, United States|Sunshine Research Center, Inc, Opa-locka, Florida, United States|Andres Patron D.O. P.A., Pembroke Pines, Florida, United States|Ellipsis Group, Atlanta, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Viable Research Management LLC, Henderson, Nevada, United States|Premier Research, Trenton, New Jersey, United States|PharmQuest, Greensboro, North Carolina, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Palmetto Primary Care Physicians (physicals only), Summerville, South Carolina, United States|Dallas Diabetes Research Center, Dallas, Texas, United States|PrimeCare Medical Group, Houston, Texas, United States|Juno Research, LLC, Houston, Texas, United States|Texas Center for Drug Development, Houston, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Oakwell Clinical Research, LLC, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, Schertz, Texas, United States|DM Clinical Research (Administrative and Storage Office only), Tomball, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States|Aggarwal and Associates Limited, Brampton, Ontario, Canada|Manna Research (Toronto), Toronto, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Manna Research (Quebec), Levis, Quebec, Canada|Manna Research (Mirabel), Mirabel, Quebec, Canada|Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|Diex Recherche Victoriaville Inc., Victoriaville, Quebec, Canada|Diex Recherche Quebec Inc., Quebec, Canada|Centre de recherche Saint-Louis, Quebec, Canada|Alpha Recherche Clinique, Quebec, Canada|Belinus Orvosi es Szamitastechnikai Bt, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|CRU Hungary Kft., Miskolc, Hungary|Borbanya Praxis Egeszsegugyi KFT, Nyiregyhaza, Hungary|Clinfan Kft., Szekszard, Hungary|Yonsei University-Wonju Severance Christian Hospital, Wonju-si, Gangwon-do, Korea, Republic of|Ajou University Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Samsung Medical Center, Gangnam-Gu, Seoul, Korea, Republic of|Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik, Bialystok, Poland|Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne DIAB-ENDO-MET Sp. z o. o., Krakow, Poland|MEDICOME Sp. z o.o., Oswiecim, Poland|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT03985293"
264,"NCT03876015","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)","SURE UK","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide","Change in Glycated Haemoglobin A1c (HbA1c)|Change in HbA1c|Change in body weight|Change in waist circumference|HbA1c level at end of study: <8.0% (64 mmol/mol) (yes/no)|HbA1c level at end of study: <7.5% (59 mmol/mol) (yes/no)|HbA1c level at end of study: <7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c of 1.0% point or more (yes/no)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"217","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN9535-4366|U1111-1199-9050","May 1, 2019","August 28, 2020","August 28, 2020","March 15, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Atherstone, United Kingdom|Novo Nordisk Investigational Site, Berkshire, United Kingdom|Novo Nordisk Investigational Site, Bradford, United Kingdom|Novo Nordisk Investigational Site, Brighton, United Kingdom|Novo Nordisk Investigational Site, Camberley, United Kingdom|Novo Nordisk Investigational Site, Cambridgeshire, United Kingdom|Novo Nordisk Investigational Site, Chiswick, United Kingdom|Novo Nordisk Investigational Site, Co Durham, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Darlington, United Kingdom|Novo Nordisk Investigational Site, Dudley, United Kingdom|Novo Nordisk Investigational Site, Durham, United Kingdom|Novo Nordisk Investigational Site, Greenisland, United Kingdom|Novo Nordisk Investigational Site, Halifax, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, Kettering, United Kingdom|Novo Nordisk Investigational Site, Leicestershire, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, Lincs, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Machester, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Merseyside, United Kingdom|Novo Nordisk Investigational Site, Nuneaton, United Kingdom|Novo Nordisk Investigational Site, Rayleigh, United Kingdom|Novo Nordisk Investigational Site, Rhyl, United Kingdom|Novo Nordisk Investigational Site, South Shields, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, Walton on Thames, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom|Novo Nordisk Investigational Site, Wellingborough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03876015"
265,"NCT03810378","Contrasting Ketogenic and Mediterranean Diets in Individuals With Type 2 Diabetes and Prediabetes: The Keto-Med Trial",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2|PreDiabetes","Behavioral: Mediterranean Diet (Med-Plus)|Behavioral: Well-Formulated Ketogenic Diet (WFKD)","Hemoglobin A1c (HbA1c)|Microbiota composition|Microbiota function|LDL Cholesterol|HDL Cholesterol|Triglycerides|Fasting insulin|Blood pressure","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","61","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","49218","June 5, 2019","December 2020","December 2020","January 18, 2019",,"March 27, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03810378"
266,"NCT04076800","Acupuncture and Insulin Doses in Insulin-treated Type 2 Diabetes","ACUDIA","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Procedure: Acupuncture","Insulin daily doses|HbA1c","Azienda Ospedaliero-Universitaria Careggi","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13181","August 1, 2019","September 30, 2020","October 31, 2020","September 3, 2019",,"January 10, 2020","Diabetologia AOU Careggi, Firenze, Italy",,"https://ClinicalTrials.gov/show/NCT04076800"
267,"NCT03922750","A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin 287|Drug: Insulin glargine U100","Time in target range 3.9-10.0 mmol/L (70-180 mg/dL) measured using continuous glucose monitoring (CGM)|Change in glycosylated haemoglobin (HbA1c)|Change in fasting plasma glucose (FPG)|Change in body weight|Weekly insulin dose|Number of treatment emergent adverse events (TEAEs)|Number of severe hypoglycaemic episodes (level 3)|Number of clinically significant hypoglycaemic episodes (level 2) (less than 3.0 mmol/L (54 mg/dL), confirmed by blood glucose (BG) meter) or severe hypoglycaemic episodes (level 3)|Number of hypoglycaemic alert episodes (level 1) (greater than or equal to 3.0 mmol/L and less than 3.9 mmol/L (greater than or equal to 54 mg/dL and less than 70 mg/dL, confirmed by BG meter)","Novo Nordisk A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","154","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN1436-4466|U1111-1219-5541|2018-003407-18","May 9, 2019","December 19, 2019","January 27, 2020","April 22, 2019",,"February 17, 2020","Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Broumov, Czechia|Novo Nordisk Investigational Site, Holešov, Czechia|Novo Nordisk Investigational Site, Hranice, Czechia|Novo Nordisk Investigational Site, Trutnov, Czechia|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT03922750"
268,"NCT04042441","A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice","ARISE","Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin Degludec/Insulin Aspart","Change in local laboratory measured glycosylated haemoglobin (HbA1c)|HbA1c less than 7% (Yes/No)|HbA1c less than pre-defined individual treatment target (Yes/No)|Change in local laboratory measured fasting plasma glucose (FPG)|Change in local laboratory measured FPG|Change in insulin dose (total, basal, prandial)|Change in body weight|Number of patient recollection of non-severe hypoglycaemic episodes|Number of patient recollection of nocturnal non-severe hypoglycaemic episodes|Number of patient recollection of overall severe hypoglycaemic episodes|Number of weekly self-measured plasma glucose (SMPG) measurements|Reason for initiating Ryzodeg® (pre-specified response option(s))|Discontinue treatment with Ryzodeg® during the treatment period (Yes/No)|Reason for discontinuing treatment with Ryzodeg® during the treatment period, if applicable, (pre-specified response option(s))|Time period from initiation to discontinuation of treatment with Ryzodeg®","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"1112","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN5401-4525|U1111-1227-8654","July 29, 2019","November 12, 2020","November 12, 2020","August 2, 2019",,"May 29, 2020","Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Wollongong, New South Wales, Australia|Novo Nordisk Investigational Site, Herston, Queensland, Australia|Novo Nordisk Investigational Site, South Brisbane, Queensland, Australia|Novo Nordisk Investigational Site, Elizabeth Vale, South Australia, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, Australia|Novo Nordisk Investigational Site, Hobart, Tasmania, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Cooloongup, Western Australia, Australia|Novo Nordisk Investigational Site, Guwahati, Assam, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Delhi, New Delhi, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, India|Novo Nordisk Investigational Site, Mohali, Punjab, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Howrah, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Kedah, Malaysia|Novo Nordisk Investigational Site, Kelantan, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuching, Malaysia|Novo Nordisk Investigational Site, Melaka, Malaysia|Novo Nordisk Investigational Site, Melaka, Malaysia|Novo Nordisk Investigational Site, Penang, Malaysia|Novo Nordisk Investigational Site, Perak, Malaysia|Novo Nordisk Investigational Site, Perlis, Malaysia|Novo Nordisk Investigational Site, Putrajaya, Malaysia|Novo Nordisk Investigational Site, Selangor, Malaysia|Novo Nordisk Investigational Site, Selangor, Malaysia|Novo Nordisk Investigational Site, Aklan, Philippines|Novo Nordisk Investigational Site, Cebu City, Philippines|Novo Nordisk Investigational Site, Davao City, Philippines|Novo Nordisk Investigational Site, Iloilo, Philippines|Novo Nordisk Investigational Site, Makati City, Philippines|Novo Nordisk Investigational Site, Manila, Philippines|Novo Nordisk Investigational Site, Manila, Philippines|Novo Nordisk Investigational Site, Quezon City, Philippines|Novo Nordisk Investigational Site, Quezon City, Philippines|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Jeddah, Saudi Arabia|Novo Nordisk Investigational Site, Makkah, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Lenasia, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Berea, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Alberton, South Africa|Novo Nordisk Investigational Site, Bloemfontein, South Africa",,"https://ClinicalTrials.gov/show/NCT04042441"
269,"NCT03929679","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)","SURE NL","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: semaglutide","Change in Glycated Haemoglobin A1c (HbA1c)|Change in body weight|Change in waist circumference|HbA1c level below 8.0% (64 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.5% (59 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c of 1.0% point or more (yes/no)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"217","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN9535-4496|U1111-1222-5565","May 28, 2019","November 26, 2020","November 26, 2020","April 29, 2019",,"May 29, 2020","Novo Nordisk Investigational Site, Alkmaar, Netherlands|Novo Nordisk Investigational Site, Almelo, Netherlands|Novo Nordisk Investigational Site, Almere, Netherlands|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Arnhem, Netherlands|Novo Nordisk Investigational Site, Bladel, Netherlands|Novo Nordisk Investigational Site, Den Bosch, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Dordrecht, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Emmen, Netherlands|Novo Nordisk Investigational Site, Enschede, Netherlands|Novo Nordisk Investigational Site, Gemert, Netherlands|Novo Nordisk Investigational Site, Groningen, Netherlands|Novo Nordisk Investigational Site, Heerlen, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Leiden, Netherlands|Novo Nordisk Investigational Site, Montfort, Netherlands|Novo Nordisk Investigational Site, Nijverdal, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Sint Anthonis, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Warmenhuizen, Netherlands|Novo Nordisk Investigational Site, Zaandam, Netherlands|Novo Nordisk Investigational Site, Zevenbergen, Netherlands|Novo Nordisk Investigational Site, Zwijndrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03929679"
270,"NCT04155619","Using Early Time Restricted Feeding and Timed Light Therapy to Improve Glycemic Control in Adults With Type 2 Diabetes",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Time Restricted Feeding|Light; Therapy, Complications","Behavioral: No change in meal timing|Behavioral: No change in light exposure|Behavioral: Early Time-Restricted Feeding|Behavioral: Timed Light Therapy","24-hour glucose levels|24-hour insulin levels|24-hour C-peptide levels|Hemoglobin A1C|Insulin sensitivity|Beta-cell responsivity index (a measure of beta-cell function)|Insulin secretion|Melatonin Amplitude|Cortisol Amplitude|Melatonin Phase|Cortisol Phase|Glycemic (""Peripheral"") Rhythm Amplitude|Glycemic (""Peripheral"") Rhythm Phase","University of Alabama at Birmingham","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","344","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB-300003964","July 2020","July 2023","July 2023","November 7, 2019",,"April 21, 2020","University of Alabama at Birmingham; Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04155619"
271,"NCT04088981","Effect of a Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Dietary intervention","Intramyocellular concentrations|Hepatocellular lipid concentrations|Insulin sensitivity|Concentration of glucose|Concentration of immunoreactive insulin|Concentration of C-peptide|Rate of glycemic control|Resting energy expenditure|Postprandial metabolism|Body Composition|Gut microbiome composition|Concentration of plasma lipids|Body weight","Physicians Committee for Responsible Medicine|Yale University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00037991","September 2020","July 2023","July 2023","September 13, 2019",,"September 18, 2019",,,"https://ClinicalTrials.gov/show/NCT04088981"
272,"NCT04051866","Effectiveness of Non-surgical Periodontal Treatment on HbA1c Levels in a Patient With Type 2 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Chronic Periodontitis|Diabetes Mellitus, Type 2","Procedure: Non-surgical periodontal treatment: Scaling and root planing (SRP)|Other: Oral hygiene instructions","Glycated Hemoglobin A (HbA1c)|Probing depth|Glomerular filtration|Quality of life of patients: EuroQol 5D-5L questionnaire|Physical activity (IPAQ questionnaire)|Diet questionnaire (MEDAS)|Therapeutic adherence questionnaire (Morisky-Green)|Cost-utility|Gingival Recession|Clinical attachment level|Gingival Probing bleeding","Gerencia de Atención Primaria, Madrid","All","35 Years and older   (Adult, Older Adult)","Not Applicable","288","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCI 20/18","March 2, 2020","April 1, 2022","December 15, 2022","August 9, 2019",,"February 6, 2020","Gerencia de Atención Primaria, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04051866"
273,"NCT03993132","A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Liraglutide in the Occurrence of Serious Cardiovascular Disease",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Empagliflozin|Drug: Liraglutide","Acute inpatient hospital admission with a diagnosis of HF and/or initiation of community prescription drug therapy with loop diuretics|Acute inpatient hospital admission with a diagnosis of HF and/or all-cause death|Major adverse cardiac events of heart failure/any cardiovascular outcome or death|All-cause acute inpatient hospital admissions or emergency room visit notleading to inpatient hospital admission|All-cause acute inpatient hospital admission|Acute hospital admission with HF|All-cause acute inpatient hospital admission or all-cause death|All-cause death","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)",,"30000","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","1245-0194","October 1, 2018","December 1, 2020","December 1, 2020","June 20, 2019",,"June 4, 2020","Department of Clinical Epidemiology - Aarhus Unversiteteshospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT03993132"
274,"NCT04018105","Influence of Preprandial Metformin Administration on Carbohydrate Absorption","METTIME","Not yet recruiting","No Results Available","Impaired Glucose Tolerance|Type2 Diabetes","Other: Oral glucose tolerance test (OGTT) with or without metformin","Area under the curve of D-Xylose|Number of Participants with gastrointestinal side effects|Area under the curve of blood glucose|Area under the curve of insulin|Area under the curve of GLP-1","University Hospital, Lille","Female","18 Years to 60 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018_35|2019-001175-36","March 2020","March 2022","March 2022","July 12, 2019",,"December 4, 2019",,,"https://ClinicalTrials.gov/show/NCT04018105"
275,"NCT03951805","A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin 287|Drug: Insulin Glargine","Time in target range 3.9-10.0 mmol/L (70-180 mg/dL) measured using CGM (continuous glucose monitoring)|Change in HbA1c (glycated haemoglobin)|Change in fasting plasma glucose (FPG)|Change in body weight|Weekly insulin dose|Number of treatment emergent adverse events (TEAEs)|Number of severe hypoglycaemic episodes (Level 3)|Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)|Number of hypoglycaemic alert episodes(level 1) (greater than or equal to 3.0 and below 3.9 mmol/L (greater than or equal to 54 and below 70 mg/dL), confirmed by BG meter)","Novo Nordisk A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","205","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN1436-4465|U1111-1219-5474|2018-003406-11","May 9, 2019","December 12, 2019","January 17, 2020","May 15, 2019",,"January 23, 2020","Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Schertz, Texas, United States|Novo Nordisk Investigational Site, Karlovac, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Pohlheim, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Kaposvár, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Radom, Poland|Novo Nordisk Investigational Site, Tomaszow Mazowiecki, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Banska Bystrica, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Rimavska Sobota, Slovakia|Novo Nordisk Investigational Site, Roznava, Slovakia|Novo Nordisk Investigational Site, Velky Meder, Slovakia|Novo Nordisk Investigational Site, Baracaldo, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, La Roca del Vallés, Spain|Novo Nordisk Investigational Site, Vic (Barcelona), Spain",,"https://ClinicalTrials.gov/show/NCT03951805"
276,"NCT04017221","Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Urosepsis|Diabetic Ketoacidosis|Lower Extremity Amputation","Drug: Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Drug: Dipeptidyl peptidase-4 (DPP-4) inhibitors|Drug: Other treatment combinations","Incidence rate of urosepsis|Incidence rate of diabetic ketoacidosis (DKA)|Incidence rate of lower extremity amputation|Incidence rate of Fournier's gangrene","Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)",,"1249636","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Q18-09/10/11","October 1, 2018","December 1, 2019","December 1, 2019","July 12, 2019",,"January 14, 2020","Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04017221"
277,"NCT03974139","Impact of Metformin on Leptin Transport in Cerebrospinal Fluid of Obese Patients","LEPTOB","Recruiting","No Results Available","Obesity Without Type 2 Diabetes, With BMI>30","Drug: Metformin Oral Tablet","cerebrospinal fluid /plasma leptin ratio|cerebrospinal fluid /plasma glucose ratio|cerebrospinal fluid /plasma glucagon like peptide 1 (GLP1) ratio|cerebrospinal fluid /plasma insulin ratio|cerebrospinal fluid /plasma ghrelin ratio|Cerebrospinal fluid levels of Agouti-Related Peptide (AgRP)|Plasma levels of Agouti-Related Peptide (AgRP)|Cerebrospinal fluid levels of proopiomelanocortin (POMC)|Plasma levels of proopiomelanocortin (POMC)|Cerebrospinal fluid levels of neuropeptide Y (NPY)|Plasma levels of neuropeptide Y (NPY)|Cerebrospinal fluid levels of leptin soluble receptor|Plasma levels of leptin soluble receptor|Apparent diffusion coefficient (ADC)|Hypothalamic concentration of N-acetyl-aspartate (NAA)|Hypothalamic concentration of creatine|Hypothalamic concentration of Choline|Hypothalamic concentration of Glutamine / glutamate|Hypothalamic concentration of gamma-aminobutyric acid (GABA)|Weight|Abdominal circumference|Percentage of body fat|Fat free mass (Kg)|Energy expenditure|Score of the Three Factor Eating Questionnaire (TFEQ)|Score of the Dutch Eating Behaviour Questionnaire (DEBQ)","Lille Catholic University|Centre Hospitalier Arras","All","18 Years to 40 Years   (Adult)","Phase 2","31","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RC-P0054","September 10, 2019","August 31, 2021","May 31, 2022","June 4, 2019",,"October 24, 2019","Centre hospitalier d'Arras, Arras, France",,"https://ClinicalTrials.gov/show/NCT03974139"
278,"NCT03842267","A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Gemigliptin 50mg|Drug: Gemigliptin Placebo","Changes from baseline HbA1c at week 24","LG Chem","All","19 Years and older   (Adult, Older Adult)","Phase 3","314","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LG-DPCL019","May 30, 2019","January 31, 2022","July 31, 2022","February 15, 2019",,"April 26, 2019",,,"https://ClinicalTrials.gov/show/NCT03842267"
279,"NCT03940300","Farming for Life - Health Impact of Organic Vegetable Prescriptions for Adults Living With or at Risk of Type 2 Diabetes","FFL","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Food Supply|Poverty|Minority Health|Obesity","Dietary Supplement: Fresh organic vegetables","Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by blood pressure.|Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by body mass index.|Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by waist circumference .|Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by hemoglobin A1c.|Improve food security for adults with or at risk for type 2 diabetes assessed by U.S. Household Food Security Survey Module: Six-item short form|Improve glycemic control measured by continuous glucose monitoring (CGM)","Sansum Diabetes Research Institute|United States Department of Agriculture (USDA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","440","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-01793","January 28, 2019","December 2023","May 2024","May 7, 2019",,"May 10, 2019","Sansum Diabetes Research Institute, Santa Barbara, California, United States",,"https://ClinicalTrials.gov/show/NCT03940300"
280,"NCT04141111","Retrospective and Prospective Study on Professional Continuous Glucose Monitoring in Insulin-treated Type 2 Diabetes","ADJUST","Completed","No Results Available","Diabetes Mellitus, Type 2","Device: Continuous Glucose Monitoring (CGM)","Glycemic control|Health status|Treatment satisfaction|Therapeutic changes","Associacao Protectora dos Diabeticos de Portugal|Medtronic","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","102","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","639/2015","March 22, 2015","January 24, 2017","March 1, 2018","October 28, 2019",,"October 28, 2019","APDP, Lisboa, Portugal",,"https://ClinicalTrials.gov/show/NCT04141111"
281,"NCT03847779","Microcirculatory Vasomotor Changes in Type 2 Diabetes With Peripheral Neuropathy","NEUROMICRO","Recruiting","No Results Available","Diabetic Neuropathy Peripheral|Small Vessel Disease of Diabetes Mellitus|Vasodilation|Vasoconstriction","Other: ""Rest""|Other: ""Exercise""|Other: ""Foot lowering""|Other: ""Hyperthermia""","Changes in average spectral amplitude of the entire frequency range between baseline and after stimulus","University of Avignon","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UAPV-012019-AVJ","February 4, 2019","June 30, 2020","June 30, 2020","February 20, 2019",,"February 20, 2019","Centre Hospitalier Henri Duffaut, Avignon, France",,"https://ClinicalTrials.gov/show/NCT03847779"
282,"NCT04123587","Genetic Variants Replication Study Associated With Dependence on Sulfonylurea in Participants With Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus","Drug: discontinuation of Sulfonylureas","the list of previously found candidate variants which are observed in the slufonylurea-dependent patients but not in the non-dependent patients","Seoul National University Hospital","All","19 Years and older   (Adult, Older Adult)","Phase 4","58","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU","September 10, 2019","August 2020","August 2021","October 11, 2019",,"October 11, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04123587"
283,"NCT04076007","The Effect of Dietary Nitrate on Blood Pressure, Insulin Sensitivity, and Vascular Function in Type 2 Diabetes",,"Completed","No Results Available","Diabetes|Hypertension","Dietary Supplement: Beetroot juice|Dietary Supplement: Nitrate depleted beetroot juice","24 hour Ambulatory Blood Pressure monitoring after 2 weeks active juice|24 hour Ambulatory Blood Pressure monitoring after 2 weeks placebo juice|Brachial artery Flow mediated vasodilation|Microvascular response to Iontophoresis of Acetylcholine and Sodium Nitroprusside|Peak reactive hyperemia|Maximum hyperemia in response to heating|Cognitive function|Insulin sensitivity","University of Exeter","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRF035","December 2009","August 2012","February 2015","September 3, 2019",,"September 3, 2019","NIHR Exeter Clinical Research Facility, Exeter, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04076007"
284,"NCT03970161","Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy",,"Recruiting","No Results Available","Diabetes Mellitus|Diabetic Retinopathy|Nerve Injury","Device: routine ophthalmic examination","Peripapillary RNFL thickness|GCL+ in the macular area obtained using the 3D wide mode|Retinal thickness in all macular regions|RNFL thickness in the macular area obtained using the 3D Macula (v) mode|GCL+ thickness in the macular region obtained using the 3D Macula (v) mode","Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","720","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Retinal nerve injury in T2DM","May 29, 2019","June 1, 2021","June 1, 2021","May 31, 2019",,"May 31, 2019","The third affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03970161"
285,"NCT03868813","An Artificial Intelligence Assisted Telehealth Intervention to Promote Self-Management in Patients With Type 2 Diabetes Mellitus (Qualitative Interview)",,"Recruiting","No Results Available","Diabetes Mellitus","Behavioral: Semi-structured Interview","Users' Expectation from a Health Coaching System","University of Alabama at Birmingham","All","18 Years to 80 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","UAB-DRC-2019-1","July 1, 2019","July 2020","July 2020","March 11, 2019",,"July 9, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03868813"
286,"NCT04157673","Imagine to Remember: Improving Medication Adherence in Pre- and Type 2 Diabetes",,"Recruiting","No Results Available","Medication Adherence","Behavioral: Episodic Future Thinking introduced at 6 weeks|Behavioral: Episodic Future Thinking introduced at 8 weeks|Behavioral: Episodic Future Thinking introduced at 10 weeks","Medication Adherence|Prospective memory|Delay Discounting|Working Memory","State University of New York at Buffalo","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","FWA00008824","September 1, 2019","May 1, 2020","May 1, 2020","November 8, 2019",,"February 25, 2020","University at Buffalo, Department of Pediatrics, Division of Behavioral Medicine, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04157673"
287,"NCT04173117","Feasibility of Low Energy Diet in HFpEF and Type 2 Diabetes","ALLEVIATE","Recruiting","No Results Available","Dietary Exposure","Dietary Supplement: Low energy meal replacement plan (12 weeks)","Recruitment and retention rates|Differences in 6 minute walk test pre- and post intervention|Differences in cardiopulmonary exercise test (peak VO2) pre- and post intervention|Differences in LV remodelling (indexed LV mass) pre- and post intervention|Differences in LV function pre- and post intervention|Differences in E/A ratio pre- and post intervention|Differences in E (cm/s) pre- and post intervention|Differences in MV deceleration time (ms) pre- and post intervention|Differences in A (cm/s) pre- and post intervention|Differences in Septal e' pre- and post intervention|Differences in Lateral e' pre- and post intervention|Differences in Septal E/e' pre- and post intervention|Differences in Lateral E/e' pre- and post intervention|Differences in Average E/e' pre- and post intervention|Differences in LA volume indexed pre- and post intervention|Differences in TR jet velocity (m/s) pre- and post intervention|Differences in BMI pre- and post intervention|Differences in Bone Mineral Density (g/cm2) pre- and post intervention|Differences in Total Fat mass (g) pre- and post intervention|Differences in Total tissue fat (%) pre- and post intervention|Differences in visceral adipose tissue mass (g) pre- and post intervention|Differences in visceral adipose tissue volume (cm3) pre- and post intervention|Differences in Total lean body mass (g) pre- and post intervention|Difference in World Health Organisation Disability Schedule (WHODAS 2.0) pre- and post intervention|Difference in Medical Research Council Dyspnoea Scale pre- and post intervention|Difference in Minnesota Living with heart Failure Questionnaire pre- and post intervention|Differences in Fasting Glucose (mmol/L) pre- and post intervention|Differences in HbA1c (%) pre- and post intervention|Differences in HbA1c (mmol/mol) pre- and post intervention|Differences in B-type (ng/L) natriuretic peptide pre- and post intervention|Differences in hs-troponin (ng/L) natriuretic peptide pre- and post intervention|Differences in CRP (mg/L), natriuretic peptide pre- and post intervention|Differences in albumin concentration pre- and post intervention|Differences in albumin/creatinine ratio concentration pre- and post intervention|Differences in sodium (mmol/L) pre- and post intervention|Differences in potassium (mmol/L) pre- and post intervention|Differences in Urea (mmol/L) pre- and post intervention|Differences in creatinine (umol/L) pre- and post intervention|Differences in eGFR (ml/min) pre- and post intervention|Differences in hsTnl(ng/L) pre- and post intervention|Differences in hALT (iu/L) pre- and post intervention|Differences in ALP (iu/L)pre- and post intervention|Differences in LDL (mmol/L) pre- and post intervention|Differences in kidney function pre- and post intervention|Differences in liver function pre- and post intervention|Differences in the levels of physical activity pre- and post intervention|Cardiac rehabilitation uptake|The number of participants who experience any Major Adverse Cardiovascular Events (MACE)","University of Leicester","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0699","February 28, 2020","July 1, 2021","December 1, 2021","November 21, 2019",,"March 10, 2020","Cardiovascular Research Centre (Glenfield Hospital), Leicester, Leicestershire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04173117"
288,"NCT04094415","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice","SURE ITALY","Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide","Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent)|Change in HbA1c (measured in mmol/mol)|Change in body weight (measured in kg)|Change in body weight (measured in percent)|Change in waist circumference|HbA1c level at end of study: below 8.0% (64 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.5% (59 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c from baseline to end of study of 1.0% point or more (Y/N)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction )|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"520","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN9535-4549|U1111-1233-2023","October 28, 2019","June 24, 2021","June 24, 2021","September 19, 2019",,"June 4, 2020","Novo Nordisk Investigational Site, Bagno a Ripoli, Italy|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Brindisi, Italy|Novo Nordisk Investigational Site, Casarano (Lecce), Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Chieri Torino, Italy|Novo Nordisk Investigational Site, Foggia, Italy|Novo Nordisk Investigational Site, Gaeta, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Negrar (VR), Italy|Novo Nordisk Investigational Site, Orbassano, Italy|Novo Nordisk Investigational Site, Pavia, Italy|Novo Nordisk Investigational Site, Prato, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Rozzano (MI), Italy|Novo Nordisk Investigational Site, Sesto San Giovanni (MI), Italy|Novo Nordisk Investigational Site, Treviglio (Bergamo), Italy|Novo Nordisk Investigational Site, Treviso, Italy|Novo Nordisk Investigational Site, Udine, Italy|Novo Nordisk Investigational Site, Vicenza, Italy|Novo Nordisk Investigational Site, Vicenza, Italy|Novo Nordisk Investigational Site, Vigevano, Italy",,"https://ClinicalTrials.gov/show/NCT04094415"
289,"NCT04067999","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice","SURE SPAIN","Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide","Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent)|Change in Glycated Haemoglobin A1c (HbA1c) (measured in mmol/mol)|Change in body weight (measured in kg)|Change in body weight (measured in percent)|Change in waist circumference|HbA1c level at end of study: below 8.0% (64 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.5% (59 mmol/mol) (yes/no)|HbA1c level at end of study: below 7.0% (53 mmol/mol) (yes/no)|Reduction in HbA1c from baseline to end of study of 1.0% point or more (Y/N)|Weight reduction of 3.0% or more (yes/no)|Weight reduction of 5.0% or more (yes/no)|HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)|Patient reported severe or documented hypoglycaemia (yes/no)|Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction|Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction )|Change in score for Short Form (SF)-36 v2: Physical summary component|Change in score for SF-36 v2: Mental summary component|Patient completed the study under treatment with semaglutide (yes/no)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"217","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN9535-4368|U1111-1217-3546","August 5, 2019","June 22, 2021","June 22, 2021","August 28, 2019",,"April 17, 2020","Novo Nordisk Investigational Site, A Coruña, Spain|Novo Nordisk Investigational Site, Baracaldo, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Bilbao, Spain|Novo Nordisk Investigational Site, Ferrol, Spain|Novo Nordisk Investigational Site, Galdakao, Spain|Novo Nordisk Investigational Site, Las Palmas de Gran Canaria, Spain|Novo Nordisk Investigational Site, Oviedo, Spain|Novo Nordisk Investigational Site, Pamplona, Spain|Novo Nordisk Investigational Site, Pontevedra, Spain|Novo Nordisk Investigational Site, Ribadeo, Spain|Novo Nordisk Investigational Site, Salamanca, Spain|Novo Nordisk Investigational Site, Valladolid, Spain|Novo Nordisk Investigational Site, Vigo, Spain|Novo Nordisk Investigational Site, Álava, Spain",,"https://ClinicalTrials.gov/show/NCT04067999"
290,"NCT04136730","Effects of Home- and Gym-based Resistance Exercise on Body Composition, Muscle Strength and Glycemic Control in People With Type 2 Diabetes.",,"Recruiting","No Results Available","Diabetes","Behavioral: Home-based|Behavioral: Gym-based","HbA1c|Fat-free mass|SPPB","Dasman Diabetes Institute|University of Glasgow","All","21 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM-2019-021","August 1, 2019","August 2020","August 2020","October 23, 2019",,"October 23, 2019","Dasman Diabetes Institute, Kuwait City, Kuwait",,"https://ClinicalTrials.gov/show/NCT04136730"
291,"NCT04125160","Glycaemic Markers in Persons With Type 2 Diabetes on Peritoneal Dialysis",,"Recruiting","No Results Available","HbA1c|Peritoneal Diseases|Glycated Albumin|Fructosamine|Continuous Glucose Monitoring","Device: Continuous glucose monitoring|Diagnostic Test: Glycaemic markers","HbA1c evaluated by the total mean glucose from continuous glucose monitoring|Glycated albumin|Fructosamine|Standard deviation|Coefficient variation|Low Blood Glucose Index|High Blood Glucose Index|Time in hypoglycaemic range below 3.0 mmol/l|Time in hypoglycaemic range below 3.9 mmol/l to 3.0 mmol/l|Time in hyperglycaemic range above 10.0 mmol/l|Time in hyperglycaemic range above 13.9 mmol/l|Hypoglycaemic events","Rigshospitalet, Denmark|Steno Diabetes Center Copenhagen|Zealand University Hospital|Herlev Hospital|Hillerod Hospital, Denmark","All","18 Years to 90 Years   (Adult, Older Adult)",,"52","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GLYCO-PD","November 12, 2019","September 2020","September 2020","October 14, 2019",,"November 13, 2019","Herlev Hospital, Copenhagen, Denmark|Rigshospitalet department of endocrinology, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark|Rigshospitalet department of nephrology, København Ø, Denmark|Roskilde Hospital, Roskilde, Denmark",,"https://ClinicalTrials.gov/show/NCT04125160"
292,"NCT03989232","A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes","SUSTAIN FORTE","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Placebo (semaglutide)","Change in HbA1c|Change in body weight (kg)|Change in fasting plasma glucose (FPG)|Change in body mass index (BMI)|Change in waist circumference|HbA1c below 7%|HbA1c equal to or below 6.5%|Weight loss equal to or above 5%|Weight loss equal to or above 10%|Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes|Change in pulse rate","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","964","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN9535-4506|U1111-1224-5162|2018-004529-96","June 19, 2019","September 16, 2020","November 11, 2020","June 18, 2019",,"January 18, 2020","Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Chandler, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Mesa, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Coral Gables, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Adairsville, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Lake Charles, Louisiana, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Trenton, New Jersey, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Salisbury, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Corvallis, Oregon, United States|Novo Nordisk Investigational Site, Gaffney, South Carolina, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Humble, Texas, United States|Novo Nordisk Investigational Site, Hurst, Texas, United States|Novo Nordisk Investigational Site, Katy, Texas, United States|Novo Nordisk Investigational Site, Plano, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Shavano Park, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Wenatchee, Washington, United States|Novo Nordisk Investigational Site, Kozloduy, Bulgaria|Novo Nordisk Investigational Site, Montana, Bulgaria|Novo Nordisk Investigational Site, Petrich, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Yambol, Bulgaria|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Stoney Creek, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Ceske Budejovice, Czechia|Novo Nordisk Investigational Site, Praha 10, Czechia|Novo Nordisk Investigational Site, Praha 5, Czechia|Novo Nordisk Investigational Site, Vlasim, Czechia|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Kaposvár, Hungary|Novo Nordisk Investigational Site, Komarom, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Szekszárd, Hungary|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gorzow Wielkopolski, Poland|Novo Nordisk Investigational Site, Katowice, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Manati, Puerto Rico|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Hnusta, Slovakia|Novo Nordisk Investigational Site, Kezmarok, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Krupina, Slovakia|Novo Nordisk Investigational Site, Levice, Slovakia|Novo Nordisk Investigational Site, Nove Zamky, Slovakia|Novo Nordisk Investigational Site, Pezinok, Slovakia|Novo Nordisk Investigational Site, Poprad, Slovakia|Novo Nordisk Investigational Site, Povazska Bystrica, Slovakia|Novo Nordisk Investigational Site, Puchov, Slovakia|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Mykolaiv, Ukraine|Novo Nordisk Investigational Site, Ternopil, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT03989232"
293,"NCT03881540","Efficacy of tDNA Care on Weight Loss and Metabolic Outcomes in Patients With Overweight, Obesity and Type 2 Diabetes",,"Completed","No Results Available","Diabetes|Obesity","Other: tDNA-MI group|Other: tDNA-CC group|Other: UC group","Change in Weight|Change in Glycated haemoglobin (A1C)|Change in percentage body fat|Change in fasting blood glucose|Change in total cholesterol, LDL-C and HDL-C|Change in High sensitivity C-Reactive Protein (HsCRP)|Change in systolic and diastolic blood pressure|Change in energy intake and macronutrients|Change in Weight Efficacy Lifestyle (WEL) scores|Change in exercise minutes","International Medical University","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IMU R 134/2014","June 2014","December 2015","December 2015","March 19, 2019",,"March 22, 2019","International Medical University, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT03881540"
294,"NCT03794232","Effect of Inulin-type Fructose Extracted From Jerusalem Artichoke on Improving Prediabetic State of Type 2 Diabetes",,"Completed","No Results Available","Prediabetes","Dietary Supplement: NIUCHANG|Dietary Supplement: Placebo","Incidence of blood sugar reversal to normal after intervention|Changes in insulin resistance index|Changes in intestinal flora|Incidence of blood glucose stabilization in pre-diabetes after intervention|Incidence of blood glucose progression to diabetes after intervention|Hemoglobin A1C、Glycated Albumin|The levels of serum insulin|The levels of serum C-peptid|Body weight","Inuling (Bei Jing) Science and Technology Co. Ltd|Peking Union Medical College Hospital|Proswell Medical Corporation","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","246","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","S-749","May 30, 2016","April 4, 2018","April 4, 2018","January 4, 2019",,"January 7, 2019",,,"https://ClinicalTrials.gov/show/NCT03794232"
295,"NCT03899883","Uric Acid Lowering Trial in Youth Onset T2D","ULTRA-T2D","Recruiting","No Results Available","Diabetic Kidney Disease|Hyperuricemia|Diabetes|Diabetes Mellitus, Type 2|Type2 Diabetes|Type 2 Diabetes Mellitus|Diabetic Nephropathies|Diabetes Complications","Drug: Pegloticase 8 MG/ML [Krystexxa]","Cardiovascular Markers|Pulse Wave Velocity (PWV)|Wall Shear Stress (WSS)|Renal Blood Flow|Glomerular Filtration Rate|Albumin Excretion Rate (AER)|Calculated parameters of intrarenal hemodynamic function|Change in serum uric acid (sUA)","University of Colorado Denver School of Medicine Barbara Davis Center","Male","18 Years to 25 Years   (Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-1700","January 1, 2020","May 31, 2020","December 31, 2020","April 2, 2019",,"March 23, 2020","Children's Hospital Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03899883"
296,"NCT03854656","Effect of Time-restricted Eating on Behaviour and Metabolism in Overweight Individuals at High Risk of Type 2 Diabetes","RESET","Recruiting","No Results Available","Overweight and Obesity|PreDiabetes","Other: Time-restricted eating","Change in body weight (kg)|Body weight (kg)|Body mass index (kg/m^2)|Fat mass (kg)|Fat free mass (kg)|Fat percentage (%)|Waist circumference (cm)|Hip circumference (cm)|HbA1c (mmol/mol and %)|Systolic blood pressure (mmHg)|Diastolic blood pressure (mmHg)|Heart rate (bpm)|Resting energy expenditure (kcal/day)|Substrate oxidation (respiratory exchange ratio)|Metabolites|Hormones|Circulating proteins that associate with low-grade inflammation and lipid metabolism|Respiratory and glycolytic capacities of isolated peripheral blood mononuclear cells (PBMCs)|Heart rate response to standing up from the supine position|Heart rate response to inhalation and exhalation|Heart rate response to forced exhalation during rest (valsalva maneuver)|Gastric emptying time (hours and minutes)|Small bowel transit time (hours and minutes)|Large bowel transit time (hours and minutes)|Total gastrointestinal transit time (hours and minutes)|Motility index|Attention measured using eye tracking|Emotions measured using facial expression analyses|Arousal measured using galvanic skin response|Food choice|Implicit wanting|Explicit liking|Explicit wanting|Insulin sensitivity (indices)|Insulin resistance (indices)|Subjective appetite|Mean amplitude of glycaemic excursions (MAGE)|Continuous overall net glycaemic action (CONGA)|Daily time spent above different glucose concentrations (e.g. >6.1 mmol/L, >7.0 mmol/L, >7.8 mmol/L, and >11.1 mmol/L)|Mean glucose concentrations|Standard deviation of glucose concentrations|Variation coefficients of glucose concentrations|Physical activity (time spent at different intensities)|Physical activity (counts/min)|Physical activity energy expenditure (kcal/day)|Physical activity (MET hours)|Timing of physical activity (hh:mm)|Energy intake (kcal/day)|Macronutrient intake (energy percentage)|Timing of dietary intake (hh:mm)|Sleep timing (hh:mm)|Sleep duration (min)|Sleep variability (min)|Sleep onset latency (min)|Sleep efficiency (%)|Wakefulness (min)|Self-reported gastrointestinal symptoms (part 1)|Self-reported gastrointestinal symptoms (part 2)|Self-reported gastrointestinal symptoms (part 3)|Self-reported autonomic symptoms|Self-reported control over eating|Self-reported sleepiness|Self-reported sleep quality|Self-reported chronotype|Self-reported physical activity|Self-reported overall health and wellbeing|Self-reported eating behavior|Self-reported night eating|Daily eating/drinking window (hh:min)|Microbiome content and diversity|Motivation for participation (qualitative methods)|Feasibility of the intervention (qualitative methods)|Satisfaction with the intervention (qualitative methods)","Kristine Færch|University of Copenhagen|Aalborg University Hospital|iMotions A/S|University of Leeds|Salk Institute for Biological Studies|Steno Diabetes Center Copenhagen","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NNF17OC0027822","February 25, 2019","June 2020","August 2020","February 26, 2019",,"November 25, 2019","Steno Diabetes Center Copenhagen, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT03854656"
297,"NCT03814694","Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes. The Hypo-energetic Study","CutDM-Hypo","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Overweight and Obesity","Dietary Supplement: CRHP Diet|Dietary Supplement: CD Diet","Change in glycated hemoglobin (HbA1c) during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.|Change in hepatic fat content after 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.|Change in fasting plasma triglycerides during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.","Bispebjerg Hospital|University of Copenhagen|University of Aarhus|The Danish Dairy Research Foundation, Denmark|Arla Foods","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CUTDM-HYPO","January 29, 2019","July 2020","December 2020","January 24, 2019",,"August 13, 2019","Bispebjerg Hospital, Copenhagen, Copenhagen NV, Denmark",,"https://ClinicalTrials.gov/show/NCT03814694"
298,"NCT03958591","Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification in Patients With Poorly Controlled Type 2 Diabetes",,"Not yet recruiting","No Results Available","Poorly Controlled Diabetes Mellitus|Intensive-de-escalation Therapy|Long-term Regimen Simplification","Drug: CSII and thereafter combination therapy with wearable devices|Drug: CSII and thereafter combination therapy|Drug: Traditionally upgrading therapy","the proportions of treatment simplification","Yanbing Li|Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","408","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018YFC1314103","June 1, 2019","June 30, 2022","December 31, 2022","May 22, 2019",,"May 22, 2019",,,"https://ClinicalTrials.gov/show/NCT03958591"
299,"NCT03987308","Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Newly Diagnosed Type 2 Diabetes",,"Not yet recruiting","No Results Available","Type 2 Diabetic Patients","Drug: Beinaglutide|Drug: Insulin aspart","The percentage of patients with at least a 0.7% change in the absolute value of glycated hemoglobin|After five weeks of treatment, the differences in the percentages of patients with at least 3% weight loss|The percentage of subjects whose blood glucose levels are within the normal range|The time required for patients' blood glucose levels to reach the normal range|Body weights of the two patient groups|Waist circumferences of the two patient groups|BMIs of the two patient groups|Waist-to-hip ratios (WHRs) of the two patient groups|Changes in the function of islet β-cells (HOMA-β)|Changes in the function of islet β-cells (insulin index ΔI30 / ΔG30)|Changes in insulin sensitivity|Changes in β-cell function (HOMA-β)|Weight changes between the two treatment groups|The percentage of responders who meet the HbA1c criteria|The differences in the duration of target blood glucose levels that are met|The percentages of responders who meet the HbAc1 criteria|Differences in HbA1c indices|Differences in weight|Differences in insulin levels|Differences in C-peptide levels|The percentages of subjects with greater than 3% weight loss","Beijing Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BN-IIT-IS-008","July 1, 2019","June 30, 2021","December 30, 2021","June 17, 2019",,"June 17, 2019","First Hospital of Peking University, Beijing, China,Beijing, China|Ninth Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Fuzhou, China,Fuzhou, China|Southern Hospital of Southern Medical University, Guangzhou, China,Guangzhou, China|Heilongjiang provincial hospital, Harbin, China,Harbin, China|Henan People's Hospital, Zhengzhou, China,Zhengzhou, China|Tangshan Workers Hospital, Tangshan, Hebei,Tangshan, China|Affiliated Hospital of Qingdao University, Qingdao, Shandong，Qingdao, China|Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan，Sichuan, China|Zhejiang People's Hospital, Hangzhou, Zhejiang,Hangzhou, China",,"https://ClinicalTrials.gov/show/NCT03987308"
300,"NCT04112875","Effect of L-arginine on Microcirculation, Myogenesis and Angiogenesis Associated With Aging, Sarcopenia and Diabetes",,"Completed","No Results Available","Aging|Sarcopenia|Type 2 Diabetes|Microcirculation","Dietary Supplement: L-arginine|Dietary Supplement: Maltodextrin","Changes in Microcirculation|Changes in Endothelium-dependent and endothelium-independent vasodilation|Change in metabolic markers|change in circulating muscle growth and degradation factors|Body composition by DXA","Rio de Janeiro State University|Laboratory for Clinical and Experimental Research on Vascular Biology","Female","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Arginine","April 2016","April 2019","September 2019","October 2, 2019",,"October 2, 2019","State University of Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT04112875"
301,"NCT03830840","Mil Familias Cohort Establishment: a Study to Understand Determinants of Diabetes and Its Complications Among US Latinos",,"Enrolling by invitation","No Results Available","Type2 Diabetes Mellitus|Cardiovascular Diseases",,"Success (evaluated by Yes/No format) recruiting and establishing an observational cohort of 1,000 Latino families with at least one family member living with type 2 diabetes by deploying the methods proven feasible by Mil Familias Operational Pilot.|Socio-demographics assessed by questionnaire.|Number of healthcare visits and the difficulty in traveling to the healthcare provider assessed by questionnaire|Questions regarding personal opinions regarding the burden of diabetes on Latinos measured by specific questions|Total daily tortilla consumption|Daily sugary drink consumption|Number of times per week eating meals prepared away from home|Laboratory blood draw for evaluation of C-Peptide related to diabetes|Laboratory blood draw for evaluation of C-Reactive protein related to diabetes|Laboratory blood draw for evaluation of Complete Blood Count|Laboratory blood draw for evaluation of Comprehensive Metabolic Panel|Laboratory blood draw for evaluation of Glutamic Acid Decarboxylase (GAD) antibodies related to diabetes|Laboratory blood draw for evaluation of HbA1c related to diabetes|Laboratory blood draw for evaluation of Insulin autoantibody related to diabetes|Laboratory blood draw for evaluation of Islet antigen 2 (IA-2) antibody related to diabetes|Laboratory blood draw for evaluation of lipids|Laboratory blood draw for evaluation of Insulin|Laboratory blood draw for evaluation of thyroid function|Microalbumin measured in a urine sample|Creatinine measured in a urine sample|Microalbumin/creatinine ratio measured in a urine sample|Cheek cells and saliva for genomic analysis|Stool samples for microbiome analysis|Height measured by Physical exam|Weight measured by Physical exam|Waist circumference measured by Physical exam|Blood pressure measured by Physical exam|Temperature measured by Physical exam|Heart rate measured by Physical exam|Foot examination evaluated by Questions and Physical exam|Neuropathy Questions during Physical exam|Retinopathy questions during Physical exam|Dental exam Questions during Physical exam|Eye exam Questions during Physical exam|Medical history, family medical history, and medication status and history assessed by interview|Menopausal status, pregnancy status, and gestational diabetes history for women determined by interview|Determination of diabetes related foot disease|Acculturation measured by the Brief Acculturation Scale for Hispanics (BASH)|Quality of life measured by the Short Form Health Survey (SF-12)|Depression measured by the Patient Health Questionnaire-9|Perceived Ethnic Discrimination measured by the Brief Perceived Ethnic Discrimination Questionnaire - Community version (PEDQ-CV)|Adverse Childhood Experiences (ACE) quantified by ACE questionnaire|Spirituality measured by a Spiritual Well Being Scale|Risk Perception Survey For Developing Diabetes (RPS-DD)|Sleep quality measured by the Oviedo Sleep Questionnaire (OSQ)|Stress measured by the 4 item Perceived Stress Scale (PSS)|Drug abuse measured by the Drug Abuse Screening Test (DAST) - 20|Diabetes management measured by the Diabetes Symptom Self-Care Inventory|Family diabetes management measured by questionnaire|Foot self care confidence measured by questionnaire|Health literacy measured by the Short Assessment of Health Literacy (SAHL)|Measurement of health numeracy|Trust in physician measured by the Trust in Physician (TPS) questionnaire|Social needs screening assessed by the Health Leads Screening toolkit|Food security assessed by U.S. Household Food Security Survey Module: Six-item short form|Functional support measured by the SSQ6|Support structure measured by Medical Outcomes Study Social Support Survey (mMOS-SS)|National survey of children's health (NSCH) for all children and youth","Sansum Diabetes Research Institute|Eli Lilly and Company","All","7 Years and older   (Child, Adult, Older Adult)",,"5000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2017 - 6004","February 1, 2019","November 2021","December 2021","February 5, 2019",,"March 20, 2020","Sansum Diabetes Research Institute, Santa Barbara, California, United States",,"https://ClinicalTrials.gov/show/NCT03830840"
302,"NCT03792685","Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention",,"Recruiting","No Results Available","Overweight and Obesity|Diabetes Mellitus, Type 2|Metabolic Syndrome|Genetic Predisposition|Diet Modification","Other: Normo-carbohydrate meal intake|Other: High-carbohydrate meal intake|Other: High-fat meal intake|Other: High-protein meal intake","The postprandial change and differences in blood glucose levels associated with investigated single nucleotide polymorphisms.|The postprandial change and differences in serum insulin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial Triglycerides (TGs) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial Free Fatty Acids (FFAs) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial energy expenditure levels associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial substrates (carbohydrate, fat and protein) utilization levels associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial ghrelin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial leptin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial adiponectin concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial peptide YY (PYY) concentrations associated with investigated single nucleotide polymorphisms.|The change and differences in postprandial plasma metabolites profiles associated with investigated single nucleotide polymorphisms.","Medical University of Bialystok|Ministry of Science and Higher Education, Poland","Male","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","N N402 477437","September 24, 2009","October 1, 2021","January 1, 2022","January 3, 2019",,"January 18, 2020","Clinical Research Centre, Medical University of Bialystok, Bialystok, Polska, Poland",,"https://ClinicalTrials.gov/show/NCT03792685"
303,"NCT03987841","Intervention Mapping to Adapt a Mindfulness-based Intervention for Adults With Diabetes and Emotional Distress",,"Not yet recruiting","No Results Available","Type 2 Diabetes|Stress","Behavioral: Integrated MBSR/DSME intervention","Diabetes distress|Hemoglobin A1c (A1C)|Diabetes self-management behaviors|Medication adherence|Acceptability of the intervention to participants: semi-structured interviews|Feasibility: percentage of screened participants who are eligible|Feasibility: percentage of eligible participants who enroll|Feasibility: distribution of participants by demographics|Feasibility: percentage of sessions attended","University of Alabama at Birmingham","All","19 Years to 64 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300003578","June 1, 2020","January 1, 2021","January 1, 2022","June 17, 2019",,"June 18, 2019","Cooper Green Mercy Health Systems, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03987841"
304,"NCT03958838","Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Dissemination To 12 Communities",,"Recruiting","No Results Available","Type2 Diabetes|PreDiabetes","Behavioral: Peer Support Integrated with Primary Care","Change from Baseline HbA1c and at 12 months|Change from Baseline Fasting Blood Glucose and at 12 months|Change from Baseline Blood Pressure and at 12 months|Change from Baseline BMI and at 12 months|Change from Baseline Blood Lipids and at 12 months|Change from Baseline Waist circumference and at 12 months|Change from Baseline Hemoglobin and at 12 months|Change from Baseline Red Blood Cell Count and at 12 months|Change from Baseline Mean Corpuscular Volume and at 12 months|Change from Baseline Mean Corpuscular Hemoglobin and at 12 months|Change from Baseline Liver Functioning and at 12 months|Change from Baseline Bilirubin and at 12 months|Change from Baseline Blood Urea and at 12 months|Change from Baseline Serum Creatinine and at 12 months|Change from Baseline Uric Acid and at 12 months|Change from Baseline Urine Albumin/Creatinine Ratio and at 12 months|Change in Insulin Functioning at 6 and 12 months|Change in C-peptides at 6 and 12 months|Change in CRP at 6 and 12 months|Change from Baseline Diabetes Self Care Behaviors and 12 months|Change from Baseline General Quality of Life and 12 months|Change from Baseline Diabetes Quality of Life and 12 months|Change from Baseline Depression and 12 months|Change from Baseline Insulin Attitudes and 12 months|Change in Neighborhood Interactions and 12 months|Change in Peer Support Engagement and Health Care Utilization and 12 months","Shanghai 6th People's Hospital|University of North Carolina, Chapel Hill|Merck Foundation","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","2160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-028","May 25, 2019","July 31, 2020","October 31, 2020","May 22, 2019",,"July 8, 2019","Anting Huangdu Community Health Center, Shanghai, Shanghai, China|Baihe Community Health Center, Shanghai, Shanghai, China|Dachang Qilian Community Health Center, Shanghai, Shanghai, China|Fangsong Community Health Center, Shanghai, Shanghai, China|Guangzhong Community Health Center, Shanghai, Shanghai, China|Huamu Community Health Center, Shanghai, Shanghai, China|Liantang Community Health Center, Shanghai, Shanghai, China|Luodian Community Health Center, Shanghai, Shanghai, China|Nanxiang Community Health Center, Shanghai, Shanghai, China|Nicheng Community Health Center, Shanghai, Shanghai, China|Ouyang Community Health Center, Shanghai, Shanghai, China|Waigang Community Health Center, Shanghai, Shanghai, China|Xiao Kunshan Community Health Center, Shanghai, Shanghai, China|Xuhang Community Health Center, Shanghai, Shanghai, China|Yichuan Community Health Center, Shanghai, Shanghai, China|Zhaoxiang Community Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03958838"
305,"NCT04159922","Study of the Psychological Profile of Type 2 Diabetic Patients With Foot Wounds, Compared to Diabetic Patients Without Foot Wounds","Bortner Pied","Recruiting","No Results Available","Type 2 Diabetes|Foot Wound","Other: questionnaire","Score of the Bortner self-questionnaire","Centre Hospitalier Universitaire Dijon","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VERGES 2019","December 3, 2019","November 2020","November 2020","November 12, 2019",,"January 2, 2020","Chu Dijon Bourogne, Dijon, France",,"https://ClinicalTrials.gov/show/NCT04159922"
306,"NCT03994289","Motor-assisted Cycling and FES Cycling for Postprandial Glucose in Diabetic Patients With ADL Disability",,"Completed","No Results Available","Type2 Diabetes|Disability Physical","Behavioral: Motor-assisted cycling|Behavioral: FES cycling","Postprandial glucose AUC","Arizona State University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00008262","February 20, 2019","November 15, 2019","November 15, 2019","June 21, 2019",,"November 15, 2019","Brookdale Senior Living Central Chandler, Chandler, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03994289"
307,"NCT04056208","Pistachios Blood Sugar Control, Heart and Gut Health",,"Recruiting","No Results Available","Type 2 Diabetes|Cardiovascular Diseases","Drug: Pistachio|Other: Usual care","Fasting plasma glucose concentration|HbA1c|Serum insulin concentration|Peripheral systolic and diastolic blood pressure|Central systolic and diastolic blood pressure|Carotid-femoral pulse wave velocity|Augmentation Index (%)|LDL cholesterol concentration|HDL cholesterol concentration|Total cholesterol concentration|Triglyceride concentration|HOMA-IR|waist circumference|body weight|Diet quality: Healthy Eating Index 2015|Change in the composition of the gut microbiome","Penn State University","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 2","59","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PKE Pistachio","September 9, 2019","May 30, 2021","May 30, 2021","August 14, 2019",,"September 18, 2019","Pennsylvania State University, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04056208"
308,"NCT04183543","Pemf Therapy for the Management of Diabetes in Obese Patients","PROMISE","Recruiting","No Results Available","Obesity|Type 2 Diabetes","Device: Pulsed Electromagnetic Fields|Device: Sham Therapy","Change in baseline HbA1c at 17 weeks.|Change in baseline fasting blood glucose level at 17 weeks.|Change in baseline serum triglycerides at 17 weeks.|Change in baseline serum HDL at 17 weeks.|Change in baseline serum LDL at 17 weeks.|Change in baseline serum cholesterol at 17 weeks.|Change in baseline BMI at 17 weeks.|Change in baseline body weight at 17 weeks.|Change in baseline waist-hip ratio at 17 weeks.|Change in baseline serum C-Peptide at 17 weeks.|Change in baseline blood pressure at 17 weeks.","National University Hospital, Singapore|National University, Singapore","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PROMISE","December 2, 2019","June 2021","December 2021","December 3, 2019",,"December 3, 2019","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04183543"
309,"NCT04200586","The Effects of SGLTi on Diabetic Cardiomyopathy","SGLTi","Recruiting","No Results Available","Type2 Diabetes|Heart Failure With Reduced Ejection Fraction","Drug: Dapagliflozin","Change in myocardial perfusion reserve index","The University of Hong Kong","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Version no.3","April 9, 2020","September 30, 2021","September 30, 2021","December 16, 2019",,"June 9, 2020","Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04200586"
310,"NCT03985384","Semaglutide Treatment On Coronary Progression","STOP","Recruiting","No Results Available","Type 2 Diabetes|Coronary Artery Disease","Drug: Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Drug: Placebo","Rate of change in non-calcified plaque volume|Rate of change in total plaque volume","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","All","40 Years and older   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","22174-01","April 30, 2019","September 2020","September 2020","June 13, 2019",,"April 9, 2020","Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT03985384"
311,"NCT04083248","Building Self-regulation Capacity in AA T2DM Women: Feasibility of EMI",,"Recruiting","No Results Available","Type 2 Diabetes|Self-regulation","Behavioral: Feasibility group","Hours of CGM data|Number of times participants accessed their CGM data|Wear time of Fitbit activity monitor|Interrelationships between real-time interstitial glucose levels (mg/dL) and activity levels (active minutes (correlation coefficients).|Interrelationships between real-time interstitial glucose levels (mg/dL) and activity levels (step counts).|Acceptability of intervention: Semi-structured Diabetes Study Acceptability Interview Guide","University of Illinois at Chicago|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Chicago","Female","40 Years and older   (Adult, Older Adult)","Not Applicable","26","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2019-0922|P30DK092949","September 20, 2019","July 31, 2020","July 31, 2020","September 10, 2019",,"April 24, 2020","University of Illinois at Chicago, College of Nursing, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04083248"
312,"NCT04020822","Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices",,"Completed","No Results Available","Type 1 Diabetes|Type 2 Diabetes","Device: Guardian Sensor (3)","Accuracy of sensor glucose after acetaminophen administration","Medtronic Diabetes","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","19","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CIP318","July 29, 2019","August 27, 2019","August 27, 2019","July 16, 2019",,"September 4, 2019","Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04020822"
313,"NCT04190212","The Effect of High-Intensity Interval Training on Glucose Variability and Atrial Fibrillation Symptoms","Glucose-AF","Active, not recruiting","No Results Available","Atrial Fibrillation|Type 2 Diabetes","Behavioral: High-intensity interval training + standard care","Glucose variability|Atrial fibrillation symptom severity|Atrial fibrillation-related quality of life|General quality of life|Sleep quality|Changes in blood biomarker concentrations","Ottawa Heart Institute Research Corporation","All","40 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","20190687","January 20, 2020","August 1, 2021","December 31, 2021","December 9, 2019",,"April 3, 2020","University of Ottawa Heart Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04190212"
314,"NCT03903757","Network Medicine, Epigenetics and Obesity","NEWTON","Not yet recruiting","No Results Available","Obesity|Type2 Diabetes","Other: DNA methylome and total RNA sequencing","DNA methylation pattern in adipose tissues|Bioinformatics analysis to predict putative novel candidate genes underlying obesity phenotype|RNA sequencing analysisin adipose tissues|ROC curves analysis to evaluate putative DNA methylation/microRNA interactions|Linear regression analysis and BMI (Kg/m2).|Linear regression to correlate epigenetic biomarkers with proinflammatory cytokines|Linear regression to correlate epigenetic biomarkers with HOMA index","University of Campania ""Luigi Vanvitelli""","All","18 Years to 60 Years   (Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PRIN2017F8ZB89","December 2019","June 2020","June 2021","April 4, 2019",,"September 18, 2019",,,"https://ClinicalTrials.gov/show/NCT03903757"
315,"NCT04109508","A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets",,"Recruiting","No Results Available","Healthy Volunteers|Type 2 Diabetes","Drug: Oral semaglutide","AUC0-24h,sema,SS; area under the semaglutide plasma concentration−time curve during a dosing interval at steady state|Cmax,sema,SS; maximum semaglutide plasma concentration at steady state|tmax,sema,SS; time to maximum semaglutide plasma contraction at steady state|t½,sema,SS; terminal half-life of semaglutide at steady state","Novo Nordisk A/S","All","18 Years to 64 Years   (Adult)","Phase 1","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN9924-4564|U1111-1233-0878|2019-002010-40","October 2, 2019","January 8, 2021","February 15, 2021","September 30, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04109508"
316,"NCT04097600","A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets",,"Recruiting","No Results Available","Healthy Volunteers|Type 2 Diabetes","Drug: Oral semaglutide","AUC0-24h,sema,SS; area under the semaglutide plasma concentration−time curve during a dosing interval at steady state|Cmax,sema,SS; maximum semaglutide plasma concentration at steady state|tmax,sema,SS; time to maximum semaglutide plasma contraction at steady state|t½,sema,SS; terminal half-life of semaglutide at steady state","Novo Nordisk A/S","All","18 Years to 64 Years   (Adult)","Phase 1","274","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN9924-4486|U1111-1226-6257|2019-000279-17","September 30, 2019","December 20, 2020","January 27, 2021","September 20, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04097600"
317,"NCT03802487","Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects",,"Completed","No Results Available","Type 2 Diabetes Mellitus|Healthy Subjects","Drug: Sotagliflozin (SAR439954)|Drug: 14C-microtracer|Drug: Charcoal","Pharmacokinetic (PK) parameter: Absolute Bioavailability (F)|Assessment of PK parameter: Area under the curve (AUC) for oral investigational medicinal product (IMP)|Assessment of PK parameter: AUC for IMP metabolite|Assessment of PK parameter: AUC for IV 14C-IMP|Assessment of PK parameter: AUC for 14C-IMP metabolite|Assessment of PK parameter: Area under curve versus time (AUClast) for oral IMP|Assessment of PK parameter: AUClast for IMP metabolite|Assessment of PK parameter: AUClast for IV 14C-IMP|Assessment of PK parameter: AUClast for 14C-IMP metabolite|Assessment of PK parameter: Cmax for oral IMP|Assessment of PK parameter: Cmax for IMP metabolite|Assessment of PK parameter: Cmax for IV 14C-IMP|Assessment of PK parameter: Cmax for 14C-IMP metabolite|Assessment of PK parameter: tmax for oral IMP|Assessment of PK parameter: tmax for IMP metabolite|Assessment of PK parameter: tmax for IV 14C-IMP|Assessment of PK parameter: tmax for 14C-IMP metabolite|Assessment of PK parameter: t1/2z for oral IMP|Assessment of PK parameter: t1/2z for IV 14C-IMP|Assessment of PK parameter: Clearance (CL/F) for oral IMP|Assessment of PK parameter: Clearance (CL/F) for IV 14C-IMP|Assessment of PK parameter: Vz/F for oral IMP|Assessment of PK parameter: Vz/F for IV 14C-IMP|Assessment of PK parameter: Vdss/F for oral IMP|Assessment of PK parameter: Vdss/F for IV 14C-IMP|Safety: Adverse events","Sanofi","All","18 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PKM15402|2017-004937-94|U1111-1200-2077","January 14, 2019","March 28, 2019","March 28, 2019","January 14, 2019",,"April 10, 2019","Investigational site number 8260001, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03802487"
318,"NCT03887936","Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus|Hypogonadism","Drug: Testosterone gel 1.62%|Drug: Placebo","Finite element analysis of bone to measure bone strength|Markers of bone turnover to measure bone metabolism|Osteoblast and osteoclast progenitor cells which are cells found in bone","VA Office of Research and Development","Male","40 Years to 65 Years   (Adult, Older Adult)","Phase 4","166","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ENDB-009-18F|1I01CX001665-01A2","October 1, 2019","September 30, 2024","September 30, 2025","March 25, 2019",,"March 4, 2020","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03887936"
319,"NCT03811548","Janagliflozin Treat T2DM Monotherapy",,"Not yet recruiting","No Results Available","Diabetes Type 2","Drug: Janagliflozin 25mg|Drug: Janagliflozin 50mg|Drug: Placebo/Janagliflozin","Change in HbA1c From Baseline to Week 24|Change in HbA1c From Baseline to Week 52|Percentage of Patients With HbA1c <7% at Week 24 (Core period) and week 52|Percentage of Patients With HbA1c <6.5% at Week 24 (Core period) and Week 52 (Extension period)|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in 2-hour Post-prandial Glucose From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Blood Lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Blood Pressure (systolic blood pressure and diastolic blood pressure) From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Body Weight From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Fasting C-peptide From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in Insulin Sensitivity From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Change in β-cell Function From Baseline to Week 24 (Core period) and Week 52 (Extension period)|Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period)","Sihuan Pharmaceutical Holdings Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","390","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","5695-DIA-3001","May 23, 2019","August 31, 2020","December 31, 2021","January 22, 2019",,"January 22, 2019",,,"https://ClinicalTrials.gov/show/NCT03811548"
320,"NCT03966911","Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics",,"Active, not recruiting","No Results Available","Type 1 Diabetes Mellitus|Type2 Diabetes Mellitus","Device: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter","20% (±20 mg/dL for SG <80) Agreement, by age group and insertion location|±15 mg/dL Agreement, SG <70 mg/dL, by age group and insertion location","Medtronic Diabetes","All","2 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","460","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CIP324","June 14, 2019","May 2020","May 2020","May 29, 2019",,"May 27, 2020","AMCR Institue, Escondido, California, United States|Sansum Diabetes Research Institute, Santa Barbara, California, United States|SoCal Diabetes, Torrance, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center - Adults, Aurora, Colorado, United States|Barbara Davis Center for Childhood Diabetes (Pediatric), Aurora, Colorado, United States|University of South Florida, Tampa, Florida, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|IDERC, Des Moines, Iowa, United States|Mayo Clinic (Rochester MN), Rochester, Minnesota, United States|AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|University of Virgina, Charlottesville, Virginia, United States|Rainer Clinical Research Center, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03966911"
321,"NCT04011904","The Role of Traditional or Western Diet in the TBC1D4 Gene on Glucose Homeostasis in Greenland Inuits",,"Recruiting","No Results Available","T2D","Other: Cross-over study","Changes in 2-h post-OGTT glucose in blood between the baseline and endpoint change in the two periods|Changes in Hba1c between the baseline and endpoint change in the two periods|Changes in fasting blood glucose between the baseline and endpoint change in the two periods|Changes in 30 min post OGTT between the baseline and endpoint change in the two periods|Continuous glucose monitoring|Insulin sensitivity and secretion|Changes in blood lipids between the baseline and endpoint change in the two periods|Changes in gastrointestinal hormones between the baseline and endpoint change in the two periods|Changes in gut microbiota composition between the baseline and endpoint change in the two periods|Changes in C-Reactive Protein between the baseline and endpoint change in the two periods|Changes in Interleukin-6 between the baseline and endpoint change in the two periods|Changes in small metabolites between the baseline and endpoint change in the two periods|Changes in weight between the baseline and endpoint change in the two periods|Changes in body composition between the baseline and endpoint change in the two periods|Changes in waist and hip circumference between the baseline and endpoint change in the two periods|Changes in fatty acids (compliance measurement) between the baseline and endpoint change in the two periods|Changes in alkylresorcinols (compliance measurement) between the baseline and endpoint change in the two periods|Changes in blood pressure (BP) between the baseline and endpoint change in the two periods","University of Copenhagen|Steno Diabetes Center Copenhagen|Novo Nordisk A/S","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","KVUG 2018-26","April 15, 2019","July 15, 2020","September 1, 2020","July 9, 2019",,"August 29, 2019","Department of Exercise, Nutrition and Sports, Faculty of Sciences, University of Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04011904"
322,"NCT03807440","DIA_CENTRAL:T2D Treatment Pattern in Central Europe",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Empagliflozin|Drug: Sodium Glucose Transporter 2 inhibitor|Drug: Dipeptidyl-peptidase 4 inhibitor|Drug: Glucagon-like peptide 1 agonist","T2D patients' baseline characteristics when initiating either empagliflozin - or other SGLT2i, DPP4i or GLP1a on top of current antidiabetic treatment by different HCP specialties in CEE countries|Burden of comorbidities (prevalence of cardiovascular disease (CVD), chronic kidney disease (CKD) and CVD/CKD risk factors) in this T2D patient population|Actual treatment use in patients with and without established CVD|Association of socioeconomic parameters with treatment decisions|Discontinuation rate for GLP1a, DPP4i and SGLT2i after a follow up of approximately one year from the initial time point|Reasons for discontinuation for GLP1a, DPP4i and SGLT2i after a follow up of approximately one year from the initial time point|Average duration of treatment for GLP1a, DPP4i and SGLT2i after a follow up of approximately one year from the initial time point","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)",,"4000","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","1245-0187","August 26, 2019","January 31, 2021","January 31, 2021","January 17, 2019",,"June 4, 2020","Practice Dr. Alice Sýkorová, Bilina, Czechia|Marie Horňáčková, Brno, Czechia|Michal Brada, Břeclav, Czechia|Barbara Buzová, Havířov, Czechia|Zaviatičová, Petra, Havířov, Czechia|Barbora Doležalová, Heřmanův Městec, Czechia|Radana Syslová, Hlušovice, Czechia|Pavel Kasík, Hořovice, Czechia|Practice Dr. Petr Maule, Humpolec, Czechia|Practice Dr. Petra Vrbová, Jilemnice, Czechia|Practice MUDr. Gita Markofová, Karlovy Vary, Czechia|MUDr.Tomáš Edelsberger, Krnov, Czechia|Śárka Drinková, Ledeč nad Sázavou, Czechia|Martina Košková, Mladá Boleslav, Czechia|Jitka Kuchařová, Mělník, Czechia|Karel Churavý, Nový jičín, Czechia|Śárka Kubánková, Nymburk, Czechia|Dobromila Vykoupilová, Němčice nad Hanou, Czechia|Agentura Science Pro spol. s.r.o., Olomouc, Czechia|Anna Rancová, Olomouc, Czechia|MUDr.Tomáš Hrdina, Opočno, Czechia|Radka Nágelová, Ostrava Poruba, Czechia|Practice Dr. René Turčínek, Ostrava, Czechia|Zdeněk Jankovec, Plzeň, Czechia|Diabetologická a interní ambulance, Poděbrady, Czechia|Practice Dr. Milena Peterková, Praha 2, Czechia|MUDr.Michala Pelikánová s.r.o., Praha 4, Czechia|Markéta Hovorková, Praha 4, Czechia|Jakub Hron, Praha 4, Czechia|Milan Flekač, Praha 5, Czechia|Jiří Jón, Praha 5, Czechia|Practice Dr. Lucie Kufová, Praha 5, Czechia|Barbora Diepoltová, Praha 9, Czechia|AIDIN VK s.r.o., Přerov, Czechia|Martin Střelka, Příbor, Czechia|Practice Dr. Petronela Janečková, Rumburk, Czechia|Practice Dr. Miroslav Lindovský, Sokolov, Czechia|Dana Fialkovičová, Strakonice, Czechia|Marek Frydrych, Třebíč, Czechia|Lubomír Kudlej, Vrchlabí, Czechia|Robin Urbánek, Zlín, Czechia|Practice MUDr. Marie Löblová, České Budějovice, Czechia|Lékařský dům Géčko, České Budějovice, Czechia",,"https://ClinicalTrials.gov/show/NCT03807440"
323,"NCT04201938","Effect of Probiotic Co-administration With Omega-3 Fatty Acids on Obesity Parameters and Insulin Resistance","ENDO-5","Completed","No Results Available","Obesity|Insulin Resistance|Insulin Sensitivity|Type2 Diabetes|Visceral Obesity","Combination Product: Symbiter-Omega|Dietary Supplement: Placebo","HOMA-2IR|insulin sensitivity (%S)|HbA1c|fasting plasma insulins (FPI)|fasting plasma glucose (FPG)|β-cell function (%B)|C-peptide|weight|waist circumferences (WC)|body mass index (BMI)|cytokines levels","Bogomolets National Medical University|Taras Shevchenko National University of Kyiv",,"Child, Adult, Older Adult","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ENDO-5","February 1, 2018","March 1, 2018","January 15, 2019","December 17, 2019",,"December 17, 2019","Bogomolets National Medical University, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT04201938"
324,"NCT04158921","Control:Diabetes Pilot Study I",,"Recruiting","No Results Available","Insulin Treated Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 1","Other: Control:Diabetes mobile app","The mean change in blood glucose.|The change in the number of hypoglycemic episodes.","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","controldiabetes01","November 7, 2019","March 31, 2020","April 30, 2020","November 12, 2019",,"November 12, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04158921"
325,"NCT03823027","STAR Study Investigating Performance and Safety of the Medical Device SiPore15™",,"Completed","No Results Available","PreDiabetes|Pre Diabetes|Prediabetic State|Type2 Diabetes|Type2 Diabetes Mellitus|Overweight|Obese","Device: SiPore15™","Performance measured as changes in HbA1c|Tolerability measured as evaluation of Adverse Events|Performance measured as changes in LDL-C|Performance measured as changes in body fat %","Sigrid Therapeutics AB","All","18 Years to 105 Years   (Adult, Older Adult)","Not Applicable","43","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STAR01","January 28, 2019","October 2, 2019","October 2, 2019","January 30, 2019",,"November 5, 2019","Pihlajalinna Ite, Satucon OY, Kuopio, Finland|Clinical Trial Consultants, Uppsala, Uppland, Sweden",,"https://ClinicalTrials.gov/show/NCT03823027"
326,"NCT03939624","Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events",,"Completed","No Results Available","Type2 Diabetes|Myocardial Infarction|Ischemic Stroke|Cardiovascular Death|Heart Failure|All-Cause Mortality","Drug: Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Drug: Dipeptidyl peptidase-4 (DPP-4) inhibitors","Myocardial infarction|Ischemic stroke|Cardiovascular death|All-cause mortality|Heart failure","Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)",,"419734","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Q18-06","October 1, 2018","October 1, 2019","October 1, 2019","May 7, 2019",,"January 14, 2020","Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03939624"
327,"NCT04166760","Metabolic Effects of Whey Compounds in Patients With Diabetes Mellitus Type 2.",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: speWHE|Dietary Supplement: WHE","Difference in iAUC for insulin between WHE and speWHE|Differences in iAUC and concentration differences for GIP|Differences in iAUC and concentration differences for GLP-1|Differences in iAUC and concentration differences for glucagon|Differences in iAUC and concentration differences for glucose|Differences in iAUC and concentration differences for C-peptid|Differences in iAUC and concentration differences for FFA|Activity measurements|continuous glucose measurement (CGM)","University of Aarhus","All","18 Years and older   (Adult, Older Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAKE4","January 6, 2020","October 1, 2020","October 31, 2020","November 18, 2019",,"January 7, 2020","Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT04166760"
328,"NCT03947879","The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: L-glutamine|Other: No L-glutamine","Change in fasting glucose|Change in hemoglobin A1c|Change in fructosamine|Change in complete blood count|Change in blood chemistry|Change in hepatic function|Change in microablbumin|Change in weight|Change in waist circumference","Hawaii Pacific Health","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-119","May 2019","May 2021","May 2022","May 13, 2019",,"May 13, 2019",,,"https://ClinicalTrials.gov/show/NCT03947879"
329,"NCT03815305","Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2",,"Active, not recruiting","No Results Available","Xerosis Cutis|Diabetes Mellitus, Type 2","Drug: Centella Asiatica Extract|Drug: Topical CA|Drug: Petroleum jelly","Change in Skin Capacitance|Change in SOD|Change in IL-1α|Change in AGEs CML|Change in SRRC","Indonesia University","All","up to 60 Years   (Child, Adult)","Phase 4","159","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","441/UN2.F1/ETIK/2018/","July 30, 2018","January 12, 2019","June 30, 2019","January 24, 2019",,"January 24, 2019","Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT03815305"
330,"NCT04143412","Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination",,"Recruiting","No Results Available","Diabetic Nephropathy Type 2|Microalbuminuria Due to Type 2 Diabetes Mellitus","Drug: Tritace (Ramipril 10 mg)","Urinary albumin/creatinin ratio (UACR)|Blood pressure|estimated Glomerular Filtration Rate (e GFR)|Serum K","Beni-Suef University","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","RAAS blockers in albuminuria","February 4, 2019","February 2020","March 2020","October 29, 2019",,"January 18, 2020","Faculty of Medicine,Beni-Suef University, Banī Suwayf, Egypt",,"https://ClinicalTrials.gov/show/NCT04143412"
331,"NCT03815955","Reducing Sedentary Behaviour in Patients With Type II Diabetes",,"Completed","No Results Available","Diabetes|Diabetes Mellitus, Type 2|Sedentary Lifestyle","Behavioral: Non-Sedentary Behaviour Modelling","Frequency of Non-Sedentary Behaviour Breaks|Non-Sedentary Behaviour Break Time|Capillary Blood Glucose|Self-efficacy|Goal Intentions|Positive and Negative Affect","Western University, Canada|St. Joseph's Health Care London","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","112907","March 14, 2019","April 25, 2019","April 25, 2019","January 25, 2019",,"October 1, 2019","University of Western Ontario, London, Ontario, Canada|St. Joseph's Family Medical and Dental Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03815955"
332,"NCT04092738","´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2.","Walk@Work","Recruiting","No Results Available","Diabetes Mellitus, Type II","Behavioral: Walk@WorkApp-Diab","Change in Fasting glucose levels|Change in concentration of HbA1c|Change in weight|Change in height|Change in Body Mass Index|Change in Waist circumference|Change in objective Occupational sedentary behaviour|Change in subjective domain-specific sedentary behaviour|Change in objective occupational physical activity|Change in subjective occupational physical activity","Jordi Gol i Gurina Foundation|Instituto de Salud Carlos III|Consorci Hospitalari de Vic|Institut Català de la Salut|University of Vic - Central University of Catalonia|Puerta de Hierro University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","368","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PI17/01788","March 4, 2019","January 2020","September 2021","September 17, 2019",,"September 17, 2019","IDIAP Jordi Gol, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04092738"
333,"NCT04004273","Diabetes, Exercise and Liver Fat (DELIVER)","(DELIVER)","Recruiting","No Results Available","Type 2 Diabetes Mellitus|Non-Alcoholic Fatty Liver Disease|Obesity|Insulin Resistance|Liver Diseases|Fatty Liver|Diabetes Mellitus|Glucose Metabolism Disorders|Glucose Intolerance|Metabolic Disease","Behavioral: Exercise","Change in liver saturated lipid index (%) determined by proton magnetic resonance spectroscopy (1H-MRS) using a 3T MRI scanner|Change in Liver unsaturated lipid index (%) - measured using 1H-MRS|Change in Liver polyunsaturated lipid index (%) - measured using 1H-MRS|Change in total hepatic lipid composition (%) - measured using 1H-MRS|Change in liver inflammation - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in visceral adipose tissue - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in subcutaneous abdominal adipose tissue - measured using magnetic resonance imaging (MRI) with a 3T Philips Ingenia MRI scanner|Change in body mass|Change in body fat percentage|Change in aerobic fitness (peak oxygen uptake)|Change in liver enzymes|Change in glucose|Change in insulin|Change in lipids|Change in HbA1c|Change in homeostasis model assessment of insulin resistance (HOMA-IR; surrogate marker of hepatic insulin resistance)|Change in adipose tissue insulin resistance (ADIPO-IR; surrogate marker of adipose tissue insulin resistance)|Change in circulating Inflammatory proteins|Change in Hepatokines|Change in objectively measured sedentary time - GENEactiv physical activity monitor|Change in objectively measured physical activity - GENEactiv physical activity monitor|Change in energy intake|Change in macronutrient intake","James King|University Hospitals, Leicester|Nottingham University Hospitals NHS Trust|University of Nottingham|Loughborough University","Male","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","241046","October 30, 2018","April 1, 2020","April 1, 2020","July 2, 2019",,"July 2, 2019","University Hospitals of Leicester Nhs Trust, Leicester, East Midlands, United Kingdom|NIHR Clinical Research Network, Leicester, East Midlands, United Kingdom|Sir Peter Mansfield Imaging Centre, Nottingham, East Midlands, United Kingdom|Nottingham University Hospitals Nhs Trust, Nottingham, East Midlands, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04004273"
334,"NCT03884920","Effective Enhancement of Glucose Tolerance and Prevention of Diabetes Mellitus Type 2 by Polyherbal Formulation","Phase-1","Completed","No Results Available","Diabetes Mellitus|Pre Diabetes","Dietary Supplement: Polyherbal formulation","Fasting Glucose Tolerance (FGT)|Glucose Tolerance (GT)|HB-A1c|Lipid Profile","Islamia University of Bahawalpur","All","18 Years to 59 Years   (Adult)",,"57","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Cross-Sectional","Hashmi5767","March 20, 2019","May 5, 2019","May 20, 2019","March 21, 2019",,"July 5, 2019","University College of Conventional Medicine, Bahawalpur, Pakistan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03884920/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03884920"
335,"NCT04178603","Copenhagen, Boston, Sydney","COBOS","Recruiting","No Results Available","Insulin Resistance|Insulin Sensitivity|Type 2 Diabetes","Other: Exercise, insulin infusion","Muscle glucose uptake during exercise and enhanced insulin sensitivity in recovery from exercise.|Posttranslational modification of proteins in muscle biopsies.","University of Copenhagen|Pfizer|University of Sydney","Male","25 Years to 40 Years   (Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","COBOS","July 5, 2018","July 1, 2020","July 1, 2020","November 26, 2019",,"November 26, 2019","Department of Exercise, Nutrition and Sports, Faculty of Sciences, University of Copenhagen, København, Denmark",,"https://ClinicalTrials.gov/show/NCT04178603"
336,"NCT04180332","Anti Oxidant Enzymes and Total Antioxidant Levels in Diabetes Mellitus Type II Patients and Healthy Individuals With Periodontitis",,"Completed","No Results Available","Periodontal Diseases|Diabetes Mellitus|Enzyme Disorder","Diagnostic Test: Blood sample","Catalase estimation|Antioxidant estimation","Ajman University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NU/CEC/Ph.D04/2010","August 10, 2017","August 10, 2018","August 10, 2018","November 27, 2019",,"November 27, 2019","AB shetty institute of dental sciences, Mangaluru, India",,"https://ClinicalTrials.gov/show/NCT04180332"
337,"NCT03807596","Hyaluronic Acid With Scaling & Root Planing In Chronic Periodontitis Patients With Diabetes Mellitus Type 2",,"Completed","No Results Available","Chronic Periodontitis","Procedure: Periodontal treatment with Hyaluronic acid associated with SRP|Procedure: Scaling & root planning alone","Gain in clinical attachment level","Cairo University","All","38 Months to 56 Months   (Child)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15062011","March 16, 2017","June 29, 2017","June 29, 2017","January 17, 2019",,"January 18, 2019","Faculty of Dentistry, Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03807596"
338,"NCT04027530","Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.","ROCKIES","Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus|Diabetic Kidney Disease|Diabetic Nephropathy|Renal Hypoxia|Renoprotection|SGLT2 Inhibitor|Ertugliflozin","Drug: Ertugliflozin 15 mg","Renal oxygenation measured by BOLD-MRI (R2*)|Renal oxygen consumption by PET/CT-scan using 11C-Acetate|Renal hemodynamics|Renal efficiency|Cortical blood flow|Renal arterial blood flow|Acute 24-hour sodium and glucose excretion|Chronic 24-hour sodium and glucose excretion|Renal tubular function: Urinary pH|Renal tubular function: Urine Osmolality|Renal tubular function: sodium transport|Renal damage markers|Changes in plasma energy substrate: glucose|Changes in plasma energy substrate: free fatty acids|Changes in plasma energy substrate: ketone bodies|Changes in plasma energy substrate:triglycerides|Energy expenditure|Changes in erythropoietin (EPO) levels|Insulin sensitivity|Beta-cell function|Peripheral insulin extraction|Total insulin extraction","VU University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DC2019 ROCKIES 1","June 2020","May 2021","December 2021","July 22, 2019",,"May 20, 2020","VU University Medical Center, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT04027530"
339,"NCT03960333","Immunometabolism in Pediatric Obesity","IPO","Recruiting","No Results Available","Obesity|Type 2 Diabetes Mellitus|Insulin Resistance",,"circulating CD4+T cells in Overweight/Obese vs Lean|circulating CD4+T cells in Type 2 Diabetic pre/post Metformin","Arkansas Children's Hospital Research Institute|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)|University of Arkansas","All","5 Years to 17 Years   (Child)",,"110","Other|NIH","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","228816|P20GM109096","April 25, 2019","February 28, 2021","February 28, 2021","May 23, 2019",,"May 23, 2019","Arkansas Children's Research Institute, Little Rock, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03960333/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03960333/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03960333"
340,"NCT03997773","Face-it: Health Promotion for Women With Prior Gestational Diabetes","Face-it","Recruiting","No Results Available","Gestational Diabetes|Type 2 Diabetes Mellitus|Quality of Life","Behavioral: Face-it Intervention","Change in Body Mass Index (BMI) in women with prior GDM|Change in glucose in women with prior GDM and their partner|Change in HbA1c in women with prior GDM and their partner|Change in insulin in women with prior GDM and their partner|Change in blood pressure in women with prior GDM and their partner|Change in waist- and hip circumference in women with prior GDM and their partner|Change in body fat% in women with prior GDM and their partner|Change in Body Mass Index (BMI) in partners|Change in plasma lipids/triglycerides, total cholesterol, HDL, LDL|Change in quality of life in women with prior GDM and their partner|Change in well-being in women with prior GDM and their partner|Change in self-perceived health in women with prior GDM and their partner|Change in stress in women with prior GDM and their partner|Change in dietary patterns in women with prior GDM and their partner|Change in physical activity patterns in women with prior GDM and their partner","Steno Diabetes Center Copenhagen|Steno Diabetes Center Odense|Steno Diabetes Center Aarhus|Rigshospitalet, Denmark|Odense University Hospital|Aarhus University Hospital|Aarhus Municipality|Odense Municipality|Copenhagen Municipality|Liva Healthcare A/S","All","Child, Adult, Older Adult","Not Applicable","460","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","StenoDC","May 21, 2019","January 30, 2023","January 30, 2023","June 25, 2019",,"June 28, 2019","Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT03997773"
341,"NCT04053621","Co-administration of Thiamine Pyrophosphate and Metformin in Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: Thiamine pyrophosphate|Other: Placebo|Drug: Metformin","hemoglobin A1c|fasting plasma glucose|Lipids profile|inflammation markers|Lifestyle measurement|heart rate variability|arterial elasticity","Laboratorios Manuell SA|Universidad Nacional Autonoma de Mexico","All","18 Years and older   (Adult, Older Adult)","Not Applicable","92","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2336732","August 2019","May 2020","June 2020","August 12, 2019",,"August 12, 2019","Centro Especializado en Diabetes, Obesidad, Prevención y Enfermedades Cardiovasculares, S.C., Mexico City, Cdmx, Mexico",,"https://ClinicalTrials.gov/show/NCT04053621"
342,"NCT04028076","Improving Diabetes Medication Adherence for African Americans in Madison and Milwaukee Through Peer Support",,"Recruiting","No Results Available","Type2 Diabetes|Medication Adherence|Medication Nonadherence|Peer Support","Behavioral: Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence","Change in Hemoglobin A1c|Beliefs about Medicines Questionnaire|Culturally adapted illness perception questionnaire|Self-Efficacy for Appropriate Medication Use Scale (SEAMS)|Newest Vital Sign|Adherence to Refills and Medications Scale for Diabetes (ARMS-D)","University of Wisconsin, Madison","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2019-0721","July 10, 2019","October 31, 2020","December 31, 2020","July 22, 2019",,"April 24, 2020","University of Wisconsin - Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04028076"
343,"NCT04076384","Effectiveness of a Team-based Follow-up Program in General Practice Among People With Chronic Conditions",,"Enrolling by invitation","No Results Available","Diabetes Type 2|COPD","Behavioral: Guided Self-Determination|Behavioral: Standard care","Patient Activation Measure (PAM-13)|HbA1c|Problem Areas in Diabetes Scale (PAID-5)|The World Health Organization 5-item Well-Being Index (WHO-5)|Quality of Life-BREF 2-Item questionnaire|The EuroQol EQ-5D-5L|The European Health Literacy survey tool (HLS-EU-Q12)|Perceived Competence for Diabetes Scale (PCDS)|The Finnish Diabetes Risc Calculator (FINDRISC)","Bergen University College|University of Bergen|University of Stavanger","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","308","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2019/28","August 19, 2019","December 2022","June 2025","September 3, 2019",,"September 3, 2019","Western Norway University of Applied Sciences, Bergen, Hordaland, Norway",,"https://ClinicalTrials.gov/show/NCT04076384"
344,"NCT04115657","The Effect of Different Starches of Boba Pearls and Sugar Substitutes Used in Milk Tea on Glycaemia, Insulinaemia and Appetite Control (Pearl Study)",,"Active, not recruiting","No Results Available","Diabete Type 2|Obese","Other: Starch 1|Other: Starch 2|Other: Starch 3|Other: Starch 4|Other: Sugar 1|Other: Sugar 2","Postprandial glucose|Postprandial insulin|Appetite control","Clinical Nutrition Research Centre, Singapore","Male","21 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2018/01194","May 2, 2019","March 31, 2020","March 31, 2020","October 4, 2019",,"January 22, 2020","Clinical Nutrition Research Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04115657"
345,"NCT03903965","Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.",,"Recruiting","No Results Available","Diabetes Mellitus Type 2|Age Related Cataracts",,"OCT Angiography parameters|aqueous humor cytokines levels","Peking University Third Hospital","All","50 Years to 80 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019032501","September 1, 2018","December 1, 2019","December 1, 2019","April 4, 2019",,"December 3, 2019","Peking University Third Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03903965"
346,"NCT04206748","iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes","iGlucose","Recruiting","No Results Available","Gestational Diabetes|Type2 Diabetes|Pregnancy in Diabetic","Device: iGlucose Smart Meter System|Device: Routine Care-RX meter","Neonatal morbidity|Neonatal gestational age at delivery|# of neonates who where Small for gestational age (SGA)|Neonatal intensive care unit (NICU) length of stay|# of Neonates with hyperbilirubinemia-requiring therapy.|Average Neonatal Weight|Maternal Mean fasting glucose|Maternal Mean post prandial glucose|Maternal # of Hypoglycemia events (<60 mg/dl)|Maternal weight gain during pregnancy|Maternal Gestational hypertension|Maternal Preeclampsia|Maternal Cesarean delivery|Maternal Operative vaginal delivery|Effect of SMBG checks on pregnancy","The University of Texas Health Science Center, Houston|Smart Meter Corporation","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HSC-MS-19-0402","November 12, 2019","November 12, 2021","November 1, 2022","December 20, 2019",,"December 20, 2019","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04206748"
347,"NCT03829046","The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease",,"Recruiting","No Results Available","Atherosclerotic Vascular Disease|Type2 Diabetes|Microvascular Dysfunction","Drug: Placebo|Drug: Evolocumab","Number of Adverse Events|Seattle Angina Questionnaire|MDA Level|MPO Level|IL-6 Level|IL-18 Level|TNF-α Level|PECAM Level|ICAM Level|VCAM Level|Alpha5/Beta3 Activation Levels","Robert Rosenson|Amgen|University of Toronto|University of Michigan|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","GCO 18-1412|20167719","June 3, 2019","October 2020","October 2020","February 4, 2019",,"October 8, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States|St. Michael's - University of Toronto, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03829046"
348,"NCT04152811","Cooking Matters for Diabetes - A 6-Week Program for Practical Application of Diabetes Self-Management Education",,"Active, not recruiting","No Results Available","Diabetes Mellitus|Type 1 Diabetes|Type 2 Diabetes","Behavioral: Cooking Matters for Diabetes|Other: Usual Diabetes Care","Change in Hemoglobin A1c over 4.5 months|Change in Health Related Quality of Life over 4.5 months using SF-12 Survey","Ohio State University|Academy of Nutrition and Dietetics","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","2019H0095","July 5, 2019","July 1, 2021","July 1, 2021","November 5, 2019",,"January 27, 2020","The Ohio State University Wexner Medical Center - Outpatient Care East, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04152811"
349,"NCT04060745","Glucose Metabolism in Brown Adipose Tissue (BAT) in Young Healthy Men Evaluated by Deuterium Metabolic Imaging (DMI)",,"Recruiting","No Results Available","Type2 Diabetes|Obesity|Metabolic Syndrome","Other: cooling using a water-perfused vest|Other: thermoneutrality","Changes in glucose metabolism between non-activated and cold-activated BAT|BAT DMI measurements compared to plasma NMR measurements|Changes in fat/water thresholds in BAT in cold versus thermoneutral conditions|Changes in metabolic profiles in cold versus thermoneutral conditions","University of Aarhus|Aarhus University Hospital|Steno Diabetes Center Copenhagen","Male","18 Years to 35 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Brown fat imaging","August 1, 2019","December 2019","August 2020","August 19, 2019",,"August 19, 2019","Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT04060745"
350,"NCT03912363","Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids",,"Recruiting","No Results Available","Type II Diabetes Mellitus|Gestational Diabetes Mellitus","Other: Rotating fluids protocol|Other: Insulin infusion protocol","Neonatal blood glucose value|Mean neonatal blood glucose value|Incidence of maternal hypoglycemia|Mean intrapartum maternal blood glucose value|Maternal blood glucose value before delivery|Incidence of composite neonatal outcome","Geisinger Clinic","Female","14 Years to 50 Years   (Child, Adult)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018-0502","November 1, 2019","December 31, 2020","June 30, 2021","April 11, 2019",,"November 4, 2019","Geisinger, Danville, Pennsylvania, United States|Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03912363"
351,"NCT03933696","Light, Metabolic Syndrome and Alzheimer's Disease",,"Recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer Disease|Type2 Diabetes","Device: Tailored Lighting Intervention","Sleep disturbance|Metabolic control|Depression|Cognition|Sleep disturbance using actigraphy|Light measurements|Melatonin Levels","Rensselaer Polytechnic Institute|Icahn School of Medicine at Mount Sinai","All","55 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Aim 2","April 1, 2019","September 1, 2022","September 1, 2022","May 1, 2019",,"May 13, 2019","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03933696"
352,"NCT03961659","Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus|Obesity|Cognitive Impairment","Drug: Liraglutid|Drug: Dapagliflozin|Drug: Acarbose","Change of olfactory brain activation by fMRI|Change of cognitive function|Proportion of patients whose MoCA＜26 scores|Change of blood glycaemic control|Proportion of patients whose HbA1c＜7%|Proportion of patients whose weight loss＞3% and ＞5%|Olfactory threshold test","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","87","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZZ2019","May 2019","August 2020","February 2021","May 23, 2019",,"May 23, 2019","at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03961659"
353,"NCT03860558","Impact of Metabolic Health on Sperm Epigenetic Marks in Humans",,"Recruiting","No Results Available","Overweight|Type 2 Diabetes Mellitus|Type 1 Diabetes Mellitus","Other: Lifestyle Intervention|Other: No Intervention","Spermatozoa concentration|Sperm DNA methylation, reported as genomic location of regions with methylation altered in response to intervention|RNA Sequencing","Joslin Diabetes Center","Male","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2015-40","May 1, 2018","May 2019","May 2019","March 4, 2019",,"March 4, 2019","Joslin Diabetes Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03860558"
354,"NCT03912909","Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans","EMPA-SNS","Recruiting","No Results Available","Metabolic Syndrome|Type 2 Diabetes Mellitus|Obesity","Drug: Empagliflozin Oral Tablet [Jardiance]|Drug: Placebo Oral Tablet","Reduction in cardiac sympathetic nerve activity|Reduction in renal sympathetic nerve activity|Reduction in muscle sympathetic nerve activity|Reduction in ambulatory BP (blood pressure)|Reduction in central Blood Pressure|Change in urinary sodium excretion|Change in glycemic control","Royal Perth Hospital","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","REG 16-157","August 1, 2018","March 31, 2022","December 30, 2022","April 11, 2019",,"June 11, 2020","Royal Perth Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03912909"
355,"NCT04098575","A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes","EDCOS","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Empagliflozin","Percentage of previous occurance of cardiovascular comorbidities|Percentage of Diabetes complications|Percentage of Antidiabetic and cardiovascular co-medication|Number of subjects with age|Baseline characteristics: gender|Baseline characteristics: Weight|Baseline characteristics: height|Baseline characteristics: HbA1c|Duration of diabetes (Time Since Diagnosis)|Number of subjects with previous glucose-lowering treatmen|Number of subjects with 10mg and 25mg dosage of empagliflozin|Number of subjects participated in Disease Management Programme (DMP) Type 2 Diabetes (from DPV registry)|Number of subjects with hospitalizations","Boehringer Ingelheim","All","18 Years to 80 Years   (Adult, Older Adult)",,"7900","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","1245-0198","September 16, 2019","December 31, 2019","December 31, 2019","September 23, 2019",,"January 23, 2020","Diabetes Agenda 2010 GmbH, Mahlow, Germany",,"https://ClinicalTrials.gov/show/NCT04098575"
356,"NCT03936660","A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease","COORDINATE","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Cardiovascular Diseases","Other: Intense Education Intervention","Implementing a clinic-level multifaceted intervention|Proportion of patients on guideline recommended therapies at 12 months.|Changes in cholesterol levels over 12 months.|Changes in blood pressure control over 12 months.|Changes in glycemic control over 12 months|Measurement of average time from baseline to patient event.","Duke University|Boehringer Ingelheim|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1380","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Pro00101556","July 18, 2019","August 1, 2021","August 1, 2026","May 3, 2019",,"March 24, 2020","Grandview Health/Alabama Cardiovascular Group, Birmingham, Alabama, United States|Alaska Heart and Vascular Institute, Anchorage, Alaska, United States|Dignity Health/DHMG Specialty Medicine, Phoenix, Arizona, United States|Stanford University, Stanford, California, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Orlando Heart and Vascular Institute, Altamonte Springs, Florida, United States|Riverside Medical Center, Bradenton, Florida, United States|Baptist Health Research Institute, Jacksonville, Florida, United States|Advanced Research for Health Improvement, LLC, Naples, Florida, United States|Bayfront Cardiovascular Associates, Saint Petersburg, Florida, United States|Interventional Cardiac Consultants, Trinity, Florida, United States|Emory/Grady Memorial Hospital, Atlanta, Georgia, United States|SouthCoast Health Cardiology, Savannah, Georgia, United States|Advocate Heart Institute, Chicago, Illinois, United States|Advanced Heart Care Group/Medicoricium LLC, Fairview Heights, Illinois, United States|Specialty Physicians of Illinois, Olympia Fields, Illinois, United States|UnityPoint Health Cardiovascular Services, Peoria, Illinois, United States|Prairie Cardiovascular Consultants, Springfield, Illinois, United States|Iowa Heart Center, Des Moines, Iowa, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Endeavor Medical Research, Alpena, Michigan, United States|Cardiology Institute of Michigan, Flint, Michigan, United States|Rajendra H Mehta, MD, PC, Jackson, Michigan, United States|Hannibal Regional Medical Group, Hannibal, Missouri, United States|Advanced Heartcare LLC, Bridgewater, New Jersey, United States|New Jersey Heart, Linden, New Jersey, United States|Garden State Heart Care, Manalapan, New Jersey, United States|Cardiovasculare Associates of the Delaware Valley, Sewell, New Jersey, United States|Long Island Cardiovascular Consultants, Lake Success, New York, United States|Northwell Health/Lenox Hill Hospital, Manhasset, New York, United States|Kernodle Clinic, Burlington, North Carolina, United States|Cone Health/LeBauer Brodie Ctr for Cardiovascular Rsch, Greensboro, North Carolina, United States|Cardiovascular Health Clinic, Oklahoma City, Oklahoma, United States|Guthrie Medical Group, Sayre, Pennsylvania, United States|Advanced Cardiology Associates, Greenwood, South Carolina, United States|Black Hills Cardiovascular Research, Rapid City, South Dakota, United States|ProHealth Care Heart and Vascular, Waukesha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03936660"
357,"NCT03925714","Impact of P53 and SIRT1 in Type 2 Diabetes",,"Recruiting","No Results Available","DM","Other: life style|Drug: Metformin|Drug: Nigetella salivata","Number of patients with improved insulin resistance","Sherief Abd-Elsalam|Tanta University","All","18 Years and older   (Adult, Older Adult)","Phase 3","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","dm 2","April 1, 2019","December 2028","December 2028","April 24, 2019",,"April 24, 2019","Sherief Abd-Elsalam, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03925714"
358,"NCT03797885","A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal","PICT2RE","Completed","No Results Available","Diabetes Mellitus, Type 2","Other: No treatment given","Proportion of type 2 diabetes mellitus (T2DM) patients with cardiovascular risk factors (CVRFs) and/or established cardiovascular disease (CVD), regardless the date of diagnosis|Hypoglycaemic episodes|Hyperglycaemic episodes|Presence of T2DM complications (yes/no)|Types of T2DM complications|Hospital appointments|Hospitalisation episodes|Emergency visits|Change in waist circumference|Change in body mass index|Change in blood pressure|Change in urine albumin|Change in glycosylated hemoglobin (HbA1c)|Change in HbA1c|Change in Estimated Glomerular Filtration Rate (eGFR)|Change in total cholesterol|Change in low-density lipoprotein cholesterol|Change in high-density lipoprotein cholesterol|Change in triglyceride|Type of pharmacological treatment","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"737","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","NN2211-4435|U1111-1207-2878","January 15, 2019","October 15, 2019","October 15, 2019","January 9, 2019",,"November 7, 2019","Novo Nordisk Investigational Site, Almada, Portugal|Novo Nordisk Investigational Site, Caldas da Rainha, Portugal|Novo Nordisk Investigational Site, Leiria, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Matosinhos, Portugal|Novo Nordisk Investigational Site, Portimão, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Viana do Castelo, Portugal|Novo Nordisk Investigational Site, Vila Nova de Gaia, Portugal|Novo Nordisk Investigational Site, Vila Real, Portugal|Novo Nordisk Investigational Site, Viseu, Portugal",,"https://ClinicalTrials.gov/show/NCT03797885"
359,"NCT04143945","A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",,"Completed","No Results Available","Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity","Drug: Semaglutide (administered by DV3396 pen)|Drug: Semaglutide (administered by PDS290 pen)","Intensity of injection site pain","Novo Nordisk A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INS-4603|2019-003654-83|U1111-1239-7955","October 28, 2019","January 4, 2020","January 4, 2020","October 30, 2019",,"March 6, 2020","Novo Nordisk Investigational Site, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04143945"
360,"NCT04007107","A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",,"Completed","No Results Available","Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity","Drug: Semaglutide (administered by DV3396 pen)|Drug: Semaglutide (administered by PDS290 pen)","Intensity of injection site pain as assessed by visual analogue scale","Novo Nordisk A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INS-4582|2019-002284-10|U1111-1233-9590","June 27, 2019","July 28, 2019","September 4, 2019","July 5, 2019",,"September 9, 2019","Novo Nordisk Investigational Site, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04007107"
361,"NCT04092959","The Effect of Different Training Programs on Patients With Chronic Diseases",,"Recruiting","No Results Available","Hypertension|Hypertension Complicated With Type 2 Diabetes|Walking|Chinese Square Dancing","Behavioral: Walking|Behavioral: Chinese square dancing group|Behavioral: Control group","Change from Baseline Systolic Blood Pressure at 3 months|Change from Baseline Fasting Blood Glucose at 3 months|Change from Cardiorespiratory Fitness at 3 months|Change from Muscle Strength at 3 months|Change from Muscle Endurance at 3 months|Change from Flexibility at 3 months|Change from Balance at 3 months|Change from Body Composition at 3 months|Time and Frequency of Adverse Reactions and Serious Adverse Events through the study completion","Beijing Sport Uninversity|Peking University","All","40 Years to 69 Years   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BSU2016YFC1300202","September 20, 2019","November 30, 2020","December 30, 2020","September 17, 2019",,"September 17, 2019","Garden Road Community Health Service Center, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04092959"
362,"NCT03890900","T2DXcel Mobile Application","T2DXcel","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: T2DXcel mobile application","Change from baseline hemoglobin A1c to 3 and 6 months|Patient satisfaction measured by the Client Satisfaction Questionnaire-8|Change from baseline diabetes knowledge to 3 months and 6 months|Change from baseline diabetes self-management capabilities to 3 months and 6 months|Change from baseline diabetes self-efficacy to 3 months and 6 months|Change from baseline diabetes quality of life to 3 months and 6 months|Change from baseline LDL cholesterol to 3 months and 6 months","Montefiore Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2018-9590","March 1, 2020","June 30, 2020","June 30, 2020","March 26, 2019",,"May 4, 2020","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT03890900"
363,"NCT03881995","Effects of Insulin Glargine and Lixisenatide on the Brain","Lixibrain01","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: IGlarLixi|Drug: Insulin Glargine 100 UNT/ML","Brain insulin sensitivity|Processing of food pictures|Cognitive function|Glycemic control|Liver fat content|Total adipose tissue (TAT)|Visceral adipose tissue (VAT)|Subcutaneous adipose tissue (SCAT)|Body fat|Lean body mass|Body weight","University Hospital Tuebingen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","808/2018AMG1|2018-003557-21","March 18, 2019","February 1, 2021","March 1, 2021","March 20, 2019",,"April 18, 2019","University of Tuebingen, Department of Internal Medicine IV, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT03881995"
364,"NCT03819790","The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","VARIATION 2 SA","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Basal insulin glargine and lixisenatide|Drug: Basal insulin Basaglar/Lantus + gliclazide MR|Drug: Metformin","Time in range at week 13|Time in range within 12-hours (6 AM -6 PM) at week 13|Daily glucose standard deviation (SD) at week 13|Overall SD of CGM glucose at week 13|Mean of glucose at week 13|Frequency of hypoglycemia at week 13|Time in hypoglycemia at week 13|Frequency of hyperglycemia at week 13|Time in hyperglycemia at week 13|Daily glucose standard deviation (SD) within 12 hours (6AM-6PM) at week 13|Overall SD of glucose within 12 hours (6AM-6PM) at week 13|Mean of glucose within 12 hours (6AM-6PM) at week 13|Frequency of hypoglycemia within 12 hours (6AM-6PM) at week 13|Time in hypoglycemia within 12 hours (6AM-6PM) at week 13|Frequency of hyperglycemia within 12 hours (6AM-6PM) at week 13|Time in hyperglycemia within 12 hours (6AM-6PM) at week 13|A1C mean at week 13|Changes A1C|Proportion of A1C <7% at week 13|Proportion of A1C <8% at week 13|Mean basal insulin dose at week 13|Change in weight|Change in waist circumference|Change in carbohydrate intake|Proportion of patients who have A1C ≤ 7% with no hypoglycemia and no weight gain from baseline|Proportion of patients who have A1C ≤ 7% with no hypoglycemia and weight gain <3% from baseline|Proportion of patients who have fasting blood glucose ≤ 5.5 mmol/L without nocturnal hypoglycemia|Change in DiabMedSat Score|Change in HFS Score|HCP treatment satisfaction score","LMC Diabetes & Endocrinology Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VARIATION 2 SA","October 2, 2018","December 30, 2019","December 30, 2019","January 29, 2019",,"May 14, 2019","LMC Brampton, Brampton, Ontario, Canada|LMC Etobicoke, Etobicoke, Ontario, Canada|LMC Scarborough, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03819790"
365,"NCT04090242","Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Device: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle","Change in Attitudes Toward Diabetes - Diabetes Empowerment Scale (DES)|Change in 24 hour average blood glucose|Time in range|Change in Mean Amplitude of Glycemic Excursion (MAGE)|Change in Diabetes Distress Screening Scale - 17 (DDS17)|Change in Insulin Delivery System Rating Questionnaire - IDSRQ|Change in Adherence to Refills and Medications Scale for Diabetes - ARMS-D|Patient Satisfaction","Becton, Dickinson and Company","All","22 Years and older   (Adult, Older Adult)","Not Applicable","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","DBC-19BRGHT02","September 6, 2019","June 12, 2020","June 12, 2020","September 16, 2019",,"May 19, 2020","Mills Pennisula Medical Center-Diabetes Research Institute, San Mateo, California, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|East West Medical Research Institute, Honolulu, Hawaii, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04090242"
366,"NCT04128995","Surgical or Medical Treatment","ST2OMP","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Pediatric Obesity|Bariatric Surgery Candidate","Procedure: Bariatric Surgery|Drug: Advanced Medical Therapy","Glycemic Control|Glycemic Variability|Beta Cell Function|Alpha cell function|Incretin Response|Fatty Liver Disease|Dyslipidemia|Hypertension|Diabetic Kidney Disease","Children's Hospital Medical Center, Cincinnati|Children's Hospital Colorado","All","13 Years to 19 Years   (Child, Adult)","Phase 4","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01DK119450","December 15, 2019","January 5, 2022","August 30, 2024","October 16, 2019",,"January 2, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|Cincinnati Childrens, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04128995"
367,"NCT04126603","Impact of Semaglutide on CD34+ EPC and Fat Derived MSC",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Placebos","CD34+ Endothelial Progenitor Cell number|CD34+ Endothelial Progenitor Cell Migration against serum SDF1a gradient|Gene Expression of CD34+ Endothelial Progenitor Cell number|Gene Expression of Subcutaneous Adipose cell|Arterial Stiffness: Pulse Wave Velocity|Arterial Stiffness: Pulse Wave Analysis|Body Composition: BMI|Body Composition: Body Fat Percent|Hip to Waist Ratio|Biochemistry: HbA1c|Biochemistry: LDL over HDl Ratio","Sabyasachi Sen|George Washington University","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NCR191206","August 1, 2019","August 1, 2021","November 30, 2021","October 15, 2019",,"October 15, 2019","The GW Medical Faculty Associates, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04126603"
368,"NCT03798717","To Bathe or Not to Bathe",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Diagnostic Test: Heating","Change in plasma [glucose]|Change in plasma [insulin]|Change in insulin sensitivity|Change in fuel utilisation|Change in cardiovascular status|Change in eHSP|Change in inflammatory status","University of Portsmouth|Portsmouth Hospitals NHS Trust","All","35 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","003AS","February 20, 2019","March 9, 2020","March 9, 2020","January 10, 2019",,"May 6, 2020","Department of Sport and Exercise Science, Portsmouth, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03798717"
369,"NCT03878706","The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2",,"Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.|Comparison of arterial stiffness markers difference among treatment groups.|Comparison of wave reflection markers difference among treatment groups|Comparison of central aortic blood pressure differences among treatment groups|Comparison of endothelial glycocalyx thickness difference among treatment groups|Comparison of oxidative stress biomarkers differences among treatment groups","University of Athens","All","45 Years to 80 Years   (Adult, Older Adult)",,"160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2790/03-11-2017","November 3, 2017","December 31, 2020","December 31, 2020","March 18, 2019",,"March 18, 2019","""Attikon"" University General Hospital, Athens, Attiki, Greece",,"https://ClinicalTrials.gov/show/NCT03878706"
370,"NCT04207853","Immediate Effect of Whole Body Vibration on Diabetics and Non-diabetics","DM","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: whole body vibration em DM|Other: Vibration ""sham"" em DM|Other: whole body vibration em NDM|Other: Vibration ""sham"" em NDM","skin temperature|circulation|peripheral sensitivity|plantar pressure","Universidade Federal de Pernambuco","All","45 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Immediate, Vibration and DM","August 8, 2019","February 20, 2020","February 28, 2020","December 23, 2019",,"December 23, 2019","Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil",,"https://ClinicalTrials.gov/show/NCT04207853"
371,"NCT03908606","Serum Hs-CRP in Periodontitis Patients With or Without Diabetes",,"Completed","No Results Available","Periodontal Disease|Diabetes Mellitus, Type 2","Procedure: Scaling and root planing","clinical attachment level","Cairo University","All","Child, Adult, Older Adult","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","1281976","April 11, 2018","January 2, 2019","January 2, 2019","April 9, 2019",,"April 9, 2019","Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03908606"
372,"NCT04082390","Effects of the GOLO for Life System Diet With and Without GOLO Release Supplement on Glycemic Control and Insulin Resistance",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: RELEASE|Dietary Supplement: Placebo","Change in Fasting Blood Glucose (FBG) at approximately 4 weeks of the GFL System Diet with Release supplement versus GFL System Diet with placebo supplement|Change from baseline in Fructosamine between the 2 groups|Change from baseline in HGB A1C between the 2 groups|Change from baseline in Insulin Levels between the 2 groups|Change from baseline in HOMA-IR between the 2 groups|Change from baseline in Weight between the 2 groups|Change from baseline in Body Mass Index between the 2 groups|Change from baseline in Hip Circumference between the 2 groups|Change from baseline in Waist Circumference between the 2 groups|Change from baseline in Blood Pressure between the 2 groups|Change from baseline in Heart Rate between the 2 groups","Golo","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GOLO 1704","October 1, 2019","January 30, 2020","January 31, 2020","September 9, 2019",,"September 9, 2019",,,"https://ClinicalTrials.gov/show/NCT04082390"
373,"NCT04011228","Epigenetics Based Diagnosis of Diabetes in Saliva and Blood Samples",,"Recruiting","No Results Available","Prediabetic State|Diabetes Mellitus, Type 2|Ectopic Lipids|Epigenetics Based Modifications","Diagnostic Test: Blood sampling|Diagnostic Test: Saliva and blood samples|Diagnostic Test: Magnet Resonance Spectroscopy","Specifying the microRNAs in saliva in diabetic patients|Correlation of the percentage of liver fat with miRNA´s in diabetic patients.|Correlation of the percentage of heart fat with miRNA´s in diabetic patients|Correlation of the percentage of the content of fat in the skeletal muscle with miRNA´s in diabetic patients.","Medical University of Vienna","All","18 Years to 75 Years   (Adult, Older Adult)",,"224","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPI-1090","February 29, 2016","December 11, 2019","January 1, 2020","July 8, 2019",,"September 3, 2019","Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04011228"
374,"NCT03936010","Replication of the CANVAS Diabetes Trial in Healthcare Claims",,"Active, not recruiting","No Results Available","Diabetes","Drug: Canagliflozin|Drug: DPP-4 inhibitor","Relative hazard of composite outcome of Stroke, MI, and Mortality","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)",,"152202","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DUPLICATE-CANVAS","September 22, 2017","September 22, 2020","September 22, 2020","May 3, 2019",,"January 2, 2020","Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03936010/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03936010"
375,"NCT03950713","Mindfulness Program for Older-Diabetes",,"Completed","No Results Available","Mental Health Wellness 1","Behavioral: Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)","HbA1c values|Relocation Stress Scale|Depression and Anxiety Stress Scale (DASS-21)","Fooyin University","All","65 Years to 85 Years   (Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FYH-IRB-1040602","January 1, 2017","July 31, 2017","July 31, 2017","May 15, 2019",,"May 15, 2019","Fooyin University, Kaohsiung City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03950713"
376,"NCT03925519","Exercise as Cardio Protective Modulates in Diabetic Patients",,"Completed","No Results Available","Diabetes Mellitus|Exercise","Other: Supervised aerobic exercise","Estimation of coronary heart disease risk score|Analysis of blood sugar, glycated hemoglobin (HbA1c)|Analysis of Nitric Oxide","King Saud University","All","45 Years to 70 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","RRC-2013-010","January 25, 2013","April 15, 2014","May 26, 2014","April 24, 2019",,"April 24, 2019",,,"https://ClinicalTrials.gov/show/NCT03925519"
377,"NCT03917758","Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors","GliRACo1","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Arterial Hypertension|Body Weight Changes","Drug: SGLT2 inhibitor","Changes from baseline of antidiuretic function parameters (BNP)|Changes from baseline of antidiuretic function parameters (vasopressin)|Changes from baseline of antidiuretic function parameters (osmolality)|Changes from baseline of antidiuretic function parameters (sodium balance)|Changes from baseline of antidiuretic function parameters (potassium balance)|Changes from baseline of renin-angiotensin-aldosterone system parameters (renin)|Long term changes from baseline of renin-angiotensin-aldosterone system parameters aldosterone)|Long term changes from baseline of renin-angiotensin-aldosterone system parameters|Changes from baseline of blood pressure values (ABPM)|Changes from baseline of body composition|Changes in basal glicemic control|Changes in long term glicemic control","University of Turin, Italy","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GliRACo 1","October 10, 2018","July 30, 2020","October 30, 2020","April 17, 2019",,"January 2, 2020","Mauro Maccario, Torino, Piemonte, Italy",,"https://ClinicalTrials.gov/show/NCT03917758"
378,"NCT04201912","Role of TLR2 and TLR4 in Stage 2 Periodontitis Patients",,"Completed","No Results Available","Periodontal Inflammation","Diagnostic Test: saliva analysis for Toll like receptor activity","Toll like receptor 2 activity|Toll like receptor 4 activity","Ajman University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","D-F-19-03-03","May 1, 2019","August 1, 2019","September 1, 2019","December 17, 2019",,"December 18, 2019","Ajman University, Ajman, Dubai, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT04201912"
379,"NCT03877406","Effect of Empagliflozin on Body Composition and Ketones",,"Recruiting","No Results Available","Diabetes Mellitus|Fat; Intolerance, Pancreas","Drug: Empagliflozin 10 MG|Drug: Hypoglycemics Oral","HbA1c|Biochemical parameters|Body weight|Body fat|Systolic and diastolic blood pressures|Lipid profile|Insulin resistance","Seoul National University Bundang Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","B-1507/307-007","August 1, 2018","December 31, 2020","December 31, 2021","March 15, 2019",,"April 8, 2020","Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03877406"
380,"NCT03920683","Toe-brachial Index and Coronary Calcification in Type 1 and 2 Diabetes","ACCoDiab","Recruiting","No Results Available","Coronary Artery Calcification","Other: Data collection","Toe-brachial index|Vital statuts|Coronary artery calcification|Stress myocardial perfusion tomography|Coronary angiography","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"650","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APHP180409|2018-A02748-47","July 8, 2019","April 2020","April 2020","April 19, 2019",,"September 10, 2019","Diabetology department, Pitié-Salpêtrière hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT03920683"
381,"NCT03970031","A Study of MSDC-0602K to Assess Glycemic Control, Resolution of NASH, and Outcomes in Patients With Diabetes and NASH",,"Not yet recruiting","No Results Available","Type2 Diabetes|NASH - Nonalcoholic Steatohepatitis|Nonalcoholic Steatohepatitis|Non-Alcoholic Fatty Liver Disease","Drug: MSDC-0602K|Drug: Placebo oral tablet","Mean change in glycosylated hemoglobin (HbA1c) from Baseline to 6 months follow-up in the first 800 subjects randomized with poorly controlled T2D|Biopsy-confirmed hepatic histological resolution of NASH as evidenced by ALL of the following at 12 months: o Inflammation score of 0-1; o Ballooning score of 0; o At least a 2-point improvement (decrease) in the NAS; and o NO worsening of fibrosis|Time to first event of Death or Hepatic and/or Major Adverse Cardiac Events","Cirius Therapeutics, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","3600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTI-0602K-C013","September 2019","December 2021","December 2021","May 31, 2019",,"May 31, 2019",,,"https://ClinicalTrials.gov/show/NCT03970031"
382,"NCT03983499","Latinos Understanding the Need for Adherence in Diabetes","LUNA-D","Completed","No Results Available","Type 2 Diabetes|Glycemic Control|Cardiovascular Risk Factors|Psychological Distress","Behavioral: Special Intervention","HbA1c Blood Value|Body Mass Index (BMI)|Total Cholesterol|Blood Pressure (BP)|Patient Health Questionnaire (PHQ-8)|Generalized Anxiety Disorder 7-item (GAD-7)","San Diego State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","456","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NR014866","July 16, 2015","December 18, 2018","December 31, 2018","June 12, 2019",,"June 12, 2019","South Bay Latino Research Center, Chula Vista, California, United States",,"https://ClinicalTrials.gov/show/NCT03983499"
383,"NCT04027712","Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD",,"Active, not recruiting","No Results Available","Diabetes|Clopidogrel Resistance|Amyloid|Insulin Resistance",,"mots-c predicts cardiovascular mortality in diabetic with coronary artery disease|b amyloid predicts cardiovascular mortality in diabetic with coronary artery disease|b amyloid predicts cardiovascular mortality in diabetic with coronary artery","University of Athens","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","LTA_MOTS-c_bamyloid_DM_CAD","January 1, 2014","December 31, 2019","December 31, 2021","July 22, 2019",,"July 23, 2019","General & University Hospital ""Attikon"", Chaidari, Attiki, Greece",,"https://ClinicalTrials.gov/show/NCT04027712"
384,"NCT04200625","Semaglutide vs Dulaglutide on Epicardial Adipose Tissue",,"Completed","No Results Available","Epicardial Fat",,"Epicardial Fat thickness","University of Miami","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","20190944","September 24, 2019","December 9, 2019","December 9, 2019","December 16, 2019",,"December 16, 2019","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04200625"
385,"NCT03891927","Extra Virgin Olive Oil on Glycemic Control ,Insulin Resistance and Insulin Secretion",,"Not yet recruiting","No Results Available","Insulin Resistance","Dietary Supplement: extra virgin olive oil","change of HBa1c (glycated hemoglobin) after intervention by extra virgin olive oil|change of fasting glucose after intervention by extra virgin olive oil|calculating of insulin resistance and insulin secretion after intervention by extra virgin olive oil|reduction of systolic and diastolic blood pressure after intervention by extra virgin olive oil .|reduction of body mass index .|changing in waist circumference .|change at Lipid profile (cholesterol, TG, LDL, HDL) after intervention .","Assiut University","All","30 Years to 60 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","olive oil on glycemic control","May 1, 2019","November 1, 2020","December 1, 2020","March 27, 2019",,"April 1, 2019",,,"https://ClinicalTrials.gov/show/NCT03891927"
386,"NCT04118257","Short-term Sugary Beverage Consumption on Glucose Control and Cardiovascular Disease Risk Factors",,"Completed","No Results Available","Metabolic Syndrome","Dietary Supplement: Sugary beverage: Fruit juice|Dietary Supplement: Sugary beverage: Soda|Dietary Supplement: Control: Water","Change in glucose iAUC|Change in plasma lipids|Change in homeostatic model assessment for insulin resistance|Change in blood pressure|Change in BMI|Change in pulmonary function|Change in insulin iAUC|Change in serum fructosamine","Kansas State University","All","18 Years to 30 Years   (Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","Pro8531","February 10, 2017","November 14, 2018","November 14, 2018","October 8, 2019",,"October 8, 2019","Lafene Health Center, Manhattan, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04118257"
387,"NCT03832907","Dexcom G6 Observational Study",,"Completed","No Results Available","Diabetes","Device: Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Diagnostic Test: POC BG - Point-of-Care Blood Glucose monitoring","Mean daily blood glucose by POC reading compared to CGM reading|Number of clinical significant hypoglycemia (<54 mg/dl) events by POC reading compared to CGM reading|Number of severe hyperglycemia (>240 mg/dl) events by POC reading compared to CGM reading|Number of clinical significant severe hyperglycemia (>240 mg/dl) events by POC reading compared to CGM reading|Number of nocturnal hypoglycemic events < 70 mg/dl and < 54 mg/dl (between 22:00 and 06:00) by POC reading compared to CGM reading|Number of of hypoglycemic events (< 70 and 54 mg/dl) in POC group by POC reading compared to CGM reading|Number of hypoglycemic events (< 70 and 54 mg/dl) by POC reading compared to CGM reading|Time in hypoglycemia (minutes) during the day and night by POC reading compared to CGM reading|Time in hyperglycemia (minutes) during the day and night> 240 mg/dl by POC reading compared to CGM reading|Number of hyperglycemic events > 240 mg/dl by POC reading compared to CGM reading|Percentage of BG readings within target BG of 70 and 180 mg/dl by POC reading compared to CGM reading|Percentage of patients with greater than 5%-time below glucose target (<70 and 54 mg/dl) by POC reading compared to CGM reading|Percentage of patients with greater than 5%-time above glucose target (>180 and 240 mg/dl) by POC reading compared to CGM reading|Glycemic variability calculated by Standard Deviation and MAGE by POC reading compared to CGM reading|Glycemic variability calculated by Standard Deviation, and MAGE by POC reading compared to CGM reading|Number of sensor removal/failures/dislodgments by POC reading compared to CGM reading|Mean absolute relative difference (MARD) by POC reading compared to CGM reading|Number of Dexcom G6 CGM sensor values within 30/30%, 20/20%, 15/15% for values < 70 mg/dl, 70-140 mg/dl, >140-180 mg/dl and > 180 mg/dl), compared to the standard-of-care POC BG|Differences in accuracy between G6 CGM in the abdomen and upper arm insertion sites|Percentage of values within Zone A, B, C of the Clarke Error Grid","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","101","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00107627","February 21, 2019","March 31, 2020","March 31, 2020","February 6, 2019",,"May 18, 2020","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03832907"
388,"NCT03790839","Drug Interaction Study Between Dorzagliatin and Sitagliptin",,"Completed","No Results Available","Patients","Drug: Sitagliptin|Drug: Dorzagliatin","Cmax,ss|AUCτ,ss","Hua Medicine Limited","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HMM0111","January 31, 2019","August 30, 2019","August 30, 2019","January 2, 2019",,"September 24, 2019","Frontage Clinical Services Inc., Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03790839"
389,"NCT03790787","Drug Interaction Study Between Dorzagliatin and Empagliflozin",,"Completed","No Results Available","Patients","Drug: Empagliflozin|Drug: Dorzagliatin","Cmax,ss|AUCτ,ss","Hua Medicine Limited","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HMM0112","April 18, 2019","March 15, 2020","March 15, 2020","January 2, 2019",,"March 25, 2020","Frontage Clinical Services Inc., Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03790787"
390,"NCT04033705","DRIVE - Perioperative Period","DRIVE-Periop","Recruiting","No Results Available","Diabetes Mellitus|Surgical Procedure, Unspecified","Device: Freestyle Libre Pro glucose sensor","The time spent within, above and below the target glucose range (4-10mmol/L) in the preoperative period|The time spent within, above and below the target glucose range (4-10mmol/L) in the post operative period|Length of hospital stay|Post operative infections","Portsmouth Hospitals NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PHT/2019/23","June 11, 2019","August 1, 2020","August 1, 2020","July 26, 2019",,"July 26, 2019","Portsmouth Hospitals NHS Trust, Portsmouth, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04033705"
391,"NCT04143321","Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina",,"Completed","No Results Available","Diabetes Mellitus","Drug: Empagliflozin 25 MG","Seattle angina questionnaire 1|Seattle angina questionnaire 2|Seattle angina questionnaire 3|Seattle angina questionnaire 4|Seattle angina questionnaire 5","Isfahan University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EMPT-ANGIN","September 10, 2018","April 15, 2019","May 23, 2019","October 29, 2019",,"October 29, 2019","Cardiac rehabilitation research center, Isfahan, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04143321"
392,"NCT04114903","Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity","SONIC","Recruiting","No Results Available","Type 2 Diabetes|Obesity|Cannabis Use|Insulin Sensitivity",,"Markers of Inflammation|Change in Matsuda Index of Insulin Sensitivity|Change in Plasma Glucose|Change in Plasma Insulin|Stanford Seven-Day Physical Activity Recall (PAR)|Sleep Quality|Marijuana Consumption Questionnaire|Marijuana Dependence Scale|Marijuana Withdrawal Checklist|The Alcohol Use Disorder Identification Test (AUDIT)|Timeline Follow-Back of Substance Use|SF-12 Health Survey|Nutrition Data System for Research 24-Hour Dietary Recall|Stanford Leisure-Time Activity Categorical Item (L-Cat)","University of Colorado, Boulder|University of Colorado, Denver","All","21 Years to 40 Years   (Adult)",,"214","Other","Observational","Observational Model: Other|Time Perspective: Prospective","19-0015","November 8, 2019","October 2024","October 2024","October 3, 2019",,"March 26, 2020","Center for Innovation and Creativity, Boulder, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04114903"
393,"NCT04019431","Effect of a Very Low-Calorie Ketogenic Diet on Gut Microbiota and Fat Distribution",,"Recruiting","No Results Available","Obesity","Dietary Supplement: Whey protein, vegetable protein or animal protein","Body Mass Index change from baseline|Fat mass percentage (%) change from baseline|Visceral adipose tissue (gr) change from baseline|Microbiome taxonomic composition change from baseline|Fasting glucose level (mg/dL) change from baseline|Fasting Insulin level (mcU/mL) change from baseline|Fasting Cholesterol level (mg/dL) change from baseline|Muscle strength (kg) change from baseline|Quality of life (subjective unit) change from baseline|Safety (subjective unit) change from baseline","University of Roma La Sapienza","All","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U1111-1236-5158","July 2019","October 2019","November 2019","July 15, 2019",,"July 15, 2019","Sapienza University of Rome, Roma, RM, Italy",,"https://ClinicalTrials.gov/show/NCT04019431"
394,"NCT04184622","A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight","SURMOUNT-1","Recruiting","No Results Available","Overweight|Obesity","Drug: Tirzepatide|Drug: Placebo","Percent Change from Baseline in Body Weight|Percentage of Participants who Achieve ≥5% Body Weight Reduction|Change from Baseline in Body Weight|Percentage of Participants who Achieve ≥10% Body Weight Reduction|Percentage of Participants who Achieve ≥15% Body Weight Reduction|Change from Baseline in Waist Circumference|Change from Baseline in Body Mass Index (BMI)|Change from Baseline in Fasting Glucose|Change from Baseline in Fasting Insulin|Time to Onset of Type 2 Diabetes|Change from Baseline in Hemoglobin A1c (HbA1c)|Change from Baseline in Triglycerides|Change from Baseline in Low-Density Lipoprotein (LDL) Cholesterol|Change from Baseline in Total Cholesterol|Change from Baseline in High-Density Lipoprotein (HDL) Cholesterol|Change from Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol|Change from Baseline in Free Fatty Acids|Change from Baseline in Systolic Blood Pressure|Change from Baseline in Diastolic Blood Pressure|Change from Baseline in Short Form Survey-36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score|Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score|Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","2400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17244|I8F-MC-GPHK","December 4, 2019","February 28, 2022","April 22, 2024","December 3, 2019",,"June 4, 2020","Cahaba Research, Pelham, Alabama, United States|Perseverance Research Center, Scottsdale, Arizona, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Valley Endocrine, Fresno, Fresno, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, LLC, Hamden, Connecticut, United States|Yale Center for Clinical Investigation, New Haven, Connecticut, United States|Suncoast Research Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|ForCare Clinical Research, Tampa, Florida, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|East West Medical Institute, Honolulu, Hawaii, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Iowa Diabetes Research, West Des Moines, Iowa, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|L-Marc Research Center, Louisville, Kentucky, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Troy Internal Medicine, PC, Troy, Michigan, United States|Sky Clinical Research - Quinn Healthcare, Ridgeland, Mississippi, United States|StudyMetrix Research, LLC, Saint Peters, Missouri, United States|Clinvest Research LLC, Springfield, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Premier Research, Trenton, New Jersey, United States|NYU Langone, New York, New York, United States|Weill Cornell Medicine, Comprehensive Weight Control Center, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|University of North Carolina Diabetes Center, Chapel Hill, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Aventiv Research, Columbus, Ohio, United States|Intend Research, Norman, Oklahoma, United States|Summit Research Network Inc, Portland, Oregon, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Preferred Primary Care Physicians - Jacob Murphy Lane, Uniontown, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|ClinSearch, Chattanooga, Tennessee, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|North Texas Endocrine Center, Dallas, Texas, United States|Research Institute of Dallas, PA, Dallas, Texas, United States|Southern Endocrinology and Associates PA, Mesquite, Texas, United States|Texas Diabetes and Endocrinology, P.A., Round Rock, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Stat Research, Caba, Buenos Aires, Argentina|Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Mautalen Salud e Investigación - Servicio de Endocrinología, Caba, Buenos Aires, Argentina|Centro Medico CICEMO, Caba, Buenos Aires, Argentina|CEDIC-Centro de Investigaciones Clinicas, Caba, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|DIM Clinica Privada, Ramos Mejía, Buenos Aires, Argentina|GO Centro Médico San Nicolás, San Nicolás, Buenos Aires, Argentina|Sanatorio Norte, Santiago del Estero, Argentina|Centro Medico Privado de Reumatologia, Tucuman, Argentina|Cedoes Centro Diagnostico Pequisa Osteoporose E Santo Ltd, Vitoria, ES, Brazil|CCBR Brasil Centro de Analises e Pesquisas Clínicas LTDA, Rio de Janeiro, RJ, Brazil|Loema - Instituto de Pesquisa Clinica, Campinas, SP, Brazil|CPQuali Pesquisa Clínica Ltda., São Paulo, SP, Brazil|Cpclin Centro de Pesquisas Clinicas, São Paulo, SP, Brazil|CEPIC-Centro Paulista de Investigacao Clinica, São Paulo, SP, Brazil|Hospital da Clinicas da Faculdade de Medicina da USP, São Paulo, SP, Brazil|IPECC - Instituto de Pesquisa Clinica de Campinas, Campinas, São Paulo, Brazil|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Nangang District, China|Jinan Central Hospital, Jinan, Shandong, China|The First Affiliated Hospital of Xi'an Medical University, XI 'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Ningbo First Hospital, Ningbo, Zhejiang, China|Beijing Tsinghua Changgung Hospital, Beijing, China|Care Hospital, Hyderabad, Andhra Pradesh, India|Gujarat Endocrine Center, Ahmedabad, Gujarat, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|CHL - Apollo Hospital, Indore, Madh Prad, India|Grant Medical College & Sir J.J. Group of Hospitals, Mumbai, Maharashtra, India|Topiwala National Medical College & BYL Nair Hospital, Mumbai, Maharashtra, India|Deenanth Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|ILS Hospital, Kolkata, West Bengal, India|All India Institue of Medical Sciences (AIIMS), New Delhi, India|Fortis Hospital, New Delhi, India|OCROM Clinic, Suita, Osaka, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|AMC nishi-umeda clinic, Osaka, Japan|Ctro Inv en Artritis y Osteoporosis SC, Mexicali, Baja California, Mexico|Centro Especializado en Diabetes Obesidad y Enfermedades, Mexico, D.f., Mexico|Unidad de Investigacion Clinica y Atencion Medica HEPA S.C., Guadalajara, Jalisco, Mexico|Virgen Cardiovascular Research S.C, Guadalajara, Jalisco, Mexico|Inst. de Diabetes, Obesidad y Nutricion S.C, Cuernavaca, Morelos, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Centro Para el Desarrollo de la Medicina y de Asistencia Med, Culiacán, Sinaloa, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|RM Pharma Specialists S.A. de C.V., Distrito Federal, Mexico|Arke Estudios Clinicos S.A. de C.V., Veracruz, Mexico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Ponce School of Medicine CAIMED Center, Ponce, Puerto Rico|Latin Clinical Trial Center, San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|Consultorio Medico, San Juan, Puerto Rico|FSBI Scientific Research Institution of Therapy of Siberian Branch of RAMS, Novosibirsk, Novosibirsk Region, Russian Federation|City Hospital #38 n. a. N.A. Semashko, St. Petersburg, Pushkin, Russian Federation|Regional Public Health Institution ""Cardiology Dispensary"", Ivanovo, Russian Federation|BHI of Republic Udmurtiya ""City clinical hospital #9 of Ministry of healthcare of Republic Udmurtiya"", Izhevsk, Russian Federation|Clinical Trials Center of Medical Institute, Kaliningrad, Russian Federation|FSBI ""National Medical Research Center for Preventive Medicine"" of MOH of Russian Fed, Moscow, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|FSBI Endocrinological Research Center of the MOH of the ROF, Moscow, Russian Federation|FSBI ""National Medical Research Center of Cardiology"" of MOH of Russian Federation, Moscow, Russian Federation|State Autonomous Healthcare Institution of the Tyumen Region ""Scientific - Pract Medical Center"", Tyumen, Russian Federation|Chung Shan Medical University Hospital, Taichung City, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Chi-Mei Medical Center, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04184622"
395,"NCT04080596","DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin",,"Completed","No Results Available","Drug Interaction","Drug: Dorzagliatin","Cmax|AUClast","Hua Medicine Limited","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HMM0107","October 13, 2017","December 5, 2017","December 5, 2017","September 6, 2019",,"September 6, 2019","The 2nd Hospital of Jilin University, Changchun, Jilin, China",,"https://ClinicalTrials.gov/show/NCT04080596"
396,"NCT03904901","Influence of Probiotics in Diabetic Cardiopathies With Excessive Weight",,"Recruiting","No Results Available","Diabetes Mellitus Type 2 in Obese|Anxiety|Cardiopathy","Dietary Supplement: Probiotics|Dietary Supplement: Placebo","Control of DM2|Anxety|Alteration of serum lipids|Weight|Height|BMI","Instituto de Cardiologia do Rio Grande do Sul","All","20 Years to 60 Years   (Adult)","Not Applicable","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SDallanora","July 20, 2018","May 2019","June 2019","April 5, 2019",,"April 5, 2019","Suelen Dallanora, Porto Alegre, RS, Brazil",,"https://ClinicalTrials.gov/show/NCT03904901"
397,"NCT04155645","To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia",,"Recruiting","No Results Available","Dyslipidemia","Drug: AZD8233 subcutaneous injection|Drug: Placebo","Number of subjects with adverse events (AEs) due to AZD8233 SC multiple ascending dose treatment.|Vital sign: Systolic blood pressure (SBP)|Vital sign: Pulse rate|Vital sign: Oral body temperature|Number of patients with abnormal findings in resting 12-lead Electrocardiogram (ECG) and digital ECG (dECG).|Number of subject with abnormal findings in cardiac telemetry|Physical examination|Injection site reaction examinations|Laboratory assessments: Hematology - Blood cells count|Laboratory assessments: Hematology - Hemoglobin (Hb)|Laboratory assessments: Hematology - Hematocrit (HCT)|Laboratory assessments: Hematology - Mean corpuscular volume (MCV)|Laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH)|Laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC)|Laboratory assessments: Hematology - Differential WBC count|Laboratory assessments: Hematology - Platelet count and platelet function assessment.|Laboratory assessments: Hematology - Reticulocytes absolute count|Laboratory assessments: Serum clinical chemistry - Electrolytes|Laboratory assessments: Serum clinical chemistry - Blood urea nitrogen (BUN)|Laboratory assessments: Serum clinical chemistry - Creatinine|Laboratory assessments: Serum clinical chemistry - Glucose (fasting)|Laboratory assessments: Serum clinical chemistry - Creatine kinase|Laboratory assessments: Serum clinical chemistry - Direct bilirubin|Laboratory assessments: Serum clinical chemistry - Hemoglobin A1c (HbA1c)|Laboratory assessments: Serum clinical chemistry - Liver enzymes|Laboratory assessments: Serum clinical chemistry - Total bilirubin|Laboratory assessments: Serum clinical chemistry - Cell enzymes|Laboratory assessments: Serum clinical chemistry - Bicarbonate|Laboratory assessments: Serum clinical chemistry - Uric acid|Laboratory assessments: Coagulation|Renal safety biomarkers - Urine clusterin|Renal safety biomarkers - Urine cystatin-C|Renal safety biomarkers - Urine N-acetyl-beta-D-glucosaminidase (NAG)|Renal safety biomarkers - Urine albumin|Renal safety biomarkers - Urine creatinine|Renal safety biomarkers - Urine Kidney injury molecule1 (KIM-1)|Renal safety biomarkers - Urine Neutrophil gelatinase-associated lipocalin (NGAL)|Renal safety biomarkers - Urine Osteopontin|Renal safety biomarkers - Urine total protein|Immune Activation Response - High-sensitivity C-reactive protein (hs-CRP)|Complement Activation panel|Laboratory assessments: Clinical urinalysis|Plasma PK analysis: Time delay between drug administration and the first observed concentration in plasma (tlag).|Plasma PK analysis: Time to reach peak or maximum observed concentration or response following drug administration (tmax).|Plasma PK analysis: Observed maximum plasma concentration (Cmax).|Plasma PK analysis: Area under the plasma concentration-curve from time zero to time last value above the limit of quantification (AUC[0-last]).|Plasma PK analysis: Area under the concentration-time curve from time zero to 24 hours post-dose (AUC[0-24]).|Plasma PK analysis: Area under the concentration-time curve from time zero to 48 hours post-dose (AUC[0-48]).|Plasma PK analysis: Area under the concentration-time curve from time zero extrapolated to infinity (AUC).|Plasma PK analysis: Area under the plasma concentration-time curve from time during the dosing interval (AUCt).|Plasma PK analysis: Observed trough plasma drug concentration (Ctrough).|Plasma PK analysis: Apparent total body clearance of drug from plasma after extravascular administration (CL/F).|Plasma PK analysis: Apparent volume of distribution for parent drug at terminal phase (extravascular administration) (Vz/F).|Plasma PK analysis: Half-life associated with the terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2).|Plasma PK analysis: Mean Residence Time (MRT).|Urine PK analysis: Amount excreted in urine (Ae).|Urine PK analysis: Fraction excreted unchanged in urine (Fe).|Urine PK analysis: Renal clearance (CLR).|PD analysis: Levels of dyslipidemia related biomarkers.","AstraZeneca|Parexel","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","D7990C00002","November 21, 2019","April 30, 2021","April 30, 2021","November 7, 2019",,"June 9, 2020","Research Site, Glendale, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04155645"
398,"NCT03863431","The Influence of Overfeeding Different Macronutrients on Whole-body Insulin Sensitivity",,"Recruiting","No Results Available","Insulin Resistance|Type 2 Diabetes|Glucose Metabolism Disorders|Metabolic Disease","Other: High-fat diet|Other: High-carbohydrate diet","Whole-body insulin sensitivity index|Body Mass Index|Fasting plasma glucose concentration|Fasting serum insulin concentration|Fasting plasma lipid profile (for example total and HDL cholesterol and TAG concentrations; all measured in mmol/L)|Indirect calorimetry|Subjective appetite ratings","Loughborough University","All","18 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R18-P222","May 22, 2019","September 2020","September 2020","March 5, 2019",,"September 4, 2019","School of Sport, Exercise and Health Sciences, Loughborough, Leicestershire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03863431"
399,"NCT04167761","Ertugliflozin: Cardioprotective Effects on Epicardial Fat",,"Not yet recruiting","No Results Available","Cardiovascular Diseases|Atherosclerosis|Type 2 Diabetes|Insulin Resistance","Drug: Ertugliflozin|Drug: Glipizide","Rate of isoproterenol-stimulated lipolysis to measure metabolic flexibility in epicardial adipose tissue samples.|Average insulin mediated glucose uptake (IMGU) to measure insulin sensitivity in epicardial adipose tissue samples.|Characterization of the inflammatory cytokine expression profile in epicardial adipose tissue samples.|Distribution of adipose cell size in epicardial tissue.","Stanford University|Merck Sharp & Dohme Corp.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","52647","December 1, 2019","July 31, 2022","July 31, 2022","November 19, 2019",,"November 19, 2019","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04167761"
400,"NCT03932721","EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial","EXCEED-BHS3","Recruiting","No Results Available","Dyslipidemia Associated With Type II Diabetes Mellitus|Diabetes Mellitus, Type 2|Hypertension Arterial","Drug: Evolocumab 140 MG/ML","Difference in the percentage change in flow mediated dilation (FMD)|Difference in the percentage change in FMD reserve","University of Campinas, Brazil","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 4","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","Exceed","October 1, 2018","June 30, 2020","October 30, 2020","May 1, 2019",,"May 10, 2019","Centro de Pesquisa Clinica - FCM/Unicamp, Campinas, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT03932721"
401,"NCT03814434","Surgical Treatment of Periimplantitis in Patients With Risk Factors",,"Recruiting","No Results Available","Peri-Implantitis|Type 2 Diabetes Mellitus|Smoking, Cigarette|Periodontal Diseases","Procedure: Non-Surgical treatment|Procedure: Surgical Treatment","Radiographic Bone height Gain|Periimplant Pocket probing depth","Luiz Antonio Pugliesi Alves de Lima|University of Sao Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RiskFactorsSurgPeriimplantitis","May 28, 2018","January 28, 2020","January 28, 2020","January 24, 2019",,"March 11, 2019","Faculdade de Odontologia Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03814434"
402,"NCT03939000","Clinical Profile and Laboratory Finding of DFU From Tertiary Hospitals in Bali",,"Completed","No Results Available","Diabetic Foot Ulcer|Type 2 Diabetes Mellitus|Laboratory Problem|Physical Findings.Skin Ulcer",,"Age|Diabetes mellitus duration|Foot ulcer duration|Gender|Foot affected|Wagner classification|Surgical procedure|Hemoglobin|Hematocrit|Leukocyte|Basophil|Eosinophil|Neutrophil|Lymphocyte|Monocyte|Platelet|Alanine aminotransferase|Aspartate aminotransferase|Serum albumin|Random blood glucose|Glycated hemoglobin|Blood urea nitrogen|Serum creatinine|Serum sodium|Serum potassium|Prothrombin time|Activated partial thromboplastin time|International normalized ratio","Udayana University","All","Child, Adult, Older Adult",,"113","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","Profile_DFU","March 2016","December 2018","January 2019","May 6, 2019",,"May 6, 2019",,,"https://ClinicalTrials.gov/show/NCT03939000"
403,"NCT03851627","Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism","Test2Func","Not yet recruiting","No Results Available","Fatty Liver|Obesity|Type2 Diabetes Mellitus|Hypogonadism, Male","Drug: Testosterone Undecanoate|Drug: Placebo","Liver fat|body weight|waist, hip and neck circumference|insulin sensitivity|Level of HbA1c|Concentration of lipids|quality of live questionnaire|blood pressure|sexual function questionnaire|diabetes management satisfaction questionnaire","Alexandra Kautzky-Willer|Bayer|Medical University of Vienna","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","T2F12017|2017-001611-37","April 2020","April 2023","December 2023","February 22, 2019",,"February 28, 2020","Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Wien, Austria",,"https://ClinicalTrials.gov/show/NCT03851627"
404,"NCT03864510","NAFLD in Diabetes Type 2 in Primary Care","EPSONIP","Recruiting","No Results Available","NAFLD",,"Prevalence of fatty liver|Prevalence of advanced liver disease|The association between physical activity and advanced liver disease (fibrosis >2)|The association between fitness and advanced liver disease (fibrosis >2)|Genetic factors associated with advanced liver disease (fibrosis >2)|Health economic model for disease management|Number of patients that develop symptoms of end-stage liver disease","Linkoeping University","All","35 Years to 75 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018:176-31","April 1, 2019","December 2020","December 2023","March 6, 2019",,"August 14, 2019","Ekholmen primary health care centre, Linköping, Swedish, Sweden|Åby primary health care centre, Norrköping, Sweden",,"https://ClinicalTrials.gov/show/NCT03864510"
405,"NCT04041492","Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Bone Loss|Insulin Resistance","Dietary Supplement: Supplementation with Vitamin D3 y K2","Non-carboxylated osteocalcin|Insulin|Weight|Height|Body mass index|HOMA Index","University of Guadalajara","All","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","F-2017-1702-14","February 14, 2017","February 14, 2018","February 14, 2019","August 1, 2019",,"August 2, 2019","Julio Iván Aguayo, Guadalajara, Jalisco, Mexico",,"https://ClinicalTrials.gov/show/NCT04041492"
406,"NCT03913793","Aerobic Training in Post-MI Patients With DPN",,"Completed","No Results Available","Myocardial Infarction|Diabetes Mellitus, Type 2|Diabetic Peripheral Neuropathy","Other: Exercise based-cardiac rehabilitation (EB-CR) program","Duke Activity Status Index (DASI) questionnaire|heart rate (HR)|blood pressure (BP),|rate pressure product (RPP),|Six minute walk test distance","Yousra Hisham Abdel Fattah|Diaa Mohamed Mohasseb|Mahmoud Mohamed Hassanein|Gihan Younis El-tantawi|Aya Hanafy Ibrahiem|University of Alexandria","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","0104363","March 1, 2016","May 30, 2018","September 30, 2018","April 12, 2019",,"April 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03913793"
407,"NCT03792646","Protein Supplementation: Body Composition, Muscle Strength and Postural Balance",,"Unknown status","No Results Available","Diabetes Mellitus, Type 2|Protein Supplementation|Body Composition|Inflammation Biomarkers|Resistance Training","Dietary Supplement: Whey protein|Other: Exercise training","Muscular strength (hand grip) change from baseline|Muscular strength (peak of torque) change from baseline|Muscular strength (total work) change from baseline|Postural Balance (weight transfer) change from baseline|Postural Balance (sway velocity) change from baseline|Inflammatory biomarkers - plasma concentration change from baseline (Interleukin 6)|Portable Bioelectrical Impedance change from baseline|Inflammatory biomarkers - plasma concentration change from baseline (Tumor necrosis factor-alpha)","University of Sao Paulo General Hospital","Male","65 Years to 79 Years   (Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Diabéticos","May 1, 2018","March 1, 2020","March 1, 2020","January 3, 2019",,"January 3, 2019","Julia Maria DÀndrea Greve, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03792646"
408,"NCT03889977","Resistance Exercise on Postprandial Hyperglycemia in Patients With B-thalassemia Exhibiting Resistance to Insulin",,"Completed","No Results Available","Beta-Thalassemia|Insulin Resistance|PreDiabetes|Diabetes Mellitus, Type 2","Other: Resistance exercise","Changes in blood glucose|Changes in blood insulin|Changes in blood triglycerides|Body mass|Body height|Body fat|Resting heart rate|Heart rate during exercise|Changes in total antioxidant capacity|Changes in reduced glutathione (GSH)|Changes in catalase|Changes in uric acid|Changes in protein carbonyls|Changes in substances that react with thiobarbituric acid (TBARS)","University of Thessaly","All","30 Years to 55 Years   (Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B-Thalassemia ResEx Glucose","February 11, 2019","August 30, 2019","October 30, 2019","March 26, 2019",,"January 18, 2020","Exercise Biochemistry Laboratory, School of Physical Education & Sports Sciences, University of Thessaly, Tríkala, Greece",,"https://ClinicalTrials.gov/show/NCT03889977"
409,"NCT04127383","Effectiveness and Implementation of the Assessment of Burden of Chronic Conditions (ABCC)-Tool",,"Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease|Asthma|Diabetes Mellitus, Type 2|Heart Failure","Device: Assessment of Burden of Chronic Conditions (ABCC)-tool","Perceived quality of care (PACIC): Patient Assessment of Chronic Illness Care|Quality of life (EQ-5D-5L)|Capability well-being (ICECAP-A)|Patients' activation (PAM)|Medical Consumption within Health Care|Productivity losses","Maastricht University|Netherlands Instititute for Health Services Research|TNO|University of Twente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","10-10400-98-001","November 1, 2019","October 1, 2021","October 1, 2021","October 15, 2019",,"February 20, 2020","Maastricht University, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT04127383"
410,"NCT04082091","Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention","SELECT","Not yet recruiting","No Results Available","Cardiovascular Diseases|Cerebral Infarction|Type2 Diabetes Mellitus|Hypertension,Essential|Prevention","Behavioral: SELECT mHealth Program","Health Service Delivery of Intervention Outreach via Short Text Messages|Health Service Delivery of Intervention Outreach via Interactive Voice Recording|Health Service Measures of Intervention Uptake|Community Participation and Uptake of Intervention|Early Impact Measure of Intervention for Prompt Referral|Early Impact Measure of Intervention for Detection|Change in Physiological Characteristics of Intervention Participants - Blood Pressure|Change in Physiological Characteristics of Intervention Participants - Weight|Change in Physiologic Characteristics of Intervention Participants- Height|Change in Physiological Characteristics of Intervention Participants - BMI|Change in Physiological Characteristics of Intervention Participants - Physical Activity","Aga Khan University|The George Institute","All","18 Years to 90 Years   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","2019-0599-2619","September 2019","September 2020","September 2020","September 9, 2019",,"September 9, 2019",,,"https://ClinicalTrials.gov/show/NCT04082091"
411,"NCT04187443","MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema",,"Not yet recruiting","No Results Available","Diabetic Macular Edema|Macular Edema|Type 2 Diabetes With Diabetic Macular Edema|Type 1 Diabetes With Diabetic Macular Edema|Diabetic Retinopathy","Drug: MS-553","Treatment-emergent adverse events|Mean change in the central retina subfield thickness (CRT)|Mean change in the retinal volume|Proportion of patients with >20% reduction in CRT|Proportion of patients with resolution of central involved macular edema|Average mean change in best corrected visual acuity","Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.|Fountain Medical Development Co., Ltd.|MingSight Pharmaceuticals Pty Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-001-CN","March 4, 2020","August 18, 2021","October 18, 2021","December 5, 2019",,"December 24, 2019","Shanghai General Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04187443"
412,"NCT03827382","Bicycle Exercise and Lifestyle Intervention in Newly Diagnosed Diabetes","BELIFE","Recruiting","No Results Available","Life Style","Behavioral: Lifestyle Intervention","metabolic control|Absolute HbA1c reduction per stratification group|Proportion of patients achieving HbA1c target in each stratification group|Feasibility of bicycle exercise at study enrollment in the ER|Changes in heart rate after bicycle intervention|Changes in respiratory rate after bicycle intervention|Changes in blood pressure after bicycle intervention|Changes in blood glucose after bicycle intervention|Changes in pH after bicycle intervention|Changes in base excess after bicycle intervention|Changes in bicarbonate after bicycle intervention|Incidence of exercise related Adverse Events (Safety) during bicycle exercise in the ER|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Re-hospitalization rate|Re-consultation rate|Changes in HbA1c at 6 months|Changes in physical activity at 6 months|Number of antidiabetic medication at 30 days|Number of antidiabetic medication 60 days|Number of antidiabetic medication at 90 days|Dosage of antidiabetic medication at 30|Dosage of antidiabetic medication at 60 days|Dosage of antidiabetic medication at 90 days|Quality of life by SF-36 Questionnaire","University Hospital, Basel, Switzerland|Kantonsspital Olten|Kantonsspital Aarau|Luzerner Kantonsspital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-01920","February 1, 2019","June 2021","December 2021","February 1, 2019",,"May 27, 2020","Cantonal Hospital Aarau, Aarau, Aargau, Switzerland|University Hospital Basel, Basel, Basel-Stadt, Switzerland|Cantonal Hospital Olten, Olten, Solothurn, Switzerland|Cantonal Hospital Lucerne, Lucerne, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03827382/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03827382"
413,"NCT04023734","A Targeted and Tailored Pharmacist Intervention to Improve Adherence to Antihypertensive Drugs Among Diabetes Patients",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Hypertension|Medication Nonadherence","Behavioral: Reminders, habit-based strategies and/or involvement of family member|Behavioral: Counselling to increase knowledge|Behavioral: Counselling to increase motivation|Behavioral: Explore/address other drug related problems|Behavioral: Usual care based on the Indonesian guideline","Medication adherence|Blood pressure level|Medication beliefs|Reach|Pharmacists' adoption of the intervention|Patients' adoption of the intervention|Pharmacists' suggestions for future implementation|Patients' suggestions for future implementation|Pharmacists' willingness to maintain the intervention|Patients' willingness to maintain the intervention","University of Groningen|Universitas Padjadjaran","All","18 Years and older   (Adult, Older Adult)","Not Applicable","113","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","PharIndo2019","August 16, 2019","December 30, 2019","January 30, 2020","July 17, 2019",,"March 24, 2020","Community Health Centers, Bandung, West Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04023734"
414,"NCT03811470","China Diabetes Registry by Metabolic Management Center","CDR-MMC","Recruiting","No Results Available","Type 2 Diabetes Mellitus|Type1 Diabetes Mellitus|Monogenetic Diabetes|Pancreatogenic Diabetes|Drug-Induced Diabetes Mellitus|Other Forms of Diabetes Mellitus","Other: Standard diabetes management model in each MMC center","Incidence of all diabetes-related clinical endpoints; including: 1. Macrovascular morbidity|Microvascular morbidity|Mortality|Major infections - pulmonary and non-pulmonary requiring hospitalizations|Heart failure|Neuropathy|All cancers|HbA1c (%)|Fasting and postprandial glucose (mmol/L)|Blood pressures (mmHg)|lipids (mg/dl)|Body mass index (BMI)|Visceral fat (cm^2)|Health related quality of life|Cognitive function|Psychological well being|Cost-effectiveness","Guang Ning|Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Older Adult)",,"500000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCEMD-2018-1201","May 31, 2017","May 31, 2037","May 31, 2039","January 22, 2019",,"January 22, 2019","National Metabolic Management center, Multiple Locations, China",,"https://ClinicalTrials.gov/show/NCT03811470"
415,"NCT04129424","Preliminary Exploration on the Operational Standards of Insulin Pump Installation in Diabetes Clinic in China",,"Not yet recruiting","No Results Available","Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus|Gestational Diabetes Mellitus|Pancreatogenic Diabetes Mellitus|Pregestational Diabetes Mellitus|Diabetes Patients in Perioperative Period","Device: Insulin pump (Microtech, Equil®)","The basal insulin dose of insulin pump at the end of the study|The preprandial insulin dose of insulin pump at the end of the study|The basal insulin dose of insulin pump at the end of the 6-day follow-up|The preprandial insulin dose of insulin pump at the end of the 6-day follow-up|The frequency of hypoglycemia|The time in range of goal blood glucose during follow-up|The frequency of pain at puncture site|The frequency of errors in patency of infusion pipeline connection|The blood glucose value of hypoglycemia|The symptoms of hypoglycemia|The frequency of bleeding at puncture site|The frequency of infection at puncture site|The frequency of errors in patency of needle fixation","Peking Union Medical College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Zhao insulin pump","December 1, 2019","December 1, 2020","December 1, 2020","October 16, 2019",,"October 16, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04129424"
416,"NCT04148482","PREMIER: PREvention of Metabolic Illness Through prEcision nutRition","PREMIER","Not yet recruiting","No Results Available","Obesity|Type 2 Diabetes|Metabolic Syndrome|Diet Habit|Nutritional and Metabolic Disease|Food Preferences","Other: Dietary intervention","Glucose|High-fat meal preference|Hunger perception before and after test meals consumption using visual analogue scales|Metabolomics by mass spectrometry analysis|Incretin levels by immunoassay kits|Appetite satiety hormones levels by immunoassay kits","Massachusetts General Hospital|NORCH (Nutrition Obesity Research Center at Harvard)|Boston Area Diabetes Endocrinology Research Center","All","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","PREMIER Study","January 2020","January 2021","January 2021","November 1, 2019",,"November 4, 2019",,,"https://ClinicalTrials.gov/show/NCT04148482"
417,"NCT04181853","The Effect of Aerobic Exercise on Genetic Molecules","xnx","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Aerobic Exercise|Genetic Response","Other: exercise","genetic molecules","Pamukkale University","All","30 Years to 74 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","60116787-020/83243","February 5, 2020","June 30, 2020","December 31, 2021","December 2, 2019",,"February 6, 2020","Pamukkale University, Denizli, Turkey|Pamukkale University, Denizli, Turkey",,"https://ClinicalTrials.gov/show/NCT04181853"
418,"NCT03834207","A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy","C3-Cloud","Recruiting","No Results Available","Diabetes Type 2|Renal Failure|Heart Failure|Depression|Chronic Disease|Aging","Device: Use of the C3-Cloud IT system","Acceptability & usefulness of the C3-Cloud system","Dr Christopher Marguerie|University of Warwick|Kronikgune|Medixine|SRDC|Institut National de la Santé Et de la Recherche Médicale, France|Eurorec|Empirica|Örebro University, Sweden|Osakidetza|Region Jamtland Harjedalen|Cambio Healthcare|South Warwickshire NHS Foundation Trust","All","55 Years and older   (Adult, Older Adult)","Not Applicable","672","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","689181","October 1, 2018","January 31, 2020","April 30, 2020","February 7, 2019",,"February 7, 2019","Osakidetza, Vitoria-Gasteiz, Araba, Spain|Region Jamtland Harjedalen, Ostersund, Sweden|South Warwickshire NHS Foundation Trust, Warwick, Warwickshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03834207"
419,"NCT03859934","Metabolic Effects of Melatonin Treatment",,"Recruiting","No Results Available","Metabolic Disease|Insulin Sensitivity|Glucose Metabolism Disorders (Including Diabetes Mellitus)|Type 2 Diabetes Mellitus|Blood Pressure|Inflammation","Drug: Melatonin|Drug: Placebo Oral Tablet","Change of insulin sensitivity|Change of insulin secretion change|MTNR1a rs10830963 influence on change in insulin sensitivity and insulin secretion|Change of insulin signalling|Change of ambulatory blood pressure|Change of arterial stiffness|Change of gut microbiome|Change of sleep evaluation 1|Change of sleep evaluation 2|Change of psychological health 1|Change of psychological health 2|Hormonal changes|Change of glucose and palmitate kinetics|Change of regional glucose and palmitate uptake|Change of DEXA-scans|Change of assessment of respiratory quotient (RQ)|Change of assessment of resting energy expenditure (REE)","University of Aarhus|University of Copenhagen","Male","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019-000213-37","September 26, 2019","September 1, 2021","September 1, 2022","March 1, 2019",,"September 30, 2019","Medical Research Laboratory, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT03859934"
420,"NCT03794531","Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico","PROSPECT","Recruiting","No Results Available","Heart Diseases|Type2 Diabetes|Hypertension|Obesity|Dyslipidemias|Metabolic Syndrome|Cardiovascular Diseases|Chronic Disease|Inflammation|Psychological Stress|Physiological Stress|Depressive Symptoms|Coping Behavior|Diet Habit|Lifestyle",,"Number of participants with self-reported medically-diagnosed chronic diseases|Difference in the number of participants with self-reported medically-diagnosed chronic diseases living urban vs. rural area","Harvard School of Public Health|National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Minority Health and Health Disparities (NIMHD)|FDI Clinical Research of Puerto Rico|University of Massachusetts, Lowell|University of Puerto Rico Medical Sciences Campus","All","30 Years to 75 Years   (Adult, Older Adult)",,"2000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","143792|R01HL143792|R21MD013650","December 17, 2018","June 30, 2022","June 30, 2023","January 7, 2019",,"February 11, 2020","FDI Clinical Research, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03794531"
421,"NCT04143269","Treatment of Complications to Diabetic Autonomic Neuropathy With Vagus Nerve Stimulation","DAN-VNS","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Gastrointestinal Dysfunction","Device: Non-invasive transcutaneous vagus nerve stimulation|Device: Sham vagus nerve stimulation","Subjective gastrointestinal symptoms|Holter monitoring|Cardiac vagal tone|Cardiovascular reflex testing|Sudomotor function|Pan-intestinal imaging|Functional brain scan|Intestinal transit|EEG spectral analysis|Pain tolerance threshold|Cold pressor test|Glycaemic control|Level of inflammation","Aalborg University Hospital|ElectroCore INC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAN-VNS|CIV-19-07-029105|N-20190020","November 2019","June 2021","June 2021","October 29, 2019",,"October 29, 2019",,,"https://ClinicalTrials.gov/show/NCT04143269"
422,"NCT03889236","Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.","Glycotreat","Recruiting","No Results Available","Diabetic Nephropathy Type 2|Albuminuria|Type2 Diabetes Mellitus|Glucose Metabolism Disorders|Microalbuminuria|Diabetic Nephropathies|Diabetic Complications Renal|Diabetes Mellitus|Kidney Diseases|South Asian","Other: Fasting mimicking diet Prolon|Dietary Supplement: Food supplement Endocalyx|Dietary Supplement: Placebo","Percentage change from baseline in the Microvascular Health Index in the fasting mimicking diet or food supplement group compared to the placebo group|Percentage change from baseline in Urine albumin-to-creatinine ratio (UACR) in the fasting mimicking diet or food supplement group compared to the placebo|Percentage change from baseline in urinary heparanase levels in the fasting mimicking diet or food supplement group compared to the placebo|Percentage change from baseline in urinary MCP-1 levels in the fasting mimicking diet or food supplement group compared to the placebo|Percentage change from baseline in specific urinary heparan sulfate domains in the fasting mimicking diet or food supplement group compared to the placebo","Leiden University Medical Center|Dutch Kidney Foundation|Health Holland|Radboud University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P17.249","May 3, 2018","December 31, 2019","December 31, 2019","March 26, 2019",,"March 26, 2019","Leiden Universitiy Medical Center (LUMC), Leiden, Noord Holland, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03889236/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03889236"
423,"NCT04164602","The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly","NODES","Not yet recruiting","No Results Available","Diabetes Mellitus|Diabetes|Diabetes Mellitus, Type 2|Diabetes type2|Cancer of Pancreas|Pancreas Neoplasm|Pancreas Adenocarcinoma|Pancreatic Cancer",,"incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes|mortality of pancreatic ductal adenocarcinoma in new-onset diabetic patients|the proportion of localised and resectable pancreatic ductal adenocarcinoma|change in body weight|Change in fasting blood glucose and HbA1c|Antidiabetic medications and the risk of pancreatic ductal adenocarcinoma|presence of concomitant diseases|smoking and alcohol intake|The sensitivity, specificity, positive and negative predictive values, and accuracy of the biomarker test|Cost-benefit analysis","University of Pecs|Hungarian Pancreatic Study Group (HPSG)","All","60 Years and older   (Adult, Older Adult)",,"2522","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","41085-6/2019EÜIG","September 11, 2020","December 31, 2022","June 30, 2023","November 15, 2019",,"June 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04164602"
424,"NCT04025489","Vitamin D Supplementation on Surrogate Markers of Ageing, Ageing Genes, Glycemic and Metabolic Markers in North India",,"Not yet recruiting","No Results Available","Vitamin D Supplementation|PreDiabetes|Aging","Dietary Supplement: Randomized control trial of vitamin D supplementation","Investigation of gene polymorphism and other markers in 500 subjects|Effect of vitamin d supplementation on raging and other metabolic measures.","Diabetes Foundation, India","All","20 Years to 60 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DFI","September 1, 2019","August 30, 2022","August 30, 2022","July 19, 2019",,"July 19, 2019","Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04025489"
425,"NCT04196348","Surgical Innovation for Diabetes Treatment","SURIDIAB-1","Recruiting","No Results Available","Obesity|Diabetes Mellitus, Type 2","Procedure: Short BPL RYGB|Procedure: Long BPL RYGB","Change in body mass index|Change in glycated haemoglobin|Change in glucose dynamic profile|Change in insulin dynamic profile|Change in glucagon dynamic profile|Change in GLP-1 dynamic profile|Change in GIP dynamic profile","Hospital de Sao Sebastiao|Instituto de Ciências Biomédicas Abel Salazar|The Novo Nordisk Foundation Center for Basic Metabolic Research","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Hsebastião","March 28, 2019","August 31, 2020","August 31, 2020","December 12, 2019",,"December 12, 2019","São Sebastião Hospital, Santa Maria Da Feira, Aveiro, Portugal",,"https://ClinicalTrials.gov/show/NCT04196348"
426,"NCT04132531","Effect of Weight Loss Surgery on Stem Cells.",,"Completed","No Results Available","Obesity, Morbid|Stem Cells|Cardiovascular Morbidity","Procedure: Bariatric (weight loss) surgery","Change in the frequency of circulating cells with aldehyde dehydrogenase activity.|Change in the frequency of circulating cells with aldehyde dehydrogenase activity and cell surface marker expression.","St. Michael's Hospital, Toronto|Humber River Hospital|University of Western Ontario, Canada","All","19 Years to 60 Years   (Adult)",,"38","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PRO_B_001","May 1, 2018","June 25, 2019","August 13, 2019","October 18, 2019",,"October 18, 2019","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04132531"
427,"NCT03988764","Monogenic Diabetes Misdiagnosed as Type 1","ADDAM","Recruiting","No Results Available","Diabetes Mellitus, Type 1|Monogenic Diabetes|Neonatal Diabetes|Maturity-onset Diabetes in the Young (MODY)|Wolfram Syndrome|Wolcott-Rallison Syndrome|Mitochondrial Diabetes",,"Proportion of monogenic diabetes among patients diagnosed as type 1 diabetes.|Proportion of patients carrying mutations in previously unstudied genes that meet statistical criteria of pathogenicity for monogenic diabetes.|Risk-prediction score for monogenic diabetes mutation in antibody negative T1D patients","Constantin Polychronakos|McGill University Health Centre/Research Institute of the McGill University Health Centre","All","up to 25 Years   (Child, Adult)",,"5000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ADDAM|Canscreen","September 24, 2019","December 31, 2022","December 31, 2022","June 17, 2019",,"October 15, 2019","The Montreal Children's Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03988764"
428,"NCT04177420","Investigation for Health Efficacy of Infrared-C Radiation on Diabetes Patients in Senior's Activity Center",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Device: FIR-C mattress|Device: FIR-C abdominal pad|Device: fake FIR-C mattress|Device: fake FIR-C abdominal pad","Hemoglobin A1c, HbA1c|Fasting Blood Sugar, GLU-AC|Insulin|Superoxide, O2−|Osteocalcin|Procollagen-I N-telopeptide, PINP|C-telopeptide of type I collagen，CTx|Total Antioxidant Capacity, TAC|Advanced glycation end-product，AGEs|Insulin resistance assessment|Beta-cell function assessment|Autonomic nervous system assessment - Heart Rate|Autonomic nervous system assessment - blood pressure|Autonomic nervous system assessment - Heart Rate Variability|Autonomic nervous system assessment - Low Frequency|Autonomic nervous system assessment - High Frequency|Autonomic nervous system assessment - Low/High Frequency standard|Autonomic nervous system assessment - Irregular Heartbeat standard|Pittsburgh sleep quality index (PSQI)|Knee Pain - Numeric Rating Scale, Knee Pain - NRS|Geriatric Depression Scale-15, GDS-15","Nanhua University|Buddhist Dalin Tzu Chi General Hospital|Solano Semiconductor Technology., LTD.","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","B10701016","March 23, 2018","December 31, 2019","February 15, 2020","November 26, 2019",,"November 26, 2019","Department of Natural Biotechnology, Master's program in Natural Healing Sciences Nanhua University, Dalin, Chiayi, Taiwan",,"https://ClinicalTrials.gov/show/NCT04177420"
429,"NCT03925948","Health Literacy Intervention for African Americans With Diabetes",,"Completed","No Results Available","Uncontrolled Diabetes","Behavioral: PLAN 4 Success-Diabetes","Change in Health literacy as assessed by Literacy Assessment in Diabetes (LAD).|Change in Health literacy as assessed by the Newest Vital Sign|Change in Diabetes knowledge measured with the validated Diabetes Knowledge Test|Change in Diabetes self-efficacy measured with Stanford Diabetes Self-Efficacy scale","Johns Hopkins University|Brancati Center for the Advancement of Community Care|Center for Community Innovation and Scholarship at the Johns Hopkins University|East Baltimore Medical Center|Shepherds Clinic|John Hopkins Aftercare Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","19","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00061339","May 6, 2015","February 1, 2019","February 1, 2019","April 24, 2019",,"April 24, 2019","Wald Community Nursing Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03925948"
430,"NCT04062890","Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance",,"Not yet recruiting","No Results Available","Hyperinsulinism|Insulin Resistance|Insulin Sensitivity|Glucose Intolerance|Hypertension","Drug: Vigabatrin Pill|Drug: Placebo oral tablet","Fasted serum glucose and insulin|Glucose Clearance|Insulin Sensitivity|Blood Pressure","University of Arizona|Arizona Department of Health Services","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ADHS18-201472b","December 15, 2019","December 30, 2021","December 30, 2022","August 20, 2019",,"August 20, 2019",,,"https://ClinicalTrials.gov/show/NCT04062890"
431,"NCT04083339","Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy",,"Recruiting","No Results Available","Diabetic Cardiomyopathies","Drug: AT-001|Drug: Placebo","Peak VO2 during cardio-pulmonary exercise test (CPET)|Changes in NT-proBNP|Changes in the modified Kansas City Cardiomyopathy Questionnaire (KCCQ) score|Percentages of patients with clinically significant changes in Peak VO2","Applied Therapeutics, Inc.","All","40 Years and older   (Adult, Older Adult)","Phase 3","675","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AT-001-2001","September 20, 2019","September 2021","September 2023","September 10, 2019",,"October 16, 2019","Mountain View Clinical Research, Greer, South Carolina, United States|Juno Research, LLC - Northwest Site, Houston, Texas, United States|Juno Research, LLC - Southwest Houston Site, Houston, Texas, United States|Juno Research, LLC - Katy, Katy, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04083339"
432,"NCT03823664","Cardiorespiratory Fitness in Prediabetic,Type 2 Diabetic and Healthy Individuals",,"Recruiting","No Results Available","Prediabetic State|Diabetes Mellitus, Type 2|Cardiorespiratory Fitness|Inflammation|Exercise Test","Diagnostic Test: Cardiorespiratory Fitness","Cardiorespiratory fitness|Functional Exercise Capacity|Pulmonary functions|Respiratory Muscle Strength|Maximal Exercise Capacity|Physical Activity Level","Hacettepe University","All","18 Years to 65 Years   (Adult, Older Adult)",,"36","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","GO 17/793","November 1, 2018","June 1, 2019","November 1, 2019","January 30, 2019",,"January 30, 2019","Hacettepe University, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT03823664"
433,"NCT04190849","European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)","EU-PNAFLD","Recruiting","No Results Available","Non-Alcoholic Fatty Liver Disease|Non-alcoholic Fatty Liver|Non-alcoholic Steatohepatitis",,"Survival|Cardiovascular morbidity|Liver morbidity|Asymptomatic progression of liver disease","Cambridge University Hospitals NHS Foundation Trust|The European Association for the Study of the Liver|Children's Liver Disease Foundation","All","up to 18 Years   (Child, Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","A094204|174534","November 14, 2017","November 2047","November 2047","December 9, 2019",,"December 9, 2019","Maastricht UMC, Maastricht, Netherlands|Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|Birmingham Children's Hospital, Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT04190849/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04190849"
434,"NCT03857191","Nutritional Rehabilitation and Sleep Apnea in the Obese","DIETSLEEP","Recruiting","No Results Available","Obese|Sleep Apnea, Obstructive","Dietary Supplement: Nutritional psychocomportemental rehabilitation","Difference in OSA risk before and after nutritional and psychocomportemental rehabilitation|Difference in daytime sleepiness before and after nutritional and psychocomportemental rehabilitation|Weight loss according to OSA status|Change in Blood pressure according to OSA status|Change in Medication use according to OSA status|To assess the effect of Weight loss on OSA","University Hospital, Grenoble|Groupe Ethique & santé","All","18 Years and older   (Adult, Older Adult)",,"396","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC18.267|2018-A02617-48","March 22, 2019","September 25, 2021","September 25, 2021","February 27, 2019",,"January 27, 2020","Chu Grenoble Alpes, Grenoble Cedex 9, France",,"https://ClinicalTrials.gov/show/NCT03857191"
435,"NCT03835923","Lifestyle Intervention in Chronic Ischemic Heart Disease and Diabetes","LeIKD","Active, not recruiting","No Results Available","Ischemic Heart Disease Chronic|Diabetes Mellitus, Type 2","Behavioral: lifestyle intervention|Behavioral: usual care","Change in HbA1c|Change in health literacy|Change in daily physical activity|Change in average steps per day|Change in eating behavior|Change in quality of life|Change of medical care expenses|Change in weight|Change in waist circumference|Change in LDL-cholesterol concentrations|Change in HDL-cholesterol concentrations|Change in triglyceride concentrations|Change in systolic blood pressure|Change in diastolic blood pressure|Number of the combined endpoint ""4P-MACE""","Techniker Krankenkasse|Technische Universität München|privates Institut für angewandte Versorgungsforschung GmbH|IDS Diagnostic Systems AG|Federal Joint Committee, Germany","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","01NVF17015|DRKS00015140","February 12, 2019","October 2020","April 2021","February 11, 2019",,"June 11, 2020","University Hospital: Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany|University Hospital: Charité - Universitätsmedizin Berlin, Berlin, Germany|University Hospital: Herzzentrum Dresden, Dresden, Germany|University Hospital: Universitäts-Herzzentrum Freiburg - Bad Krozingen, Freiburg, Germany|University Hospital: Universitätsmedizin Greifswald, Greifswald, Germany|Doctor's Practice: Dr. Rüdell, Kassel, Germany|University Hospital: Klinik und Poliklinik für Kardiologie - Universitätsklinikum Leipzig, Leipzig, Germany|University Hospital: Magdeburg, Magdeburg, Germany|University Hospital: Klinikum rechts der Isar, Technische Universität München, Munich, Germany|Doctor's Practice: Prof. Dr. Jacob und Dr. Jacob, Villingen-Schwenningen, Germany",,"https://ClinicalTrials.gov/show/NCT03835923"
436,"NCT03840161","Use of CoG by Patients With Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus","Device: non-invasive tissue glucose prediction","CoG accuracy in measuring glucose levels (non-invasively) during a standardized meal experiment.|CoG accuracy in monitoring glucose levels (invasively) during a standardized meal experiment.|Impact of the CoG on long-term (three month) glycemic control (HbA1c using standard laboratory procedures) in patients with type 1 and 2 diabetes|Treatment satisfaction questionnaire","Sciema UG|Cnoga Medical Ltd.","All","18 Years to 90 Years   (Adult, Older Adult)",,"40","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CNG-NGM-003","July 16, 2018","February 28, 2019","March 31, 2019","February 15, 2019",,"January 18, 2020","Mills-Penisnsula Medical Center, San Mateo, California, United States",,"https://ClinicalTrials.gov/show/NCT03840161"
437,"NCT03857802","Efficiency of a Nursing Intervention in Sleep Hygiene","ENISH","Recruiting","No Results Available","Sleep Disorder|Metabolic Glucose Disorders","Behavioral: Sleep hygiene intervention","Change of glycated hemoglobin levels.|Change in sleep quality: Pittsburgh Sleep Quality Index","Jordi Gol i Gurina Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","JordiGol","September 1, 2017","April 2019","April 2019","February 28, 2019",,"March 7, 2019","Centro Atención Primaria - Institut Català de la Salut, Balaguer, Lleida, Spain",,"https://ClinicalTrials.gov/show/NCT03857802"
438,"NCT03889600","Re-Engineered Discharge for Diabetes-Computer Adaptive Testing (REDD-CAT)",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: REDD-CAT","Feasibility - Recruitment potential: percentage of eligible patients willing to enroll in the study|Feasibility - Participant burden: time required for participants to complete data collection measures|Feasibility - Subject retention: percentage of patients who complete the 30-day follow-up time point|Feasibility - Implementation fidelity: percentage of indicated referrals that are made|Limited Efficacy - Change in coping: Ways of Coping scale|Limited Efficacy - Change in diabetes related distress: Diabetes Distress scale|Limited Efficacy - Change in depression: Patient Health Questionnaire (PHQ-9)|Limited Efficacy - Change in anxiety: The Generalized Anxiety Disorder 7 (GAD-7)|Limited Efficacy - 30-Day readmission rate","Boston Medical Center|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","H-38545","September 2020","March 2021","March 2021","March 26, 2019",,"October 29, 2019",,,"https://ClinicalTrials.gov/show/NCT03889600"
439,"NCT03940209","Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries",,"Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Basic needs navigation","HbA1c|Health-related Quality of Life","Washington University School of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Louisiana Healthcare Connections","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","HRPO201811020|1R01DK115916-01A1","November 1, 2019","June 30, 2023","June 30, 2024","May 7, 2019",,"December 9, 2019","Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03940209"
440,"NCT04120259","Effect of Apple Cider Vinegar and Metformin Combination vs Metformin Alone in Type 2 Diabetics",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Metformin Oral Tablet|Dietary Supplement: Vinegar","BMI (Anthropometric Measurement)|Measurement of Hemoglobin A1c|Measurement of Fasting Blood Sugar","Ziauddin University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","002","April 22, 2019","August 26, 2019","August 26, 2019","October 9, 2019",,"October 21, 2019","Ziauddin University, Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT04120259"
441,"NCT03968380","Contextualizing Evidence for Action on Diabetes","CEAD","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: Population survey with biological and physical measurements.","Glucose Tolerance|Fasting blood glucose|Obesity|Blood pressure|Cholesterol|Tobacco consumption|Alcohol consumption|Fruit and vegetable intake|Physical activity|Waist circumference","Universidad Miguel Hernandez de Elche|European Research Council","All","18 Years and older   (Adult, Older Adult)",,"1440","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ERC-2018-STG-804761","September 2019","December 2022","December 2023","May 30, 2019",,"May 30, 2019",,,"https://ClinicalTrials.gov/show/NCT03968380"
442,"NCT03949504","Diabetes Risk Diagnosis and Management","DIARIO","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Procedure: New Find-risk questionnaire software","Number of subjects at high risk for Diabetes|Number of subjects with diabetes|Concentration of glucose in plasma","Neuromed IRCCS","All","34 Years to 100 Years   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","DEP3_2019","January 9, 2019","July 30, 2021","December 31, 2021","May 14, 2019",,"May 17, 2019","IRCCS INM Neuromed, Department of Epidemiology and Prevention, Pozzilli, IS, Italy",,"https://ClinicalTrials.gov/show/NCT03949504"
443,"NCT03998046","Coordinating Pragmatic Primary Care Population Management for Obesity","C3PO","Not yet recruiting","No Results Available","Obesity|Cardiovascular Risk Factor","Behavioral: Outreach Support for Weight Loss Goal Setting and Self-Weighing|Behavioral: Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions|Behavioral: Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support","Achieve 5% Weight Loss Goal at 6 Months|Costs to Implement the Intervention|Change in Hemoglobin A1C|Change in Systolic Blood Pressure|Change in Total Cholesterol|Change in Non-HDL Cholesterol|Body Mass Change at 6 Months|Body Mass Change at 12 Months|Achieve 5% Weight Loss Goal in 12 Months","Northwestern University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","STU00207153|R34DK114773","August 2019","April 30, 2020","October 30, 2020","June 25, 2019",,"June 25, 2019",,,"https://ClinicalTrials.gov/show/NCT03998046"
444,"NCT04094194","Meta-analysis of the Nordic Dietary Pattern on Cardiometabolic Risk and Cardiovascular Outcomes",,"Active, not recruiting","No Results Available","Body Weight|Obesity|Overweight and Obesity|Obesity, Abdominal|Hypertension|Hyperlipidemias|Cardiovascular Diseases|Coronary Heart Disease|Stroke|Mortality|Dyslipidemias|Diabetes|PreDiabetes|Insulin Tolerance|Dysglycemia|Metabolic Syndrome","Other: Nordic diet","Incident Cardiovascular Disease (Prospective Cohort Studies)|LDL-cholesterol (randomized and non-randomized controlled trials)|Glycemic control - Fasting blood glucose (randomized and non-randomized controlled trials)|Glycemic control - HbA1c (randomized and non-randomized controlled trials)|Glycemic control - Fasting insulin (randomized and non-randomized controlled trials)|Blood lipids - non-HDL-cholesterol (randomized and non-randomized controlled trials)|Blood lipids - HDL-cholesterol (randomized and non-randomized controlled trials)|Blood lipids - Triglycerides (randomized and non-randomized controlled trials)|Blood lipids - apo B (randomized and non-randomized controlled trials)|Adiposity - Body mass index (BMI) (randomized and non-randomized controlled trials)|Adiposity - Body weight (randomized and non-randomized controlled trials)|Adiposity - Waist circumference (randomized and non-randomized controlled trials)|Blood pressure - systolic blood pressure (randomized and non-randomized controlled trials)|Blood pressure - diastolic blood pressure (randomized and non-randomized controlled trials)|Inflammation - C-reactive protein (CRP) (randomized and non-randomized controlled trials)|Incident Coronary Heart Disease (Prospective Cohort Studies)|Incident Stroke (Prospective Cohort Studies)","University of Toronto|Canadian Institutes of Health Research (CIHR)|Canada Research Chairs Endowment of the Federal Government of Canada|The Physicians' Services Incorporated Foundation|Canadian Diabetes Association","All","Child, Adult, Older Adult",,"1","Other","Observational","Observational Model: Other|Time Perspective: Prospective","DNSG-Nordic diet","December 1, 2017","December 1, 2019","December 1, 2019","September 18, 2019",,"September 18, 2019","The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04094194"
445,"NCT03950219","CUlturally Sensitive TOols for Ethnic Minorities in Diabetes Self-management Education and Support","CUSTOM","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: Group course","Well-being|diabetes self-management|HbA1c","Steno Diabetes Center Copenhagen|Centre for Diabetes, Copenhagen municipality","All","18 Years and older   (Adult, Older Adult)","Not Applicable","309","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CUSTOM","March 1, 2019","December 31, 2020","October 2022","May 15, 2019",,"May 16, 2019","Centre for Diabetes, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03950219"
446,"NCT03938233","Diabetes Self Management Education Programme in Thailand","DSMET","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system","Hemoglobin A1c levels (HbA1c)|Total cardiovascular risk|EQ-5D|Hospital Anxiety and Depression scale (HADS)|Perceived Stress Questionnaire (PSQ)|Summary of Diabetes Self-Care Activities Assessment (SDSCA)|International Physical Activity Questionnaire|Body mass index (BMI)","London School of Hygiene and Tropical Medicine|Medical Research Council|Chiang Mai University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","693","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","1","March 1, 2020","September 1, 2022","March 1, 2023","May 6, 2019",,"January 18, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03938233/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03938233/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03938233"
447,"NCT03947333","Evaluation of a Patient Portal Intervention for Diabetes: A Randomized Controlled Trial",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: My Diabetes Care","Change in Patient Activation at 6 months|Change in Patient Activation at 3 months|Change in Diabetes Knowledge|Change in Diabetes Self-Care|Change in Diabetes Medication Adherence|Change in Diabetes Self-Efficacy|Change in Diabetes Distress|Satisfaction/Usability of My Health at Vanderbilt (for control group) and My Diabetes Care (for intervention group)|System Usage Data for My Health at Vanderbilt (for control group) and My Diabetes Care (for intervention group)|Change in Blood Glucose Control|Change in Blood Pressure Control|Treatment Intensification|Change in Flu Vaccination Status for 2019-20 Flu Season|Change in Low Density Lipoprotein","Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","190825|5K23DK106511","March 9, 2020","December 2020","December 2020","May 13, 2019",,"May 18, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03947333"
448,"NCT03890991","Self-Care for Older People With Diabetes Mellitus","SCOPE-DM","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: SCOPE-DM|Behavioral: SCOPE-DM with 3 months' supply of glucometer|Behavioral: SCOPE-DM with 6 months' supply of glucometer","Self-efficacy assessed using the General Self-efficacy Scale|Diabetes self-care activities measured using the Revised Summary of Diabetes Self-care Activities|Diabetes-specific quality of life measured using the Audit of Diabetes-Dependent Quality of Life|Participants' level of knowledge of Diabetes assessed using the Revised Michigan Diabetes Knowledge Questionnaire|Participants' level of medication adherence assessed using Medication Adherence Report Scale|Proportion of participants with optimal Glycated haemoglobin Level (HbA1c Level) of 7% or lower|Proportion of participants with optimal Systolic and Diastolic Blood Pressure|Proportion of participants with optimal levels of Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglyceride|Proportion of participants with optimal Body Mass Index between 18.5 and 22.9|Proportion of participants who adhere to yearly eye and foot screening","National University, Singapore|Tsao Foundation Singapore","All","55 Years to 99 Years   (Adult, Older Adult)","Not Applicable","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","H-18-074","February 26, 2019","June 30, 2020","June 30, 2020","March 26, 2019",,"March 27, 2019","Whampoa Community Club, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03890991"
449,"NCT04080960","Dining With Diabetes in Pennsylvania","DWD","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Lifestyle modification education","hemoglobin A1C","Penn State University","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PRAMS00036501|208113","May 1, 2019","April 30, 2020","April 30, 2020","September 6, 2019",,"September 6, 2019","Penn State University, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04080960"
450,"NCT03865381","Onduo Virtual Diabetes Clinic Study","VDC","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Device: Onduo App","Mean change in hemoglobin A1c|Change in weight from enrollment|Time to first change in diabetes medication or dosage from enrollment|Change in CGM summary measures from the first wear period versus the final wear period including glycemic variability, time spent in glycemic range, and mean glucose.|Mean Change in A1c","Verily Life Sciences LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","100901","February 8, 2019","February 12, 2020","October 15, 2020","March 6, 2019",,"May 6, 2020","Palo Alto Medical Foundation, Palo Alto, California, United States|Premier Medical Associates, Monroeville, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03865381"
451,"NCT03800680","A Randomized Trial to Slow the Progression of Diabetes","TRIPOD","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Diabetes Management Package (DMP)|Behavioral: M-POWER Rewards","Change in HbA1c levels at Month 12|Change in HbA1c levels at Month 6|Change in weight at Months 6 and 12|Change in blood pressure at Months 6 and 12|Proportion of participants that had insulin treatment initiated by Months 6 and 12|Change in self-reported physical activity at Months 6 and 12|Change in self-reported weight monitoring at Months 6 and 12|Change in self-reported blood glucose monitoring at Months 6 and 12|Change in self-reported medication adherence at Months 6 and 12|Change in self-reported diabetes self-management at Months 6 and 12|Change in self-reported sleep quality at Months 6 and 12|Change in self-reported work productivity and daily activity impairment at Months 6 and 12|Change in self-reported health utility index at Months 6 and 12|Incremental cost-effectiveness ratios based on HbA1c at Month 12|Incremental cost-effectiveness ratios based on QALY at Month 12","Duke-NUS Graduate Medical School|National Medical Research Council (NMRC), Singapore|SingHealth Polyclinics|Singapore General Hospital|Changi General Hospital","All","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","339","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","HSRGDB16Dec003","October 19, 2019","April 2022","April 2022","January 11, 2019",,"May 18, 2020","Duke-NUS Medical School, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03800680"
452,"NCT04052815","Community Based DPP Program for Hispanic/Latino Females",,"Recruiting","No Results Available","Pre Diabetes|Obesity","Behavioral: Diabetes prevention program culturally tailored","Change from Baseline Weight at 12 month|Change from Baseline waist circumference at 12 months|Change from Baseline Glycated hemoglobin at 12 months|Change from Baseline low density lipoprotein (LDL) at 12 months|Change from baseline High-density lipoprotein (HDL) at 12 months|Dietary assessment for fruits and vegetables|Dietary assessment of fat consumption","Loyola University","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","212259","January 1, 2020","December 30, 2020","April 30, 2021","August 12, 2019",,"February 21, 2020","Quinn Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04052815"
453,"NCT03918525","Diabetes In Sindhi Families In Nagpur (DISFIN)","DISFIN","Completed","No Results Available","Diabetes Mellitus, Type 2","Other: Sindhi families","Type 2 diabetes|Insulin resistance|Hypertension|Obesity|Central obesity|Dyslipidemia","Lata Medical Research Foundation, Nagpur","All","20 Years and older   (Adult, Older Adult)",,"1462","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","RPC#23A","February 20, 2017","February 20, 2018","February 20, 2018","April 17, 2019",,"April 17, 2019","Lata Medical Research Foundation, Nagpur, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03918525"
454,"NCT04198935","Evaluating a Digital Diabetes Education Program",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Device: Span Health Mobile Application","Change in weight|Blood pressure|Hemoglobin A1C (HbA1C) level|Lipid profile|Participant's experience|Adherence to the the program","Adam Bataineh|Span Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0000001","May 2020","July 2020","August 2020","December 13, 2019",,"December 23, 2019",,,"https://ClinicalTrials.gov/show/NCT04198935"
455,"NCT04132089","Mobile Health Application for Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Behavioral: capABILITY","20 participants baseline self-efficacy score will be measured at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.|20 participants baseline diabetes knowledge score will be measure at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.|20 participants baseline diabetes self-management score will be measured at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.|Participants will login and use capABILITY quicker (time measured in seconds) after receiving a behavioral trigger message than those participants who don't receive a behavioral trigger.|Participants who receive a Spark trigger message will login and use capABILITY quicker (time measured in seconds) than those participants who receive Facilitator trigger message.","University of South Alabama","All","21 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","1122","January 1, 2015","January 1, 2017","April 1, 2017","October 18, 2019",,"October 18, 2019",,,"https://ClinicalTrials.gov/show/NCT04132089"
456,"NCT04034511","Food and Education Effects on Diabetes Study","FEED","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: Medically-tailored meal delivery and medical nutrition therapy","Change in hemoglobin A1c|Change in Hemoglobin A1c","Johns Hopkins University|Moveable Feast|Priority Partners MCO|Leonard & Helen R. Stulman Charitable Foundation|France-Merrick Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00200526","January 21, 2020","September 2020","March 2021","July 26, 2019",,"January 28, 2020","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04034511"
457,"NCT04068805","Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Happify","Change in Positive Affect [Quality of Life in Neurological Disorders, Positive Affect and Well-being (Neuro-QOL)]|Change in Positive Affect [Patient-Reported Outcomes Measurement Information System (PROMIS) positive affect subscale]|Self-reported HbA1C levels|Change in Depression symptoms (PHQ-9 questionnaire)|Change in Depression symptoms (CES-D questionnaire)|Change in Diabetes distress [Diabetes distress scale (DDS)]|Diabetes self-care adherence [Summary of Diabetes Self-Care Adherence (SDSCA)]|Perceived Stress (Perceived Stress Scale)","Happify Inc.|Northwestern University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","450","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","7","February 1, 2020","May 2020","June 2020","August 28, 2019",,"January 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04068805"
458,"NCT03971838","Diabetes Prevention Programming for Women With a History of Gestational Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Positive Outcomes for Women","Enrollment and participation rates in a diabetes prevention intervention|HbA1c|BMI","Indiana University","Female","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1812789354","June 1, 2019","June 2021","June 2022","June 3, 2019",,"August 7, 2019","Riley Hospital for Children, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03971838"
459,"NCT03821662","OT-Led Interdisciplinary Diabetes Self-Management Prgm",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Diabetes Mellitus","Behavioral: OT Diabetes Self-Management Intervention","Change from Baseline Glycated hemoglobin (HbA1C)|Canadian Occupational Therapy Measure (COPM)|Change from Baseline Patient-Reported Outcomes Measurement Information SystemⓇ (PROMIS) 29|Change from Baseline Diabetes Empowerment Scale (DES-SF)|Change from Baseline Medication Adherence Assessment Scale","Arizona State University|Hand Therapy Partners","All","18 Years and older   (Adult, Older Adult)","Not Applicable","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00009334","April 11, 2019","July 30, 2019","July 30, 2019","January 30, 2019",,"June 9, 2020","Hand Therapy Partners, Mesa, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03821662"
460,"NCT04160078","Mindfulness IN-home for Diabetes and Sleep Health","MINDS","Suspended","No Results Available","Diabetes|Diabetes Mellitus, Type 2","Behavioral: Mindfulness-based stress reduction (MBSR) Intervention","Change in average nightly sleep duration from baseline|Change in sleep timing from baseline|Change in sleep quality from baseline|Change in average high-density lipoproteins (HDL) Cholesterol from baseline|Change in triglycerides from baseline|Change in fasting blood glucose|Change in hemoglobin A1c (HbA1c) from baseline|Change in Blood pressure from baseline|Change in C-reactive protein from baseline","Emory University|Georgia Center for Diabetes Translation Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00112861|P30DK111024","December 18, 2019","May 2020","May 2020","November 12, 2019",,"May 4, 2020","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04160078"
461,"NCT04131257","Nurse-led Continuum of Care for People With Diabetes and Pre-diabetes in Nepal","NUCOD","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Nurse-led Continuum of Care","Change in Glycated Hemoglobin (HbA1c) level|Change in the incidence of diabetes among individuals with pre-diabetes|Change in Blood Pressure|Change in lipid profile levels (HDL, LDL, Triglycerides, Total cholesterol)|Change in Body Mass Index|Change in the ""Reach"" of people participating in the program|Change in the ""Adoption at the patient level"" measured by the Summary of Diabetes Self-Care Activities Scale|Change in the ""Adoption at the patient level"" measured by the Diabetes Treatment Satisfaction Questionnaire|Change in the ""Adoption at the clinic level""","Kathmandu University School of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1236","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","KathmanduUSMS","December 2019","December 2020","December 2020","October 18, 2019",,"October 18, 2019",,,"https://ClinicalTrials.gov/show/NCT04131257"
462,"NCT04213651","A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Diabetes Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus|Diabetes Mellitus, Type 2","Other: No intervention","Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing","ProgenaBiome","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ProgenaBiome-032","March 2, 2020","March 2023","July 2023","December 30, 2019",,"March 6, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04213651"
463,"NCT03826290","Evaluation of a Dashboard for Diabetes Care Integrated With the Electronic Health Record",,"Recruiting","No Results Available","Diabetes Mellitus|Diabetes Mellitus, Type 2","Other: EHR-integrated diabetes dashboard","Per-patient change in Hemoglobin A1c (HbA1c) levels from beginning to end of evaluation period|Per-patient change in body mass index (BMI) from beginning to end of evaluation period|Cost of diabetes medications prescribed","University of Utah|Hitachi, Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","17000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UUtah_00109162","January 9, 2019","January 2020","May 2020","February 1, 2019",,"February 1, 2019","University of Utah Health, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03826290"
464,"NCT03999268","Insulin Start Therapy Application With Resources and Training","I-START","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: I-START|Behavioral: Standard Insulin Administration Education","Change from baseline in psychological insulin resistance at 2 weeks|Change from baseline in psychological insulin resistance at 3 months|Change from baseline in psychological insulin resistance at 6 months|Change from baseline in glycemic control at 3 months|Change from baseline in glycemic control at 6 months|Change from baseline in medication adherence at 3 months|Change from baseline in medication adherence at 6 months|Change from baseline in diabetes empowerment at 3 months|Change from baseline in diabetes empowerment at 6 months|Change from baseline in diabetes distress at 3 months|Change from baseline in diabetes distress at 6 months|Patient Satisfaction|Provider Satisfaction","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY19040017","November 25, 2019","December 31, 2020","December 31, 2020","June 26, 2019",,"December 17, 2019","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03999268"
465,"NCT04016012","Overweight and Obesity in Relation to Type ll Diabetes Melitus",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Overweight and Obesity","Dietary Supplement: Local Zambian Foods","Change in Blood glucose levels|Change in Body weight|Change of Body Mass Index (BMI)","Mukuba University|University of Zambia|Afe Babalola University, Nigeria|National Food and Nutrition Commission, Zambia|University of Ghana|Sokoine University of Agriculture|Kitwe Teaching Hospital, Zambia","All","18 Years to 55 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MU0619","January 5, 2020","June 5, 2020","June 15, 2020","July 11, 2019",,"July 11, 2019","Kitwe Teaching Hospital, Kitwe, Copperbelt, Zambia",,"https://ClinicalTrials.gov/show/NCT04016012"
466,"NCT03930758","Preventing Diabetic Osteoporosis With Exercise","DIABETICBONE","Completed","No Results Available","Diabetes Mellitus, Type 2","Combination Product: Behavior intervention of uphill exercise|Combination Product: Dietary intervention of exercise before the meal|Combination Product: Dietary intervention of uphill exercise|Combination Product: Dietary intervention of exercise after the meal|Combination Product: Behavior intervention of downhill exercise|Combination Product: Behavioral intervention of downhill exercise|Combination Product: Behavioral intervention of sedentary no-exercise trial|Combination Product: Dietary intervention of eating two meals","C-terminal propeptide of type I collagen|C-terminal telopeptide of type 1 collagen|Osteocalcin|Bone-specific alkaline phosphatase|Insulin|Parathyroid hormone|Cortisol|Growth hormone|Glucose|Dual-energy X-ray radiography|Novel Pedar","University of Michigan|University of Wisconsin, La Crosse|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","50 Years to 65 Years   (Adult, Older Adult)","Not Applicable","15","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HUM32227/ HUM32700|R15DK082800|M01RR024986","October 8, 2009","December 5, 2012","December 20, 2012","April 29, 2019",,"April 29, 2019",,,"https://ClinicalTrials.gov/show/NCT03930758"
467,"NCT03842475","Who Will Benefit From Bariatric Surgery for Diabetes?",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Obesity","Procedure: Roux-en-Y gastric bypass (RYGB)","Diabetes remission (partial or complete)|Diabetes remission (complete)|Waist circumference, waist/hip ratio (cm)|Body mass index (kg/m2)|Weight loss|Change in visceral adipose tissue|Change in ectopic fat","Imperial College London|National Institute for Health Research, United Kingdom","All","18 Years to 80 Years   (Adult, Older Adult)",,"210","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRAS:231300","October 1, 2018","December 1, 2021","June 5, 2028","February 15, 2019",,"February 15, 2019","Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03842475"
468,"NCT04125784","Lipid Profile and Diabetes Mellitus in People With HIV",,"Not yet recruiting","No Results Available","HIV Infections|Dyslipidemias|Diabetes Mellitus|Cardiovascular Risk Factor",,"Changes in dyslipidemia prevalence from baseline - total cholesterol|Changes in dyslipidemia prevalence from baseline- triglycerides|Changes in dyslipidemia prevalence from baseline - HDL-cholesterol|Changes in dyslipidemia prevalence from baseline - Apolipoprotein B|Changes in dyslipidemia prevalence from baseline - LDL-cholesterol|Changes in dyslipidemia prevalence from baseline - Non-HDL-Cholesterol|Changes from baseline in diabetes mellitus type II prevalence|Description of risk profile for cardiovascular events in the sample population|Changes from baseline in drug utilization for PLWHIV|Prevalence of diabetes mellitus type 2 in correlation to the prescribed antiretroviral regime during the follow up time|Changes from baseline in the lipid profile of patients in correlation to prescribed antiretroviral regime|Changes from baseline in therapy prescriptions of patients who were found to have hyperlipidaemia during first study in 2014|Documentation of any major cardiovascular events (stroke or heart attack)|Incidence of diabetes mellitus type 2 in patients who were diagnosed found to be insulin resistant in the first study in 2014|Changes from baseline in therapeutic regimes within those patients who were identified as having diabetes mellitus type 2 in the first study in 2014","Igor Grabovac|Merck Gesellschaft mbH, Austria|Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)",,"450","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","V2_02082019","September 7, 2020","September 30, 2021","January 30, 2022","October 14, 2019",,"June 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04125784"
469,"NCT03877523","Cocarnit Effects on Macrophages Polarization","COMP-DM","Completed","No Results Available","Diabetes Mellitus, Type 2|Diabetes Complications","Dietary Supplement: Cocarnit","Change in macrophages activation after single Cocarnit administration|Change in macrophages activation after 30-days Cocarnit administration","Institute for Atherosclerosis Research, Russia","All","Child, Adult, Older Adult","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IAR-CS1","October 3, 2018","November 18, 2018","December 20, 2018","March 15, 2019",,"March 21, 2019","Institute for Atherosclerosis Research, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03877523"
470,"NCT04198948","Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers","INTERGLIKOM","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Omeprazole|Drug: Placebo oral tablet|Drug: Gliclazide","Gliclazide AUC|Glucose|Insulin","University of Sarajevo|General Hospital Prim. Dr. Abdulah Nakas|University of Dundee","Male","18 Years to 30 Years   (Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","0101-3678/18","March 4, 2019","August 5, 2019","August 5, 2019","December 13, 2019",,"February 5, 2020","General Hospital Prim. Dr. Abdulah Nakas, Sarajevo, Bosnia and Herzegovina",,"https://ClinicalTrials.gov/show/NCT04198948"
471,"NCT04180813","Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Linagliptin|Drug: Acarbose","Proportion of T2DM patients with high medication adherence with MMAS-8 questionnaire|The effectiveness of linagliptin and acarbose on glycemic control evaluated by reducing HbA1c during a 24 week follow-up in two groups|Proportion of T2DM patients achieving a therapeutic glycemic response defined as HbA1c < 7.0% or a lowering of HbA1c ≥ 0.5%|To compare the composite endpoint (proportion of achieving HbA1c < 7.0% without gastrointestinal adverse events (GI AEs) and without an investigator defined hypoglycaemic event)|Patient satisfaction by Diabetes Treatment Satisfaction Questionnaire (DTSQ) among linagliptin and acarbose initiators. The DTSQ would be completed at routine physician visits since initiation of the drug","Boehringer Ingelheim","All","18 Years to 80 Years   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1218-0184","March 4, 2020","June 30, 2021","June 30, 2021","November 29, 2019",,"June 11, 2020","Civil Aviation General Hospital, Beijing, China|No.731 Hospital of China Aerospace Science & Industry Corp., Beijing, China|Dongying People's Hospital, Dongying, China|Zhangjiagang First People Hospital, Suzhou, China",,"https://ClinicalTrials.gov/show/NCT04180813"
472,"NCT04135287","Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: GLP-1 receptor agonist","HbA1c|Beta cell function|Weight loss|Fasting Plasma Glucagon","Dasman Diabetes Institute","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 4","315","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RA HM-2019-004","March 1, 2020","March 1, 2023","July 15, 2023","October 22, 2019",,"February 17, 2020","Dasman Diabetes Institute, Kuwait, Kuwait",,"https://ClinicalTrials.gov/show/NCT04135287"
473,"NCT04094649","Acute Study of Effect of Ultrasound Vagus Nerve Stimulation on Glycemia",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Device: Ultrasound Vagus Nerve Stimulation (DECIMA)","Change in blood glucose Area Under the Curve (AUC, mg/dL ● hours) from baseline to 3 hours after an Oral Glucose Tolerance Test (OGTT) with Ultrasonic Vagus Nervous Stimulation (uVNS).hyperglycemia|Change in whole blood lipospolysaccharide-induced TNF-Alpha (pg/mL) production from base line to 4 hours post stimulation.","Aucta Technologies, Inc.|STATKING Clinical Services","All","21 Years to 60 Years   (Adult)","Not Applicable","10","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Device Feasibility","AT-C-19-01","August 1, 2019","January 2020","February 2020","September 19, 2019",,"September 19, 2019","Synexus, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04094649"
474,"NCT04093284","Evaluation of Efficacy and Safety of Insulin Glargine Injected by Needle-free Jet Syringe",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Device: The needle-free jet injector","Blood glucose profile|Sensitivity Questionnaire of Patients","Nanjing First Hospital, Nanjing Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY20190823-01","September 12, 2019","October 20, 2019","October 30, 2019","September 18, 2019",,"September 18, 2019",,,"https://ClinicalTrials.gov/show/NCT04093284"
475,"NCT04065581","Bioequivalence Study for Acarbose/Metformin FDC",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: Acarbose/Metformin FDC(BAY81-9783)|Drug: Glucobay|Drug: Glucophage","RatioCmax (serum glucose)|RatioAUC(0-4) (serum glucose)|Cmax (plasma metformin)|AUC (0-tlast) (plasma metformin)|AUC (plasma metformin)|Frequency of TEAE (treatment-emergent adverse event）","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","19843","October 14, 2019","November 25, 2019","March 6, 2020","August 22, 2019",,"April 13, 2020","Zhongshan Hospital, Fudan University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04065581"
476,"NCT03990844","Glycemic Evaluation of Okra Seed Noodles",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: Okra seed","Change in glucose response|Change in insulin response|Change in ghrelin level|Change in glucagon-like peptide 1 (GLP-1) level|Change in satiety rating","National University, Singapore|National University Health System","All","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2018/00964","January 12, 2019","December 30, 2020","December 30, 2020","June 19, 2019",,"February 26, 2020","National University of Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03990844"
477,"NCT03989908","Effects of Microfluidic Noodle on Blood Glucose Levels of Healthy Volunteers.",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: Microfludic noodle|Other: Control noodle","Change in glucose response|Change in insulin response|Change in ghrelin level|Change in glucagon-like peptide 1 (GLP-1) level|Change in satiety rating","National University, Singapore|National University Health System","All","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2018/01062","January 13, 2019","December 30, 2019","December 30, 2019","June 18, 2019",,"June 18, 2019","National University of Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03989908"
478,"NCT03985566","Effects of Fixed Meals With Special Formulated Rice on Blood Glucose Levels of Healthy Volunteers.",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Dietary Supplement: Fibre Grain|Dietary Supplement: Jasmine white rice","Change in glucose response|Change in insulin response|Change in ghrelin level|Change in glucagon-like peptide 1 (GLP-1) level|Change in satiety rating|Change in glucose trajectories over 14 days of continous glucose monitoring","National University, Singapore|Alchemy Foodtech Pte Ltd","All","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2017/01126","July 3, 2018","December 30, 2020","December 30, 2020","June 13, 2019",,"February 26, 2020","National University of Singapore, Singapore, Singapore","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03985566/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03985566"
479,"NCT03970044","Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Exenatide 2 MG|Drug: Dapagliflozin 10 MG","MAGE|Fasting Plasma Glucose|HbA1c|Weight|Blood Pressure|Blood Glucose Variability|24 Hour Mean Blood Glucose|Blood Glucose Time In Range","Consano Clinical Research, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WCCR-2019-1","June 2019","June 2022","June 2022","May 31, 2019",,"June 3, 2019",,,"https://ClinicalTrials.gov/show/NCT03970044"
480,"NCT03957811","Effect of Whole-body Vibration on TcPO2","WBV","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: Whole body Vibration exercise","Effect of whole body vibration on TcPO2 levels","Instituto Nacional de Rehabilitacion|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","40 Years to 69 Years   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2416|2234","April 4, 2017","December 20, 2019","June 2020","May 21, 2019",,"August 26, 2019","Instituto Nacional de Rehabilitacion, Mexico City, DF, Mexico",,"https://ClinicalTrials.gov/show/NCT03957811"
481,"NCT03923114","Imaging Pituitary ActiVation by Exendin","iPAVE","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Radiation: Ga-68-NODAGA-exendin-4 PET/CT","Pituitary uptake of Ga-68-NODAGA-exendin|Metabolic status (OGTT)|Metabolic status (ACTH)","Radboud University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","NL67316.091.18","May 23, 2019","May 1, 2020","May 1, 2020","April 22, 2019",,"September 23, 2019","Radboud university medical center, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03923114"
482,"NCT03921203","ApoB48 Metabolism in Plasma and Interstitial Fluid",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2",,"ApoB48 levels in blood and interstitial fluid","Karolinska University Hospital","All","18 Years and older   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","ApoB48IC2","April 17, 2019","June 1, 2020","December 31, 2021","April 19, 2019",,"April 19, 2019","Patient research centre, Clinic of endocrinology, Karolinska University Hospital, Stockholm, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT03921203"
483,"NCT03907423","Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Rosuvastatin10 mg tablet|Drug: Placebo Oral Tablet","serum levels of fetuin A|serum levels of Sortilin","Damanhour University","All","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rosuvastatin on diabetics","April 1, 2019","October 1, 2019","November 1, 2019","April 9, 2019",,"April 16, 2019","Damanhour Medical National Institute, Damanhūr, N/A = Not Appُlicable, Egypt",,"https://ClinicalTrials.gov/show/NCT03907423"
484,"NCT03887403","The COMUNICARE Study: the Effectiveness of a Multimodal Intervention Based on Person-centered Communication","COMUNICARE","Completed","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Multimodal Intervention|Other: Usual care","Assess the effectiveness of a complex intervention to improve metabolic control of patients with DM2, as measured through decreases in HbA1c values.|Assess the effectiveness of the intervention to increase adherence to OAD treatment.","Gerencia de Atención Primaria, Madrid|Instituto de Salud Carlos III","All","Child, Adult, Older Adult","Not Applicable","310","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","PI10/00667","March 2016","August 2017","October 2017","March 25, 2019",,"March 25, 2019",,,"https://ClinicalTrials.gov/show/NCT03887403"
485,"NCT03839641","Novel Approach to Assess Metabolic Flexibility in a Respiratory Chamber","METFLEX","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: High fat meal|Other: Low fat meal","change in respiratory quotient","Pennington Biomedical Research Center","All","18 Years to 40 Years   (Adult)","Not Applicable","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","PBRC 2018-029","January 14, 2019","December 31, 2019","December 31, 2020","February 15, 2019",,"March 30, 2020","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03839641/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03839641"
486,"NCT03837262","GLucose Monitoring Programme SingaporeE (GLiMPSE)","GLiMPSE","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Combination Product: Flash Glucose Monitoring and structured education","Recruitment and retention|Questionnaire|HbA1c|DSS questionnaire|EQ-5D-5L Questionnaire|WPAI questionnaire","Singapore General Hospital|KK Women's and Children's Hospital|SingHealth Polyclinics","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GLiMPSE-POC1","March 25, 2019","October 31, 2019","October 31, 2019","February 12, 2019",,"April 5, 2019","Singapore General Hospital, Singapore, Singapore|KKH, Singapore, Singapore|Pasir Ris Polyclinic, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03837262"
487,"NCT03804411","Prognostic Predictors of Response to Hypoglycemic Therapy",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Automatic system guided treatment|Drug: Standard treatment","HbA1c|Body mass index|Estimated glomerular filtration rate|HOMA-IR index|Urinary creatinine-adjusted excretion of albumin|Cardiovascular parameters of PAT and IMT|LDL cholesterol|Triglycerides|NT-proBNP|hsCRP|PAT|IMT|LV ejection fraction|LV mass index|GLS by 2D-STE|Molecular-genetic markers of endothelial damage","Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","11/2017","August 1, 2017","March 2020","May 2020","January 15, 2019",,"February 10, 2020","Alina Babenko, Saint-Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03804411"
488,"NCT04028427","Impact of ACT-based Interventions on Diabetes-related Outcomes",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Behavioral: Values-plus-goals intervention|Behavioral: Mindfulness-based intervention","Change in Diabetes Self-Management Questionnaire|Change in Well-Being Questionnaire|Change in Brief COPE|Change in Diabetes Acceptance Scale|Change in Valued Living Questionnaire|Change in HbA1c level","Sophini Logeswaran|Royal Holloway University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RoyalHollowayU","October 14, 2019","April 30, 2020","July 1, 2020","July 22, 2019",,"May 12, 2020","Ashford and St Peter's Hospitals NHS Foundation Trust, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04028427"
489,"NCT03991299","Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects",,"Not yet recruiting","No Results Available","Obese|Diabetes Mellitus, Type 2","Drug: Botox 200 UNT Injection","Change in body weight at 6 months|Change in body weight at 3 months|Change in body weight at 1 month|Change in glucose tolerance at 6 months|Change in glucose tolerance at 3 months|Change in glucose tolerance at 1 month|Change in insulin tolerance|Change in C-peptide tolerance|Change in ghrelin tolerance|Change in GIP tolerance|Change in GLP-1 tolerance|Change in PP tolerance|Change in PYY tolerance","Vanderbilt University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","181978","February 2, 2020","August 31, 2020","December 31, 2020","June 19, 2019",,"December 18, 2019",,,"https://ClinicalTrials.gov/show/NCT03991299"
490,"NCT03987802","An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Drug: Faster-acting insulin aspart","Adverse Events (AEs)|Serious Adverse Events (SAEs)|Adverse Drug Reactions (ADRs)|Serious Adverse Drug Reactions (SADRs)|Patient reported severe hypoglycaemia|Patient reported Blood Glucose (BG) confirmed (below 56 mg/dl) hypoglycaemia|Patient reported Severe or BG confirmed (below 56 mg/dl) hypoglycaemia|Change in HbA1c","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN1218-4489|U1111-1222-9492","July 15, 2020","July 15, 2021","July 15, 2021","June 17, 2019",,"March 9, 2020",,,"https://ClinicalTrials.gov/show/NCT03987802"
491,"NCT04035395","Salud y Vida 2.0: Enhancing Integrated Behavioral Health for Diabetics in the Rio Grande Valley",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Behavior, Health","Other: Peer-led Support Group|Other: Behavioral Health Consult|Other: Medication Therapy Management Consult|Other: La Cocina Alegre/ The Happy Kitchen|Other: Mind, Exercise, Nutrition, Do it!","Rate of Change in Hemoglobin A1c|Rate of Change in Blood Pressure|Rate of Change in BMI|Rate of Change in Depressive Symptoms|Rate of Change in Quality of Life: Duke Health Profile|Rate of Change in Total Cholesterol|Rate of Change in Self-efficacy: Diabetes Self-Efficacy Scale","The University of Texas Health Science Center, Houston|Health Resources in Action, Inc.","All","18 Years to 74 Years   (Adult, Older Adult)","Not Applicable","353","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","HSC-SPH-16-0044","September 29, 2016","June 13, 2018","June 13, 2018","July 29, 2019",,"August 2, 2019",,,"https://ClinicalTrials.gov/show/NCT04035395"
492,"NCT03875625","Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention",,"Recruiting","No Results Available","Non-Alcoholic Fatty Liver Disease|Obesity, Morbid|Brown Fat|Metabolic Disease|Diabetes Mellitus|Insulin Resistance|Abdominal Subcutaneous Fat","Procedure: Bariatric surgery|Behavioral: Dietitian led life style modification intervention|Behavioral: Conventional care (control)","Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery|Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery 2|Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery- 3|Use of modified Dixon Magnetic Resonance Imaging method to measure the response of adipose tissue in different organs following life style modification program or Bariatric surgery- 4|Use of modified Dixon Magnetic Resonance Imaging method to assess the relationship between Brown Adipose Tissue and Non Alcoholic Fatty Liver Disease|Blood biochemistry for assessing β-cell function and insulin resistance (IR)|Blood biochemistry- 1|Blood biochemistry- 2|Blood biochemistry- 3|Blood biochemistry- 4|Blood biochemistry- 5|Blood biochemistry- 6|Anthropomorphic measurements using measuring tape and weight scale|Anthropomorphic measurements using BP machine","Chinese University of Hong Kong","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","No. 2018.612","March 12, 2019","January 12, 2022","January 12, 2022","March 15, 2019",,"June 11, 2020","The Chinese University of Hong Kong, Prince of Wale Hospital, Hong Kong, Shatin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03875625"
493,"NCT04071626","Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure","EMMED-HF","Not yet recruiting","No Results Available","Heart Failure, Diastolic|Diabetes Mellitus, Type 2","Drug: Ertugliflozin 5 mg|Drug: Placebo oral tablet","Peak VO2, ml/kg/min, as measured by metabolic gas exchange|Left ventricular mass index (gm/m2), as measured by cardiac MRI|Serum ketone bodies (betahydroxybutyrate)","University Hospitals Cleveland Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MISP 58605","October 1, 2019","June 30, 2021","June 30, 2021","August 28, 2019",,"August 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04071626"
494,"NCT04190251","PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program","PANDIA_IRIS","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Renal Insufficiency, Chronic","Other: Inteprofessional medication adherence support program (IMAP)","Medication adherence (longitudinal data)|Clinical outcomes|Medication adherence|Patients' satisfaction","Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland|pharmaSuisse|santésuisse|Curafutura","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PB_2016-01674(454/15)","April 14, 2016","August 30, 2020","October 1, 2022","December 9, 2019",,"December 9, 2019","Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland|Unisante, Lausanne, Vaud, Switzerland",,"https://ClinicalTrials.gov/show/NCT04190251"
495,"NCT04104711","Home-Based Intervention to the Diabetics",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Home Visit","Other: Home visits, health education","Health Belief Model Scale in Patients with Diabetes|Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes|Fasting plasma glucose level (mg/dl)|Postprandial glucose level (mg/dl)|Hemoglobin A1c level (%)|Body mass index (kg/m2)|Blood pressure level (mmHg)|Costs via frequency of complication-related hospital admissions","Dilay AÇIL,PhD|Dokuz Eylul University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","970-GOA, 2014 / 07-20","January 1, 2015","March 30, 2017","July 14, 2017","September 26, 2019",,"September 30, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04104711/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04104711"
496,"NCT04115579","The Impact of Low Glycaemic Index (GI) Biscuits on Postprandial Glycaemia Using the Continuous Glucose Monitoring System (CGMS™) (Biscuit Study (BIS) Study)",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2|Diabetes","Other: Biscuit 1 Control|Other: Biscuit 2 Test","Postprandial glucose|Postprandial insulin","Clinical Nutrition Research Centre, Singapore","Male","21 Years to 40 Years   (Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2018/01066","February 20, 2019","February 28, 2020","February 28, 2020","October 4, 2019",,"January 23, 2020","Clinical Nutrition Research Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04115579"
497,"NCT04150315","Arterial Composition and Cardiovascular Outcome in DIabeteS","ACCODIS","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2|Artery Disease|Protein Deposition","Diagnostic Test: Proteome analysis","Major adverse coronary or cerebral event","University of Southern Denmark|Odense University Hospital|Steno Diabetes Center Odense","All","up to 110 Years   (Child, Adult, Older Adult)",,"763","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SDUSF-2016-70-(605)","June 1, 2018","January 1, 2020","May 31, 2021","November 4, 2019",,"November 4, 2019","University of Southern Denmark / Odense University Hospital, Odense, Funen, Denmark",,"https://ClinicalTrials.gov/show/NCT04150315"
498,"NCT04115592","The Effect of Different States of Lipid in Food on Glycaemia, Lipaemia and Insulinaemia.",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2|Cardiovascular Risk Factor","Other: Cocoa butter|Other: Cocoa butter oleogel|Other: Sal seed oil|Other: Sal seed oleogel","Postprandial triglycerides|Postprandial glucose|Postprandial insulin","Clinical Nutrition Research Centre, Singapore","Male","21 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","2018/01193","February 20, 2019","June 20, 2020","June 20, 2020","October 4, 2019",,"January 22, 2020","Clinical Nutrition Research Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04115592"
499,"NCT04062773","Time-Restricted Feeding on Glucose Homeostasis and Quality of Life",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Time Restricted Feeding","Behavioral: TRF|Behavioral: Normal timing of food intake","HbA1c|Body weight|Insulin sensitivity|Diabetes medications|Inflammatory markers","Dasman Diabetes Institute","All","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RA HM-2019-012","July 10, 2019","March 1, 2020","March 1, 2020","August 20, 2019",,"December 13, 2019","Dasman Diabetes Institute, Kuwait City, Kuwait",,"https://ClinicalTrials.gov/show/NCT04062773"
500,"NCT03985098","Motivational Interviewing (MI) Intervention to Improve Adherence","MI","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Hypertension","Behavioral: Motivational interviewing intervention arm","Adherence measure","University of Houston|National Heart, Lung, and Blood Institute (NHLBI)","All","65 Years and older   (Older Adult)","Not Applicable","500","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","STUDY00000718|R15HL135700-01A1","May 29, 2019","June 2020","June 2021","June 13, 2019",,"June 13, 2019","Omar Serna, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03985098"
501,"NCT04152915","A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens",,"Completed","No Results Available","Healthy Volunteers|Diabetes Mellitus, Type 2","Drug: Semaglutide","AUC0-last,sema,1mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period|Cmax,sema,1mg: Maximum observed semaglutide concentration after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period|AUC0-168h,sema,0.25mg,SS: Area under the semaglutide concentration time curve from time 0 until 168 hours at steady state after the last dose of s.c. semaglutide 0.25 mg administration|Cmax,sema,0.25mg,SS: Maximum observed semaglutide concentration at steady state after the last dose of s.c. semaglutide 0.25 mg administration|AUC0-∞,sema,1mg: Area under the semaglutide concentration time curve from time 0 until infinity after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period|tmax,sema,1mg: Time of maximum observed semaglutide concentration after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period|tmax,sema,0.25mg,SS: Time of maximum observed semaglutide concentration at steady state after the last dose of s.c. semaglutide 0.25 mg administration|t½,sema,1mg: terminal elimination half-life of semaglutide after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period","Novo Nordisk A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN9535-4588|U1111-1235-3506|2019-002588-92","November 25, 2019","May 25, 2020","May 25, 2020","November 5, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Mainz, Germany",,"https://ClinicalTrials.gov/show/NCT04152915"
502,"NCT04016974","A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese",,"Recruiting","No Results Available","Healthy Volunteers|Diabetes Mellitus, Type 2","Drug: Oral semaglutide|Drug: Placebo","AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0−24 hours) at steady state|Cmax,sema,SS, maximum observed semaglutide plasma concentration during a dosing interval (0−24 hours) at steady state|tmax,sema,SS, time to maximum observed semaglutide plasma concentration during a dosing interval (0−24 hours) at steady state|CL/Fsema,SS, total apparent clearance of semaglutide at steady state|Ctrough,sema,SS, trough semaglutide plasma concentration at steady state|t½,sema,SS, terminal half-life of semaglutide at steady state|Vss/Fsema, apparent volume of distribution of semaglutide at steady state|MRTsema,SS, mean residence time of semaglutide at steady state|Rtheor,sema,SS, theoretical accumulation index, which is defined as [1/(1-Exp (-λZ,sema,SS*24h))], where λZ,sema,SS=log(2)/t½,sema,SS|Change in body weight from baseline|Change in fasting plasma glucose from baseline|Number of treatment-emergent adverse events|Number of treatment-emergent hypoglycaemic episodes","Novo Nordisk A/S","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN9924-4303|U1111-1186-6753","October 8, 2019","September 17, 2020","October 27, 2020","July 12, 2019",,"June 9, 2020","Novo Nordisk Investigational Site, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04016974"
503,"NCT04120974","The Role of Proper Insulin Injection Technique in the Treatment of Diabetes. Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Lipohypertrophy","Behavioral: Optimal insulin injection","Change in Glycemic Control|Change in Insulin Total Daily Dose (TDD)|Incidence of Hypoglycemic Events|Change in Blood Glucose Levels","Becton, Dickinson and Company","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DBC-19INJCTRU|BD-4MM","October 1, 2019","June 1, 2020","June 30, 2020","October 9, 2019",,"October 9, 2019","State Healthcare Institution ""Sverdlovsk Regional Clinical Hospital No. 1"" (EKB), Ekaterinburg, Russian Federation|National Medical Research Center of Endocrinology (ENC), Moscow, Russian Federation|Russian Medical Academy of Continuing Professional Education (RMANPO), Moscow, Russian Federation|Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russian Federation|Endocrinological Dispensary of the Moscow Department of Health (DZM), Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04120974"
504,"NCT03908762","mHealth Titration and Management",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Diabetic Complication","Device: iSage App with connected glucometer|Behavioral: Magnet","Change in A1C|A1C in Target|Rate of Hypoglycemia","Amalgam Rx, Inc.|Kansas City Area Life Sciences Institute, Inc.|University of Kansas|LifeScan","All","21 Years to 100 Years   (Adult, Older Adult)","Not Applicable","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00142758","January 1, 2019","December 2019","March 2020","April 9, 2019",,"April 9, 2019","Cray Diabetes Self-Management Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03908762"
505,"NCT04183257","Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics",,"Completed","No Results Available","Vitamin D Deficiency|Insulin Resistance|Diabetes Mellitus, Type 2","Drug: oral vitamin D","Homeostatic Model Assessment of Insulin Resistance|Glycated Hemoglobin (HbA1C)","King Edward Medical University","All","25 Years to 50 Years   (Adult)","Phase 4","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","to be ascertained","September 30, 2016","April 30, 2017","July 30, 2017","December 3, 2019",,"December 3, 2019",,,"https://ClinicalTrials.gov/show/NCT04183257"
506,"NCT04007003","An Audit of the Impact of Tailored Information Delivered Via a Digital Learning Platform",,"Terminated","No Results Available","Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Behavioral: training in optimal insulin injection technique","Change in Insulin Use|Change in Glycemic Control|Incidence of Hypoglycemic Events|Change in Needle Re-Use","Becton, Dickinson and Company","All","18 Years and older   (Adult, Older Adult)","Not Applicable","170","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","LiMo Audit","June 26, 2018","August 10, 2019","August 10, 2019","July 5, 2019",,"December 3, 2019","Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium|Imeldaziekenhuis, Bonheiden, Belgium|Universitair Ziekenhuis Brussel, Brussel, Belgium|UZ Gent, Gent, Belgium|Virga Jesse Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|AZ Turnhout, Turnhout, Belgium|AZ Jan Portaels, Vilvoorde, Belgium",,"https://ClinicalTrials.gov/show/NCT04007003"
507,"NCT03927859","Increasing DR Screening Through TOP: Supporting Implementation and Identifying Opportunities for Scale up in Ontario","TOP","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Other: a mail letter, a phone call and a phone call plus mailed letter","Number of bookings made through the TOP program|Number of self-reported booking made outside of TOP","Women's College Hospital|Canadian Institutes of Health Research (CIHR)|Diabetes Action Canada","All","18 Years and older   (Adult, Older Adult)","Not Applicable","420","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2018-0068-E","July 5, 2018","June 30, 2019","August 30, 2019","April 25, 2019",,"April 25, 2019","Black Creek Community Health Centre, Toronto, Ontario, Canada|Women's College Hospital Family Health Team, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03927859"
508,"NCT03867942","BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Dyslipidemias","Drug: Monolayer group|Drug: Bilayer group","Gemigliptin AUC|Rosuvastain AUC|Rosuvastain Cmax|Gemigliptin Cmax","LG Chem","All","19 Years to 45 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LG-GSCL006","March 21, 2019","May 24, 2019","August 31, 2019","March 8, 2019",,"March 8, 2019",,,"https://ClinicalTrials.gov/show/NCT03867942"
509,"NCT03792321","Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients"" (SETH2)","SETH2","Completed","No Results Available","Hypogonadism, Male|Diabetes Mellitus, Type 2|Obesity","Drug: Testosterone Undecanoate|Drug: Placebo","Effects of testosterone replacement therapy on glycemic control - fasting plasma glucose (FPG) mmol/l|Effects of testosterone replacement therapy on glycemic control - glycated hemoglobin A1c (HbA1c) %|Effects of testosterone replacement therapy on parameters of metabolic syndrome - change in HOMA-IR|Effects of testosterone replacement therapy on vascular function - change in flow mediated dilatation (FMD) %|Effects of testosterone replacement therapy on vascular morphology - intima-media thickness (IMT)|Effects of testosterone replacement therapy on non-alcoholic fatty liver disease (NAFLD)|Effects of testosterone replacement therapy on bone mineral density (BMD)|Effects of testosterone replacement on total testosterone (TT), calculated free testosterone (cFT), and calculated bioavailable testosterone (BT) concentrations|Effects of testosterone replacement on prostate specific antigen (PSA)|Effects of testosterone replacement on hematocrit","University Medical Centre Ljubljana","Male","35 Years and older   (Adult, Older Adult)","Phase 4","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SBCE-KG-2014-1","January 10, 2014","March 5, 2015","March 5, 2018","January 3, 2019",,"January 4, 2019",,,"https://ClinicalTrials.gov/show/NCT03792321"
510,"NCT03814512","Improving Insulin Resistance and Energy Metabolism Through Sleep Extension in Adolescents","REM","Recruiting","No Results Available","Sleep|Diabetes Mellitus, Type 2","Behavioral: Extended Sleep Intervention","Change in Total Sleep Time","University of Colorado, Denver","All","13 Years to 19 Years   (Child, Adult)","Not Applicable","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18-2396","March 21, 2019","December 31, 2020","December 31, 2020","January 24, 2019",,"December 18, 2019","Children's Hospital Colorado, Lafayette, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03814512"
511,"NCT03946631","GDM Post Partum Screening",,"Recruiting","No Results Available","Diabetes|Gestational Diabetes|Diabetes Mellitus, Type 2","Diagnostic Test: 2 hour glucose tolerance test using 75g glucose drink","Sensitivity of early postpartum overt diabetes screening by 2-hour glucose tolerance testing in postpartum women.","Mednax Center for Research, Education, Quality and Safety|Banner University Medical Center","Female","18 Years to 60 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GDM 2019 iris 01-18-0028","August 20, 2019","June 1, 2021","September 1, 2021","May 10, 2019",,"August 22, 2019","Banner - University Medical Center Phoenix, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03946631"
512,"NCT03806920","Isomaltulose VS Sucrose - Postprandial Effect on Incretin Profile and Second Meal Effect",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Metabolic Syndrome","Dietary Supplement: Intervention A|Dietary Supplement: Intervention B|Dietary Supplement: Intervention C|Dietary Supplement: Intervention D","disposition index|insulinogenic index|hepatic insulin extraction|incretin response|inflammatory reaction|Lipid status|additional endocrine parameters","German Institute of Human Nutrition|Beneo GmbH","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","PALA","November 5, 2016","March 31, 2019","March 31, 2019","January 16, 2019",,"March 5, 2019","German Institute of Human Nutrition, Potsdam, Brandenburg, Germany",,"https://ClinicalTrials.gov/show/NCT03806920"
513,"NCT04076995","INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers","INDIGO-2","Completed","No Results Available","Dehydration|Diabetes Mellitus, Type 2","Other: Water Intake","Area under the curve of Glucose at lunch|Area under the curve of Glucose at Dinner|Area under the curve of Glucose for the entire experiment|Area under the curve of Copeptin for the entire experiment|Area under the curve of Glucagon at lunch|Area under the curve of Glucagon at dinner|Urinary glucose excretion|Area Under the Curve for Plasma osmolality|Area under the curve of Insulin at lunch|Area under the curve of Insulin at dinner|Area under the curve of Glucagon like peptide 1 at dinner|Area under the curve of Glucagon like peptide 1at lunch|Area under the curve of plasma cortisol|Area under the curve for Thirst rating|Mood assessment with a questionnaire","Arizona State University","All","30 Years to 55 Years   (Adult)","Not Applicable","7","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00010276","September 18, 2019","December 19, 2019","December 19, 2019","September 4, 2019",,"February 11, 2020","Arizona Biomedical Collaborative, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04076995"
514,"NCT04012983","Possible Role of Gingival Crevicular Fluid Levels of Chemerin and Fibroblast Growth Factor 21 as Biomarkers of Periodontal Disease in Diabetic and Non-diabetic Patients",,"Completed","No Results Available","Periodontal Disease (Diagnosis)|Diabetes Mellitus, Type 2","Diagnostic Test: gingival crevicular fluid level","measurement of the level of FGF21 (pg/ml) in gingival crevicular fluid of diabetic patients with periodontitis|measurement of the level of FGF21 (pg/ml) in gingival crevicular fluid of periodontitis patients|measurement of the level of FGF21 (pg/ml) in gingival crevicular fluid of healthy controls|measurement of the level of chemerin (ng/ml) in gingival crevicular fluid of diabetic patients with periodontitis|measurement of the level of chemerin (ng/ml) in gingival crevicular fluid of periodontitis patients|measurement of the level of chemerin (ng/ml) in gingival crevicular fluid of healthy controls","Cairo University","All","35 Years to 60 Years   (Adult)",,"45","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","chemerin and FGF21","March 1, 2018","August 1, 2018","September 1, 2018","July 9, 2019",,"July 16, 2019","Faculty of Dentistry, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04012983"
515,"NCT03805412","Continuous Glucose Monitoring in Diabetes and Prediabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|PreDiabetes|Obesity","Device: DEXCOM G6 RT-CGM","BMI|waist circumference|Body Fat Percentage|Questionnaire: Perception continuous glucose monitoring(CGM)|Effect of real-time continuous glucose monitoring on glycemic variability|Mean glucose|food frequency|physical activity","Nicole Ehrhardt, MD|DexCom, Inc.|George Washington University","All","18 Years to 55 Years   (Adult)","Not Applicable","45","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","180609","January 10, 2019","June 2020","June 2020","January 15, 2019",,"February 6, 2020","GWU Medical Faculty Associates, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT03805412"
516,"NCT03976271","Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses","HCIR","Recruiting","No Results Available","Hypoglycemia|Inflammatory Response|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Procedure: hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp","Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA|Atherogenic responses of (recurrent) hypoglycaemia using foam cell formation.|Metabolomics profile of each group|Epigenetic modifications|Cardiac function responses to hypoglycaemia using echocardiography|Cognitive function responses to hypoglycaemia using cognitive function tests (TAP, PASAT)|Oxidative stress responses using oxidative stress marker","Radboud University|Rigshospitalet, Denmark","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","112","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HCIR","August 12, 2019","October 4, 2020","December 4, 2020","June 6, 2019",,"April 22, 2020","Nordsjællands University Hospital, Hillerød, Nordsjaelland, Denmark|Radboudumc, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03976271"
517,"NCT04119167","Use of GDF15 as a Biomarker for Early Diagnosis of DM and Monitoring of Progress of Complications in Asians",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Diabetic Polyneuropathy|Diabetic Nephropathies",,"Level of GDF15|Complication of diabetes|Level of glycated hemoglobin (HbA1c)|Level of fasting blood sugar","Chang Gung Memorial Hospital","All","20 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","201900948B0","August 1, 2019","July 30, 2021","October 30, 2021","October 8, 2019",,"October 8, 2019","Chang Gung Memorial Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT04119167"
518,"NCT04068272","Safety of Bosentan in Type II Diabetic Patients","BOSRET","Suspended","No Results Available","Diabetes Mellitus","Drug: Bosentan|Drug: Placebo","Epitheliopathy|Presence of ocular discomfort|Anterior segment inflammation","Retinset SL|Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","22","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IOBA-02-2016","September 7, 2019","December 31, 2020","December 31, 2020","August 28, 2019",,"May 21, 2020","Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|IOBA, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04068272"
519,"NCT03868683","The Glycemic Effect of Added Sugar on Bake Beans","GIF","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2|Obesity|PreDiabetes","Other: Glucose Reference 1|Other: Glucose Reference 2|Other: Glucose reference 3|Other: Sucrose|Other: Regular Bake beans in tomato sauce|Other: Bake beans in tomato sauce, reduced sugar|Other: Bake beans in tomato sauce, low GI","Glucose [|Insulin","Clinical Nutrition Research Centre, Singapore","Male","21 Years to 60 Years   (Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2016/00926","August 20, 2018","December 31, 2019","December 31, 2019","March 11, 2019",,"March 11, 2019","Clinical Nutrition Research Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03868683"
520,"NCT04051008","CTSI Pilot: Improving Adherence to Diabetic Diet",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Diet, Healthy|Pre-diabetes","Behavioral: Online - use of online grocery shopping platform|Behavioral: Default - use of online grocery shopping platform with default shopping carts","Calories purchased|Change in calories purchased|Carbohydrates purchased|Change in carbohydrates purchased|Sugars purchased|Change in sugars purchased|Nutritional quality of purchases|Change in nutritional quality of purchases|Dollars spent|Change in dollars spent|Nutritional quality of foods consumed","State University of New York at Buffalo","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","STUDY00003054|1154678","October 14, 2019","December 31, 2020","December 31, 2020","August 9, 2019",,"May 1, 2020","State University of New York at Buffalo, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04051008"
521,"NCT03908125","Post Approval Study of the Eversense® Continuous Glucose Monitoring","PAS","Recruiting","No Results Available","Diabetes Mellitus|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Device: Eversense® CGM system","Incidence of procedure-related adverse events|Time in Range","Senseonics, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CTP-0034","March 19, 2019","March 2023","March 2023","April 9, 2019",,"March 4, 2020","Hoag Memorial Hospital Presbyterian/Mary Dick Allen Diabetes Center, Newport Beach, California, United States|Denver Endocrinology, Diabetes & Thyroid Center, Englewood, Colorado, United States|The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|MODEL Clinical research, Baltimore, Maryland, United States|Metro Detroit Endocrinology Center, Dearborn, Michigan, United States|Diabetes and Endocrinology Specialists, Inc., Chesterfield, Missouri, United States|Albany Medical College, Albany, New York, United States|Physicians East, Greenville, North Carolina, United States|Wilmington Health/PMG, Wilmington, North Carolina, United States|Diabetes & Endocrinology Consultants of Pennsylvania, LLC, Feasterville, Pennsylvania, United States|AM Diabetes & Endocrinology, Bartlett, Tennessee, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|Javara, Inc., Houston, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States|Consano Clinical Research, Diabetes and Metabolism Specialists, Shavano Park, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03908125"
522,"NCT03808376","PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days","PROMISE","Active, not recruiting","No Results Available","Diabetes Mellitus|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Device: Continuous Glucose Monitoring System","Effectiveness Measure - mean absolute relative difference (MARD)|Safety Endpoint - Incidence of device-related or sensor insertion/removal procedure-related serious adverse","Senseonics, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","181","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CTP-0036","December 27, 2018","March 2020","March 2020","January 17, 2019",,"December 18, 2019","John Muir Physician Network Clinical Research Center, Concord, California, United States|AMCR Institute Inc., Escondido, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Atlanta Diabetes Care, Atlanta, Georgia, United States|Rocky mountain Diabetes Center C/O Research Department, Idaho Falls, Idaho, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Rainier Clinical Research Center, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03808376"
523,"NCT03891056","Metabolic Surgery; Gastric Bypass vs Sleeve Gastrectomy; Efects Over Type 2 DM With Bad Metabolic Control (MSO1CT)","MSO1CT","Recruiting","No Results Available","Diabetes Mellitus|Metabolic Surgery|Sleeve Gastrectomy|BPGY","Procedure: metabolic surgery","Number of participans with normal glycosylated hemoglobin levels|Number of participants with partial remission or improvement of diabetes|Comparison of weight loss between the two techniques; bypass and sleeve.|Evaluation of postoperative complications in patients undergoing bypass and slevee with Clavien-Dindo classification.|Comparison postoperative pain in sleeve and bypass with analogue assessment scale of postoperative pain.","Hospital Universitario Doctor Peset","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MSO1CT","January 15, 2019","January 2021","January 2022","March 26, 2019",,"March 26, 2019","Department of General and Digestive Surgery of the Dr. Peset Hospital, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03891056"
524,"NCT04161859","Use of Nutraceuticals in Clinical Practice",,"Recruiting","No Results Available","Dyslipidemias|Diabetes Mellitus, Type 2|Hypertension","Dietary Supplement: Nutraceutical","Prevalence of the use of nutraceutical in clinical practice","University of Pavia","All","18 Years to 75 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","P-20160020534","May 1, 2017","December 31, 2019","March 1, 2020","November 13, 2019",,"November 13, 2019","IRCCS Policlinico San Matteo, Pavia, Lombardy, Italy",,"https://ClinicalTrials.gov/show/NCT04161859"
525,"NCT04094064","Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).",,"Recruiting","No Results Available","Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Device: Continuous Glucose Monitor","Mean Absolute Relative Difference between CGM value and capillary blood glucose|Duration of Hemodialysis|Volume removed during hemodialysis therapy|Basic Metabolic Panel prior to hemodialysis session|Medications|Daily Weights","University of Virginia|DexCom, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","HSR190012","February 19, 2020","May 2020","May 2020","September 18, 2019",,"February 26, 2020","Meaghan Stumpf, MD, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04094064"
526,"NCT03821961","18F-FDOPA PET/CT Imaging in Patients Undergoing Metabolic Surgery",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|PreDiabetes|Obesity","Procedure: Metabolic Surgery","Change in Uptake value of 18F-FDOPA PET/CT from baseline|Change in Glycated Hemoglobin from baseline|Change in Fasting Plasma Glucose from baseline|Changes in c-peptide level from baseline|Changes in Insulinogenic index from baseline|Changes in HOMA-IR(homeostatic model assessment for insulin resistance) from baseline|Changes in Matsuda index from baseline|Change in Body Mass Index (BMI) from baseline|Change in Systolic Blood Pressure from baseline|Change in serum level of HDL cholesterol from baseline|Change in serum level of Triglycerides from baseline|Change in serum level of LDL cholesterol from baseline|Change in serum level of Total Cholesterol from baseline|Change in serum level of High-sensitivity C-reactive Protein|Change in number of diabetes medication from baseline|Change in dosage of diabetes medication from baseline|Change in number of hypertension medication from baseline|Change in dosage of hypertension medication from baseline|Change in number of dyslipidemia medication from baseline|Change in dosage of dyslipidemia medication from baseline|Change in serum level of amino acid metabolites from baseline|Change in BDI scores of questionnaire from baseline|Change in HDRS scores of questionnaire from baseline|Change in SF-36 scores of questionnaire from baseline|Change in IWQOL scores of questionnaire from baseline|Change in MAQOL scores of questionnaire from baseline","Korea University Anam Hospital|Myungmoon Pharma. Co. Ltd.","All","19 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STARDOM-PET","September 3, 2018","November 30, 2020","December 31, 2020","January 30, 2019",,"February 26, 2020","Korea University Anam Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03821961"
527,"NCT04117763","Effect of Empagliflozin on Ventricular Repolarization.","EMPATHYHEART","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Coronary Heart Disease|Arrythmia, Cardiac","Drug: Empagliflozin 25 MG","Arrhythmogenic burden","University of Sao Paulo","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","99613518.9.0000.0068","October 4, 2019","January 31, 2021","January 31, 2021","October 7, 2019",,"April 7, 2020","InCor, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04117763"
528,"NCT04170790","Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy Volunteers",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Erectile Dysfunction With Diabetes Mellitus|Drug Interaction","Drug: Saxagliptin 5mg|Drug: Sildenafil 50 mg","Cmax|(AUC0→∞)|(AUC0→t)|tmax;|T½|Ke|ka|Blood Pressure|Heart Rate","Ain Shams University","Male","18 Years to 45 Years   (Adult)","Not Applicable","18","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","57","December 1, 2019","December 30, 2019","January 30, 2020","November 20, 2019",,"November 20, 2019",,,"https://ClinicalTrials.gov/show/NCT04170790"
529,"NCT03962686","Molecular Mechanisms and Carotid Atherosclerosis",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Atherosclerosis of Artery|Atherosclerotic Plaque","Drug: MetFORMIN 1000 Mg Oral Tablet","methylase status","University of Campania ""Luigi Vanvitelli""","All","18 Years to 75 Years   (Adult, Older Adult)",,"76","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SecondUNI 22.05.2019","January 1, 2015","January 1, 2017","January 1, 2018","May 24, 2019",,"May 24, 2019","Raffaele Marfella, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT03962686"
530,"NCT04208295","24-hour Blood Pressure Dynamics and Autonomic Adrenergic Regulation in Type 2 Diabetics",,"Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 2|Polyneuropathy Diabetes|Autonomic Neuropathy|Diabetic Neuropathies|Diabetic Complications Neurological",,"24 hour Blood Pressure|Autonomic adrenergic measure","University of Aarhus","All","50 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IDNC_Adrenergic_BP_Testing","May 1, 2019","June 2020","June 2021","December 23, 2019",,"December 23, 2019","Danish Pain Research Center, Aarhus University Hospital, Aarhus, Skejby, Denmark",,"https://ClinicalTrials.gov/show/NCT04208295"
531,"NCT03829982","The Effects of Light on Glucose Metabolism",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Glucose Intolerance|Prediabetic State","Behavioral: Exposure to bright light during the day|Behavioral: Exposure to dim light during the day","Postprandial glucose (mg/dL)|Glucose levels (mmol/L) in the postprandial state|Free fatty acid levels (µmol/L) in the postprandial state|Triglycerides levels (mmol/L) in the postprandial state|Insulin levels (µU/mL) in the postprandial state|Continuous interstitial glucose (mg/dL)|Energy expenditure|Core body temperature (CBT) and skin temperature","Maastricht University|Maastricht University Medical Center","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NL63655.068.17","July 13, 2018","December 2019","December 2019","February 4, 2019",,"August 16, 2019","Maastricht University, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT03829982"
532,"NCT03816488","Oral Peri-operative TIming of Metformin (or) Salsalate to Improve Non-cardiac Surgery Glucose Control","OPTIM(i)SING","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Hyperglycemia|Perioperative/Postoperative Complications","Drug: Metformin|Drug: Salsalate","Feasibility: recruitment rate (percentage)|Participants with hyperglycemia|Feasibility: recruitment rate (total number per month)|Blood glucose levels (glycemic control)|Number of participants with inflammation","McMaster University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","5451","June 1, 2020","June 1, 2021","December 1, 2021","January 25, 2019",,"August 7, 2019",,,"https://ClinicalTrials.gov/show/NCT03816488"
533,"NCT04032561","Relationship Between HbA1c Level, Sleep Quality and Sleep Duration",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2|Pre Diabetes|Sleep Disorder",,"Sleep Quality|Sleep Duration|HbA1c","University of Hertfordshire","All","18 Years to 65 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LMS/UG/NHS/02928","January 8, 2019","September 6, 2019","September 6, 2019","July 25, 2019",,"July 29, 2019","NHS/HSC Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04032561"
